0001558370-18-001172.txt : 20180227 0001558370-18-001172.hdr.sgml : 20180227 20180227161635 ACCESSION NUMBER: 0001558370-18-001172 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180227 DATE AS OF CHANGE: 20180227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 18645300 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 10-K 1 clvs-20171231x10k.htm 10-K clvs_Current_Folio_10K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-K


ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the fiscal year ended December 31, 2017.

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the transition period from                   to                  .

 

Commission file number: 001-35347

 


Clovis Oncology, Inc.

(Exact name of Registrant as specified in its charter)


 

Delaware

    

90-0475355

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

 

 

5500 Flatiron Parkway, Suite 100
Boulder, Colorado

 

80301

(Address of principal executive offices)

 

(Zip Code)

 

(303) 625-5000

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

    

Name of each exchange on which registered

Common Stock par value $0.001 per share

 

The NASDAQ Global Select Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 


 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     Yes   ☒     No   ☐ 

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.     Yes   ☐     No   ☒ 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes   ☒     No   ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405) of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes   ☒     No   ☐ 

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐ 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

 

 

 

 

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes   ☐     No   ☒ 

 

The aggregate market value of the registrant’s common stock, par value $0.001 per share, held by non-affiliates of the registrant on June 30, 2017, the last business day of the registrant’s most recently completed second quarter, was $4,220,084,525 based on the closing price of the registrant’s common stock on the NASDAQ Global Market on that date of $93.63 per share.

 

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of February 21, 2018 was 50,573,183.  

 

DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2017 Annual Meeting of Stockholders, which is to be filed within 120 days after the end of the registrant’s fiscal year ended December 31, 2017, are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated therein.

 

 

 


 

TABLE OF CONTENTS

 

 

 

Page

PART I 

 

 

ITEM 1. 

BUSINESS

3

ITEM 1A. 

RISK FACTORS

29

ITEM 1B. 

UNRESOLVED STAFF COMMENTS

53

ITEM 2. 

PROPERTIES

53

ITEM 3. 

LEGAL PROCEEDINGS

53

ITEM 4. 

MINE SAFETY DISCLOSURES

55

PART II 

 

 

ITEM 5. 

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

56

ITEM 6. 

SELECTED FINANCIAL DATA

58

ITEM 7. 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

60

ITEM 7A. 

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

74

ITEM 8. 

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

75

ITEM 9. 

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

75

ITEM 9A. 

CONTROLS AND PROCEDURES

75

ITEM 9B. 

OTHER INFORMATION

78

PART III 

 

 

ITEM 10. 

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

78

ITEM 11. 

EXECUTIVE COMPENSATION

78

ITEM 12. 

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

78

ITEM 13. 

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

78

ITEM 14. 

PRINCIPAL ACCOUNTING FEES AND SERVICES

78

PART IV 

 

 

ITEM 15. 

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

79

 

SIGNATURES

83

 

 

 

 

2


 

PART I

 

This Annual Report filed on Form 10-K and the information incorporated herein by reference includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Annual Report on Form 10-K and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the market acceptance and commercial viability of our approved product, the development of our sales and marketing capabilities, the performance of our third party manufacturers, our ongoing and planned non-clinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, including our ability to confirm the clinical benefit of our approved product through confirmatory trials and other post-marketing requirements, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, expectations regarding sales of our products, our results of operations, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate, including our competition, and the trends that may affect the industry or us.

 

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein.

 

Any forward-looking statements that we make in this Annual Report on Form 10-K speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Annual Report on Form 10-K or to reflect the occurrence of unanticipated events. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. 

 

You should also read carefully the factors described in the “Risk Factors” section of this Annual Report on Form 10-K to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. You are advised, however, to consult any further disclosures we make on related subjects in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and our website.

 

Clovis Oncology®, the Clovis logo and Rubraca® are trademarks of Clovis Oncology, Inc. in the United States and in other selected countries. All other brand names or trademarks appearing in this report are the property of their respective holders. Unless the context requires otherwise, references in this report to “Clovis,” the “Company,” “we,” “us” and “our” refer to Clovis Oncology, Inc., together with its consolidated subsidiaries.

 

ITEM  1.BUSINESS

 

Overview

 

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

 

Our marketed product Rubraca® (rucaparib) is approved on an accelerated basis in the United States by the Food and Drug Administration (“FDA”) as monotherapy for the treatment of patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. We launched Rubraca in the United States in December 2016 for this indication.

3


 

 

The FDA is currently reviewing on a priority review timeline our supplemental New Drug Application (“sNDA”) for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

 

Our Marketing Authorization Application (“MAA”) submitted to the European Union’s European Medicines Agency (“EMA”) for an ovarian cancer treatment indication for Rubraca is currently under review by the EMA’s Committee for Medicinal Products for Human Use (“CHMP”). Following a Scientific Advisory Group - Oncology meeting and an oral explanation by us before the CHMP in February 2018, the CHMP has communicated a positive trend vote for the MAA and their intention to hold a final vote on the treatment indication at their March 2018 meeting.

 

Beyond our labeled indication, we have a robust Rubraca clinical development program underway in a variety of solid tumor types, also including prostate and bladder cancers, and in July 2017, we entered into a broad clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of their immunotherapy Opdivo® (nivolumab) with Rubraca in several tumor types. We hold worldwide rights for Rubraca.  

 

In addition, we have two other product candidates: lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (“VEGFR”) 1-3, platelet-derived growth factor receptors (“PDGFR”) alpha and beta and fibroblast growth factor receptors (“FGFR”) 1-3, and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor (“EGFR”).  While we have stopped enrollment in ongoing trials for each of these candidates, we continue to provide drug to patients whose clinicians recommend continuing therapy. We maintain certain development and commercialization rights for lucitanib and global development and commercialization rights for rociletinib.

 

Clovis was founded in 2009. We have built our organization to support innovative oncology drug development for the treatment of specific subsets of cancer populations. To implement our strategy, we have assembled an experienced team with core competencies in global clinical and non-clinical development, regulatory operations and commercialization in oncology, as well as conducting collaborative relationships with companies specializing in companion diagnostic development.

 

Rubraca – a PARP Inhibitor

 

Overview

 

Rubraca (rucaparib) is an oral, small molecule poly ADP-ribose polymerase (“PARP”) inhibitor of PARP1, PARP2 and PARP3. We in-licensed Rubraca from Pfizer Inc. in June 2011. In the United States, Rubraca is approved by the FDA for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The indication is approved under the FDA’s accelerated approval program based on objective response rate and duration of response, and is based on results from two multicenter, single-arm, open-label clinical trials. Continued approval for this indication may be contingent upon verification and description of clinical benefit in ARIEL3 and/or ARIEL4, our confirmatory trials. Foundation Medicine, Inc. has developed two companion diagnostics that are FDA-approved and commercially available for selection of patients for treatment with Rubraca in this indication:  FoundationFocus™ CDxBRCA and FoundationOne CDx™.

 

In October 2017 we submitted a sNDA for Rubraca for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. In December 2017, the FDA accepted our sNDA for Rubraca and granted priority review status to the application with a Prescription Drug User Free Act (“PDUFA”) goal date of April 6, 2018. If approved, we expect that diagnostic testing would not be required for patients to be prescribed Rubraca in this maintenance treatment indication. We have approximately 150 field-based personnel in the United States, and these commercial and medical affairs organizations already in place will support the commercial launch of Rubraca, if approved in this expanded maintenance treatment indication.

 

The second-line maintenance treatment paradigm in ovarian cancer is being rapidly adopted in the U.S. following the approval of two other PARP inhibitors in this setting during 2017. If Rubraca is approved in this setting, with no requirement for diagnostic testing as supported by the ARIEL3 data, it would be possible to address a patient population

4


 

approximately four times larger than our initial niche treatment indication, which is limited to women with ovarian cancer in the third-line setting with a BRCA mutation. BRCA mutations are believed to occur in approximately 25 percent of women with ovarian cancer.

 

Our MAA submitted to the EMA for an ovarian cancer treatment indication is currently under review. Following a Scientific Advisory Group - Oncology meeting and an oral explanation before the CHMP in February 2018, the CHMP communicated to us that they held a trend vote for the MAA and the result was positive. The CHMP also communicated to us their intention to hold a final vote on the treatment indication at their March 2018 meeting. The CHMP’s trend vote is not binding on the CHMP with respect to the final vote. The indication currently under consideration by the CHMP focuses on a subset of platinum-sensitive ovarian cancer where there is particular unmet need. If Rubraca receives a favorable opinion from the CHMP in March, a potential approval from the European Commission is expected during the second quarter of 2018. In the event of such an approval for the treatment indication, we intend to submit a variation to the marketing authorization (“MA”) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, for which we anticipate a CHMP opinion may come during the fourth quarter of 2018. The EMA’s Committee for Orphan Medicinal Products (“COMP”) will meet in March 2018 to review and issue a final opinion on our application to maintain the orphan drug designation for Rubraca submitted as part of the MAA review process. While Rubraca currently has orphan drug designation in the EU, there is no assurance that COMP will maintain such designation post-approval. In the event of a negative opinion for the treatment indication, we expect to file a new MAA for the maintenance treatment indication during the second quarter of 2018. If approved in the EU, we intend to commercialize Rubraca on our own and we are building our commercial and medical affairs infrastructure in Europe. The leadership of those teams is in place, and we intend to hire field sales personnel as pricing and reimbursement decisions are made and approvals are received.

 

The Role of PARP Inhibition in Cancer Therapy

 

Cells in the human body are under constant attack from agents that can cause damage to DNA, including sunlight and other forms of radiation, as well as DNA-binding chemicals that can cause changes in the composition of DNA. Cells have evolved multiple mechanisms to enable such DNA repair, and these mechanisms are complementary to each other, each driving repair of specific types of DNA damage. If a cell’s DNA damage repair system is overwhelmed, then the cell will die undergoing a form of suicide termed apoptosis. A fundamental principle of cancer therapy is to damage cells profoundly with radiation or DNA-binding drugs, such as alkylating agents or platinums, to induce apoptosis and, subsequently, cancer cell death. Multiple DNA repair mechanisms active in the cell may reduce the activity of these anti-cancer therapies.

 

The PARP family comprises 17 structurally related proteins that have been identified on the basis of sequence similarity. PARP1, PARP2, and PARP3 play a central role in DNA repair. They are rapidly recruited to the sites of DNA damage and catalyze the recruitment of additional proteins that initiate the repair of damaged DNA. The breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes also have important roles in DNA repair pathways such as homologous recombination. According to the National Cancer Institute, BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian, breast, prostate, and pancreatic cancers.

 

Rubraca is an inhibitor of PARP enzymes, including PARP1, PARP2, and PARP3. PARP inhibitors have shown activity in BRCA1/2 mutant and homologous recombination (“HR”) repair deficient cancer cell lines through a mechanism known as synthetic lethality in which the loss of two genes/pathways is required for cell death. The inhibition/inactivation of repair pathways by administration of a PARP inhibitor in the context of an underlying genetic defect such as a BRCA mutation results in tumor cell death through accumulation of unrepaired DNA damage.

 

Alterations in DNA repair genes other than BRCA1/2 have been observed in, and contribute to the hereditary risk of, ovarian, breast, prostate and pancreatic cancers. PARP inhibitors have shown evidence of nonclinical and clinical activity in tumors with alterations in non-BRCA HR genes. DNA repair deficiencies resulting from genetic and epigenetic alterations can result in a “BRCA-like” phenotype that may also render tumor cells sensitive to PARP inhibitors. One approach to identify patients with DNA repair deficiencies due to mechanisms other than a mutation in BRCA or other non-BRCA HR genes is to assess loss of heterozygosity (“LOH”), or the loss of one normal copy of a gene, which arises from error-prone DNA repair pathways when HR is compromised.

 

5


 

On the basis of these scientific observations, we initially developed Rubraca in ovarian cancer patients with tumors having BRCA mutations or other homologous recombination deficiencies (“HRD”). These molecular markers also may be used to select patients with other tumors for treatment with Rubraca. Thus, in addition to ovarian trials, studies open for enrollment or under consideration to further evaluate Rubraca, either alone or in combination with other agents, include prostate, breast, pancreatic, bladder, gastroesophageal and lung cancers.

 

Rubraca Clinical Development

 

We are developing Rubraca for selected patient populations and collaborating with partners for companion diagnostic development. We have focused our development strategy for Rubraca on indications where we believe patient populations exhibit higher frequencies of mutant BRCA tumors or HRD, where PARP inhibitors have demonstrated clinical or pre-clinical activity in tumors. In certain of these trials, we or our partners will have access to interim data on a periodic or continuing basis that will not be made available publicly on the same timeframe as such data becomes available to us, or at all. The following table summarizes the ongoing Clovis- or partner-sponsored studies:

 

pipeline_Jan2018.jpg

 

Ovarian cancer

 

According to the American Cancer Society, an estimated more than 22,000 women were diagnosed with ovarian cancer in the United States in 2017, and according to GLOBOCAN in 2012, an estimated more than 65,000 women in Europe are diagnosed each year with ovarian cancer, and ovarian cancer is among those cancers with the highest rate of deaths. Approximately 80% to 85% of ovarian cancer cases are not diagnosed, and therefore remain untreated, until the disease has spread to other parts of the body, or metastasized. Most women with ovarian cancer will relapse after surgery and/or chemotherapy. BRCA mutations, either germline or somatic, are believed to occur in approximately 25 percent of women with ovarian cancer according to an article published in Clinical Cancer Research in 2014.

 

The ARIEL (Assessment of Rucaparib In Ovarian CancEr TriaL) program is a novel, integrated translational-clinical program designed to accurately and prospectively identify ovarian cancer patients with tumor genotypes associated with benefit from Rubraca therapy.

 

ARIEL2 (NCT01891344) is a two-part single-arm open label study designed to identify pre-specified tumor characteristics that predict sensitivity to Rubraca using DNA sequencing to evaluate each patient’s tumor. Part 1 enrolled 204 platinum-sensitive patients and updated results were presented in June 2016. Part 2 enrolled 286 patients with advanced ovarian cancer who have received at least three prior chemotherapy regimens and includes platinum-sensitive, -resistant and -refractory patients. ARIEL2 is evaluating clinical response in patients classified into molecularly-defined subgroups, including germline BRCA-mutant, somatic BRCA-mutant and HRD by a prospectively defined genomic signature.

 

The efficacy of Rubraca in the ovarian cancer treatment setting was assessed in 106 patients from ARIEL2 and Study 10 (NCT01482715, a multicenter, single-arm, open-label clinical trial of Rubraca), in patients with advanced BRCA-

6


 

mutant ovarian cancer who had progressed after two or more prior chemotherapies. Median age was 59 years and median number of prior chemotherapy regimens was three. All 106 patients received the starting dose of Rubraca 600 mg twice daily. The major efficacy outcome measure of both trials was objective response rate (ORR) and duration of response (DOR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. All responses were confirmed. ORR assessed by investigator was 54% (95% Confidence Interval, or CI: 44, 64), with a median DOR of 9.2 months (95% CI: 6.6, 11.6). ORR by independent radiology review was 42% (95%: 32, 52), with a median DOR of 6.7 months (95% CI: 5.5, 11.1).

 

The overall safety evaluation of Rubraca in the advanced ovarian cancer treatment setting is based on data from 377 patients with ovarian cancer from ARIEL2 and Study 10. The most common adverse reactions (≥ 20% of patients; Grade 1-4) were nausea, asthenia/fatigue, vomiting, anemia, constipation, dysgeusia, decreased appetite, diarrhea, abdominal pain, thrombocytopenia and dyspnea. The most common laboratory abnormalities (≥ 35% of patients; Grade 1-4) were increase in creatinine, increase in aspartate aminotransferase (“AST”) levels, increase in alanine aminotransferase (“ALT”) levels, decrease in hemoglobin, decrease in lymphocytes, increase in cholesterol, decrease in platelets and decrease in absolute neutrophil count. Elevations in ALT/AST concentrations were generally self-limiting and not associated with other signs of liver toxicity. Rubraca requires monitoring of complete blood counts at baseline, and monthly thereafter. The most common Grade 3-4 adverse reaction was anemia, and the most common Grade 3-4 laboratory abnormality was a decrease in hemoglobin. Myelodysplastic Syndrome/Acute Myeloid Leukemia, or MDS/AML, was reported in two of the 377 (0.5%) patients with ovarian cancer treated with Rubraca. Both of these patients had received prior treatment with platinum and other DNA damaging agents. In addition, AML was reported in two (<1%) patients with ovarian cancer enrolled in ARIEL3. One case of AML was fatal. Both patients had received prior treatment with platinum and other DNA damaging agents.

 

The data from the two studies formed the basis of our submission of a New Drug Application (“NDA”) in the United States to the FDA in late June 2016. The application was granted priority review and approved under FDA’s accelerated approval program on December 19, 2016 as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Continued approval for this indication may be contingent upon verification and description of clinical benefit in ARIEL3 and/or ARIEL4, our confirmatory trials.

 

The efficacy of Rubraca in the ovarian cancer maintenance treatment setting was investigated in ARIEL3 (NCT01968213), a double-blind, multicenter clinical trial in which 564 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in response to platinum-based chemotherapy were randomized (2:1) to receive Rubraca tablets 600 mg orally twice daily (n=375) or placebo (n=189). Treatment was continued until disease progression or unacceptable toxicity. All patients had achieved a response (complete or partial) to their most recent platinum-based chemotherapy. Randomization was stratified by best response to last platinum (complete or partial), time to progression following the penultimate platinum therapy (6 to < 12 months and ≥ 12 months), and tumor biomarker status. The major efficacy outcome was investigator-assessed progression-free survival (“PFS”) evaluated according to RECISTv1.1.

 

The primary efficacy analysis evaluated three prospectively defined molecular sub-groups in a step-down manner: 1) tumor BRCA mutant (tBRCAmut) patients, inclusive of germline and somatic BRCA mutations (n=196); 2) HRD patients, including tBRCAmut patients and BRCA wild-type with high LOH (n=354), and, finally, 3) the intent-to-treat population, or all patients treated in ARIEL3 (n=564). ARIEL3 demonstrated a statistically significant improvement in PFS for patients randomized to Rubraca as compared with placebo in all patients, and in the HRD and tBRCAmut subgroups. Median PFS in the tBRCAmut patients was 16.6 months (95% CI: 13.4–22.9) in the Rubraca group (n=130) versus 5.4 months (95% CI: 3.4–6.7) in the placebo group (n=66) (Hazard Ratio, or HR: 0.23 [95% CI: 0.16–0.34]; p<0.0001).  Median PFS in the HRD patients was 13.6 months (95% CI: 10.9–16.2) in the Rubraca group (n=236) versus 5.4 months (95% CI: 5.1–5.6) in the placebo group (n=118) (HR: 0.32 [95% CI: 0.24–0.42]; p<0·0001). Median PFS in the intent-to-treat population was 10.8 months (95% CI: 8.3–11.4) in the Rubraca group (n=375) versus 5.4 months (95% CI: 5.3–5.5) in the placebo group (n=189) (HR: 0.36 [95% CI: 0.30–0.45]; p<0·0001).

 

Results from a blinded independent radiology review (“BICR”) were consistent. In a pre-specified analysis of the key stand-alone secondary endpoint of progression-free survival assessed by BICR, PFS was also improved in the Rubraca group compared with placebo in all three populations.  Median PFS in the tBRCAmut patients was 26.8 months (95% CI: 19.2 to not reached) in the Rubraca group versus 5.4 months (95% CI: 4.9–8.1) in the placebo group (HR: 0.20 [95%

7


 

CI: 0.13–0.32]; p<0.0001).  Median PFS in the HRD patients was 22.9 months (95% CI: 16.2 to not reported) in the Rubraca group versus 5.5 months (95% CI: 5.1–7.4) in the placebo group (HR: 0.34 [95% CI: 0.24–0.47]; p<0.0001). Median PFS in the intent-to-treat population was 13.7 months (95% CI: 11.0–19.1) versus 5.4 months (95% CI: 5.1–5.5) in the placebo group (HR: 0.35 [0.28–0.45]; p<0.0001).

 

Enrollment in ARIEL3 included one-third of patients who had achieved a complete response to their prior platinum-based therapy, and two-thirds of patients who had achieved a partial response to their prior platinum-based therapy. Of those with a partial response, 37% had measurable disease at the time of enrollment and were therefore evaluable for response. The confirmed overall response rate by investigator-assessed RECISTv1.1 in the tBRCAmut group treated with Rubraca was 37.5% (15/40), of these, 17.5% (7/40) were complete responses. This compared with 9% (2/23) in the placebo group (p=0.0055). No complete responses were seen in the tBRCAmut placebo group. RECIST responses were also observed in BRCA wild-type HRD-positive and BRCA wild-type HRD-negative subgroups. RECIST responses were not assessed by independent blinded review.

 

Safety data from ARIEL3 demonstrated consistency with prior Rubraca studies. Treatment emergent adverse events (“TEAEs”) in the ARIEL3 Rubraca group were generally managed with dose modifications and not associated with increased mortality or morbidity compared with the placebo group. The most common (occurring in ≥5% of patients) TEAEs of grade ≥3 reported in patients treated with Rubraca in the ARIEL3 study were anemia/decreased hemoglobin (21%), increase in ALT/AST (10%), neutropenia (7%), asthenia/fatigue (7%) and thrombocytopenia (5%). The discontinuation rate for TEAEs (excluding disease progression) was 15% for Rubraca-treated patients and 2% for the placebo arm. In ARIEL3, the rate of treatment-emergent myelodysplastic syndrome (“MDS”)/acute myeloid leukemia (“AML”) in the Rubraca arm was <1% (3/372), and no patients on the placebo arm experienced treatment-emergent MDS/AML. In approximately 1,100 patients treated with Rubraca, MDS/AML occurred in 10 patients (0.9%), including those in long term follow-up. Of these, 5 occurred during treatment or during the 28 day safety follow-up (0.5%). The duration of Rubraca treatment prior to the diagnosis of MDS/AML ranged from 1 month to approximately 28 months. The cases were typical of secondary MDS/cancer therapy-related AML; in all cases, patients had received previous platinum-containing chemotherapy regimens and/or other DNA damaging agents.

 

At the time of the analysis of PFS, overall survival (OS) data were not mature (with 22% of events). The comprehensive dataset for ARIEL3 was presented at the 2017 European Society of Medical Oncology (“ESMO”) Congress in early September 2017 and subsequently published in The Lancet.  

 

Based on the ARIEL3 dataset, in October 2017 we submitted a supplemental NDA for Rubraca as maintenance treatment in adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The application was granted priority review status by the FDA and has a PDUFA date of April 6, 2018.

 

The ARIEL4 confirmatory study (NCT 02855944), which is open for enrollment, is a Phase 3 multicenter, randomized study of Rubraca versus chemotherapy in relapsed ovarian cancer patients with BRCA mutations (inclusive of germline and/or somatic) who have failed two prior lines of therapy. The primary endpoint of the study is PFS.

 

The Phase 1 RUCA-J study, sponsored by us, recently initiated with the first patient dosed with Rubraca in Japan. The Phase 1 study seeks to identify the recommended dose of rucaparib in Japanese patients.

 

Prostate cancer

 

The American Cancer Society estimates that more than 164,000 men in the United States will be diagnosed with prostate cancer in 2018, and the GLOBOCAN Cancer Fact Sheets estimated that approximately 345,000 men in Europe were diagnosed with prostate cancer in 2012. Castrate-resistant prostate cancer has a high likelihood of developing metastases. Metastatic castrate-resistant prostate cancer, or mCRPC, is an incurable disease, usually associated with poor prognosis. According to the American Cancer Society, the five-year survival rate for mCRPC is approximately 29%. Germline or somatic mutations in BRCA, ATM and other DNA repair genes are believed to be present at frequencies of 20 percent or higher in mCRPC, according to an article published in JCO Precision Oncology in 2017.  These molecular markers may be used to select patients for treatment with a PARP inhibitor. Additionally, preclinical studies of rucaparib have demonstrated activity in prostate cell cancer lines deficient in BRCA or ATM.

8


 

 

The TRITON (Trial of Rucaparib in Prostate Indications) program in prostate cancer initiated in the second half of 2016, and currently includes two Clovis-sponsored potential registration studies currently open for enrollment:

·

The TRITON2 study (NCT02952534), a Phase 2 single-arm study of Rubraca in men with mCRPC enrolling patients with BRCA mutations and ataxia-telangiectasia mutations, or ATM, (both inclusive of germline and/or somatic) or other deleterious mutations in other homologous recombination repair genes. All patients will have progressed after receiving one line of taxane-based chemotherapy and one or two lines of androgen receptor (“AR”) targeted therapy in the castrate-resistant setting. The primary endpoints of the study are radiologic ORR in patients with measurable disease and protein-specific antigen (“PSA”) response rate in patients who do not have measurable disease. TRITON2 initiated during the fourth quarter of 2016, and interim data are expected at a medical meeting during the second half of 2018. The estimated primary completion date for TRITON2 is the second half of 2019. Pending positive data, TRITON2 could potentially serve as the basis for an accelerated approval in the U.S.

·

The TRITON3 study (NCT02975934), a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM (both inclusive of germline and/or somatic) patients who have progressed on AR-targeted therapy and who have not yet received chemotherapy in the castrate-resistant setting. TRITON3 will compare Rubraca to physician’s choice of AR-targeted therapy or chemotherapy in these patients. The planned primary endpoint of the study is radiologic PFS. TRITON3 initiated during the first quarter of 2017, and this earlier-line comparative study could potentially serve as a confirmatory study in the advanced prostate setting.

 

Bladder cancer

 

According to GLOBOCAN Cancer Fact Sheets, bladder cancer was one of the top six most common cancers in the United States as of 2012, with an estimated 79,000 new cases of bladder cancer diagnosed in the United States in 2017, according to the National Cancer Institute. Approximately 20% to 30% of newly diagnosed bladder cancer patients have disease that has invaded the muscle, according to the National Cancer Institute. Muscle-invasive bladder cancer is a disease with poor prognosis. Overall survival of these patients after initial cisplatin-containing chemotherapy is 13-15 months, with most patients experiencing relapse of disease in 9 months, according to an article published in the European Journal of Cancer in 2006. After the first one or two lines of anti-cancer treatments, options for these patients are limited, with platinum therapy as the current standard of care. Based an analysis of The Cancer Genome Atlas (“TCGA”), bladder cancer data set, we believe approximately 60% of bladder cancer tumors have alterations in homologous recombination repair genes or other genomic features associated with HRD.

 

We initiated a potential registration study in bladder cancer during the first quarter of 2018, called ATLAS (A Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma). ATLAS (NCT03397394) is a phase 2 single-arm study enrolling patients with relapsed metastatic urothelial carcinoma following one or two prior standard of care regimens, with measurable disease, and no prior PARP treatment.  The planned primary endpoint is overall response rate, and the study will enroll all comers, with no selection based on HRD status. Pending positive data, we believe this trial design could support a sNDA in an all comers population, without regard to biomarker status.

 

Combination trials

In July 2017, we and Bristol-Myers Squibb Company (“BMS”) announced a broad clinical collaboration evaluating the combination of Rubraca with BMS’s immunotherapy Opdivo® (nivolumab) in multiple tumor types.  Three trials are underway or expected to initiate in the first half of 2018:

·

The ATHENA study, a phase 3 study in advanced ovarian cancer, sponsored by Clovis;

·

A phase 3 study in advanced triple-negative breast cancer (TNBC), sponsored by BMS; and

·

A phase 2 study in mCRPC sponsored by BMS.

We believe that a preclinical rationale supports the conduct of clinical trials of the combination of our PARP inhibitor Rubraca with immune checkpoint inhibitors such as the PD-1 inhibitor Opdivo. BRCA1 and BRCA2 and other HRD mutations are associated with increased tumor mutational burden, which may create additional tumor-specific antigens or “neoepitopes.” Increased tumor mutation burden has been shown to correlate with increased benefit from immune checkpoint blockade. In addition, cell death that is induced by a PARP inhibitor is considered immunogenic, and stimulates a “STING-like” pathway due to fragmented DNA release into cytosol. In mice studies, rucaparib and an anti-

9


 

PD-1 antibody demonstrated anti-tumor activity in BRCA1 mutant ovarian tumors. The combination of rucaparib and either an anti-PD-L1 or anti-CTLA-4 antibody were equally compelling in preclinical studies.

ATHENA is a four-arm first-line maintenance treatment study to evaluate Rubraca and Opdivo,  Rubraca, Opdivo and placebo in an estimated 1,000 newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube, or primary peritoneal cancer who have completed platinum-based chemotherapy.  The primary objectives are to determine if the combination of Rubraca and Opdivo meaningfully extends PFS versus Rubraca monotherapy, or versus placebo, and to determine if Rubraca extends PFS versus placebo. The analysis of the study results will evaluate, in a step-down manner, the tBRCA/HRD and intent-to-treat subpopulations. We are the sponsor, and will also conduct and fund the ATHENA study, which is expected to initiate in the first half of 2018.

The combination study of Rubraca and Opdivo in patients with advanced TNBC will be sponsored and conducted by BMS, with study costs to be shared by Clovis and BMS. The study is expected to initiate in the first half of 2018.

The mCRPC study is a three-arm study evaluating Opdivo + Rubraca, Opdivo + docetaxel + prednisone, and Opdivo + enzalutamide, with the objective of determining how the combination affects objective response rate and PSA response. The study will enroll patients with biomarker negative or positive disease, and tumor tissue samples will be used to determine biomarker status. BMS is sponsoring, conducting and funding the 300 patient study in mCRPC, which initiated in the fourth quarter of 2017.

In addition, a Phase 1b study (WO39409; NCT NCT03101280) sponsored by Hoffman-La Roche (Genentech) is underway evaluating the combination of cancer immunotherapy Tecentriq® (atezolizumab; anti-PDL1) and Rubraca for the treatment of advanced gynecological cancers and TNBC in patients with a tumor BRCA or HRD mutation.  This study began enrolling patients in the first half of 2017.

 

Companion Diagnostics

We partnered with Foundation Medicine, Inc. to co-develop a companion diagnostic test, the FDA approved FoundationFocus™ CDx BRCA, to select patients for treatment with Rubraca in the ovarian cancer treatment indication. FoundationFocus CDx BRCA is a next-generation sequencing (“NGS”) assay that assesses tumor BRCA mutations from tumor tissue samples from patients with ovarian cancer.

On November 30, 2017, Foundation announced FDA approval of its comprehensive companion diagnostic test for solid tumors, FoundationOne™ CDx, a NGS based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability and tumor mutational burden. Among the genes assessed by the test are BRCA1/2, and FoundationOne™ CDx is approved as a companion diagnostic to select patients for treatment with Rubraca in the advanced ovarian cancer treatment indication.

As part of our collaboration with Foundation, we also developed an NGS test to use as a diagnostic to assess genomic LOH in tumor samples, and this biomarker has the potential to expand the clinical utility of Rubraca in ovarian cancer and other indications.  This test, FoundationFocus™ CDx BRCA HRD test, was used to assess HRD status in patient tumor samples in the ARIEL3 study.

We also have a companion diagnostic collaboration with Myriad Genetics, Inc. (“Myriad”) to support a post-marketing regulatory commitment related to Rubraca’s initial approval in the ovarian cancer treatment setting. Myriad will submit a supplementary premarket approval (“sPMA”) application under its existing PMA for BRACAnalysis CDx to include Rubraca. BRACAnalysis CDx is Myriad’s blood-based assay for the qualitative detection and classification of germline mutations in BRCA1/2 genes.

10


 

 

Lucitanib – a VEGFR, PDGFR and FGFR Inhibitor

 

Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Lucitanib was previously evaluated in breast and lung cancers. Development in those indications has ceased and we continue to provide drug to patients whose clinicians recommend continuing lucitanib therapy. We are continuing to evaluate what, if any, further development of lucitanib will be pursued. We hold development and commercialization rights in the U.S. and Japan and have sublicensed rights to Europe and rest of world markets, excluding China, to Servier.

 

Rociletinib - an Oral EGFR Mutant-Selective Inhibitor

 

Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (“EGFR”). We terminated enrollment in all sponsored clinical studies, although we continue to provide drug to patients whose clinicians recommend continuing rociletinib therapy. We are continuing analyses of rociletinib data to determine whether certain populations of patients may represent an opportunity for a partner committed to investing in further clinical development. We hold global development and commercialization rights for rociletinib.

 

Competition

 

The development and commercialization of new drugs is competitive, and we face competition from major pharmaceutical and biotechnology companies worldwide. Our competitors may develop or market products or other novel technologies that are more effective, safer or less costly than any that have been or will be commercialized by us, or may obtain regulatory approval for their products more rapidly than we may obtain approval for ours.

 

The acquisition or licensing of pharmaceutical products is also very competitive, and a number of more established companies, which have acknowledged strategies to license or acquire products, may have competitive advantages over us, as may other emerging companies taking similar or different approaches to product acquisitions. Many of our competitors have substantially greater financial, technical and human resources than we have. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances made in the commercial applicability of technologies and greater availability of capital for investment in these fields. Our success will be based in part on our ability to build and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient therapy.

 

Rubraca Competition

 

Lynparza®/olaparib (AstraZeneca) was the first PARP inhibitor to market and has been approved in the US in the following indications:

·

as monotherapy for the treatment of adult patients who have deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy;

·

as monotherapy for the maintenance treatment of adult patients with recurrent epithelial, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and

·

as monotherapy in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.

   

Lynparza is approved in the EU for use as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. In February 2018, the CHMP adopted a positive opinion recommending this label be changed and expanded to remove the limitation of use in BRCA-mutated patients. Lynparza has indications for ovarian cancer across 57 countries (as of year-end 2017).

 

11


 

In July 2017, AstraZeneca and Merck & Co., Inc. announced a global strategic oncology collaboration to co-develop and co-commercialise Lynparza for multiple cancer types. Lynparza is being investigated, alone and in combination with other agents, in multiple indications across several tumor types, including breast, prostate, and pancreatic cancers.

 

Zejula®/niraparib (Tesaro) was approved in March 2017 in the United States as monotherapy for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Zejula was approved in November 2017 in the EU for the same indication. Additional clinical investigations of Zejula in ovarian, breast and lung cancers are ongoing or planned. Janssen Biotech has licensed rights to develop and commercialize niraparib specifically for patients with prostate cancer worldwide, except in Japan.

 

There are a number of PARP inhibitors in clinical development including AbbVie’s veliparib and ABT-767, Pfizer’s talazoparib, BeiGene’s BGB-290, and Checkpoint Therapeutics’ CK-102. While most PARP inhibitor development focuses on ovarian, breast and prostate cancers, additional efforts are aimed toward bladder, lung, and pancreatic cancers as well.

 

In addition, combination approaches that include PARP inhibitors, including Lynparza or Zejula, with other anticancer agents are in various phases of clinical development across a variety of oncology indications. These combination therapies may result in future competitive pressure on Rubraca, and multiple data readouts for such studies are anticipated throughout 2018 and beyond.

 

Outside of the PARP class, Avastin®/bevacizumab is approved in the US for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that is platinum-resistant in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, and was approved in December 2016 in the US for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that is platinum-sensitive in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent.  Other out of class agents approved for use in advanced ovarian cancer include chemotherapeutic agents (e.g. platinum-based doublets, platinum monotherapy, non-platinum chemotherapy, etc.), Doxil® (Janssen), and Hycamtin® (Novartis). There are additional out-of-class agents in clinical development that may pose a future competitive threat to Rubraca.

 

License Agreements

 

Pfizer Inc.

 

In June 2011, we entered into a license agreement with Pfizer Inc. (“Pfizer”) to obtain the exclusive global rights to develop and commercialize Rubraca. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of Rubraca, we made milestones payments of $1.4 million, which were recognized as acquired in-process research and development expense.

 

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) European Commission approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that we defer such milestone payments, we have agreed to pay an additional $3.0 million related to the achievement of each such milestone.

 

On December 19, 2016, the FDA approved Rubraca as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was made in the first quarter of 2017. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we have exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. These payments were recognized as intangible assets and amortized over the estimated remaining useful life of Rubraca.

 

12


 

We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize Rubraca and we are responsible for all ongoing development and commercialization costs for Rubraca. We are required to make regulatory milestone payments to Pfizer of up to an additional $69.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for Rubraca are met, which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize Rubraca.

 

The license agreement with Pfizer will remain in effect until the expiration of all of our royalty and sublicense revenue obligations to Pfizer, determined on a product-by-product and country-by-country basis, unless we elect to terminate the license agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Pfizer can terminate the agreement, resulting in a loss of our rights to Rubraca and an obligation to assign or license to Pfizer any intellectual property rights or other rights we may have in Rubraca, including our regulatory filings, regulatory approvals, patents and trademarks for Rubraca.

 

AstraZeneca UK Limited

 

In April 2012, we entered into a license agreement with AstraZeneca UK Limited (“AstraZeneca”) to acquire exclusive rights associated with Rubraca under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of Rubraca for the uses claimed by these patents. Pursuant to the terms of the license agreement, we made an upfront payment of $0.25 million upon execution of the agreement. During the second quarter of 2016, we made a milestone payment of $0.3 million to AstraZeneca upon the NDA submission for Rubraca. These payments were recognized as acquired in-process research and development expense. The FDA approval of Rubraca on December 19, 2016 resulted in a final $0.35 million milestone payment to AstraZeneca as required by the license agreement. This payment was recognized as intangible assets and amortized over the estimated remaining useful life of Rubraca. AstraZeneca also receives royalties on net sales of Rubraca.

 

Advenchen Laboratories LLC

 

In October 2008, Ethical Oncology Science, S.p.A. (“EOS”) (now known as Clovis Oncology Italy S.r.l.) entered into an exclusive license agreement with Advenchen Laboratories LLC (“Advenchen”) to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, we receive from sublicensees, in lieu of the milestone obligations set forth in the agreement. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib.

 

The license agreement with Advenchen will remain in effect until the expiration of all of our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in a loss of our rights to lucitanib.

 

Les Laboratoires Servier

 

In September 2012, EOS entered into a collaboration and license agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier (collectively, “Servier”), whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an upfront payment of €45.0 million. We are entitled to receive additional payments on the achievement of specified development, regulatory and commercial milestones up to €100.0 million in the aggregate, €10.0 million of which was received in the first quarter of 2014. In addition, we are entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, each of which relates to annual sales targets of €250.0 million and above, which, in the aggregate, could amount to a total of €250.0 million. We are also entitled to receive royalties at percentage rates ranging from low-to-mid teens on sales of lucitanib by Servier.

13


 

 

We and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for all of the development costs for lucitanib up to €80.0 million. Cumulative global development costs in excess of €80.0 million, if any, will be shared equally between us and Servier. During the second quarter of 2016, we and Servier agreed to discontinue the development of lucitanib for breast cancer. During 2017, we completed the committed on-going development activities and received full reimbursement of our development costs from Servier. Reimbursements are recorded as reduction to research and development expense on the Consolidated Statement of Operations.

 

The collaboration and license agreement will remain in effect until the expiration of all of Servier’s royalty obligations to us, determined on a product-by-product and country-by-country basis, unless Servier elects to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Servier can terminate the agreement, resulting in the granting of a perpetual license to Servier of rights to lucitanib.

 

Celgene Corporation

In May 2010, we entered into an exclusive worldwide license agreement with Avila Therapeutics, Inc. (now Celgene Avilomics Research Inc., part of Celgene Corporation (“Celgene”)) to discover, develop and commercialize a covalent inhibitor of mutant forms of the EGFR gene product. Rociletinib was identified as the lead inhibitor candidate under the license agreement. We are responsible for all non-clinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib.

 

We made an upfront payment of $2.0 million upon execution of the license agreement, a $4.0 million milestone payment in the first quarter of 2012 upon the acceptance by the FDA of our Investigational New Drug (“IND”) application for rociletinib and a $5.0 million milestone payment in the first quarter of 2014 upon the initiation of the Phase II study for rociletinib. In the third quarter of 2015, we made milestone payments totaling $12.0 million upon acceptance of the NDA and MAA for rociletinib by the FDA and EMA, respectively. We recognized all payments prior to commercial approval as acquired in-process research and development expense.

 

We are obligated to pay royalties at percentage rates ranging from mid-single digits to low teens on the volume of annual net sales achieved. We are required to pay up to an additional aggregate of $98.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are required to pay up to an aggregate of $120.0 million in sales milestone payments if certain annual sales targets are achieved. 

 

We have full sublicensing rights under the license agreement, subject to our sharing equally with Celgene any upfront payments from any sub-licensing arrangements relating to Japan, or Japan and any one or more of China, South Korea and Taiwan, which we refer to herein as an Asian Partnership, and subject to our paying royalties on sales in Asia equal to the greater of the royalty rates contained in our license agreement or 50% of the royalties we receive from our Asian Partnership.

 

The license agreement will remain in effect until the expiration of all of our royalty and sublicense revenue obligations to Celgene, determined on a product-by-product and country-by-country basis, unless we elect to terminate the license agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Celgene can terminate the agreement, resulting in a loss of our rights to rociletinib and an obligation to assign or license to Celgene any intellectual property rights or other rights we may have in rociletinib, including our regulatory filings, regulatory approvals, patents and trademarks for rociletinib.

 

Government Regulation

 

Government authorities in the United States (including federal, state and local authorities) and in other countries, extensively regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution, post-approval monitoring and reporting, advertising and promotion, pricing and export and import of pharmaceutical products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Moreover, failure to comply with applicable regulatory requirements may result in, among other

14


 

things, warning letters, clinical holds, civil or criminal penalties, recall or seizure of products, injunction, disbarment, partial or total suspension of production or withdrawal of the product from the market.

 

U.S. Government Regulation

 

In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (“FDCA”) and its implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process required by the FDA before product candidates may be marketed in the United States generally involves the following:

·

completion of extensive non-clinical laboratory tests and non-clinical animal studies, all performed in accordance with the FDA’s Good Laboratory Practice regulations;

·

submission to the FDA of an IND which must become effective before human clinical trials may begin and must be updated at least annually;

·

performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication;

·

submission to the FDA of a marketing authorization application in the form of an NDA for the initial commercial sale of a product, or of a sNDA, for approval of a new indication if the product is already approved for another indication;

·

satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities at which the active pharmaceutical ingredient (“API”) and finished drug product are produced and tested to assess compliance with Current Good Manufacturing Practices (“cGMP”) and/or sites involved in clinical studies to assess compliance with Good Clinical Practices (“GCP”);

·

if FDA convenes an advisory committee, satisfactory completion of the advisory committee review; and

·

FDA review and approval of the marketing authorization application and product prescribing information prior to any commercial marketing or sale of the drug for the intended use.  

 

An IND is a request for authorization from the FDA to administer a product candidate to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human studies. The IND also includes results of animal studies or other human studies, as appropriate, as well as manufacturing information, analytical data and any available clinical data or literature to support the use of the product candidate. An IND must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the proposed clinical trials, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND may be placed on clinical hold requiring delay of a proposed clinical investigation, and the IND sponsor and the FDA must resolve any outstanding concerns or questions before clinical trials can begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical trials to commence.

 

Clinical trials involve the administration of the drug candidate to human subjects under the supervision of qualified investigators in accordance with GCP, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from an Institutional Review Board (“IRB”) for each medical center proposing to conduct the clinical trial before the trials may be initiated, and the IRB must monitor the study until completed. Clinical trials are subject to central registration and results reporting requirements, such as on www.clinicaltrials.gov.

 

The clinical investigation of a drug is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined. The three phases of an investigation are as follows:

·

Phase 1. Phase 1 includes the initial introduction of the product candidate into humans. Phase 1 clinical trials are typically closely monitored and may be conducted in patients with the target disease or condition or in healthy volunteers. These studies are designed to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of product candidate in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness. During Phase 1 clinical trials, sufficient information about the

15


 

product candidate’s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials. The total number of participants included in Phase 1 clinical trials varies, but is generally in the range of 20 to 80.

·

Phase 2. Phase 2 includes controlled clinical trials conducted to preliminarily or further evaluate the effectiveness of the product candidate for a particular indication(s) in patients with the disease or condition under study, to determine dosage tolerance and optimal dosage, and to identify possible adverse side effects and safety risks associated with the drug. Phase 2 clinical trials are typically well-controlled, closely monitored, and conducted in a limited patient population, usually involving no more than several hundred participants.

·

Phase 3. Phase 3 clinical trials are generally controlled clinical trials conducted in an expanded patient population generally at geographically dispersed clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the investigational drug product and to provide an adequate basis for product approval. Phase 3 clinical trials usually involve several hundred to several thousand participants.

 

A pivotal study is a clinical study which adequately meets regulatory agency requirements for the evaluation of a drug candidate’s efficacy and safety such that it can be used to justify the approval of the product. Generally, pivotal studies are also Phase 3 studies but may be Phase 2 studies if the trial design provides a well-controlled and reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need.

 

The FDA, an IRB or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as an Independent Data Monitoring Committee (“IDMC”). The IDMC receives special access to un-blinded data during the clinical trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.

 

Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed product development information is submitted to the FDA in the form of an NDA or sNDA requesting approval to market the product for one or more indications.

 

The application includes all relevant data available from pertinent non-clinical and clinical trials, including negative or ambiguous results, as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the product candidate to the satisfaction of the FDA.

 

Once the marketing application submission has been accepted for filing, the FDA’s goal is to review applications within 10 months of acceptance for filing or, if the application relates to treatment of a serious or life-threatening condition and is granted fast track priority review designation, six months from acceptance for filing. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it typically follows such recommendations.

 

After the FDA evaluates the NDA or sNDA and conducts inspections of clinical research facilities and/or manufacturing facilities where the drug product and/or its API will be produced, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application is not ready for approval. A Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials, non-clinical studies or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the application does not satisfy the criteria for approval. The FDA could also approve the NDA with a Risk Evaluation and Mitigation Strategies plan to mitigate risks, which could include

16


 

medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include Phase IV clinical trials and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization. Regulatory approval of oncology products often requires that patients in clinical trials be followed for long periods to determine the overall survival benefit of the drug.

 

Products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including recordkeeping requirements and reporting of adverse experiences with the drug. Adverse event experience with the product must be reported to the FDA in a timely fashion and pharmacovigilance programs to proactively look for these adverse events are mandated by the FDA. Newly discovered or developed safety or effectiveness data may require changes to a product’s approved labeling, including the addition of new warnings and contraindications and also may require the implementation of other risk management measures.

 

Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Following such inspections, the FDA may issue notices on Form FDA 483 and Warning Letters that could cause us to modify certain activities. A Form FDA 483 notice, if issued at the conclusion of an FDA inspection, can list conditions the FDA investigators believe may have violated cGMP or other FDA regulations or guidance. Failure to adequately and promptly correct the observations(s) can result in further regulatory enforcement action. In addition to Form FDA 483 notices and Warning Letters, failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.

 

Government Regulation Outside of the United States

 

In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary greatly from country to country, and the time may be longer or shorter than that required for FDA approval.

 

Regardless of whether we hold FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In Europe, for example, a clinical trial application, (“CTA”) must be submitted to each country’s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country’s requirements, clinical trial development may proceed.

 

Medicines can be authorized in the European Union by using either the centralized authorization procedure or national authorization procedures. Under the centralized procedure, marketing authorization applications are submitted to the EMA whose CHMP reviews the application and issues an opinion on it. The opinion is considered by the European Commission (“EC”) which is responsible for deciding applications. If the application is approved, the EC grants a single marketing authorization that is valid for all European Union member states as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human medicines that contain a new active substance indicated for the treatment of certain diseases, including cancer. 

 

The national authorization procedures, the decentralized and mutual recognition procedures, are available for products for which the centralized procedure is not compulsory. Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one European Union country of medicinal products that have not yet

17


 

been authorized in any European Union country and that do not fall within the mandatory scope of the centralized procedure. Under the mutual recognition procedure, a medicine is first authorized in one European Union Member State, in accordance with the national procedures of that country. Following this, further marketing authorizations can be sought from other European Union countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization

 

Available Special Regulatory Procedures

 

Formal Meetings

 

We are encouraged to engage and seek guidance from health authorities relating to the development and review of investigational drugs, as well as marketing applications. In the United States, there are different types of official meetings that may occur between us and the FDA. Each meeting type is subject to different procedures. Conclusions and agreements from each of these meetings are captured in the official final meeting minutes issued by the FDA.

 

The EMA also provides the opportunity for dialogue with us. This is usually done in the form of Scientific Advice, which is given by the Scientific Advice Working Party of CHMP. A fee is incurred with each Scientific Advice meeting.

 

Advice from either the FDA or EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies and pharmacovigilance plans and risk-management programs. Such advice is not legally binding on the sponsor. To obtain binding commitments from the FDA in the United States, Special Protocol Assessment (“SPA”) procedures are available. A SPA is an evaluation by the FDA of a protocol with the goal of reaching an agreement with the sponsor that the protocol design, clinical endpoints and statistical analyses are acceptable to support regulatory approval of the product candidate with respect to effectiveness in the indication studied. The FDA’s agreement to a SPA is binding upon the FDA except in limited circumstances, such as if the FDA identifies a substantial scientific issue essential to determining the safety or effectiveness of the product after clinical studies begin, or if the study sponsor fails to follow the protocol that was agreed upon with the FDA. There is no guarantee that a study will ultimately be adequate to support an approval even if the study is subject to a SPA.

 

Orphan Drug Designation

 

The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making the drug for this type of disease or condition will be recovered from sales in the United States. In the European Union, the EMA’s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in the European Union Community. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product.

 

In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity.

 

In the European Union, orphan drug designation also entitles a party to financial incentives such as reduction of fees or fee waivers and 10 years of market exclusivity is granted following drug or biological product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.

 

Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

18


 

 

Pediatric Development

 

In the United States, the FDCA provides for an additional six months of marketing exclusivity for a drug if reports are filed of investigations studying the use of the drug product in a pediatric population in response to a written request from the FDA. Separate from this potential exclusivity benefit, NDAs must contain data (or a proposal for post-marketing activity) to assess the safety and effectiveness of an investigational drug product for the claimed indications in all relevant pediatric populations in order to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers if certain criteria are met. Discussions about pediatric development plans can be discussed with the FDA at any time, but usually occur any time between the end-of-Phase II meeting and submission of the NDA.

 

For the EMA, a Pediatric Investigation Plan, and/or a request for waiver or deferral, is required for submission prior to submitting a marketing authorization application.

 

Breakthrough Therapy Designation in the United States

 

The U.S. Congress created the Breakthrough Therapy designation program as a result of the passage of the Food and Drug Administration Safety and Innovation Act of 2012. FDA may grant Breakthrough Therapy status to a drug intended for the treatment of a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The Breakthrough Therapy designation, which may be requested by a sponsor when filing or amending an IND, is intended to facilitate and expedite the development and FDA review of a product candidate. Specifically, the Breakthrough Therapy designation may entitle the sponsor to more frequent meetings with the FDA during drug development, intensive guidance on clinical trial design and expedited FDA review by a cross-disciplinary team comprised of senior managers. The designation does not guarantee a faster development or review time as compared to other drugs, however, nor does it assure that the drug will obtain ultimate marketing approval by the FDA. Once granted, the FDA may withdraw this designation at any time.

 

Expedited Review and Approval in the United States

 

The FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify the process for reviewing drugs and biologics, and/or provide for the approval of a drug or biologic on the basis of a surrogate endpoint. Even if a drug qualifies for one or more of these programs, the FDA may later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will be shortened. Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, based on results of the Phase 3 clinical trial(s) submitted in an NDA, upon the request of an applicant, the FDA may grant the NDA a priority review designation, which sets the target date for FDA action on the application at six months from the 60-day filing date, if the drug is anew molecular entity, rather than to the standard FDA review period of 10 months. Priority review is granted where preliminary estimates indicate that a product, if approved, has the potential to provide a safe and effective therapy where no satisfactory alternative therapy exists, or a significant improvement compared to marketed products is possible. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.

 

Accelerated approval provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit and is better than available therapy. A surrogate endpoint is a laboratory measurement or physical sign used as an indirect or substitute measurement representing a clinically meaningful outcome. The FDA will also take into account the severity, rarity or prevalence of the condition. As a condition of approval for drugs granted accelerated approval, one or more post-marketing confirmatory studies are required to confirm as predicted by the surrogate marker trial an effect on clinical benefit, which is defined as having a positive effect on how a patient feels, functions or survives.

 

19


 

Accelerated Review in the European Union

 

Under the Centralized Procedure in the European Union, the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP). Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, defined by three cumulative criteria: the seriousness of the disease (e.g. heavy disabling or life-threatening diseases) to be treated; the absence or insufficiency of an appropriate alternative therapeutic approach; and anticipation of high therapeutic benefit. In this circumstance, EMA ensures that the opinion of the CHMP is given within 150 days of submission of the MAA, excluding clock stops.

 

Pharmaceutical Coverage, Pricing and Reimbursement

 

Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale depend in part on the availability of reimbursement from third-party payors. Third-party payors include government health administrative authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost effectiveness of our products, in addition to the costs required to obtain FDA approvals. The development of a product dossier and a Budget Impact Model may be helpful in assisting the payors in evaluating cost effectiveness. Our approved products may not be considered medically necessary or cost-effective. A payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be established. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

 

There have been a number of federal and state proposals in recent years regarding the pricing of pharmaceutical products, government control and other changes to the healthcare system of the United States. The U.S. government enacted legislation providing a partial prescription drug benefit for Medicare beneficiaries. Government payment for some of the costs of prescription drugs may increase demand for any products for which we receive marketing approval; however, to obtain payments under this program, we are required to sell products to Medicare recipients through prescription drug plans operating pursuant to this legislation. These plans will likely negotiate discounted prices for our products. Additionally, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the “Affordable Care Act”) was enacted in 2010 with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. Among other cost containment measures, the Affordable Care Act established:

·

An annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents;

·

A Medicare Part D coverage gap discount program, in which pharmaceutical manufacturers who wish to have their drugs covered under Part D must offer discounts to eligible beneficiaries during their coverage gap period (the “donut hole”); and

·

A formula that increases the rebates a manufacturer must pay under the Medicaid Drug Rebate Program.

 

Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act. We expect that the current presidential administration and U.S. Congress will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the Affordable Care Act. Most recently, the Tax Cuts and Jobs Act was enacted, which, among other things, removes penalties for not complying with Affordable Care Act’s individual mandate to carry health insurance. There is still uncertainty with respect to the impact President Trump’s administration and the U.S. Congress may have, if any, and any changes will likely take time to unfold, and could have an impact on coverage and reimbursement for healthcare items and services covered by plans that were authorized by the Affordable Care Act.

 

20


 

In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2025 unless additional Congressional action is taken. Additionally, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that federal, state and local governments in the United States will continue to consider legislation to limit the growth of healthcare costs, including the cost of prescription drugs. Future legislation could limit payments for pharmaceuticals such as our products.

 

Moreover, payment methodologies, including payment for companion diagnostics, have been subject to changes due to healthcare legislation and regulatory initiatives. For example, CMS began bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting. Additionally, on April 1, 2014, the Protecting Access to Medicare Act of 2014, or PAMA, was signed into law, which, among other things, significantly alters the current payment methodology under the Clinical Laboratory Fee Schedule. Beginning on January 1, 2018, the Medicare payment rate for each clinical diagnostic lab test, with some exceptions, is equal to the weighted median private payer payment for the test, as calculated using data collected by applicable laboratories during the data collection period and reported to CMS during a specified data reporting period. Also under PAMA, CMS is required to adopt temporary billing codes to identify new clinical diagnostic laboratory tests and advanced diagnostic laboratory tests that do not already have unique diagnostic codes, and that have been cleared or approved by the FDA.

 

Different pricing and reimbursement schemes exist in other countries. In the European Community, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.

 

The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on reducing the rate of healthcare spending in the United States has increased, and we expect will continue to increase the pressure on pharmaceutical pricing. There has been particular and increasing legislative interest in the United States with respect to drug pricing practices, particularly with respect to drugs that have been subject to relatively large price increases over relatively short time periods. Certain independent charitable foundations operate programs that provide grants to defray medical expenses (including cost-sharing obligations for drug treatments and health insurance premiums) for patients who meet certain financial need criteria and suffer from specific chronic illnesses or rare disorders. There has been recent enforcement interest regarding donations by pharmaceutical manufacturers to such foundations on the bases that such donations were used in part to guide patients to those donors’ products or that the donors obtained data on how the donations were used, including how often donations correlate to the frequency of referrals to donors’ products. There have been several U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.

21


 

 

Advertising and Promotion

 

The FDA and other U.S. federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, the FDCA and the FDA’s implementing regulations and standards. The FDA’s review of marketing and promotional activities encompasses, but is not limited to, direct-to-consumer advertising, healthcare provider-directed advertising and promotion, sales representative communications to healthcare professionals, communications regarding unapproved or “off-label” uses, industry-sponsored scientific and educational activities and promotional activities involving the internet. A product cannot be commercially promoted before it is approved. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA. FDA regulations impose stringent restrictions on manufacturers’ communications regarding off-label uses. Failure to comply with applicable FDA requirements and restrictions regarding unapproved uses of a drug or for other violations of its advertising and labeling laws and regulations, may result in adverse publicity and enforcement action by the FDA, the Department of Justice or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. A range of penalties are possible that could have significant commercial consequences, including product seizures, injunctions, civil and/or criminal fines and agreements that materially restrict the manner in which a company promotes or distributes its products or regulatory letters, which may require corrective advertising or other corrective communications to healthcare professionals.

 

Other Healthcare Laws and Compliance Requirements

 

We are subject to various laws targeting fraud and abuse in the healthcare industry, including anti-kickback laws and false claims laws. For example, in the United States, there are federal and state anti-kickback laws that prohibit the payment or receipt of kickbacks, bribes or other remuneration intended to induce the purchase or recommendation of healthcare products and services or reward past purchases or recommendations. Violations of these laws can lead to civil and criminal penalties, including fines, imprisonment and exclusion from participation in federal healthcare programs.

 

The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The reach of the Anti-Kickback Statute was broadened by the Affordable Care Act, which, among other things, amended the intent requirement of the federal Anti-Kickback Statute and the applicable criminal healthcare fraud statutes contained within 42 U.S.C. § 1320a-7b. Pursuant to the statutory amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs.

 

The federal False Claims Act imposes liability on any person who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal program, including federal healthcare programs. The “qui tam” provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties.

 

In addition, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary’s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to $15,270 for each wrongful act. Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-kickback Statute and civil False Claims Act, which can impose additional penalties associated with the wrongful act. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable

22


 

collection efforts. The Office of Inspector General of the Department of Health and Human Services emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, the routine waivers of copayments and deductibles offered to patients covered by commercial payers may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. To the extent our patient assistance programs are found to be inconsistent with applicable laws, we may be required to restructure or discontinue such programs, or be subject to other significant penalties.

 

In addition to the laws described above, the Affordable Care Act also imposed new reporting requirements on drug manufacturers for payments made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $165,786 per year (or up to an aggregate of $1.105 million per year for “knowing failures”), for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Applicable drug manufacturers are required to collect data for each calendar year and submit reports to CMS by March 31st of each subsequent calendar year. In addition, there are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us.

 

For those marketed products which are covered in the United States by the Medicaid programs, we have various obligations, including government price reporting and rebate requirements, which generally require products be offered at substantial rebates/discounts to Medicaid and certain purchasers (including “covered entities” purchasing under the 340B Drug Discount Program). We are also required to discount such products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply. These programs require submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing such calculations is not always clear. Compliance with such requirements can require significant investment in personnel, systems and resources, but failure to properly calculate our prices, or offer required discounts or rebates could subject us to substantial penalties. One component of the rebate and discount calculations under the Medicaid and 340B programs, respectively, is the “additional rebate”, a complex calculation which is based, in part, on the rate at which a branded drug price increases over time more than the rate of inflation (based on the CPI-U). This comparison is based on the baseline pricing data for the first full quarter of sales associated with a branded drug’s NDA, and baseline data cannot generally be reset, even on transfer of the NDA to another manufacturer. This “additional rebate” calculation can, in some cases where price increase have been relatively high versus the first quarter of sales of the NDA, result in Medicaid rebates up to 100% of a drug’s “average manufacturer price” and 340B prices of one penny. Subject to the control of Directive 89/105/EEC, pricing and reimbursement in the EU/EEA (European Economic Area) is governed by national rules and policy and may vary from Member State to Member State.

 

Also, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) created several new federal crimes, including health care fraud and false statements relating to health care matters. Most healthcare providers who are expected to prescribe our products and from whom we obtain patient health information are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the EU Data Privacy Directive (95/46/EC), which will be replaced on May 28, 2018 by the more restrictive General Data Protection Regulation (Regulation (EU) 2016/679) and the Swiss Federal Act on Data Protection, regulate the processing of personal data within the European Union and between countries in the European Union and countries outside of the European Union, including the U.S. Failure to provide adequate privacy protections and maintain compliance with the new EU-U.S. Privacy Shield framework, which will replace the previous safe harbor mechanisms, could jeopardize business transactions across borders and result in significant penalties, These laws could create liability for us or increase our cost of doing business.

 

23


 

Regulation of Diagnostic Tests

 

In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, non-clinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Diagnostic tests are classified as medical devices under the FDCA. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA approval. Because the diagnostic tests being developed by our third-party collaborators are of substantial importance in preventing impairment of human health, they are subject to the PMA approval process.

 

PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical, non-clinical, clinical and manufacturing data, to demonstrate to the FDA’s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA application typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the Quality System Regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. FDA review of an initial PMA application is required by statute to take between six to ten months, although the process typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA’s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing.

 

We and our third-party collaborators who are developing companion diagnostics work cooperatively to generate the data required for submission with a PMA application, and remain in close contact with the Center for Devices and Radiological Health (“CDRH”) at the FDA to ensure that any changes in requirements are incorporated into the development plans. Meetings with the FDA with regard to our drug product candidates, as well as companion diagnostic product candidates, typically include representatives from the Center for Drug Evaluation and Research and CDRH when appropriate to ensure that the NDA and PMA submissions are coordinated to enable FDA to conduct a parallel review of both submissions. The FDA has issued guidance documents addressing the development and approval process for “In Vitro Companion Diagnostic Devices.” According to these guidance documents, for novel therapeutic products such as our product candidates, the PMA for a companion diagnostic device should generally be developed and approved or cleared contemporaneously with the therapeutic.

 

In the EEA, in vitro medical devices are required to conform to the essential requirements of the E.U. Directive on in vitro diagnostic medical devices (Directive No 98/79/EC, as amended). To demonstrate compliance with the essential requirements, the manufacturer must undergo a conformity assessment procedure. The conformity assessment varies according to the type of medical device and its classification. For low-risk devices, the conformity assessment can be carried out internally, but for higher risk devices it requires the intervention of an accredited EEA Notified Body. If successful, the conformity assessment concludes with the drawing up by the manufacturer of an EC Declaration of Conformity entitling the manufacturer to affix the CE mark to its products and to sell them throughout the EEA. The data generated for the U.S. registration will be sufficient to satisfy the regulatory requirements for the European Union and other countries.

 

Patents and Proprietary Rights

 

The proprietary nature of, and protection for, our product candidates, processes and know-how are important to our business. Our success depends in part on our ability to protect the proprietary nature of our product candidates, technology, and know-how, to operate without infringing on the proprietary rights of others, and to prevent others from infringing our proprietary rights. We seek patent protection in the United States and internationally for our product

24


 

candidates and other technology. Our policy is to patent or in-license the technology, inventions and improvements that we consider important to the development of our business. We also rely on trade secrets, know-how and continuing innovation to develop and maintain our competitive position. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology.

 

In June 2011, we obtained an exclusive, worldwide license from Pfizer to develop and commercialize rucaparib. U.S. Patent 6,495,541, and its equivalent counterparts issued in dozens of countries, directed to the rucaparib composition of matter, expire in 2020 and are potentially eligible for up to five years patent term extension in various jurisdictions. We believe that patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the “Hatch-Waxman Act”) could be available to extend our patent exclusivity for rucaparib to the fourth quarter of 2023 in the United States. In Europe, we believe that patent term extension under a supplementary protection certificate could be available for an additional five years to at least 2025. In April 2012, we obtained an exclusive license from AstraZeneca under a family of patents and patent applications which will permit the development and commercialization of rucaparib for certain methods of treating patients with PARP inhibitors. Additionally, other patents and patent applications are directed to methods of making, methods of using, dosing regimens, various salt and polymorphic forms and formulations and have expiration dates ranging from 2020 through potentially 2035, including the camsylate salt/polymorph patent family licensed from Pfizer, which expires in 2031 and a patent application directed to high dosage strength rucaparib tablets that, if issued, will expire in 2035. As of February 27, 2018, the rucaparib camsylate salt patent was issued in 47 countries to date (including US and Europe), with applications pending in 9 countries, and the rucaparib composition of matter patent was issued in 48 countries. We are aware of a number of challenges of salt and polymorph patents. Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. European oppositions are commonly filed against patents related to pharmaceutical products. The grounds of opposition related to Rubraca were lack of novelty and lack of inventive step. The novelty and inventive step challenges are based on prior art references (or closely related disclosures) that were previously raised by the European patent examiner during prosecution of the application.  The claims of the granted patent were found to be patentable over this prior art. While the ultimate results of patent challenges can be difficult to predict, we believe a number of factors, including a constellation of unexpected properties, support the novelty and non-obviousness of our rucaparib camsylate salt/polymorph composition of matter patent. Based on these facts, we believe, a successful challenge of that patent would be difficult.

 

We obtained rights to lucitanib by acquiring EOS in November 2013, along with its license agreements with Advenchen and Servier. In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. Composition of matter and method of use patent protection for lucitanib and a group of structurally-related compounds is issued in the U.S., Europe and Japan and is issued or pending in other jurisdictions. In the U.S., the composition of matter patent will expire in 2030, and in other jurisdictions, it expires in 2028. We believe that patent term extension could be available to extend our composition of matter patent up to five years beyond the scheduled expiration under the Hatch-Waxman Act. Additionally, patents or patent applications directed to methods of manufacturing lucitanib are issued or pending in the United States, Europe, Japan, and China.

 

In May 2010, we acquired an exclusive, worldwide license to rociletinib from Celgene. U.S. Patent 8,975,927, directed to rociletinib composition of matter, expires in 2032 and U.S. Patent 9,108,927, directed to rociletinib HBr salts and polymorphs, expires in 2033. Other patent applications are pending that claim rociletinib generically that, if issued, would have expiration dates in 2029. In January 2013, we acquired from Gatekeeper Pharmaceuticals, Inc. an exclusive worldwide sub-license to a Dana Farber patent family having claims directed to wild-type sparing irreversible EGFR inhibitors, such as rociletinib. We or our licensors have filed additional patent applications related to rociletinib methods of use, metabolites, combinations, diagnostic methods and dosing regimens.

 

In addition, we intend to seek patent protection whenever available for any products or product candidates and related technology we acquire in the future.

 

The patent positions of pharmaceutical firms like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent

25


 

is issued. Consequently, we do not know whether any of the product candidates we acquire or license will gain patent protection or, if any patents are issued, whether they will provide significant proprietary protection or will be challenged, circumvented or invalidated. Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, until that time we cannot be certain that we were the first to file any patent application related to our product candidates. Moreover, we may have to participate in interference proceedings declared by the United States Patent and Trademark Office (“U.S. PTO”) to determine priority of invention or in opposition or other third-party proceedings in the U.S. or a foreign patent office, either of which could result in substantial cost to us, even if the eventual outcome is favorable to us. There can be no assurance that the patents, if issued, would be held valid by a court of competent jurisdiction. An adverse outcome in a third-party patent dispute could subject us to significant liabilities to third parties, require disputed rights to be licensed from third parties or require us to cease using specific compounds or technology.

 

The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, a patent’s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. PTO in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent.

 

The patent term of a patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other non-U.S. jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical products receive FDA approval, we expect to apply for patent term extensions on patents covering those products.

 

To protect our rights to any of our issued patents and proprietary information, we may need to litigate against infringing third parties, or avail ourselves of the courts or participate in hearings to determine the scope and validity of those patents or other proprietary rights. These types of proceedings are often costly and could be very time-consuming to us, and we cannot assure you that the deciding authorities will rule in our favor. An unfavorable decision could allow third parties to use our technology without being required to pay us licensing fees or may compel us to license needed technologies to a third-party. Such a decision could even result in the invalidation or a limitation in the scope of our patents or forfeiture of the rights associated with our patents or pending patent applications. To the extent prudent, we intend to bring litigation against third parties that we believe are infringing one or more of our patents.

 

In addition, we have sought and intend to continue seeking orphan drug status whenever it is available. If a product which has an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, meaning that the applicable regulatory authority may not approve any other applications to market the same drug for the same indication, except in certain very limited circumstances, for a period of seven years in the United States and ten years in the European Union. Orphan drug designation does not prevent competitors from developing or marketing different drugs for an indication.

 

We also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. However, we believe that the substantial costs and resources required to develop technological innovations will help us to protect the competitive advantage of our products.

 

It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual

26


 

shall be our exclusive property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.

 

Manufacturing

 

We currently contract with third parties for the manufacture of our product candidates for non-clinical studies and clinical trials and intend to do so in the future. We currently have long-term agreements with third-party contract manufacturing organizations (“CMOs”) for the production of the active ingredient and final product for Rubraca. We do not own or operate manufacturing facilities for the production of clinical quantities of our product candidates. We currently have no plans to build our own clinical or commercial scale manufacturing capabilities. To meet our projected needs for commercial manufacturing, we are working with our current third party suppliers to increase their scale of production and we are in the process of evaluating additional second source suppliers. Although we rely on contract manufacturers, we have personnel with extensive manufacturing experience to oversee the relationships with our contract manufacturers.

 

We have developed the process for manufacturing Rubraca’s active pharmaceutical ingredient (“API”) to a degree sufficient to meet clinical demands and, as production capacity is increased as described below under “Lonza Agreement,” projected commercial requirements. Manufacturing of Rubraca API is being performed at a single CMO. The Rubraca drug product formulation and manufacturing process to produce that formulation have been developed to a degree sufficient to meet clinical demands and projected commercial requirements. A single third-party CMO capable of both formulation development and drug product manufacturing is currently producing Rubraca drug product. Our operating plan for the next 12 months includes a significant investment in inventory to meet the projected commercial requirements for Rubraca.

 

To date, our third-party manufacturers have met our manufacturing requirements. We expect third-party manufacturers to be capable of providing sufficient quantities of our product candidates to meet anticipated full scale commercial demands.

 

Lonza Agreement

 

On October 3, 2016, we entered into an agreement with Lonza Ltd (“Lonza”) for the long-term manufacture and supply of the API for rucaparib.

 

Under this agreement, Lonza will be a non-exclusive manufacturer of the rucaparib API during the 10 year term of the agreement. Lonza will construct, in an existing Lonza facility, a production train that will be exclusively dedicated to the manufacture of the rucaparib API. The dedicated production train will provide manufacturing capacity to meet our currently anticipated needs for commercial supply of rucaparib API. We are obligated to make scheduled capital program fee payments towards capital equipment and other costs associated with the construction of the dedicated production train and, once the facility is operational, to pay a fixed facility fee each quarter for the duration of the term of the agreement. The dedicated production train is estimated to be completed during the fourth quarter of 2018 at which time Lonza will begin producing API under this agreement.

 

Lonza will manufacture and store an advanced intermediate to be used in the subsequent production of the rucaparib API. We will pay fixed fees on a per kilogram basis for quantities of the advanced intermediate and the rucaparib API ordered by us, subject to certain adjustments. Until the dedicated facility is completed and operationally qualified, Lonza will manufacture the rucaparib API in existing Lonza facilities at pricing established in the agreement.

 

Either party may terminate the agreement due to a material breach of the agreement by the other party, subject to prior written notice and a cure period. We may terminate the agreement, subject to 90 days’ prior written notice, in the event rucaparib is withdrawn from the market for certain reasons. In the event of such a termination by us, or termination by Lonza due to material breach by us, we are obligated to compensate Lonza for any services rendered, or for which costs have been incurred by Lonza in anticipation of services to be provided to us, and to pay to Lonza the remaining amount of any capital program fees and quarterly fixed facility fees for the remainder of the term of the agreement. In the event we terminate the agreement due to material breach by Lonza, Lonza is obligated to repay all or a portion of the capital program fees previously paid by us.

 

27


 

The active pharmaceutical ingredient for lucitanib is currently being produced by a third-party supplier. To date, the current production process has been sufficient to satisfy immediate clinical demands. We may undertake additional development work to further optimize the active pharmaceutical ingredient manufacturing process. The finished drug product for lucitanib is currently being manufactured at a CMO. The current product and process are sufficiently developed to meet immediate clinical demands. Additional scale-up work and/or additional production capacity will be necessary to support larger clinical development or commercialization requirements.

 

The active pharmaceutical ingredient for rociletinib is currently being manufactured by one CMO. The current drug substance production process has already been sufficiently developed to satisfy immediate clinical demands. We have engaged a single CMO capable of both formulation development and drug product manufacturing. The current drug product production process has already been sufficiently developed to satisfy immediate clinical demands. Additional scale-up work and/or additional production capacity may be necessary to support larger clinical development or commercialization requirements.

 

Commercial Operations

 

Our commercial organization in the U.S. is in place and supporting the commercial sale of Rubraca. We believe the U.S. oncology market for Rubraca in both of its approved indications is addressable with a targeted sales and marketing organization, with capabilities that include the management of key accounts such as managed care organizations, group-purchasing organizations, oncology group networks and government accounts. We sell Rubraca through a limited distribution network consisting of select number of specialty pharmacies and distributors. Healthcare providers prescribe Rubraca to patients and the specialty pharmacies and distributors dispense Rubraca directly to patients. We intend to continue promoting Rubraca ourselves in the U.S. for its current indications and any additional indications we may obtain in the future. We retain the rights to Rubraca in the rest of the world. The MAA submission with the EMA for an ovarian cancer treatment indication is currently under review. If approved in the EU, we intend to commercialize rucaparib on our own and we are building our commercial and medical affairs infrastructure in Europe. The leadership of those teams is in place, and we will hire field sales personnel as pricing and reimbursement decisions are made and approvals are received.

 

Customers

 

We are currently approved to sell Rubraca in the U.S. market. We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently sell our products to patients and health care providers, at which time we recognize the associated revenue.

 

Our customers, which distribute our product, consist of three specialty distributors and four specialty pharmacy providers. Furthermore, we do not believe the loss of one of these customers would significantly impact the ability to distribute our product as we expect that sales volume would be absorbed evenly by the remaining customers.

 

Employees

 

As of February 16, 2018, we employed 360 full-time employees. None of our employees is represented by labor unions, and a very small number of international employees are covered by collective bargaining agreements. We consider our relationship with our employees to be good.

 

As part of the Compensation Committee’s annual review of overall employee compensation, effective March 1, 2018, in order to align their base salary compensation with the 50th percentile of similarly situated employees at the Company’s peer group companies, the Compensation Committee approved for Mr. Mahaffy a base salary increase of 7.1% to $696,300, for Mr. Muehl a base salary increase of 15.7% to $433,800, for Ms. Ivers-Read a base salary increase of 3.0% to $450,246, for Dr. Rolfe a base salary increase of 4.1% to $489,300 and for Mr. Hooks a base salary increase of 5.3% to $421,300. Also, the Compensation Committee approved new bonus targets (as a percentage of their new annual base salaries) for each of these executive officers as follows: for Mr. Mahaffy, 70%; for Ms. Ivers-Read and Dr. Rolfe, 50%; and for Messrs. Muehl and Hooks, 45%.  In addition, as part of the annual grants of equity awards to employees of the Company, the Compensation Committee approved the following equity awards to such executive officers to be made on March 1, 2018: Mr. Mahaffy, options to purchase 120,000 shares of the Company’s common stock; Mr. Muehl, options to purchase 9,000 shares of the Company’s common stock and 9,000 restricted stock units (“RSUs”); Ms. Ivers-Read, options to purchase 11,000 shares of the Company’s common stock and 11,000 restricted

28


 

stock units; Dr. Rolfe, options to purchase 11,000 shares of the Company’s common stock and 11,000 restricted stock units; and Mr. Hooks, options to purchase 9,000 shares of the Company’s common stock and 9,000 restricted stock units.

 

Research and Development

 

We invested $142.5 million, $251.1 million and $269.3 million in research and development during the years ended December 31, 2017, 2016 and 2015, respectively.

 

About Clovis

 

We were incorporated under the laws of the State of Delaware in April 2009 and completed our initial public offering of our common stock in November 2011. Our common stock is listed on the NASDAQ Global Select Market under the symbol “CLVS.” Our principal executive offices are located at 5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301, and our telephone number is (303) 625-5000. We maintain additional offices in San Francisco, California, Cambridge, UK, and Milan, Italy. Our website address is www.clovisoncology.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this report.

 

Available Information

 

As a public company, we file reports and proxy statements with the Securities and Exchange Commission (“SEC”). These filings include our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and proxy statements on Schedule 14A, as well as any amendments to those reports and proxy statements, and are available free of charge through our website as soon as reasonably practicable after we file them with, or furnish them to, the SEC. Once at www.clovisoncology.com, go to Investors & News/SEC Filings to locate copies of such reports. You may also read and copy materials that we file with SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains a website at www.sec.gov that contains reports, proxy statements and other information regarding us and other issuers that file electronically with the SEC.

 

ITEM  1A.    RISK FACTORS

 

Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors, in its entirety, in addition to other information contained in or incorporated by reference into this Annual Report on Form 10-K and our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

 

Risks Related to Our Financial Position and Capital Requirements

 

We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We have generated only modest historical revenues, which makes it difficult to assess our future viability.

 

We are a biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We have focused primarily on in-licensing and developing our product candidates. We are not profitable and have incurred losses in each year since our inception in April 2009. We have only a limited operating history upon which you can evaluate our business and prospects. There are many risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. Three of our product candidates, CO-101, CO-1686 (rociletinib) and CO-3810 (lucitanib), encountered development and/or regulatory setbacks after initial promising data, leading us to discontinue enrollment in then-ongoing clinical trials. We have received regulatory approval to market Rubraca in the U.S., but we do not yet know whether it will be approved in other jurisdictions or whether it will achieve market acceptance and be commercially successful.  We have generated only modest revenues from product sales to date. We continue to incur

29


 

significant research and development and other expenses related to our ongoing operations. For the years ended December 31, 2017, 2016 and 2015, we had net losses of $346.4 million, $349.1 million and $352.9 million, respectively. As of December 31, 2017, we had an accumulated deficit of $1,447.4 million. We expect to continue to incur losses for the foreseeable future. As such, we are subject to all of the risks incident to the development of new biopharmaceutical products and related companion diagnostics, and we may encounter unforeseen expenses, difficulties, complications, regulatory scrutiny, delays and other unknown factors that may adversely affect our business. If any of our product candidates fail in clinical trials or do not gain regulatory approval, or if Rubraca or any of our product candidates, if approved, fail to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital.

 

We will require substantial additional funding which may not be available to us on acceptable terms, or at all. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates or continue our development programs.

 

Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to advance the clinical development of our product candidates and launch and commercialize any product candidates for which we receive regulatory approval, including building our own commercial organizations to address certain markets.

 

Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months. We do not have any material committed external source of funds or other support for our development efforts.

 

Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do in sufficient amounts, we expect to finance future cash needs through a combination of public or private equity offerings, collaborations, strategic alliances and other similar licensing arrangements. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates, or our plans for acquisition or in-license of new product candidates. We may also seek collaborators for one or more of our current or future product candidates on terms that are less favorable than might otherwise be available. Any of these events could significantly harm our business, financial condition and prospects.

 

Servicing our long-term debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.

 

In September 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “Notes”), resulting in net proceeds to the Company of $278.3 million after deducting offering expenses. The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. Interest is payable on the Notes semi-annually, and the Notes mature on September 15, 2021, unless redeemed, repurchased or converted prior to that date. In addition, if, as defined by the terms of the indenture, a fundamental change occurs, holders of the Notes may require us to repurchase for cash all or any portion of their Notes at a purchase price equal to 100% of the principal amount of the Notes to be repurchased plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. As of December 31, 2017, all $287.5 million principal amount of the Notes remained outstanding.

 

Our ability to make scheduled payments of interest and principal on the Notes, or to pay the repurchase price for the Notes on a fundamental change, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. We may not have sufficient cash in the future to service our debt. If we are unable to generate such cash flow or secure additional sources of funding, we may be required to adopt one or more alternatives, such as restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.

 

30


 

We and certain of our officers and directors have been named as defendants in several lawsuits that could result in substantial costs and divert management’s attention.

 

We and certain of our officers have been named as defendants in a number of lawsuits that generally allege that we and certain of our officers violated federal securities laws by making allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib.  Some of these lawsuits have been settled while others remain outstanding and others may still be brought.  See “Part I, Item 3-Legal Proceedings” in this report.

 

We intend to engage in a vigorous defense of these lawsuits; however, we are unable to predict the outcome of these matters at this time. If we are not successful in our defense of these litigation matters, we could be forced to make significant payments to, or enter into other settlements with, our security holders and their lawyers (and in certain circumstances reimburse costs and expenses incurred by the underwriters), and such payments or settlement arrangements could have a material adverse effect on our business, operating results and financial condition. For example, we could suffer a significant adverse impact on our reputation and divert management’s attention and resources from other priorities, any of which could have a material adverse effect on our business. In addition, any of these matters could require payments that are not covered by, or exceed the limits of, our available directors’ and officers’ liability insurance, which could have a material adverse effect on our operating results or financial condition.  We will not receive any further contributions from our insurance carriers for any amounts (including damages, settlement costs or legal fees) relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib.

 

Additional lawsuits with similar claims may be filed by other parties against us and our officers and directors. Even if such claims are not successful, these lawsuits or other future similar actions, or other regulatory inquiries or investigations, may result in substantial costs and have a significant adverse impact on our reputation and divert management’s attention and resources, which could have a material adverse effect on our business, operating results or financial condition.

 

The recently passed comprehensive tax reform bill could adversely affect our business and financial condition.

 

On December 22, 2017, President Trump signed into law new legislation that significantly revises the Internal Revenue Code of 1986, as amended. The newly enacted federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as “orphan drugs”). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain, and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the newly enacted federal tax law. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse. Investors should consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.

 

Risks Related to Our Business and Industry

 

We are highly dependent on the commercial success of Rubraca in the U.S.; Rubraca may not achieve market acceptance and may not be commercially successful and we may not attain profitability and positive cash flow from operations.

 

On December 19, 2016, the FDA granted approval for Rubraca as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA approved companion diagnostic for Rubraca.  Our MAA submitted to the EMA for an ovarian cancer treatment indication is currently under review by the CHMP, and in February 2018, the CHMP communicated to us their intention to hold a final vote on the treatment indication at their

31


 

March 2018 meeting. Rubraca is commercially available in the U.S. The degree of market acceptance and the commercial success of Rubraca will depend on a number of factors, including:

·

the effectiveness of our sales and marketing strategy and operations;

·

maintaining compliance with all regulatory requirements applicable to Rubraca and our commercial activities, including the post-marketing requirements and post-marketing commitments required by the FDA and, if approved in Europe, the EMA, to verify Rubraca’s clinical benefit or safety by completing certain confirmatory trials, pharmacology studies and additional diagnostic development;

·

the acceptance of Rubraca by patients and the medical community and the availability, perceived advantages and relative cost, safety and efficacy of alternative and competing products and therapies;

·

the continued acceptable safety profile of Rubraca and the occurrence of any unexpected side effects, adverse reactions or misuse, or any unfavorable publicity in these areas;

·

the ability of our third-party manufacturers to manufacture commercial supplies of Rubraca, to remain in good standing with regulatory agencies, and to develop, validate and maintain commercially viable manufacturing processes that are, to the extent required, compliant with current good manufacturing practice (“cGMP”) regulations;

·

the availability of coverage and adequate reimbursement from managed care plans, private health insurers and other third party payors and the willingness and ability of patients to pay for Rubraca;

·

the development or commercialization of competing products or therapies;

·

marketing and distribution support for Rubraca, including the degree to which the approved labeling supports promotional initiatives for commercial success;

·

the actual market size for Rubraca, which may be different than expected;

·

our ability to enforce our intellectual property rights in and to Rubraca;

·

our ability to avoid third party patent interference or patent infringement claims; and

·

our ability to obtain regulatory approvals to commercialize Rubraca in markets outside of the U.S.

 

As many of these factors are beyond our control, we cannot assure you that we will ever be able to generate meaningful revenue through the sale of Rubraca. In addition, we may experience significant fluctuations in sales of Rubraca from period to period. We currently do not have any other product candidates in active development though we are exploring rucaparib in other indications. Any inability on our part to successfully commercialize Rubraca in the United States and any foreign territories where it may be approved, or any significant delay in such approvals, could have a material adverse impact on our ability to execute upon our business strategy and, ultimately, to generate sufficient revenues from Rubraca to reach or maintain profitability or sustain our anticipated levels of operations.

 

Rubraca may cause undesirable side effects or have other properties that could limit its commercial potential.

 

If we or others identify previously unknown side effects or if known side effects are more frequent or severe than in the past, then:

·

sales of Rubraca may decline;

·

regulatory approvals for Rubraca may be restricted or withdrawn;

·

we may decide to, or be required to, send product warning letters or field alerts to physicians, pharmacists and hospitals;

·

additional nonclinical or clinical studies, changes in labeling or changes to manufacturing processes, specifications and/or facilities may be required;

·

government investigations or lawsuits, including class action suits, may be brought against us; and

·

our reputation may suffer.

 

32


 

Any of the above occurrences would harm or prevent sales of Rubraca, increase our expenses and impair our ability to successfully commercialize Rubraca. As Rubraca is commercially available, it may be used in a wider population and in a less rigorously controlled environment than in clinical studies. As a result, regulatory authorities, healthcare practitioners, third-party payors or patients may perceive or conclude that the use of Rubraca is associated with previously unknown serious adverse effects, undermining our commercialization efforts.

 

If our sales, marketing and distribution capabilities for Rubraca or our product candidates for which we obtain marketing approval are inadequate, we may be unable to generate revenue from sales of our products.

 

Prior to the launch of Rubraca, we had not commercialized any drug products as a company. To achieve commercial success for Rubraca and any product candidate that may be approved by the FDA or comparable foreign regulatory authorities, we must continue to expand our sales, marketing, managerial and other nontechnical capabilities or make arrangements with third parties to perform these services. We will be competing with companies that currently have extensive, well-funded, and more experienced sales and marketing operations. We may be unable to compete successfully against these more established companies.

 

We have recently built a field organization and other capabilities for the sales, marketing and distribution of Rubraca in the United States and have hired the commercial infrastructure in the European Union, and there are significant risks involved with building and managing a sales organization. Factors that may inhibit our efforts to effectively commercialize Rubraca on our own include:

·

our inability to recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel;

·

the inability of sales personnel to generate sufficient sales leads and to obtain access to physicians or persuade adequate numbers of physicians to use or prescribe Rubraca;

·

our inability to effectively manage a geographically dispersed sales and marketing team.

 

If we are unable to maintain effective sales, marketing and distribution capabilities for Rubraca or if we are unable to establish and maintain sales, marketing and distribution capabilities for Rubraca outside of the United States, if approved, or for any other product candidate for which we obtain marketing approval, whether independently or with third parties, we may not be able to generate product revenue or may not become profitable. If the cost of establishing and maintaining a sales and marketing organization exceeds the cost-effectiveness of doing so, we may not become profitable.

 

With respect to our product candidates, we may elect to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems in certain territories. To the extent that we enter into licensing or co-promotion arrangements for any of our product candidates, our product revenue may be lower than if we directly marketed or sold our approved products. In addition, any revenue we receive as a result of such arrangements would depend in whole or in part upon the efforts of such third parties, which may not be successful and are generally not within our control. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates that receive regulatory approval. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.

 

We cannot give any assurance that rucaparib will receive regulatory approval outside the United States or that the rucaparib development program in other lines of therapies and indications will be successful or that our other product candidates will receive regulatory approval.

 

To date, we have invested a significant portion of our efforts and financial resources in the acquisition and development of our product candidates. Our business depends entirely on the successful development and commercialization of our product candidates.

 

Each of our product candidates requires clinical development, management of clinical, non-clinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, building of a commercial organization and significant marketing efforts in order to generate any revenues from product sales. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA

33


 

or comparable foreign regulatory authorities. To date, we have received regulatory approval from the FDA to market Rubraca in the United States for a certain limited indication. We may not receive similar regulatory approvals outside the United States and we may never receive regulatory approval for any of our other product candidates. In addition, our product development programs contemplate the development of companion diagnostics by third-party collaborators. Companion diagnostics are subject to regulation as medical devices and must themselves be approved for marketing by the FDA or certain other foreign regulatory agencies before our product candidates may be commercialized.

 

We cannot be certain that rucaparib will be successfully developed in other lines of therapy, tumor types or other indications or that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. Three of our product candidates, CO-101, rociletinib and lucitanib encountered development and regulatory setbacks after initial promising data, leading us to discontinue enrollment in ongoing clinical trials. Even if we successfully obtain regulatory approvals to market one or more of our product candidates, our revenues will be dependent, in part, upon our diagnostic collaborators’ ability to obtain regulatory approval of the companion diagnostics to be used with our product candidates, as well as the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.

 

We plan to seek regulatory approval to commercialize our product candidates, and for other lines of therapies, indications or tumor types for rucaparib, in the United States, the European Union and in additional foreign countries. While the scope of regulatory approval is similar in other countries, obtaining separate regulatory approval in many other countries requires compliance with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions.

 

Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.

 

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of non-clinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through non-clinical studies and initial clinical trials. It is not uncommon for companies in the biopharmaceutical industry to suffer significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Indeed, based on the negative results of a pivotal study, we ceased further development of our previous product candidate CO-101, and we decided to discontinue ongoing development of rociletinib as a result of the issuance of a Complete Response Letter by the FDA. Additionally, our future clinical trial results may not be successful.

 

Although we have clinical trials ongoing, we may experience delays in our ongoing clinical trials, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:

·

obtaining regulatory approval to commence a trial;

·

reaching agreement on acceptable terms with prospective contract research organizations (“CROs”) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

·

obtaining institutional review board (“IRB”) approval at each site;

·

recruiting suitable patients to participate in a trial;

·

developing and validating companion diagnostics on a timely basis;

·

having patients complete a trial or return for post-treatment follow-up;

·

clinical sites deviating from trial protocol or dropping out of a trial;

·

adding new clinical trial sites; or

·

manufacturing sufficient quantities of product candidate for use in clinical trials.

34


 

 

Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance.

 

We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities. Such authorities may impose a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

 

The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for rucaparib in other indications and lines of therapy or for our other product candidates, our business will be substantially harmed.

 

The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. We have obtained regulatory approval for Rubraca in the United States for a specific indication, and it is possible that Rubraca may not obtain regulatory approval outside the United States or for broader indications and lines of therapy or other tumor types or that any of our other existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. Indeed, with the issuance of a Complete Response Letter by the FDA with respect to the rociletinib NDA, we decided to discontinue ongoing development of rociletinib.

 

Our product candidates could fail to receive regulatory approval or approval may be delayed for many reasons, including the following:

·

the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;

·

we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;

·

the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;

·

the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from non-clinical studies or clinical trials;

·

the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere;

·

the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;

35


 

·

the FDA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we contemplate developing with partners; and

·

the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

 

This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.

 

Even if we receive regulatory approval for our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if and when approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.

 

Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing and clinical trials and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the FDA or comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, pricing, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practices and good clinical practices for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes or failure to comply with regulatory requirements, may result in, among other things:

·

restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls;

·

fines, warning letters or holds on clinical trials;

·

refusal by the FDA and comparable foreign authorities to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;

·

product seizure or detention, or refusal to permit the import or export of products; and

·

injunctions or the imposition of civil or criminal penalties.

 

All of the foregoing limitations, obligations, and requirements also apply to Rubraca, for which we have received regulatory approval in the United States for certain limited indications.

 

We may seek approval from U.S. and foreign regulatory authorities for one or more product candidates on a conditional basis with full approval conditioned upon fulfilling the requirements of regulators. For example, we received accelerated approval from the FDA for the initial indication for Rubraca and are seeking conditional marketing authorization from the E.U. for rucaparib. Each of these approval pathways has certain conditions to approval, some of which may be post-approval, such as the conduct of a post-approval, or confirmatory, trial using due diligence. For example, continued approval of Rubraca by the FDA may be contingent upon verification and description of clinical benefit in ARIEL3 and/or ARIEL4, our confirmatory trials.  If we are unable to fulfill the requirements of regulators that are conditions of a product’s accelerated or conditional approval, if the confirmatory trial shows unfavorable results or increased or additional undesirable side effects, or if regulators re-evaluate the data or risk-benefit profile of our product candidate, the availability of accelerated or conditional approval may be withdrawn or our conditional approval may not result in full approval or may be revoked or not renewed. Alternatively, we may be required to change a product candidate’s labeled indications or even withdraw the product, if approved, from the market.

 

The FDA’s and comparable foreign authorities’ policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the

36


 

adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability, which would adversely affect our business. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.

 

Rubraca and our other product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.

 

Adverse events (“AEs”) attributable to our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Clinical studies conducted to date have generated AEs related to our product candidates, some of which have been serious. Patients treated with Rubraca have commonly experienced nausea, vomiting, constipation, dysgeusia, anemia/decreased hemoglobin, decreased appetite, diarrhea, abdominal pain, thrombocytopenia and fatigue/asthenia. In studies of lucitanib, hypertension, proteinuria and subclinical hypothyroidism requiring supplementation are the most common AEs observed. The most notable AEs experienced by patients treated with rociletinib include hyperglycemia and OTc prolongation. As is the case with all oncology drugs, it is possible that there may be other potentially harmful characteristics associated with their use in future trials, including larger and lengthier Phase III clinical trials. As we evaluate the use of our product candidates in combination with other active agents, we may encounter safety issues as a result of the combined safety profiles of each agent, which could pose a substantial challenge to that development strategy.

 

Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related AEs could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.

 

Additionally, if we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:

·

regulatory authorities may withdraw approvals of such product;

·

regulatory authorities may require additional warnings on the label;

·

we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;

·

we could be sued and held liable for harm caused to patients; and

·

our reputation may suffer.

 

Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.

 

Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics could harm our drug development strategy.

 

As one of the key elements of our clinical development strategy, we seek to identify patient subsets within a disease category who may derive selective and meaningful benefit from the product candidates we are developing. In collaboration with partners, we plan to develop companion diagnostics to help us to more accurately identify patients within a particular subset, both during our clinical trials and in connection with the commercialization of our product candidates. Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and require separate regulatory approval prior to commercialization. We do not develop companion diagnostics internally and thus we are dependent on the sustained cooperation and effort of our third-party collaborators in developing and obtaining approval for these companion diagnostics. We and our collaborators may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our

37


 

collaborators to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates. In addition, our collaborators may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the clinical community. If such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales of our products. In addition, the diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates. 

 

We rely on third parties to conduct our non-clinical and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.

 

We have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for our ongoing non-clinical and clinical programs. We rely on these parties for execution of our non-clinical and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP, which are regulations and guidelines enforced by the FDA, the EEA and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under current GMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.

 

Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.

 

If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going clinical and non-clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.

 

Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially influence our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse effect on our business, financial condition and prospects.

 

38


 

We rely completely on third parties to manufacture our clinical drug supplies and we intend to rely on third parties to produce commercial supplies of any approved product candidate, and our commercialization of any of our product candidates could be stopped, delayed or made less profitable if those third parties fail to obtain approval of the FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities of drug product or fail to do so at acceptable quality levels or prices.

 

We do not currently have nor do we plan to acquire the infrastructure or capability internally to manufacture our clinical drug supplies for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the GMP regulatory requirements for manufacture of both active drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms to the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly affect our ability to develop, obtain regulatory approval for or market our product candidates, if approved.

 

We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials. There are a limited number of suppliers of raw materials that we use to manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.

 

We are dependent on our third party manufacturers to conduct process development and scale-up work necessary to support greater clinical development and commercialization requirements for our product candidates. Carrying out these activities in a timely manner, and on commercially reasonable terms, is critical to the successful development and commercialization of our product candidates. We expect that our third-party manufacturers are capable of providing sufficient quantities of our product candidates to meet anticipated clinical and full-scale commercial demands, however if third parties with whom we currently work are unable to meet our supply requirements, we will need to secure alternate suppliers. While we believe that there are other contract manufacturers having the technical capabilities to manufacture our product candidates, we cannot be certain that identifying and establishing relationships with such sources would not result in significant delay or material additional costs.

 

We expect to continue to depend on third-party contract manufacturers for the foreseeable future. While we have long-term agreements with Lonza for the manufacture of API for Rubraca and with the manufacturer of the finished drug product, we have not entered into agreements with any alternate suppliers. We currently obtain our supplies of finished drug product through individual purchase orders.

 

Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and major operators of cancer clinics.

 

Even if we obtain regulatory approval for our other product candidates, the product may not gain market acceptance among physicians, health care payors, patients and the medical community, which are critical to commercial success. Market acceptance of any product candidate for which we receive approval depends on a number of factors, including:

·

the efficacy and safety as demonstrated in clinical trials;

·

the timing of market introduction of such product candidate as well as competitive products;

39


 

·

the clinical indications for which the drug is approved and the product label approved by regulatory authorities, including any warnings that may be required on the label;

·

the approval, availability, market acceptance and reimbursement for the companion diagnostic;

·

acceptance by physicians, major operators of cancer clinics and patients of the drug as a safe and effective treatment;

·

the potential and perceived advantages of such product candidate over alternative treatments, especially with respect to patient subsets that we are targeting with such product candidate;

·

the safety of such product candidate seen in a broader patient group, including its use outside the approved indications;

·

the cost, safety and efficacy of the product in relation to alternative treatments;

·

the availability of adequate reimbursement and pricing by third-party payors and government authorities;

·

relative convenience and ease of administration;

·

the prevalence and severity of adverse side effects; and

·

the effectiveness of our sales and marketing efforts.

 

If our product candidates are approved but fail to achieve an adequate level of acceptance by physicians, healthcare payors and patients, we will not be able to generate significant revenues, and we may not become or remain profitable.

 

We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.

 

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. In addition, the competition in the oncology market is intense. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions.

 

Lynparza™ (olaparib) is approved in the U.S. as monotherapy in patients with germline BRCA mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy, as monotherapy for the maintenance treatment of adult patients with recurrent epithelial, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy and as monotherapy in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Lynparza is also approved in the EU for the maintenance treatment of BRCA mutated platinum-sensitive relapsed serous ovarian cancer. In February 2018, the CHMP adopted a positive opinion recommending this label be changed and expanded to remove the limitation of use in BRCA-mutated patients. Lynparza has indications for ovarian cancer across 57 countries (as of year-end 2017). In July 2017, AstraZeneca and Merck & Co., Inc. announced a global strategic oncology collaboration to co-develop and co-commercialise Lynparza for multiple cancer types. Lynparza is being investigated, alone and in combination with other agents, in multiple indications across several tumor types, including breast, prostate, and pancreatic cancers.

 

Zejula®/niraparib (Tesaro) was approved in March 2017 in the United States as monotherapy for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Zejula was approved in November 2017 in the EU for the same indication. Additional clinical investigations of Zejula in ovarian, breast and lung cancers are ongoing or planned. Janssen Biotech has licensed rights to develop and commercialize niraparib specifically for patients with prostate cancer worldwide, except in Japan.

 

There are a number of PARP inhibitors in clinical development including AbbVie’s veliparib and ABT-767, Pfizer’s talazoparib, BeiGene’s BGB-290, and Checkpoint Therapeutics’ CK-102. While most PARP inhibitor development focuses on ovarian, breast and prostate cancers, additional efforts are aimed toward bladder, lung, and pancreatic cancers as well.

 

40


 

In addition, combination approaches that include PARP inhibitors, including Lynparza or Zejula, with other anticancer agents are in various phases of clinical development across a variety of oncology indications. These combination therapies may result in future competitive pressure on Rubraca, and multiple data readouts for such studies are anticipated throughout 2018 and beyond.

 

Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis drug products that are more effective or less costly than any drug candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs, as well as drugs that are in the development pipelines of our competitors and later enter the market.

 

Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA, European Commission or other regulatory approval or discovering, developing and commercializing medicines before we do, which would have a material adverse effect on our business.

 

Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.

 

There is significant uncertainty related to the third-party coverage and reimbursement of newly approved drugs. We have received approval for Rubraca in the United States for a limited indication. We intend to seek additional approvals to market Rubraca and other product candidates in the United States, Europe and other selected foreign jurisdictions. Market acceptance and sales of our product candidates in both domestic and international markets will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for any of our product candidates and may be affected by existing and future healthcare reform measures. Government and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for new drugs and, as a result, they may not cover or provide adequate payment for our product candidates. These payors may conclude that our product candidates are less safe, less effective or less cost-effective than existing or later introduced products, and third-party payors may not approve our product candidates for coverage and reimbursement or may cease providing coverage and reimbursement for these product candidates.

 

Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Even if we obtain coverage for our product candidates, third-party payors may not establish adequate reimbursement amounts, which may reduce the demand for, or the price of, our products. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.

 

In both the United States and certain foreign jurisdictions, there have been and we expect there will continue to be a number of legislative and regulatory changes to the health care system that could affect our ability to sell our products profitably. The U.S. government and other governments have shown significant interest in pursuing healthcare reform. In particular, the Medicare Modernization Act of 2003 revised the payment methodology for many products under the Medicare program in the United States. This has resulted in lower rates of reimbursement. In 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the “Affordable Care Act”), was enacted. The Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers. Such government-adopted reform measures may adversely affect the pricing of

41


 

healthcare products and services in the United States or internationally and the amount of reimbursement available from governmental agencies or other third-party payors.

 

Moreover, payment methodologies, including payment for companion diagnostics, may be subject to changes in healthcare legislation and regulatory initiatives. For example, the CMS has begun bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting and, in 2018, the CMS began paying for clinical laboratory services based on a weighted average of reported prices that private payors, Medicare Advantage plans, and Medicaid Managed Care plans pay for laboratory services.

 

There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. Recently there has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, as well as our ability to set satisfactory prices for our products, to generate revenues, and to achieve and maintain profitability.

 

In some foreign countries, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. To obtain reimbursement or pricing approval in some countries, we may be required to conduct additional clinical trials that compare the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our product candidates is unavailable or limited in scope or amount in a particular country, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability of our products in such country.

 

If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Further, we will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.

 

Our industry has experienced a high rate of turnover of management personnel in recent years. Our ability to compete in the highly competitive biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, especially Patrick J. Mahaffy, our President and Chief Executive Officer, Lindsey Rolfe, our Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance and Chief Medical Officer, Dale Hooks, our Senior Vice President and Chief Commercial Officer and Gillian C. Ivers-Read, our Executive Vice President, Technical Operations and Chief Regulatory Officer, whose services are critical to the successful implementation of our product candidate acquisition, development and regulatory strategies.

 

Despite our efforts to retain valuable employees, members of our management, scientific, development and commercial teams may terminate their employment with us on short notice. Pursuant to their employment arrangements, each of our executive officers may voluntarily terminate their employment at any time by providing as little as thirty days advance notice. Our employment arrangements with all of our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with or, other than our executive officers, without notice. For example, Andrew R. Allen, our former Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer, resigned in July 2015, and Steven L. Hoerter, our former Executive Vice President and Chief Commercial Officer, resigned in January 2016 and Erle T. Mast, our former Executive Vice President and Chief Financial Officer, resigned in March 2016. The loss of the services of any of our executive officers or other key employees and our inability to find suitable replacements could potentially harm our business, financial condition and prospects. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.

 

42


 

As of February 16, 2018, we employed 360 full-time employees. As our development plans and strategies develop, we expect to expand our employee base for managerial, operational, financial and other resources. Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy.

 

We may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical, biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high quality candidates than what we have to offer. In order to induce valuable employees to continue their employment with us, we have provided stock options that vest over time. The value to employees of stock options that vest over time is significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. If we are unable to continue to attract and retain high quality personnel, the rate and success at which we can develop and commercialize product candidates will be limited.

 

Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.

 

We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Ethics and other compliance policies, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant effect on our business and results of operations, including the imposition of significant fines or other sanctions.

 

Our relationships with healthcare professionals, investigators, consultants, customers (actual and potential) and third-party payors are and will continue to be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency and disclosure (or “sunshine”) laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.

 

Our operations may be directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may affect, among other things, our current activities with clinical study investigators and research subjects, as well as proposed and future sales, marketing, disease awareness, and patient assistance programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, but are not limited to:

·

the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, including any kickback, bribe, or certain rebate, directly

43


 

or indirectly, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment will be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or special intent to violate the law in order to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; 

·

federal false claims laws, including the False Claims Act, which impose criminal and civil penalties, including through civil “qui tam” or “whistleblower” actions, against individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from federal programs, such as Medicare and Medicaid, that are false or fraudulent, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;

·

the Health Insurance Portability and Accountability Act of 1996, or HIPAA which imposes criminal and civil liability for, among other things, willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

·

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which also imposes certain requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

·

the federal civil monetary penalties statute, which prohibits, among other things, the offering or giving of remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary’s election of a particular supplier of items or services reimbursable by a Federal or state governmental program;

·

the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare and Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;

·

federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;

·

federal government price reporting laws, which require drug manufacturers to calculate and report complex pricing metrics to government agencies, including CMS, where such reported prices may be used in the calculation of reimbursement and/or discounts on marketed products. Participation in these programs and compliance with the applicable requirements may result in potentially significant discounts on products subject to reimbursement under federal healthcare programs and increased infrastructure costs, and may potentially limit a drug manufacturer’s ability to offer certain marketplace discounts; and

·

analogous state laws and regulations, such as state anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

44


 

 

In addition, the research and development of our product candidates outside the United States, and any sales of our products or product candidates once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.

 

Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs, including investments in infrastructure and additional resources. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities, including our consulting agreements and other relationships with physicians, could be subject to challenge under one or more of such laws. Governmental and enforcement authorities may conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

 

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.

 

We face an inherent risk of product liability. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates, if approved. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

·

decreased demand for our product candidates or products that we may develop;

·

injury to our reputation;

·

withdrawal of clinical trial participants;

·

initiation of investigations by regulators;

·

costs to defend the related litigation;

·

a diversion of management’s time and our resources;

·

substantial monetary awards to trial participants or patients;

·

increase in insurance premiums;

·

product recalls, withdrawals or labeling, marketing or promotional restrictions;

·

loss of revenues from product sales; 

·

the inability to commercialize our product candidates; and

·

a decline in our stock price.

 

Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We have a program of product liability insurance covering our ongoing clinical trials; however, the amount of insurance we maintain may not be adequate to cover all liabilities that we may incur. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any

45


 

amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.

 

Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches.

 

We and our business partners maintain sensitive company data on our computer networks, including our intellectual property and proprietary business information, as well as certain clinical trial information. Cybersecurity attacks are becoming more commonplace and include, but are not limited to, malicious software, attempts to gain unauthorized access to data and other electronic security breaches that could lead to disruptions in systems, misappropriation of information and corruption of data. Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and business operations. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed.

 

Risks Related to Our Intellectual Property

 

If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.

 

We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.

 

The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or license may fail to result in issued patents in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications we hold or pursue with respect to our product candidates is threatened, it could threaten our ability to commercialize our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, an interference proceeding can be provoked by a third-party or instituted by the United States Patent and Trademark Office (“U.S. PTO”) to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.

 

In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug development processes that involve proprietary know-how, information or technology that is not covered by patents. Although we require all of our employees to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United

46


 

States and abroad. If we are unable to prevent material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.

 

Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.

 

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including interference, inter parties review and reexamination proceedings before the U.S. PTO or oppositions and other comparable proceedings in foreign jurisdictions. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.

 

Third parties may assert that we are employing their proprietary technology without authorization. There are or may be third-party patents with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications, which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license, limit our uses, or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all.

 

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, limit our uses, pay royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly.

 

The patent protection, patent prosecution and patent enforcement for some of our product candidates is dependent on third parties.

 

While we normally seek and gain the right to fully prosecute, maintain and enforce the patents relating to our product candidates, there may be times when platform technology patents that relate to our product candidates are controlled by our licensors. This is the case with the method of use patents licensed under the AstraZeneca license. This is also the case with our license to rociletinib, under which Celgene holds the right to prosecute and maintain the patents and patent applications covering its core discovery technology, including molecular backbones, building blocks and classes of compounds generated by that technology, aspects of which relate to rociletinib. We have the right to jointly prosecute and maintain, and the first right to enforce, the patent rights for the composition of matter for rociletinib. If AstraZeneca, Celgene or any of our future licensing partners fail to appropriately prosecute, maintain or enforce, as applicable, patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product

47


 

candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.

 

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.

 

Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing.

 

Interference proceedings provoked by third parties or brought by the U.S. PTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees.

 

We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.

 

We may not be able to protect our intellectual property rights throughout the world.

 

Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.

 

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.

 

If we breach any of the agreements under which we license commercialization rights to our product candidates from third parties, we could lose license rights that are important to our business.

 

We license the use, development and commercialization rights for all of our product candidates, and may enter into similar licenses in the future. Under each of our existing license agreements we are subject to commercialization and development, diligence obligations, milestone payment obligations, royalty payments and other obligations. If we fail to comply with any of these obligations or otherwise breach our license agreements, including by failing to use commercially reasonable efforts to develop or commercialize the product candidate, our licensing partners may have the right to terminate the license in whole or in part. Generally, the loss of any one of our licenses or other licenses in the future could materially harm our business, prospects, financial condition and results of operations.

 

48


 

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

 

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:

·

others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;

·

we or our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;

·

we or our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions;

·

others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;

·

it is possible that our pending patent applications will not lead to issued patents;

·

issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;

·

our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

·

we may not develop additional proprietary technologies that are patentable; and

·

the patents of others may have an adverse effect on our business.

 

Should any of these events occur, they could significantly harm our business, results of operations and prospects.

 

Risks Related to Ownership of our Common Stock and Convertible Senior Notes

 

There may not be a viable public market for our common stock and as a result it may be difficult for you to sell your shares of our common stock.

 

Our common stock had not been publicly traded prior to our initial public offering in November 2011. An active trading market for our common stock on the NASDAQ Global Select Market may not be sustained. As a result of these and other factors, you may be unable to resell your shares at a price that is attractive to you or at all. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.

 

The price of our stock has been, and may continue to be, volatile, and you could lose all or part of your investment.

 

The trading price of our common stock has been, and may continue to be, volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. During the 12-month period ended December 31, 2017, the price of our common stock on the NASDAQ Global Select Market ranged from $39.83 per share to $99.45 per share. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this report, these factors include:

·

adverse results of regulatory actions or decisions;

·

our failure to successfully commercialize our product candidates, if approved;

·

actual or anticipated adverse results or delays in our clinical trials;

·

unanticipated serious safety concerns related to the use of any of our product candidates;

·

changes in laws or regulations applicable to our product candidates, including but not limited to clinical trial requirements for approvals;

49


 

·

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our product candidates;

·

our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;

·

inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;

·

our dependence on third parties, including CMOS and CROs, as well as our partners that provide us with companion diagnostic products;

·

additions or departures of key scientific or management personnel;

·

failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the public;

·

actual or anticipated variations in quarterly operating results;

·

failure to meet or exceed the estimates and projections of the investment community;

·

overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies;

·

conditions or trends in the biotechnology and biopharmaceutical industries;

·

introduction of new products offered by us or our competitors;

·

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;

·

issuances of debt or equity securities;

·

significant lawsuits, including patent or stockholder litigation;

·

sales of our common stock by us or our stockholders in the future;

·

trading volume of our common stock;

·

publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;

·

ineffectiveness of our internal controls;

·

general political and economic conditions;

·

effects of natural or man-made catastrophic events; and

·

other events or factors, many of which are beyond our control.

 

In addition, the stock market in general, and the NASDAQ Global Select Market and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in these “Risk Factors,” could have a dramatic and material adverse effect on the market price of our common stock.

 

Because our outstanding Notes are convertible into shares of our common stock, volatility or depressed prices of our common stock could have a similar effect on the trading price of our Notes. In addition, the existence of the Notes may encourage short selling in our common stock by market participants because the conversion of the Notes could depress the price of our common stock.

 

The conversion of some or all of the Notes may dilute the ownership interest of existing stockholders. Holders of the outstanding Notes are able to convert them at any time prior to the close of business on the business day immediately preceding September 15, 2021. Upon conversion, holders of the Notes will receive shares of common stock. Any sales in the public market of shares of common stock issued upon conversion of such Notes could adversely affect the trading price of our common stock. We cannot predict the size of future issuances or the effect, if any, that they may have on the

50


 

market price of our common stock. The issuance and sale of substantial amounts of common stock, or the perception that such issuances and sales may occur, could adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity or convertible debt securities.

 

Following periods of volatility in a company’s stock price, litigation has often been initiated against companies. Following the decline in our stock price related to the rociletinib regulatory update in November 2015, a number of lawsuits have been filed against us (see “Part I, Item 3-Legal Proceedings”). These proceedings and other similar litigation, if instituted against us, could result in substantial costs and diversion of management’s attention and resources, which could materially and adversely affect our business and financial condition.

 

Certain members of management and their affiliates own a significant percentage of our stock and will be able to exert influence over matters subject to stockholder approval.

 

Our executive officers, directors and their respective affiliates known to us beneficially owned approximately 6.7% of our voting stock as of February 21, 2018. These stockholders may have the ability to influence the outcome of matters submitted to our stockholders for approval. The interests of our executive officers, directors, and their affiliates might not coincide with the interests of the other holders of our capital stock which may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.

 

Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.

 

Shares of common stock that are either subject to outstanding options or reserved for future issuance under our equity incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.

 

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

 

We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock.

 

Pursuant to our equity incentive plan(s), our compensation committee (or its designee) is authorized to grant equity-based incentive awards to our employees, directors and consultants. As of December 31, 2017, the number of shares of our common stock available for future grant under our 2011 Stock Incentive Plan (“2011 Plan”) is 3,147,903. The number of shares of our common stock reserved for issuance under our 2011 Plan will be increased (i) from time to time by the number of shares of our common stock forfeited upon the expiration, cancellation, forfeiture, cash settlement or other termination of awards under our 2009 Equity Incentive Plan, and (ii) at the discretion of our board of directors, on the date of each annual meeting of our stockholders, by up to the lesser of (x) a number of additional shares of our common stock representing 4% of our then-outstanding shares of common stock on such date and (y) 2,758,621 shares of our common stock. Future option and restricted stock unit, or RSU, grants and issuances of common stock under our 2011 Plan may have an adverse effect on the market price of our common stock. In addition, a substantial number of shares of our common stock are reserved for issuance upon conversion of the Notes.

 

Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.

 

Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third-party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management. These provisions include:

51


 

·

authorizing the issuance of “blank check” preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;

·

limiting the removal of directors by the stockholders;

·

creating a staggered board of directors;

·

prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;

·

eliminating the ability of stockholders to call a special meeting of stockholders;

·

permitting our board of directors to accelerate the vesting of outstanding option grants upon certain transactions that result in a change of control; and

·

establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.

 

These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. Because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under Delaware law, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any provision of our certificate of incorporation or bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock. Additionally, certain provisions of our outstanding Notes could make it more difficult or more expensive for a third party to acquire us. The repurchase price of the Notes must be paid in cash, and this obligation may have the effect of discouraging, delaying or preventing an acquisition of the Company that would otherwise be beneficial to our security holders.

 

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

 

The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.

 

We may not be able to raise the funds necessary to repurchase the Notes upon a fundamental change, and our future debt may contain limitations on our ability to repurchase the Notes.

 

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the Notes, holders may require us to repurchase for cash all or any portion of the Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. We may not have or be able to borrow the funds required to repurchase the Notes on the fundamental change repurchase date. In addition, our ability to repurchase the Notes may otherwise be limited by law, regulatory authority or agreements governing our future indebtedness. Our failure to repurchase the Notes at a time when the repurchase is required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes when required.

 

We may incur substantially more debt or take other actions which would intensify the risks discussed above; and we may not generate cash flow from operations in the future sufficient to satisfy our obligations under the Notes and any future indebtedness we may incur.

 

52


 

We may incur substantial additional debt in the future, subject to the restrictions contained in any debt instruments that we enter into in the future, some of which may be secured debt. We are not restricted under the terms of the indenture governing the Notes from incurring additional debt, securing existing or future debt, recapitalizing our debt or taking a number of other actions that are not limited by the terms of the indenture governing the Notes that could have the effect of diminishing our ability to make payments on the Notes when due. Our ability to refinance the Notes or future indebtedness will depend on the capital markets and our financial condition at such time. In addition, agreements that govern any future indebtedness that we may incur may contain financial and other restrictive covenants that will limit our ability to engage in activities that may be in our long-term best interests. Our failure to comply with those covenants could result in an event of default that, if not cured or waived, could result in the acceleration of some or all of our debt.

 

ITEM 1B.UNRESOLVED STAFF COMMENTS

 

Not applicable.

 

ITEM  2.PROPERTIES

 

Our principal offices are located at five leased facilities, a 29,177 square foot facility in Boulder, Colorado used primarily for corporate functions, a 24,877 square foot facility in San Francisco, California and a 32,660 square foot facility in Oakland, CA used for clinical development operations and research laboratory space, a 3,350 square foot facility in Cambridge, United Kingdom used for our European regulatory and clinical operations and a 416 square foot facility in Milan, Italy used for clinical operations. These leases expire in January 2023, December 2021, April 2028, May 2019 and March 2018, respectively. We believe that our existing facilities are sufficient for our needs for the foreseeable future.

 

ITEM  3.LEGAL PROCEEDINGS 

Rociletinib-Related Litigation

 

Following Clovis’ regulatory announcement in November 2015 of adverse developments in its ongoing clinical trials for rociletinib, Clovis and certain of its current and former executives were named in various securities lawsuits, the largest of which was a putative class action lawsuit in the District of Colorado (the “Medina Action”) which was settled on October 26, 2017 (the “Medina Settlement”).  The open actions currently pending against Clovis are discussed below.   While other entities have threatened to bring claims relating to rociletinib and the November 2015 announcement, none have commenced litigation as of the date of this filing. 

 

On January 22, 2016, the Electrical Workers Local #357 Pension and Health & Welfare Trusts, a purported shareholder of Clovis, filed a purported class action complaint (the “Electrical Workers Complaint”) against Clovis and certain of its officers, directors, investors and underwriters in the Superior Court of the State of California, County of San Mateo (the “Electrical Workers Court”). The Electrical Workers Complaint purports to be asserted on behalf of a class of persons who purchased stock in the July 2015 Offering. The complaint asserted claims under certain provisions of the Securities Act of 1933 (the “Securities Act”) relating to a July 2015 follow-on offering of Clovis securities (the “July 2015 Offering”) based on substantially similar allegations to those asserted in the Medina Action. On June 30, 2016, the Electrical Workers Plaintiffs filed an amended complaint adding new allegations (the “Amended Complaint”).

   

On July 28, 2016, the defendants filed a motion to stay the Electrical Workers action pending resolution of the Medina Action and a demurrer to the Amended Complaint. On September 23, 2016, after hearing oral argument, the Electrical Workers Court granted the motion to stay and reserved on issuing a ruling on defendants’ pending demurrer.

 

The Company believes that the claims asserted in the Electrical Workers Action are released and barred by operation of law through the Medina Settlement, and accordingly plans to seek dismissal of the Electrical Workers Action on that basis.

 

On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the offering materials for the July 2015 Offering relating to the

53


 

efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages.

   

On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.

   

On January 31, 2017, Defendants filed a motion to stay the Antipodean action pending resolution of the Medina Action in the District of Colorado. Defendants also filed a motion to dismiss the Antipodean Amended Complaint on March 29, 2017.

   

On March 14, 2017, the Clovis Defendants and Antipodean participated in a mediation, which did not result in a settlement.

   

On August 8, 2017, the parties participated in a scheduled hearing on Defendants’ motion to stay and motion to dismiss before Justice Masley of the New York Supreme Court, County of New York. At the hearing, Justice Masley granted Defendants’ motion to stay. Per the Court’s August 10, 2017 order, Defendants’ motion to dismiss was held in abeyance and deemed submitted on November 1, 2017.  On November 1, 2017, the Defendants provided a status update to the Court regarding the outcome of the hearing.  The update informed the Court that Antipodean had excluded itself from the Medina Settlement, as memorialized in the final judgment entered by the Medina Court.  No date has been scheduled for argument on Defendants’ motion to dismiss.

   

The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint.  However, there can be no assurance that the defense will be successful.

      

In March 2017, two putative shareholders of the Company, Macalinao and McKenry (the “Derivative Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”).

   

On May 18, 2017, the Derivative Plaintiffs filed a Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to prior demands for inspection of the Company’s books and records served on the Company by each of Macalinao and McKenry under 8 Del. C. § 220. The Consolidated Derivative Complaint sought, among other things, an award of money damages.

   

On July 31, 2017, the defendants filed a motion to dismiss the Consolidated Derivative Complaint. Plaintiffs filed an opposition to the motion to dismiss on August 31, 2017, and the defendants filed a reply in further support of the motion to dismiss on September 26, 2017. No date has been scheduled for argument on Defendants’ motion to dismiss the Consolidated Derivative Complaint.

   

The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful.

   

On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of

54


 

materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages.

   

On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative Complaint. On June 20, 2017, the court granted the motion to stay.

   

The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.

 

In addition, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. The Company is continuing to cooperate with these agencies with respect to their investigations. The Medina Settlement does not resolve these inquiries and the Company cannot predict their timing or outcome.

 

Director Compensation Litigation

 

On May 10, 2017, John Solak, a purported shareholder of the Company, filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware (the “Solak Complaint”) against certain directors and an officer of the Company. The Solak Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by adopting a compensation plan that overcompensated the non-employee director defendants, in relation to companies of comparable market capitalization and size. The Solak Complaint also alleged claims of waste of corporate assets and unjust enrichment due to this allegedly wrongful compensation plan. The Solak Complaint sought, among other things, an award of money damages and the imposition of corporate governance reforms.

   

The Court has entered a number of orders extending the defendants’ time to respond to the Solak Complaint based on, among other factors, the fact that the parties are engaged in discussions in an effort to resolve the Solak action. On February 14, 2018, the parties filed a joint letter to the Court requesting that all deadlines in the action be held in abeyance while the parties engaged in final settlement discussions.

 

On February 26, 2018, the defendants entered into a stipulation of compromise and settlement with plaintiff that is intended to settle the Solak action. The proposed settlement is subject to Court approval upon the conclusion of a settlement hearing concerning the fairness of the terms of the proposed settlement, which will be scheduled following the provision of notice to shareholders of the Company.

 

In accordance with the terms of the proposed settlement, the Company will present a new non-employee director compensation policy for shareholder vote at the next annual shareholder meeting. Under the proposed new non-employee director compensation policy, annual base compensation for incumbent non-employee directors would be set at an amount between $350,000 and $425,000, which would remain in place for a period between two and five years. Additionally, the proposed policy sets annual base compensation for new non-employee directors at an amount between $525,000 and $637,500 and includes fixed annual fees for board and committee service. The proposed settlement also sets forth a number of corporate governance reforms that the Company will undertake, including, enhanced proxy disclosures, the codification of the Company’s stock ownership guidelines for directors, and enhanced disclosure requirements for certain forms of director compensation. While no cash payments will be made to investors as part of the proposed settlement, plaintiff’s counsel is expected to file a fee application which the Company has agreed not to oppose up to an agreed-upon amount. The proposed settlement contains no admission of wrongdoing.

 

ITEM  4.MINE SAFETY DISCLOSURES

Not applicable.

 

55


 

PART II

 

ITEM  5.MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information and Holders

 

Our common stock trades on the NASDAQ Global Select Market under the symbol “CLVS.” The following table sets forth, for the periods indicated, the high and low sales prices for our common stock as reported on the NASDAQ Global Select Market:

 

 

 

 

 

 

 

 

 

 

    

HIGH

    

LOW

 

Balance, December 31,  2017

 

 

 

 

 

 

 

First Quarter

 

$

74.94

 

$

39.83

 

Second Quarter

 

$

96.92

 

$

45.42

 

Third Quarter

 

$

99.45

 

$

64.61

 

Fourth Quarter

 

$

86.26

 

$

57.33

 

Balance, December 31,  2016

 

 

  

 

 

  

 

First Quarter

 

$

34.75

 

$

16.78

 

Second Quarter

 

$

20.90

 

$

11.57

 

Third Quarter

 

$

40.29

 

$

13.43

 

Fourth Quarter

 

$

46.97

 

$

25.50

 

 

On February 21, 2018, there were approximately 24 holders of record of our common stock. The holders of record number does not include a substantially greater number of holders whose shares are held of record in nominee or street name accounts through banks, brokers and/or other financial institutions.

 

Dividends

 

We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.

 

Securities Authorized for Issuance Under Equity Compensation Plans

 

Equity Compensation Plan Information

As of December 31, 2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number of

 

 

 

 

 

 

 

 

securities

 

 

 

 

 

 

 

 

remaining

 

 

 

 

 

 

 

 

available

 

 

 

 

 

 

 

 

for issuance

 

 

 

 

 

 

 

 

under equity

 

 

 

 

 

 

 

 

compensation

 

 

 

 

 

Weighted-

 

plans

 

 

 

Number of securities to

 

average

 

(excluding

 

 

 

be issued upon exercise

 

exercise price

 

securities

 

 

 

of outstanding options

 

of outstanding

 

reflected

 

 

 

and restricted stock

 

options

 

in column (a))

 

Plan Category

    

(a)

    

(b)

    

(c)

 

Equity compensation plans approved by security holders (1) (2)

 

6,379,264

 

$

46.77

 

3,147,903

 

Equity compensation plans not approved by security holders

 

 —

 

 

 —

 

 —

 

Total

 

6,379,264

 

$

46.77

 

3,147,903

 


56


 

(1)As of December 31, 2017, 9,590,378 shares were authorized for issuance under our 2011 Stock Incentive Plan (“2011 Plan”), which became effective upon closing of our initial public offering in November 2011, including 192,185 remaining shares available for future issuance under the 2009 Equity Incentive Plan (“2009 Plan”), which were transferred to the 2011 Plan. The number of shares of our common stock reserved for issuance under the 2011 Plan will be increased (i) from time to time by the number of shares of our common stock forfeited upon the expiration, cancellation, forfeiture, cash settlement or other termination of awards under the 2009 Plan and (ii) at the discretion of our board of directors, on the date of each annual meeting of our stockholders, by up to the lesser of (x) a number of additional shares of our common stock representing 4% of our then-outstanding shares of common stock on such date and (y) 2,758,621 shares of our common stock.

 

(2)As of December 31, 2017, 558,870 shares were reserved for issuance under our 2011 Employee Stock Purchase Plan (“ESPP”), which became effective upon closing of our initial public offering in November 2011. The number of shares of our common stock reserved for issuance under the ESPP will be increased at the discretion of our board of directors, on the date of each annual meeting of our stockholders, by up to the lesser of (x) a number of additional shares of our common stock representing 1% of our then-outstanding shares of common stock on such date and (y) 344,828 shares of our common stock.

 

Performance Graph (1) 

 

The following graph shows a comparison from December 31, 2012 through December 31, 2017 of the cumulative total return on an assumed investment of $100 in cash in our common stock, the NASDAQ Composite Index and the NASDAQ Biotechnology Index. Such returns are based on historical results and are not intended to suggest future performance. Data for the NASDAQ Composite Index and the NASDAQ Biotechnology Index assume reinvestment of dividends.

 

C:\Users\108968\Desktop\chart2.jpg


(1)This performance graph shall not be deemed “soliciting material” or to be “filed” with the SEC for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section, and shall not be deemed incorporated by reference into any filing of Clovis Oncology, Inc. under the Securities Act of 1933, as amended. 

 

57


 

ITEM 6.SELECTED FINANCIAL DATA

 

The following table sets forth certain of our selected historical financial data at the dates and for the periods indicated. The selected historical statement of operations data presented below for the years ended December 31, 2017, 2016 and 2015 and the historical balance sheet data as of December 31, 2017 and 2016 have been derived from our audited financial statements, which are included elsewhere in this Annual Report on Form 10-K. The historical statement of operations data presented below for the years ended December 31, 2014 and 2013 and the historical balance sheet data as of December 31, 2015, 2014 and 2013 have been derived from our audited financial statements that do not appear in this report.

 

Our historical results are not necessarily indicative of results expected in any future period.

 

The selected historical financial data presented below should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the related notes thereto, which are included elsewhere in this Annual Report on Form 10-K. The selected historical financial information in this section is not intended to replace our financial statements and the related notes thereto.

 

Statement of Operations Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 

 

 

    

2017

    

2016

    

2015

    

2014

    

2013

 

 

 

(in thousands, except per share amounts)

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue, net

 

$

55,511

 

$

78

 

$

 —

 

$

 —

 

$

 —

 

License and milestone revenue

 

 

 —

 

 

 —

 

 

 —

 

 

13,625

 

 

 —

 

Total revenues

 

 

55,511

 

 

78

 

 

 —

 

 

13,625

 

 

 —

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales - product

 

 

10,251

 

 

70

 

 

 —

 

 

 —

 

 

 —

 

Cost of sales - intangible asset amortization

 

 

1,486

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

Research and development

 

 

142,498

 

 

251,129

 

 

269,251

 

 

137,705

 

 

66,545

 

Selling, general and administrative

 

 

138,907

 

 

40,731

 

 

30,524

 

 

21,457

 

 

16,567

 

Acquired in-process research and development

 

 

 —

 

 

1,300

 

 

12,000

 

 

8,806

 

 

250

 

Impairment of intangible asset

 

 

 —

 

 

104,517

 

 

89,557

 

 

3,409

 

 

 —

 

Change in fair value of contingent purchase consideration

 

 

 —

 

 

(24,936)

 

 

(24,611)

 

 

707

 

 

405

 

Total expenses

 

 

293,142

 

 

372,811

 

 

376,721

 

 

172,084

 

 

83,767

 

Operating loss

 

 

(237,631)

 

 

(372,733)

 

 

(376,721)

 

 

(158,459)

 

 

(83,767)

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(10,428)

 

 

(8,491)

 

 

(8,372)

 

 

(2,604)

 

 

 —

 

Foreign currency gain (loss)

 

 

(82)

 

 

(580)

 

 

2,740

 

 

3,580

 

 

(535)

 

Legal settlement loss

 

 

(105,477)

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

Other income (expense)

 

 

3,643

 

 

633

 

 

416

 

 

(240)

 

 

(178)

 

Other income (expense), net

 

 

(112,344)

 

 

(8,438)

 

 

(5,216)

 

 

736

 

 

(713)

 

Loss before income taxes

 

 

(349,975)

 

 

(381,171)

 

 

(381,937)

 

 

(157,723)

 

 

(84,480)

 

Income tax benefit (expense)

 

 

3,578

 

 

32,034

 

 

29,076

 

 

(2,308)

 

 

(52)

 

Net loss

 

$

(346,397)

 

$

(349,137)

 

$

(352,861)

 

$

(160,031)

 

$

(84,532)

 

Basic and diluted net loss per common share

 

$

(7.36)

 

$

(9.07)

 

$

(9.79)

 

$

(4.72)

 

$

(2.95)

 

Basic and diluted weighted average common shares outstanding

 

 

47,047

 

 

38,478

 

 

36,026

 

 

33,889

 

 

28,672

 

 

58


 

Balance Sheet Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of  December 31, 

 

 

     

2017

     

2016

    

2015

    

2014

    

2013

 

 

 

(in thousands)

 

Cash, cash equivalents and available-for-sale securities

 

$

563,731

 

$

266,183

 

$

528,588

 

$

482,677

 

$

323,228

 

Working capital

 

 

545,423

 

 

213,813

 

 

464,125

 

 

443,400

 

 

307,644

 

Total assets

 

 

735,230

 

 

364,557

 

 

713,386

 

 

786,206

 

 

649,635

 

Convertible senior notes

 

 

282,406

 

 

281,126

 

 

279,885

 

 

278,680

 

 

 —

 

Common stock and additional paid-in capital

 

 

1,887,249

 

 

1,174,989

 

 

1,130,016

 

 

785,123

 

 

762,204

 

Total stockholders’ equity (deficit)

 

 

367,636

 

 

(3,634)

 

 

300,650

 

 

331,630

 

 

497,886

 

 

 

59


 

ITEM 7.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing at the end of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read the “Risk Factors” section of this report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

 

Overview

 

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

 

Our marketed product Rubraca® (rucaparib) is approved on an accelerated basis in the United States by the Food and Drug Administration (“FDA”) as monotherapy for the treatment of patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. We launched Rubraca in the United States in December 2016 for this indication.

 

The FDA is currently reviewing on a priority review timeline our sNDA for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

 

Our MAA submitted to the EMA for an ovarian cancer treatment indication for Rubraca is currently under review by the EMA’s CHMP. Following a Scientific Advisory Group - Oncology meeting and an oral explanation by us before the CHMP in February 2018, the CHMP has communicated a positive trend vote for the MAA and their intention to hold a final vote on the treatment indication at their March 2018 meeting.

 

In addition, we have two other product candidates: lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (“VEGFR”) 1-3, platelet-derived growth factor receptors (“PDGFR”) alpha and beta and fibroblast growth factor receptors (“FGFR”) 1-3, and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor (“EGFR”).  While we have stopped enrollment in ongoing trials for each of these candidates, we continue to provide drug to patients whose clinicians recommend continuing therapy. We maintain certain development and commercialization rights for lucitanib and global development and commercialization rights for rociletinib.

 

We commenced operations in April 2009. To date, we have devoted substantially all of our resources to identifying and in-licensing product candidates, performing development activities with respect to those product candidates and the general and administrative support of these operations. Through December 31, 2017, we have generated $13.6 million in license and milestone revenue related to our collaboration and license agreement with Servier and for the year ended December 31, 2017 have generated $55.5 million product revenue related to sales of Rubraca, which we began to commercialize on December 19, 2016. We have principally funded our operations using the net proceeds from the sale of convertible preferred stock, the issuance of convertible promissory notes, public offerings of our common stock and our convertible senior notes offering.

 

We have never been profitable and, as of December 31, 2017, we had an accumulated deficit of $1,447.4 million. We incurred net losses of $346.4 million, $349.1 million and $352.9 million for the years ended December 31, 2017, 2016 and 2015, respectively, and had cash, cash equivalents and available-for-sale securities totaling $563.7 million at December 31, 2017.

 

60


 

We expect to incur significant losses for the foreseeable future, as we incur costs related to commercial activities associated with Rubraca. In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses. Based on our current estimates, we believe that our cash, cash equivalents and available-for-sale securities will allow us to fund activities through at least the next 12 months. Until we can generate a sufficient amount of revenue from Rubraca, we expect to finance our operations in part through additional public or private equity or debt offerings and may seek additional capital through arrangements with strategic partners or from other sources. Adequate additional financing may not be available to us on acceptable terms, or at all.  Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.  We will need to generate significant revenues to achieve profitability, and we may never do so.

 

Product License Agreements

 

For a discussion of our product license agreements, see Note 13, License Agreements, in the Notes to Consolidated Financial Statements included in Part II, Item 8, Financial Statements and Supplementary Data, of this Annual Report on Form 10-K.

 

Financial Operations Overview

 

Revenue

 

During 2017, we recorded $55.5 million in revenue related to sales of Rubraca, which we began to commercialize on December 19, 2016. In addition, we distributed free drug to eligible patients through our patient assistance program that represented approximately $14.1 million in commercial value. For further discussion of our revenue recognition policy, see “Critical Accounting Policies and Significant Judgments and Estimates” below. Our ability to generate revenue and become profitable depends upon our ability to successfully commercialize products. Any inability on our part to successfully commercialize Rubraca in the United States and any foreign territories where it may be approved, or any significant delay in such approvals, could have a material adverse impact on our ability to execute upon our business strategy and, ultimately, to generate sufficient revenues from Rubraca to reach or maintain profitability or sustain our anticipated levels of operations.

 

Currently, we only recognize revenue on product sales once the product is sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns. Effective January 1, 2018, we adopted Accounting Standards Codification (“ASC”), Topic 606, “Revenue from Contracts with Customers”. Upon adoption, we will begin recognizing revenue when our customers, the specialty distributors and specialty pharmacy providers, take control of our product. This will have the impact of us recognizing revenue approximately two to four weeks earlier than before adopting the new standard and will also increase the significance of estimating variable consideration, including product returns, rebates and chargebacks.

 

We used the modified retrospective method to adopt the new standard. This means that we will not restate previously issued financial statements, but will record a one-time adjustment to retained earnings of $2.3 million. This adjustment represents the sales of our product to our customers prior to January 1, 2018, that have not been sold to patients or healthcare providers, offset by related gross-to-net adjustments and other direct costs, including royalties and sales incentive compensation.

 

During 2017, revenue was recognized for U.S. tax purposes when our product was sold to the specialty distributors and pharmacies, a method that differs from book treatment. This difference in revenue recognition resulted in the establishment of the deferred tax asset for the sales value of our product held by our specialty distributor and pharmacy providers at December 31, 2017. The deferred tax asset was offset by a full valuation allowance and has no impact to our statement of operations. With the adoption of ASC 606 effective January 1, 2018, revenue will be recognized when our product is sold to the specialty distributors pharmacies, which will match the tax treatment resulting in no deferred tax asset.

 

61


 

For a complete discussion of this adoption and the accounting for net product revenue, see Note 2, Summary of Significant Accounting Policies in the “Recently Issued Accounting Standards” section and Note 11, Revenue Recognition.

 

Research and Development Expenses

 

Research and development expenses consist of costs incurred for the development of our product candidates and companion diagnostics, which include:

·

license fees and milestone payments related to the acquisition of in-licensed products, which are reported on our Consolidated Statements of Operations and Comprehensive Loss as acquired in-process research and development;

·

employee-related expenses, including salaries, benefits, travel and share-based compensation expense;

·

expenses incurred under agreements with CROs and investigative sites that conduct our clinical trials;

·

the cost of acquiring, developing and manufacturing clinical trial materials;

·

costs associated with non-clinical activities and regulatory operations; 

·

market research, disease education and other commercial product planning activities, including the hiring of a U.S. sales and marketing and medical affairs organization in preparation for commercial launch of rucaparib; and

·

activities associated with the development of companion diagnostics for our product candidates.

 

Research and development costs are expensed as incurred. License fees and milestone payments related to in-licensed products and technology are expensed if it is determined that they have no alternative future use. Costs for certain development activities, such as clinical trials and manufacturing of clinical supply, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors. As a result of the FDA approval of Rubraca and the discontinuation of enrollment in rociletinib, our research and development expenses decreased for 2017 as commercialization related expenses are classified as selling, general and administrative expenses and not research and development costs. Our research and development expenses will increase in 2018 as our ongoing rucaparib studies progress.

 

The following table identifies research and development and acquired in-process research and development costs on a program-specific basis for our products under development. Personnel-related costs, depreciation and share-based compensation are not allocated to specific programs, as they are deployed across multiple projects under development and, as such, are separately classified as personnel and other expenses in the table below.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 

 

 

 

2017

     

2016

     

2015

 

 

 

(in thousands)

 

Rucaparib Expenses

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

72,901

 

$

101,598

 

$

58,922

 

Acquired in-process research and development

 

 

 —

 

 

1,300

 

 

 —

 

Rucaparib Total

 

 

72,901

 

 

102,898

 

 

58,922

 

Lucitanib Expenses

 

 

 

 

 

 

 

 

 

 

Research and development (a)

 

 

(1,187)

 

 

(1,337)

 

 

1,923

 

Lucitanib Total

 

 

(1,187)

 

 

(1,337)

 

 

1,923

 

Rociletinib Expenses

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

7,712

 

 

43,768

 

 

122,912

 

Acquired in-process research and development

 

 

 —

 

 

 —

 

 

12,000

 

Rociletinib Total

 

 

7,712

 

 

43,768

 

 

134,912

 

Personnel and other expenses

 

 

63,072

 

 

107,100

 

 

85,494

 

Total

 

$

142,498

 

$

252,429

 

$

281,251

 


(a)This amount reflects actual costs incurred less amounts due from Servier for reimbursable development expenses pursuant to the collaboration and license agreement described in Note 13, License Agreements, to our audited consolidated financial statements included in this Annual Report on Form 10-K.

 

For 2017 and 2016, research and development expenses have continued to decrease primarily due to decreased development activities for the rociletinib program.

62


 

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses consist principally of salaries and related costs for personnel in executive, finance, legal, investor relations, human resources and information technology functions. Other general and administrative expenses include facilities expenses, communication expenses, information technology costs, corporate insurance and professional fees for legal, consulting and accounting services. With the FDA approval of Rubraca on December 19, 2016, all sales and marketing expenses associated with Rubraca are included in selling, general and administrative expenses. We anticipate that our selling, general and administrative expenses will continue to increase in the future in support of our commercial activities related to Rubraca in the U.S. and Europe.

 

Acquired In-Process Research and Development Expenses

 

Acquired in-process research and development expenses consist of upfront payments to acquire a new drug compound, as well as subsequent milestone payments. Acquired in-process research and development payments are immediately expensed provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use. Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to product cost of sales.

 

Impairment of Intangible Asset

 

In connection with the acquisition of EOS in November 2013, we recorded intangible assets to reflect the fair value of acquired in-process research and development (“IPR&D”) as of the acquisition date. The fair value was established based upon discounted cash flow models using assumptions related to the timing of development, probability of development and regulatory success, sales and commercialization factors and estimated product life. During the second quarter of 2016, we recorded a $104.5 million impairment charge due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. During the fourth quarter of 2015, we recorded an $89.6 million impairment charge to the IPR&D intangible assets. At December 31, 2017, the IPR&D intangible asset recorded on the Consolidated Balance Sheets was zero.

 

Change in Fair Value of Contingent Purchase Consideration

 

In connection with the acquisition of EOS in November 2013, we also recorded a purchase consideration liability equal to the estimated fair value of future payments that are contingent upon the achievement of various regulatory and sales milestones. Subsequent to the acquisition date, we re-measure contingent consideration arrangements at fair value each reporting period and record changes in fair value to change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss. Changes in fair value are primarily attributed to new information about the likelihood of achieving such milestones and the passage of time. In the absence of new information, changes to fair value reflect only the passage of time as we progress towards the achievement of future milestones. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. During the fourth quarter of 2015, we recorded a $26.9 million reduction in the fair value of the contingent purchase consideration liability due to a change in the estimated probability-weighted future milestone payments, as well as the timing of such payments, for the lucitanib program. At December 31, 2017, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets remained at zero due to the uncertainty of achieving any of the lucitanib regulatory milestones, and therefore the remote likelihood of future milestone payout amounts to the former EOS shareholders.

 

Other Income and Expense

 

Other income and expense is primarily comprised of foreign currency gains and losses resulting from transactions with CROs, investigational sites and contract manufacturers where payments are made in currencies other than the U.S. dollar. Other expense also includes interest expense recognized related to our convertible senior notes.

 

63


 

Critical Accounting Policies and Significant Judgments and Estimates

 

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

Our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K. We believe the following accounting policies to be most critical to the judgments and estimates used in the preparation of our financial statements.

 

Revenue Recognition

 

We are currently approved to sell Rubraca in the United States markets.  We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers.  Our customers subsequently sell our products to patients and health care providers.  Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. 

   

Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Product sales are recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns. Estimating rebates, chargebacks, discounts, product returns and other deductions requires significant judgments about future events and uncertainties, and requires us to rely heavily on assumptions, as well as historical experience. We only recognize revenue on product sales once the product is sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns.

   

For the year ended December 31, 2017, we recognized $55.5 million of product revenue. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the costs of Rubraca units recognized as revenue during the year ended December 31, 2017 were expensed prior to the December 19, 2016 FDA approval, and a minimal amount is included in cost of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories. The majority of products sales were of pre-commercialization inventory in 2017.

 

Revenue is recognized from milestone payments when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. We exercise judgment in determining that collectability is reasonably assured or that services have been delivered in accordance with the arrangement. We assess whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. We assess collectability based primarily on the customer’s payment history and creditworthiness of the customer. Payments that are contingent upon the achievement of a milestone will be recognized in the period in which the milestone is achieved.

 

Accrued Research and Development Expenses

 

As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make

64


 

estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include:

 

·

fees paid to CROs in connection with clinical studies;

·

fees paid to investigative sites in connection with clinical studies;

·

fees paid to vendors in connection with non-clinical development activities;

·

fees paid to vendors associated with the development of companion diagnostics; and

·

fees paid to vendors related to product manufacturing, development and distribution of clinical supplies.

 

We base our expenses related to clinical studies on our estimates of the services received and efforts expended pursuant to contracts with multiple CROs that conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period.

 

Share-Based Compensation

 

Determining the amount of share-based compensation to be recorded requires us to develop estimates of the fair value of stock options as of their grant date. Compensation expense is recognized over the vesting period of the award. Calculating the fair value of share-based awards requires that we make highly subjective assumptions. We use the Black-Scholes option pricing model to value our stock option awards. Use of this valuation methodology requires that we make assumptions as to the expected dividend yield, price volatility of our common stock, the risk-free interest rate for a period that approximates the expected term of our stock options and the expected term of our stock options. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends.

 

The fair value of stock options for the years ended December 31, 2017, 2016 and 2015 was estimated at the grant date using the following weighted average assumptions for the respective periods:

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 

 

 

    

2017

 

2016

    

2015

 

Dividend yield

 

 

 

 

Volatility (a)

 

89

%  

93

%  

72

%

Risk-free interest rate (b)

 

2.16

%  

1.77

%  

1.77

%

Expected term (years) (c)

 

5.8

 

5.8

 

6.1

 


(a)Volatility:  The expected volatility was estimated using our historical data.

(b)Risk-free interest rate:  The rate is based on the yield on the grant date of a zero-coupon U.S. Treasury bond whose maturity period approximates the option’s expected term.

(c)Expected term:  The expected term of the award was estimated using our historical data.

 

We recognized share-based compensation expense of approximately $44.7 million, $39.8 million and $40.4 million for the years ended December 31, 2017, 2016 and 2015, respectively. As of December 31, 2017, we had $89.4 million in total unrecognized share-based compensation expense, net of related forfeiture estimates, which is expected to be recognized over a weighted-average remaining vesting period of 3.3 years. We expect our share-based compensation to continue to grow in future periods due to the potential increases in the value of our common stock and headcount.

 

We estimate the level of forfeitures expected to occur and record compensation expense only for those awards that we ultimately expect will vest.

65


 

 

Valuation of Contingent Consideration Resulting from a Business Combination

 

Contingent consideration resulting from a business combination is reported at its fair value on the acquisition date. Each subsequent reporting period, the contingent consideration obligations are revalued and changes in fair value are recorded to change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss.

 

Changes to contingent consideration obligations can result from adjustments to discount rates and time periods, updates in the assumed achievement or timing of any development milestone or changes in the probability of certain clinical events and regulatory approvals. The assumptions related to determining the value of contingent consideration require significant judgment and changes to the assumptions may have a material impact on the amount of expense recorded in any given period. The acquisition of EOS resulted in the recognition of a contingent consideration liability, based on assumptions related to potential future payout amounts, estimated discount rate, probability of success for each milestone achievement and the estimated timing of the milestone payments to the former EOS shareholders.

 

During the second quarter 2016, we recorded $25.5 million reduction in fair value of the contingent purchase consideration due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At December 31, 2017, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets remained at zero due to the uncertainty of achieving any of the lucitanib regulatory milestones, and therefore the remote likelihood of future milestone payout amounts to the former EOS shareholders.

 

Intangible Assets

 

Definite-lived intangible assets related to capitalized milestones under license agreements are amortized on a straight-line basis over their remaining useful lives, which are estimated to be the remaining patent life.  If our estimate of the product’s useful life is shorter than the remaining patent life, then a shorter period is used. Amortization expense is recorded as a component of cost of sales in the Consolidated Statements of Operations and Comprehensive Loss.

 

IPR&D assets were established as part of the acquisition of EOS in November 2013 and have not been amortized, but have been assessed for impairment.

 

Intangible assets are evaluated for impairment at least annually in the fourth quarter or more frequently if impairment indicators exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the decision to discontinue the development of a drug, the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate, or new information regarding potential sales for the drug. In connection with any impairment assessment, the fair value of the intangible assets as of the date of assessment is compared to the carrying value of the intangible asset. Impairment losses are recognized if the carrying value of an intangible asset is both not recoverable and exceeds its fair value. During the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&D intangible assets due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer, thereby reducing the remaining carrying value to zero.

 

66


 

Results of Operations

 

Comparison of the Year Ended December 31, 2017 to the Year Ended December 31, 2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change

 

 

 

Year ended December 31, 

 

Favorable/(Unfavorable)

 

 

    

2017

    

2016

    

$

    

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue, net

 

$

55,511

 

$

78

 

$

55,433

 

 

71,068

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales - product

 

 

10,251

 

 

70

 

 

10,181

 

 

14,544

%

Cost of sales - intangible asset amortization

 

 

1,486

 

 

 —

 

 

1,486

 

 

100

%

Research and development

 

 

142,498

 

 

251,129

 

 

(108,631)

 

 

(43)

%

Selling, general and administrative

 

 

138,907

 

 

40,731

 

 

98,176

 

 

241

%

Acquired in-process research and development

 

 

 —

 

 

1,300

 

 

(1,300)

 

 

(100)

%

Impairment of intangible asset

 

 

 —

 

 

104,517

 

 

(104,517)

 

 

(100)

%

Change in fair value of contingent purchase consideration

 

 

 —

 

 

(24,936)

 

 

24,936

 

 

(100)

%

 Total expenses

 

 

293,142

 

 

372,811

 

 

(79,669)

 

 

(21)

%

Operating loss

 

 

(237,631)

 

 

(372,733)

 

 

135,102

 

 

(36)

%

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(10,428)

 

 

(8,491)

 

 

(1,937)

 

 

23

%

Foreign currency gain (loss)

 

 

(82)

 

 

(580)

 

 

498

 

 

(86)

%

Legal settlement loss

 

 

(105,477)

 

 

 —

 

 

(105,477)

 

 

100

%

Other income (expense)

 

 

3,643

 

 

633

 

 

3,010

 

 

476

%

Other income (expense), net

 

 

(112,344)

 

 

(8,438)

 

 

(103,906)

 

 

1,231

%

Loss before income taxes

 

 

(349,975)

 

 

(381,171)

 

 

31,196

 

 

(8)

%

Income tax benefit

 

 

3,578

 

 

32,034

 

 

(28,456)

 

 

(89)

%

Net loss

 

$

(346,397)

 

$

(349,137)

 

$

2,740

 

 

(1)

%

 

Product Revenue, Net. Product revenue for the year ended December 31, 2017 was due to the recognition of $55.5 million of net product revenue from the sale of Rubraca, which was approved for sale in the United States markets on December 19, 2016. Revenue is recorded net of sales deductions comprised of rebates, chargebacks and other discounts. Sales deductions represented approximately 8.1% of the gross product revenue recognized in the year ended December 31, 2017 and summarized as follows:

 

 

 

 

 

 

 

 

 

 

 

Year ended

 

 

    

December 31, 2017

 

 

    

$

    

% of Gross Sales

 

 

 

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

Gross product revenue

 

$

60,384

 

 

100.0%

 

Sales deductions:

 

 

 

 

 

 

 

Government rebates and chargebacks

 

 

2,575

 

 

4.3%

 

Discounts and fees

 

 

2,298

 

 

3.8%

 

Total sales deductions

 

 

4,873

 

 

8.1%

 

Product revenue, net

 

$

55,511

 

 

91.9%

 

 

Cost of Sales - Product. Product cost of sales for the year ended December 31, 2017 relate to freight and royalties costs associated with Rubraca sales for the period. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the costs of Rubraca units recognized as revenue during the year ended December 31, 2017 were expensed prior to the December 19, 2016 FDA approval, and therefore are not included in costs of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories. The majority of product sales were of pre-commercialization inventory in 2017.

 

Cost of Sales – Intangible Asset Amortization. For the year ended December 31, 2017, we recognized cost of sales of $1.5 million associated with the amortization of capitalized milestone payments related to the FDA approval of Rubraca.

67


 

Prior to the FDA approval on December 19, 2016, all acquired license and milestone payments were expensed as incurred. 

 

Research and Development Expenses. Research and development expenses decreased during the year ended December 31, 2017 compared to 2016 primarily due to lower research and development costs for rucaparib and rociletinib and classification of commercialization related expenses associated with Rubraca in selling, general and administrative expenses rather than research and development expenses. In the year ended December 31, 2017, Rubraca commercialization costs included in selling, general and administrative expenses were $95.2 million.

   

Clinical trial costs for rucaparib were $0.3 million lower compared to the same period a year ago due to completed enrollment in our ARIEL2 and ARIEL 3 studies, partially offset by higher costs from enrollment in ARIEL4, our confirmatory ovarian cancer trials, and enrollment in our TRITON2 and TRITON3 studies for prostate cancer. Diagnostic development costs were $4.4 million lower compared to the prior year as the prior year included the costs associated with our collaboration with Foundation Medicine, Inc. to develop a novel companion diagnostic test to identify patients most likely to respond to rucaparib. Finally, clinical supply and related manufacturing development costs were $15.9 million lower than 2016 due to the capitalization of these costs subsequent to the FDA approval of rucaparib. 

   

Clinical trial costs for rociletinib were $23.6 million lower than 2016 primarily due to the completion of patient enrollment for all of the TIGER studies in non-small cell lung cancer. Clinical supply and related manufacturing development costs were $6.6 million lower than 2016 driven by timing of production to support our clinical studies. 

 

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased during the year ended December 31, 2017 compared to 2016 primarily due to classification of commercialization related expenses associated with Rubraca in selling, general and administrative expenses rather than research and development expenses.

 

Acquired In-Process Research and Development Expenses.  During 2016, we made a milestone payment of $0.3 million to AstraZeneca upon the NDA submission for rucaparib and we made milestone payments totaling $1.0 million to Pfizer upon acceptance of the NDA and MAA for rucaparib by the FDA and EMA, respectively. No such payments occurred during 2017.

 

Impairment of Intangible Asset. During the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&D intangible asset relating to our lucitanib product candidate which reduced the carrying value of the intangible assets related to the product to zero. This reduction in the estimated fair value of lucitanib was the result of our and our development partner’s decision to discontinue the development of lucitanib for breast cancer.

 

Change in Fair Value of Contingent Purchase Consideration. The fair value of contingent purchase consideration decreased $24.9 million for the year ended December 31, 2016, which is due to a $25.5 million reduction in the fair value of the contingent purchase consideration liability we recorded during the second quarter of 2016 due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer.

 

Legal Settlement Loss, Net of Insurance Receivable. During 2017, we recorded a $105.5 million legal settlement loss, net of insurance receivable, related to a stipulation agreement of settlement whereby we issued the plaintiff and participating class members a total consideration comprised of $25.0 million in cash and the issuance of 1.5 million shares. The cash portion of the consideration was funded by Clovis’ insurance carriers.

 

Other Income (Expense). Other income increased for the year ended December 31, 2017 compared to 2016 due to interest income earned on our available-for-sale securities.

 

Income Tax Benefit (Expense). For the year ended December 31, 2016, we recognized a $28.4 million deferred tax benefit associated with the impairment of the IPR&D intangible assets recorded in the second quarter of 2016. In addition, during the first quarter 2016, we recognized a $3.6 million deferred tax benefit due to a reduction in the enacted corporate tax rate of a foreign jurisdiction in which we operate.

68


 

 

Comparison of the Year Ended December 31, 2016 to the Year Ended December 31, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change

 

 

 

Year ended December 31, 

 

Favorable/(Unfavorable)

 

 

    

2016

    

2015

    

$

    

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue, net

 

$

78

 

$

 —

 

$

78

 

 

100

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales - product

 

 

70

 

 

 —

 

 

70

 

 

100

%

Research and development

 

 

251,129

 

 

269,251

 

 

(18,122)

 

 

(7)

%

Selling, general and administrative

 

 

40,731

 

 

30,524

 

 

10,207

 

 

33

%

Acquired in-process research and development

 

 

1,300

 

 

12,000

 

 

(10,700)

 

 

(89)

%

Impairment of intangible asset

 

 

104,517

 

 

89,557

 

 

14,960

 

 

17

%

Change in fair value of contingent purchase consideration

 

 

(24,936)

 

 

(24,611)

 

 

(325)

 

 

 1

%

 Total expenses

 

 

372,811

 

 

376,721

 

 

(3,910)

 

 

(1)

%

Operating loss

 

 

(372,733)

 

 

(376,721)

 

 

3,988

 

 

(1)

%

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(8,491)

 

 

(8,372)

 

 

(119)

 

 

 1

%

Foreign currency gain (loss)

 

 

(580)

 

 

2,740

 

 

(3,320)

 

 

(121)

%

Other income (expense)

 

 

633

 

 

416

 

 

217

 

 

52

%

Other income (expense), net

 

 

(8,438)

 

 

(5,216)

 

 

(3,222)

 

 

62

%

Loss before income taxes

 

 

(381,171)

 

 

(381,937)

 

 

766

 

 

(0)

%

Income tax benefit

 

 

32,034

 

 

29,076

 

 

2,958

 

 

10

%

Net loss

 

$

(349,137)

 

$

(352,861)

 

$

3,724

 

 

(1)

%

 

Product Revenue, Net. Product revenue for the year ended December 31, 2016 was due to the recognition of $0.1 million of net product revenue from the sale of Rubraca, which was approved for sale in the United States markets on December 19, 2016.

 

Cost of Sales - Product. Product cost of sales for the year ended December 31, 2016 relate to freight and royalties costs associated with Rubraca sales for the period. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the costs of Rubraca units recognized as revenue during the year ended December 31, 2016 were expensed prior to the December 19, 2016 FDA approval, and therefore are not included in costs of sales during the current period.

 

Research and Development Expenses. The decrease in research and development expenses for the year ended December 31, 2017 compared to 2016 was primarily due to decreased development activities for the rociletinib program partially offset by higher expenses related to the rucaparib program.

 

Clinical trial costs for rucaparib were $14.0 million higher in 2016 than the prior year primarily due to higher enrollment in the ARIEL2 and ARIEL3 studies in ovarian cancer. Market research, disease education and other commercial product planning activities were $16.6 million higher than the prior year due to the preparation for the potential regulatory approval and commercial launch of rucaparib. Clinical supply and related manufacturing development costs were $9.2 million higher than the prior year, as we increased production to support the expanded clinical studies. In addition, diagnostic development costs for rucaparib were $0.9 million higher than the prior year due to the advancement of our collaboration with Foundation Medicine, Inc. to develop a novel companion diagnostic test to identify patients most likely to respond to rucaparib.

 

Salaries, share-based compensation expense and other personnel-related costs were $24.0 million higher in 2016 driven by increased headcount to support our expanded development and commercial planning activities. During the third quarter of 2015, we completed the hiring of our U.S. sales and marketing and medical affairs organization in preparation for the potential regulatory approval and commercial launch of rociletinib.

 

Clinical trial costs for rociletinib were $41.0 million lower in 2016 than the prior year primarily due to the completion of patient enrollment in the TIGER-1, TIGER-2 and TIGER-X studies in non-small cell lung cancer. This decrease was

69


 

partially offset by higher clinical trial costs for the TIGER-3 study, which began enrolling patients during the second quarter of 2015. Market research, disease education and other commercial planning activities were $19.7 million lower than the prior year. We incurred higher costs during 2015 due to the preparation for the potential regulatory approval and commercial launch of rociletinib. In addition, clinical supply and related manufacturing development costs were $17.2 million lower than the prior year driven by timing of production to support our clinical studies.

 

Selling, General and Administrative Expenses. The increase in selling, general and administrative expenses for the year ended December 31, 2016 over 2015 was primarily due to $3.1 million of selling expenses related to the commercialization of Rubraca, $5.3 million higher legal expense and, to a lesser extent, higher personnel costs. Pre-commercialization activities for Rubraca were included in research and development expenses.

 

Acquired In-Process Research and Development Expenses. Acquired in-process research and development expenses decreased for the year ended December 31, 2016 compared to 2015. During the third quarter of 2015, we made milestone payments totaling $12.0 million to Celgene upon acceptance of the NDA and MAA for rociletinib by the FDA and EMA, respectively. During the second quarter of 2016, we made a milestone payment of $0.3 million to AstraZeneca upon the NDA submission for rucaparib. During 2016, we made milestone payments totaling $1.0 million to Pfizer upon acceptance of the NDA and MAA for rucaparib by the FDA and EMA, respectively.

 

Impairment of Intangible Asset. During the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&D intangible asset relating to our lucitanib product candidate which reduced the carrying value of the intangible assets related to the product to zero. This reduction in the estimated fair value of lucitanib was the result of our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. During the fourth quarter of 2015, we recorded an $89.6 million impairment charge to the IPR&D intangible asset relating to our lucitanib product candidate. This reduction in the estimated fair value of lucitanib was the result of our and our development partner’s decision to terminate the development of lucitanib for lung cancer, as well as updates to the probability-weighted discounted cash flow assumptions for the breast cancer indication.

 

Change in Fair Value of Contingent Purchase Consideration. Change in fair value of contingent purchase consideration was a decrease of $24.9 million for the year ended December 31, 2016 compared to a decrease of $24.6 million for the year ended December 31, 2015. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. During the fourth quarter of 2015, we recorded a $26.9 million reduction in the fair value of the contingent purchase consideration liability due to a change in the estimated probability-weighted future milestone payments, as well as the timing of such payments, for the lucitanib program.

 

Other Income (Expense), Net. Other expense increased for the year ended December 31, 2016 compared to 2015. During 2016, we recognized $0.6 million of foreign currency losses compared with $2.7 million of gains in 2015. The change in the foreign currency gains and losses was driven by fluctuations in the foreign currency rate utilized to translate our Euro-denominated contingent purchase consideration liability into U.S. dollars.

 

Income Tax Benefit (Expense). For the year ended December 31, 2016, we recognized a $28.4 million deferred tax benefit associated with the impairment of the IPR&D intangible assets recorded in the second quarter of 2016. In addition, during the first quarter 2016, we recognized a $3.6 million deferred tax benefit due to a reduction in the enacted corporate tax rate of a foreign jurisdiction in which we operate.

 

For the year ended December 31, 2015, we recognized a $29.1 million deferred tax benefit primarily associated with the impairment of the IPR&D intangible assets recorded in the fourth quarter of 2015.

 

Liquidity and Capital Resources

 

To date, we have funded our operations through the public offering of our common stock and the private placement of convertible debt securities and preferred stock. In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2017, we had cash, cash equivalents and available-for-sale securities totaling $563.7 million.

70


 

 

The following table sets forth the primary sources and uses of cash for each of the periods set forth below:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 

 

 

 

2017

    

2016

    

2015

 

 

 

(in thousands)

 

Net cash used in operating activities

 

$

(260,904)

 

$

(266,680)

 

$

(253,066)

 

Net cash (used in) provided by investing activities

 

 

(54,102)

 

 

199,299

 

 

(254,578)

 

Net cash provided by financing activities

 

 

562,075

 

 

5,176

 

 

304,480

 

Effect of exchange rate changes on cash and cash equivalents

 

 

943

 

 

(365)

 

 

(757)

 

Net increase (decrease) in cash and cash equivalents

 

$

248,012

 

$

(62,570)

 

$

(203,921)

 

 

Operating Activities

 

Net cash used in operating activities for the year ended December 31, 2017 decreased by $5.8 million compared to 2016 due to a decrease in net loss adjusted for non-cash items of $63.3 million, primarily due the recognition of $55.5 million of revenue during 2017, partially offset by inventory purchases and deposits of $48.0 million and the recognition of $6.2 million in accounts receivable in 2017.

 

Net cash used in operating activities increased $13.6 million for the year ended December 31, 2016 compared to 2015 driven by an increase in payments for other accrued expenses related to the rociletinib program of non-clinical and clinical development studies, for which enrollment was completed in 2016.

 

Investing Activities

 

Net cash used in investing activities for the year ended December 31, 2017 includes $263.5 million in purchases of available-for-sale securities compared to no purchases in 2016.

 

Net cash provided by investing activities for the year ended December 31, 2016 includes $200.0 million in sales of available-for-sale securities compared to $251.5 million in net purchases in 2015.

 

Financing Activities

 

Net cash provided by financing activities for the year ended December 31, 2017 includes $545.8 million in net proceeds received from our common stock offerings in January and June 2017 and $16.2 million received from employee stock option exercises and stock purchases under the employee stock purchase plan.

 

Net cash provided by financing activities for the year ended December 31, 2016 is due to $5.2 million received from employee stock option exercises and stock purchases under the employee stock purchase plan.

 

Net cash provided by financing activities for the year ended December 31, 2015 includes $298.5 million in net proceeds received from our common stock offering in July 2015 and $6.0 million received from employee stock option exercises and stock purchases under the employee stock purchase plan.

 

Operating Capital Requirements

 

On December 19, 2016, the FDA approved Rubraca tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated with advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on FDA-approved companion diagnostic for Rubraca. We expect to incur significant losses for the foreseeable future, as we commercialize Rubraca and expand our selling, general and administrative functions to support the growth in our commercial organization. Additionally, our operating plan for the next 12 months includes a significant investment in inventory to meet the projected commercial requirements for Rubraca. We receive the active pharmaceutical ingredient in Rubraca from one supplier and we experience long lead times associated with its production. Accordingly, we expect to experience a decrease in our liquidity at the beginning of a production cycle and an increase as the inventory produced is sold. 

 

71


 

As of December 31, 2017, we had cash, cash equivalents and available-for-sale securities totaling $563.7 million and total current liabilities of $81.5 million. In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including commercial planning and sales and marketing expenses associated with the launch of Rubraca in the United States and, if approved by the European Commission in Europe, funding of its development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months.

 

Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including but not limited to:

 

·

the number and characteristics of the product candidates, companion diagnostics and indications we pursue;

·

the achievement of various development, regulatory and commercial milestones resulting in required payments to partners pursuant to the terms of our license agreements;

·

the scope, progress, results and costs of researching and developing our product candidates and related companion diagnostics and conducting clinical and non-clinical trials;

·

the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates and companion diagnostics;

·

the cost of commercialization activities, including marketing and distribution costs;

·

the cost of manufacturing any of our product candidates we successfully commercialize;

·

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and outcome of such litigation; and

·

the timing, receipt and amount of sales, if any, of our product candidates.

 

Contractual Obligations and Commitments

 

The following table summarizes our contractual obligations at December 31, 2017 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

Less than 1

    

 

 

    

 

 

    

More Than 5

    

 

 

 

 

 

Year

 

1 to 3 Years

 

3 to 5 Years

 

Years

 

Total

 

Convertible senior notes

 

$

 —

 

$

 —

 

$

287,500

 

$

 —

 

$

287,500

 

Interest on convertible senior notes

 

 

7,187

 

 

14,376

 

 

5,091

 

 

 —

 

 

26,654

 

Operating lease commitments

 

 

3,050

 

 

7,646

 

 

6,374

 

 

11,563

 

 

28,633

 

Milestone payments (a)

 

 

23,000

 

 

 —

 

 

 —

 

 

 —

 

 

23,000

 

Purchase and other commitments (b)

 

 

137,154

 

 

25,179

 

 

24,630

 

 

36,945

 

 

223,908

 

Total

 

$

170,391

 

$

47,201

 

$

323,595

 

$

48,508

 

$

589,695

 


(a)Amount relates to a $20 million milestone payment, which we have exercised the option to defer payment by agreeing to pay $23 million within 18 months after the date of the FDA approval of Rubraca on December 19, 2016.

 

(b)On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for rucaparib. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in rucaparib that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified in any forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the rucaparib active ingredient.  We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties.

 

72


 

Royalty and License Fee Commitments

 

We have certain obligations under licensing agreements with third parties contingent upon achieving various development, regulatory and commercial milestones. On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) European Commission approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones.

 

On December 19, 2016, the FDA approved Rubraca tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated with advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, in which we have exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. These payments were recognized as intangible assets and will be amortized over the estimated remaining useful life of rucaparib.

 

Pursuant to our license agreements for the development of rucaparib, we are required to make regulatory milestone payments up to an additional $69.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments if specified annual sales targets for rucaparib are met, which relate to annual sales targets of $250.0 million and above, which, in aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib.

 

We are obligated to pay additional consideration to the former EOS shareholders if certain future regulatory and lucitanib-related sales milestones are achieved. The estimated fair value of these payments was recorded as contingent purchase consideration on our Consolidated Balance Sheets. The potential contingent milestone payments range from a zero payment, which assumes lucitanib fails to achieve any of the regulatory milestones, to $186.0 million ($65.0 million and €115.0 million) if all regulatory and sales milestones are met, utilizing the translation rate at December 31, 2017. The estimated fair value of the liability was zero at December 31, 2017 due to the uncertainty of achieving any of the lucitanib regulatory milestones, and therefore the remote likelihood of future milestone payout amounts to the former EOS shareholders. We are also obligated to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier.

 

Pursuant to our license agreement for the development and commercialization of rociletinib, we may be required to pay up to an additional aggregate of $98.0 million in regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptance and approvals are achieved. Further, we may be required to pay up to an aggregate of $120.0 million in sales milestone payments if certain annual sales targets are met for rociletinib.

 

Finally, pursuant to terms of each of our product license agreements, we will pay royalties to our licensors on sales, if any, of the respective products.

 

Off-Balance Sheet Arrangements

 

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under the rules promulgated by the U.S. Securities and Exchange Commission.

 

Tax Loss Carryforwards

 

As of December 31, 2017, we have net operating loss (“NOL”) carryforwards of approximately $1.0 billion to offset future federal income taxes. We also have research and development and orphan drug tax credit carryforwards of $245.1 million to offset future federal income taxes. The federal net operating loss carryforwards and research and development and orphan drug tax credit carryforwards expire at various times through 2037.

 

73


 

We believe that a change in ownership as defined under Section 382 of the U.S. Internal Revenue Code occurred as a result of our public offering of common stock completed in April 2012. Future utilization of the federal net operating losses and tax credit carryforwards accumulated from inception to the change in ownership date will be subject to annual limitations to offset future taxable income. At this time, we do not believe this limitation will prevent the utilization of the federal NOL or credit carryforward prior to expiration. It is possible that a change in ownership will occur in the future, which will limit the NOL amounts generated since the last estimated change in ownership. At December 31, 2017, we recorded a 100% valuation allowance against our net deferred tax assets in the U.S. of approximately $561.1 million and a $3.0 million valuation allowance against tax assets in foreign jurisdictions, as we believe it is more likely than not that the tax benefits will not be fully realized. In the future, if we determine that a portion or all of the tax benefits associated with our tax carryforwards will be realized, net income would increase in the period of determination.

 

Recently Adopted and Issued Accounting Standards

For a discussion of recently adopted and issued accounting standards, see Note 2, Summary of Significant Accounting Policies, in the Notes to Consolidated Financial Statements included in Part II, Item 8, Financial Statements and Supplementary Data, of this Annual Report on Form 10-K.

 

ITEM 7A.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are exposed to market risk related to changes in interest rates. As of December 31, 2017, we had cash, cash equivalents and available-for-sale securities of $563.7 million, consisting of bank demand deposits, money market funds and U.S. treasury securities. The primary objectives of our investment policy are to preserve principal and maintain proper liquidity to meet operating needs. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Our available-for-sale securities are subject to interest rate risk and will decline in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our portfolio.

 

We contract with contract research organizations, investigational sites and contract manufacturers globally where payments are made in currencies other than the U.S. dollar. In addition, on October 3, 2016, we entered into a Manufacturing and Services Agreement with a Swiss company for the production and supply of the active ingredient for rucaparib. Under the terms of this agreement, payments for the supply of the active ingredient in rucaparib as well as scheduled capital program fee payment toward capital equipment and other costs associated with the construction of a dedicated production train will be made in Swiss francs. Once the production facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the agreement, which expires on December 31, 2025.

 

As of December 31, 2017, $223.9 million of purchase commitments exist under the Swiss Manufacturing and Services Agreement and we are required to remit amounts due in Swiss francs. Due to other variables that may exist, it is difficult to quantify the impact of a particular change in exchange rates. However, we estimate that if the value of the US dollar was to strengthen by 10% compared to the value of Swiss franc as of December 31, 2017, it would decrease the total US dollar purchase commitment under the Swiss Manufacturing and Services Agreement by approximately $20.4 million. Similarly, a 10% weakening of the US dollar compared to the Swiss franc would increase the total US dollar purchase commitment by approximately $24.9 million.

 

While we periodically hold foreign currencies, primarily Euro and Pound Sterling, we do not use other financial instruments to hedge our foreign exchange risk. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. As of December 31, 2017 and 2016, approximately 1% of our total liabilities were denominated in currencies other than the functional currency.

 

74


 

ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

The financial statements required by this Item are included in Item 15 of this report and are presented beginning on page F-1.

 

ITEM  9.CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

 

ITEM  9A.CONTROLS AND PROCEDURES

 

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

 

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (“Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective.

 

As of December 31, 2017, our management, with the participation of our Chief Executive Officer and Principal Financial and Accounting Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and Principal Financial and Accounting Officer concluded that, as of December 31, 2017, the design and operation of our disclosure controls and procedures were effective at the reasonable assurance level.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining effective internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, a company’s principal executive officer and principal financial officer and affected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:

·

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;

·

provide reasonable assurance that transactions are recorded as necessary to permit preparation of the consolidated financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

·

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate.

 

As of December 31, 2017, our management, with the participation of our Chief Executive Officer and Principal Financial and Accounting Officer, assessed the effectiveness of our internal control over financial reporting as defined in Rules 13a-15(f) or 15d-15(f) of the Exchange Act. In making its assessment, management used the criteria established in Internal Control—Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its assessment, our management determined that, as of December 31, 2017, we maintained effective internal control over financial reporting based on those criteria.

75


 

 

In addition, the effectiveness of our internal control over financial reporting as of December 31, 2017 has been audited by Ernst & Young, LLP, an independent registered public accounting firm.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal controls over financial reporting during the quarter ended December 31, 2017 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

76


 

Report of Independent Registered Public Accounting Firm

 

The Stockholders and Board of Directors of Clovis Oncology, Inc.

 

Opinion on Internal Control over Financial Reporting

We have audited Clovis Oncology, Inc.’s internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Clovis Oncology Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on the COSO criteria.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company, as of December 31, 2017 and 2016, and the related consolidated statements of operations and comprehensive loss, stockholders' equity (deficit), and cash flows for each of the three years in the period ended December 31, 2017, and the related notes  and our  report dated February 27, 2018 expressed an unqualified opinion thereon.

 

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

 

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

 

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

/s/ Ernst & Young LLP

 

Denver, Colorado

February 27, 2018

 

77


 

ITEM  9B.OTHER INFORMATION

 

None.

PART III

 

Certain information required by Part III is omitted from this Annual Report on Form 10-K and is incorporated herein by reference from our definitive proxy statement relating to our 2018 annual meeting of stockholders, pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended, also referred to in this Form 10-K as our 2018 Proxy Statement, which we expect to file with the SEC no later than April 30, 2018.  

 

ITEM  10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Information regarding our directors, including the audit committee and audit committee financial experts, and executive officers and compliance with Section 16(a) of the Exchange Act will be included in our 2018 Proxy Statement and is incorporated herein by reference.

 

We have adopted a Code of Business Ethics for all of our directors, officers and employees as required by NASDAQ governance rules and as defined by applicable SEC rules. Stockholders may locate a copy of our Code of Business Ethics on our website at www.clovisoncology.com or request a copy without charge from:

 

Clovis Oncology, Inc.

Attention: Investor Relations

5500 Flatiron Parkway, Suite 100

Boulder, CO 80301

 

We will post to our website any amendments to the Code of Business Ethics and any waivers that are required to be disclosed by the rules of either the SEC or NASDAQ.

 

ITEM  11.EXECUTIVE COMPENSATION

 

The information required by this item regarding executive compensation will be included in our 2018 Proxy Statement and is incorporated herein by reference.

 

ITEM  12.SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The information required by this item regarding security ownership of certain beneficial owners and management will be included in the 2018 Proxy Statement and is incorporated herein by reference.

 

ITEM  13.CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The information required by this item regarding certain relationships and related transactions and director independence will be included in the 2018 Proxy Statement and is incorporated herein by reference.

 

ITEM  14.PRINCIPAL ACCOUNTING FEES AND SERVICES

 

The information required by this item regarding principal accounting fees and services will be included in the 2018 Proxy Statement and is incorporated herein by reference.

 

78


 

PART IV

 

ITEM  15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a)The following documents are being filed as part of this report: 

 

(1) Financial Statements.

 

Reference is made to the Index to Financial Statements of Clovis Oncology, Inc. appearing on page F-1 of this report.

 

(2) Financial Statement Schedules.

 

All financial statement schedules have been omitted because they are not applicable or not required or because the information is included elsewhere in the Financial Statements or the Notes thereto.

 

(3) Exhibits.

 

Reference is made to the Index to Exhibits filed as a part of this Annual Report on Form 10-K.

79


 

INDEX TO EXHIBITS

 

Exhibit
Number

    

Exhibit Description

 

 

 

3.1(5)

 

Amended and Restated Certificate of Incorporation of Clovis Oncology, Inc.

 

 

 

3.2(5)

 

Amended and Restated Bylaws of Clovis Oncology, Inc.

 

 

 

4.1(3)

 

Form of Common Stock Certificate of Clovis Oncology, Inc.

 

 

 

4.2(8)

 

Indenture, dated as of September 9, 2014, by and between the Company and The Bank of New York Mellon Trust Company, N.A.

 

 

 

10.1*(4)

 

Amended and Restated Strategic License Agreement, dated as of June 16, 2011, by and between Clovis Oncology, Inc. and Avila Therapeutics, Inc.

 

 

 

10.2*(4)

 

License Agreement, dated as of June 2, 2011, by and between Clovis Oncology, Inc. and Pfizer Inc.

 

 

 

10.3+(1)

 

Clovis Oncology, Inc. 2009 Equity Incentive Plan.

 

 

 

10.4+(4)

 

Clovis Oncology, Inc. 2011 Stock Incentive Plan.

 

 

 

10.5+(1)

 

Form of Clovis Oncology, Inc. 2009 Equity Incentive Plan Stock Option Agreement.

 

 

 

10.6+(4)

 

Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan Stock Option Agreement.

 

 

 

10.7+(3)

 

Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

 

 

 

10.8+(3)

 

Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

 

 

 

10.9+(1)

 

Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Paul Klingenstein.

 

 

 

10.10+(1)

 

Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and James C. Blair.

 

 

 

10.11+(1)

 

Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Edward J. McKinley.

 

 

 

10.12+(1)

 

Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Thorlef Spickschen.

 

 

 

10.13+(1)

 

Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and M. James Barrett.

 

 

 

10.14+(1)

 

Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Brian G. Atwood.

 

 

 

10.15+(1)

 

Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

 

 

 

10.16+(1)

 

Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Erle T. Mast.

 

 

 

10.17+(1)

 

Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

 

 

 

80


 

Exhibit
Number

    

Exhibit Description

10.18+(1)

 

Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Andrew R. Allen.

 

 

 

10.19+(4)

 

Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan.

 

 

 

10.20+(4)

 

Clovis Oncology, Inc. 2011 Cash Bonus Plan.

 

 

 

10.21+(6)

 

Indemnification Agreement, dated as of March 22, 2012, by and between Clovis Oncology, Inc. and Steven L. Hoerter.

 

 

 

10.22+(2)

 

Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Ginger L. Graham.

 

 

 

10.23+(2)

 

Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Keith Flaherty.

 

 

 

10.24(7)

 

Stock Purchase Agreement, dated as of November 19, 2013, by and among the Company, EOS, the Sellers listed on Exhibit A thereto and Sofinnova Capital V FCPR, acting in its capacity as the Sellers’ Representative.

 

 

 

10.25*(7)

 

Development and Commercialization Agreement, dated as of October 24, 2008, by and between Advenchen Laboratories LLC and Ethical Oncology Science S.p.A., as amended by the First Amendment, dated as of April 13, 2010 and the Second Amendment, dated as of July 30, 2012.

 

 

 

10.26*(7)

 

Collaboration and License Agreement, dated as of September 28, 2012, by and between Ethical Oncology Science S.p.A. and Les Laboratoires Servier and Institut de Recherches Internationales Servier.

 

 

 

10.27+(12)

 

Indemnification Agreement, effective as of August 3, 2015, by and between Clovis Oncology, Inc. and Lindsey Rolfe.

 

 

 

10.28+(12)

 

Employment Agreement, dated as of February 25, 2016, by and between Clovis Oncology, Inc. and Lindsey Rolfe.

 

 

 

10.29+(12)

 

Indemnification Agreement, effective as of February 1, 2016, by and between Clovis Oncology, Inc. and Dale Hooks.

 

 

 

10.30+(12)

 

Employment Agreement, effective as of February 1, 2016, by and between Clovis Oncology, Inc. and Dale Hooks.

 

 

 

10.31+(9)

 

Indemnification Agreement, dated as of February 17, 2016, by and between Clovis Oncology, Inc. and Daniel W. Muehl.

 

 

 

10.32+(15)

 

Employment Agreement, dated as of July 6, 2017, by and between Clovis Oncology, Inc. and Daniel W. Muehl.

 

 

 

10.33+(10)

 

Salary Waiver Letter, dated as of May 9, 2016, by and between Clovis Oncology, Inc. and Patrick J. Mahaffy.

 

 

 

10.34*(11)

 

First Amendment to License Agreement, by and between Clovis Oncology, Inc. and Pfizer Inc., dated as of August 30, 2016.

 

 

 

10.35+(13)

 

Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan RSU Agreement.

 

 

 

10.36*(13)

 

Manufacturing Services Agreement, by and between Clovis Oncology, Inc. and Lonza Ltd, dated as of October 3, 2016.

 

 

 

81


 

Exhibit
Number

    

Exhibit Description

10.37*(14)

 

Strata Trial Collaboration Agreement, by and between Clovis Oncology, Inc. and Strata Oncology, Inc., dated as of January 30, 2017.

 

 

 

12.1

 

Computation of Ratios of Earnings to Fixed Charges

 

 

 

21.1(16)

 

List of Subsidiaries of Clovis Oncology, Inc.

 

 

 

23.1

 

Consent of Independent Registered Public Accounting Firm

 

 

 

31.1

 

Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

 

 

 

31.2

 

Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

 

 

 

32.1

 

Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2

 

Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document


(1)

Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on June 23, 2011.

(2)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on June 14, 2013.

(3)

Filed as an exhibit with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on August 31, 2011.

(4)

Filed as an exhibit with Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on October 31, 2011.

(5)

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on March 15, 2012.

(6)

Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-180293) on March 23, 2012.

(7)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on November 19, 2013.

(8)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on September 9, 2014.

(9)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on April 1, 2016.

(10)

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on May 9, 2016.

(11)

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on November 4, 2016.

(12)

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 29, 2016.

(13)

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 23, 2017.

(14)

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on May 4, 2017.

(15)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on July 7, 2017.

(16)

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on August 3, 2017.

+     Indicates management contract or compensatory plan.

*     Confidential treatment has been sought or granted with respect to portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission.

82


 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

CLOVIS ONCOLOGY, INC.

 

 

 

By:

/S/ PATRICK J. MAHAFFY

 

 

Patrick J. Mahaffy

Date: February 27, 2018

 

President and Chief Executive Officer; Director

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

 

Name

   

Title

   

Date

 

 

 

 

 

/S/ PATRICK J. MAHAFFY

 

President and Chief Executive Officer; Director
(Principal Executive Officer)

 

February 27, 2018

Patrick J. Mahaffy

 

 

 

 

 

/S/ DANIEL W. MUEHL

Daniel W. Muehl

 

Senior Vice President of Finance

(Principal Financial Officer and Principal         Accounting Officer)

 

February 27, 2018

 

 

 

 

 

/S/ BRIAN G. ATWOOD

Brian G. Atwood

 

Director

 

February 27, 2018

 

 

 

 

 

/S/ M. JAMES BARRETT

M. James Barrett

 

Director

 

February 27, 2018

 

 

 

 

 

/S/ JAMES C. BLAIR

James C. Blair

 

Director

 

February 27, 2018

 

 

 

 

 

/S/ KEITH FLAHERTY

Keith Flaherty

 

Director

 

February 27, 2018

 

 

 

 

 

/S/ GINGER L. GRAHAM

Ginger L. Graham

 

Director

 

February 27, 2018

 

 

 

 

 

/S/ PAUL KLINGENSTEIN

Paul Klingenstein

 

Director

 

February 27, 2018

 

 

 

 

 

/S/ EDWARD J. MCKINLEY

Edward J. McKinley

 

Director

 

February 27, 2018

 

 

 

 

 

/S/ THORLEF SPICKSCHEN

Thorlef Spickschen

 

Director

 

February 27, 2018

 

 

 

83


 

F-1


 

Report of Independent Registered Public Accounting Firm

 

The Stockholders and Board of Directors of Clovis Oncology, Inc.

 

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Clovis Oncology, Inc. (the Company) as of December 31, 2017 and 2016, and the related consolidated statements of operations and comprehensive loss, stockholders' equity (deficit), and cash flows for each of the three years in the period ended December 31, 2017, and the related notes (collectively referred to as the consolidated “financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company at December 31, 2017 and 2016, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity of U.S. generally accepted accounting principles.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 27, 2018 expressed an unqualified opinion thereon.

 

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ Ernst & Young LLP

 

We have served as the Company’s auditor since 2009.

 

Denver, Colorado

February 27, 2018

 

F-2


 

 

CLOVIS ONCOLOGY, INC.

 

Consolidated Statements of Operations and Comprehensive Loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Year ended December 31, 

 

 

 

2017

    

2016

    

2015

 

 

 

(in thousands, except per share amounts)

 

Revenues:

 

 

  

 

 

  

 

 

  

 

Product revenue, net

 

$

55,511

 

$

78

 

$

 —

 

Operating expenses:

 

 

  

 

 

  

 

 

  

 

Cost of sales - product

 

 

10,251

 

 

70

 

 

 —

 

Cost of sales - intangible asset amortization

 

 

1,486

 

 

 —

 

 

 —

 

Research and development

 

 

142,498

 

 

251,129

 

 

269,251

 

Selling, general and administrative

 

 

138,907

 

 

40,731

 

 

30,524

 

Acquired in-process research and development

 

 

 —

 

 

1,300

 

 

12,000

 

Impairment of intangible asset

 

 

 —

 

 

104,517

 

 

89,557

 

Change in fair value of contingent purchase consideration

 

 

 —

 

 

(24,936)

 

 

(24,611)

 

Total expenses

 

 

293,142

 

 

372,811

 

 

376,721

 

Operating loss

 

 

(237,631)

 

 

(372,733)

 

 

(376,721)

 

Other income (expense):

 

 

  

 

 

  

 

 

  

 

Interest expense

 

 

(10,428)

 

 

(8,491)

 

 

(8,372)

 

Foreign currency gain (loss)

 

 

(82)

 

 

(580)

 

 

2,740

 

Legal settlement loss

 

 

(105,477)

 

 

 —

 

 

 —

 

Other income

 

 

3,643

 

 

633

 

 

416

 

Other income (expense), net

 

 

(112,344)

 

 

(8,438)

 

 

(5,216)

 

Loss before income taxes

 

 

(349,975)

 

 

(381,171)

 

 

(381,937)

 

Income tax benefit

 

 

3,578

 

 

32,034

 

 

29,076

 

Net loss

 

$

(346,397)

 

$

(349,137)

 

$

(352,861)

 

Other comprehensive income (loss):

 

 

  

  

 

  

 

 

  

  

Foreign currency translation adjustments, net of tax

 

 

5,517

  

 

(357)

 

 

(22,629)

  

Net unrealized gain (loss) on available-for-sale securities, net of tax

 

 

(110)

  

 

237

 

 

(383)

  

Other comprehensive income (loss)

 

 

5,407

  

 

(120)

 

 

(23,012)

  

Comprehensive loss

 

$

(340,990)

 

$

(349,257)

 

$

(375,873)

 

 

 

 

 

 

 

 

 

 

 

 

Loss per basic and diluted common share:

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per common share

 

$

(7.36)

 

$

(9.07)

 

$

(9.79)

 

Basic and diluted weighted average common shares outstanding

 

 

47,047

 

 

38,478

 

 

36,026

 

 

See accompanying Notes to Consolidated Financial Statements.

F-3


 

 

 

CLOVIS ONCOLOGY, INC.

 

Consolidated Balance Sheets

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

December 31, 

 

 

    

2017

    

2016

 

 

 

 

 

 

 

 

 

ASSETS

 

 

  

 

 

  

 

Current assets:

 

 

  

 

 

  

 

Cash and cash equivalents

 

$

464,198

 

$

216,186

 

Accounts receivable, net

 

 

6,181

 

 

121

 

Inventories

 

 

27,508

 

 

 —

 

Available-for-sale securities

 

 

99,533

 

 

49,997

 

Prepaid research and development expenses

 

 

1,559

 

 

6,427

 

Deposit on inventory

 

 

20,461

 

 

 —

 

Other current assets

 

 

7,500

 

 

6,679

 

Total current assets

 

 

626,940

 

 

279,410

 

Property and equipment, net

 

 

4,007

 

 

4,440

 

Intangible assets, net

 

 

19,561

 

 

21,047

 

Goodwill

 

 

65,217

 

 

57,192

 

Other assets

 

 

19,505

 

 

2,468

 

Total assets

 

$

735,230

 

$

364,557

 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 

 

  

 

 

  

 

Current liabilities:

 

 

  

 

 

  

 

Accounts payable

 

$

15,147

 

$

10,912

 

Accrued research and development expenses

 

 

18,465

 

 

35,198

 

Milestone liability

 

 

22,022

 

 

 —

 

Other accrued expenses

 

 

25,883

 

 

19,487

 

Total current liabilities

 

 

81,517

 

 

65,597

 

Milestone liability

 

 

 —

 

 

20,062

 

Convertible senior notes

 

 

282,406

 

 

281,126

 

Deferred rent, long-term

 

 

3,671

 

 

1,406

 

Total liabilities

 

 

367,594

 

 

368,191

 

Commitments and contingencies (Note 14)

 

 

  

 

 

  

 

Stockholders' equity (deficit):

 

 

  

 

 

  

 

Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2017 and December 31, 2016

 

 

 —

 

 

 —

 

Common stock, $0.001 par value per share, 100,000,000 shares authorized at December 31, 2017 and December 31, 2016; 50,565,119 and 38,724,090 shares issued and outstanding at December 31, 2017 and December 31, 2016 respectively

 

 

51

 

 

39

 

Additional paid-in capital

 

 

1,887,198

 

 

1,174,950

 

Accumulated other comprehensive loss

 

 

(42,173)

 

 

(47,580)

 

Accumulated deficit

 

 

(1,477,440)

 

 

(1,131,043)

 

Total stockholders' equity (deficit)

 

 

367,636

 

 

(3,634)

 

Total liabilities and stockholders' equity (deficit)

 

$

735,230

 

$

364,557

 

 

See accompanying Notes to Consolidated Financial Statements.

F-4


 

CLOVIS ONCOLOGY, INC.

 

Consolidated Statements of Stockholders’ Equity (Deficit)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

    

    

    

 

    

    

 

    

Accumulated

    

    

 

    

    

 

 

 

 

 

 

 

 

 

Additional

 

Other

 

 

 

 

 

 

 

 

 

Common Stock

 

Paid-In

 

Comprehensive

 

Accumulated

 

 

 

 

 

 

Shares

 

Amount

 

Capital

 

Income (Loss)

 

Deficit

 

Total

 

 

 

(in thousands, except for share amounts)

 

Balance at January 1,2015

 

33,977,187

 

$

34

 

$

785,089

 

$

(24,448)

 

$

(429,045)

 

$

331,630

 

Issuance of common stock, net of issuance costs of $17,741

 

4,054,487

 

 

 4

 

 

298,505

 

 

 —

 

 

 —

 

 

298,509

 

Issuance of common stock under employee stock purchase plan

 

32,021

 

 

 —

 

 

493

 

 

 —

 

 

 —

 

 

493

 

Exercise of stock options

 

295,759

 

 

 —

 

 

5,534

 

 

 —

 

 

 —

 

 

5,534

 

Share-based compensation expense

 

 —

 

 

 —

 

 

40,357

 

 

 —

 

 

 —

 

 

40,357

 

Net unrealized loss on available-for-sale securities

 

 —

 

 

 —

 

 

 —

 

 

(383)

 

 

 —

 

 

(383)

 

Foreign currency translation adjustments

 

 —

 

 

 —

 

 

 —

 

 

(22,629)

 

 

 —

 

 

(22,629)

 

Net loss

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

(352,861)

 

 

(352,861)

 

Balance at December 31, 2015

 

38,359,454

 

 

38

 

 

1,129,978

 

 

(47,460)

 

 

(781,906)

 

 

300,650

 

Issuance of common stock under employee stock purchase plan

 

110,508

 

 

 —

 

 

1,965

 

 

 —

 

 

 —

 

 

1,965

 

Exercise of stock options

 

247,431

 

 

 1

 

 

3,268

 

 

 —

 

 

 —

 

 

3,269

 

Issuance of common stock from vesting of restricted stock units, net of shares withheld for taxes

 

6,697

 

 

 —

 

 

(57)

 

 

 —

 

 

 —

 

 

(57)

 

Share-based compensation expense

 

 —

 

 

 —

 

 

39,796

 

 

 —

 

 

 —

 

 

39,796

 

Net unrealized gain on available-for-sale securities

 

 —

 

 

 —

 

 

 —

 

 

237

 

 

 —

 

 

237

 

Foreign currency translation adjustments

 

 —

 

 

 —

 

 

 —

 

 

(357)

 

 

 —

 

 

(357)

 

Net loss

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

(349,137)

 

 

(349,137)

 

Balance at December 31, 2016

 

38,724,090

 

 

39

 

 

1,174,950

 

 

(47,580)

 

 

(1,131,043)

 

 

(3,634)

 

Issuance of common stock, net of issuance costs

 

9,670,454

 

 

10

 

 

545,828

 

 

 —

 

 

 —

 

 

545,838

 

Issuance of common stock under employee stock purchase plan

 

51,681

 

 

 —

 

 

2,312

 

 

 —

 

 

 —

 

 

2,312

 

Exercise of stock options

 

465,690

 

 

 1

 

 

13,924

 

 

 —

 

 

 —

 

 

13,925

 

Issuance of common stock from vesting of restricted stock units, net of shares withheld for taxes

 

180,912

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

Share-based compensation expense

 

 —

 

 

 —

 

 

44,707

 

 

 —

 

 

 —

 

 

44,707

 

Legal settlement

 

1,472,324

 

 

 1

 

 

105,477

 

 

 —

 

 

 —

 

 

105,478

 

Net unrealized loss on available-for-sale securities

 

 —

 

 

 —

 

 

 —

 

 

(110)

 

 

 —

 

 

(110)

 

Foreign currency translation adjustments

 

 —

 

 

 —

 

 

 —

 

 

5,517

 

 

 —

 

 

5,517

 

Net loss

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

(346,397)

 

 

(346,397)

 

Balance at December 31, 2017

 

50,565,151

 

$

51

 

$

1,887,198

 

$

(42,173)

 

$

(1,477,440)

 

$

367,636

 

 

See accompanying Notes to Consolidated Financial Statements.

F-5


 

CLOVIS ONCOLOGY, INC.

 

Consolidated Statements of Cash Flows

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

 

2017

    

2016

    

2015

 

 

 

(in thousands)

 

Operating activities

 

 

  

 

 

  

 

 

  

 

Net loss

 

$

(346,397)

 

$

(349,137)

 

$

(352,861)

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

  

 

 

  

 

 

  

 

Share-based compensation expense

 

 

44,707

 

 

39,796

 

 

40,357

 

Depreciation and amortization

 

 

2,504

 

 

1,141

 

 

761

 

Amortization of premiums and discounts on available-for-sale securities

 

 

354

 

 

211

 

 

1,400

 

Amortization of debt issuance costs

 

 

1,279

 

 

1,242

 

 

1,205

 

Legal settlement loss

 

 

105,477

 

 

 —

 

 

 —

 

Impairment of intangible asset

 

 

 —

 

 

104,517

 

 

89,557

 

Change in fair value of contingent purchase consideration

 

 

 —

 

 

(24,661)

 

 

(27,792)

 

Loss on disposal of property and equipment

 

 

 —

 

 

105

 

 

39

 

Deferred income taxes

 

 

(3,218)

 

 

(31,771)

 

 

(28,874)

 

Changes in operating assets and liabilities:

 

 

  

 

 

  

 

 

  

 

Accounts receivable

 

 

(6,061)

 

 

(121)

 

 

 —

 

Inventory

 

 

(27,508)

 

 

 —

 

 

 —

 

Prepaid and accrued research and development expenses

 

 

(17,297)

 

 

(15,364)

 

 

14,122

 

Deposit on inventory

 

 

(20,461)

 

 

 —

 

 

 —

 

Other operating assets

 

 

(6,476)

 

 

1,039

 

 

(4,380)

 

Accounts payable

 

 

5,637

 

 

(1,544)

 

 

8,105

 

Other accrued expenses

 

 

6,556

 

 

7,867

 

 

5,295

 

Net cash used in operating activities

 

 

(260,904)

 

 

(266,680)

 

 

(253,066)

 

Investing activities

 

 

  

 

 

  

 

 

  

 

Purchases of property and equipment

 

 

(487)

 

 

(766)

 

 

(3,035)

 

Proceeds from sale of property and equipment

 

 

 —

 

 

65

 

 

 —

 

Deposits for purchases of property and equipment

 

 

(2,515)

 

 

 —

 

 

 —

 

Purchases of available-for-sale securities

 

 

(263,500)

 

 

 —

 

 

(392,540)

 

Sales of available-for-sale securities

 

 

213,500

 

 

200,000

 

 

140,997

 

Acquired in-process research and development - milestone payment

 

 

(1,100)

 

 

 —

 

 

 —

 

Net cash (used in) provided by investing activities

 

 

(54,102)

 

 

199,299

 

 

(254,578)

 

Financing activities

 

 

  

 

 

  

 

 

  

 

Proceeds from the sale of common stock, net of issuance costs

 

 

545,838

 

 

 —

 

 

298,509

 

Proceeds from the exercise of stock options and employee stock purchases

 

 

16,237

 

 

5,176

 

 

5,971

 

Net cash provided by financing activities

 

 

562,075

 

 

5,176

 

 

304,480

 

Effect of exchange rate changes on cash and cash equivalents

 

 

943

 

 

(365)

 

 

(757)

 

Increase (decrease) in cash and cash equivalents

 

 

248,012

 

 

(62,570)

 

 

(203,921)

 

Cash and cash equivalents at beginning of period

 

 

216,186

 

 

278,756

 

 

482,677

 

Cash and cash equivalents at end of period

 

$

464,198

 

$

216,186

 

$

278,756

 

Supplemental disclosure of cash flow information:

 

 

  

 

 

  

 

 

  

 

Cash paid for interest

 

$

7,188

 

$

7,188

 

$

7,307

 

Non-cash investing and financing activities:

 

 

  

 

 

  

 

 

  

 

Acquired in-process research and development - milestone not paid as of period end

 

$

 —

 

$

21,100

 

$

 —

 

Vesting of restricted stock units

 

$

12,170

 

$

175

 

$

 —

 

 

 

 

 

 

 

 

 

 

 

 

 

See accompanying Notes to Consolidated Financial Statements.

F-6


 

 

CLOVIS ONCOLOGY, INC.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

1. Nature of Business

 

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. We have and intend to continue to license or acquire rights to oncology compounds in all stages of clinical development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities.

 

Our marketed product Rubraca® (rucaparib) is approved on an accelerated basis in the United States by the FDA as monotherapy for the treatment of patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. We launched Rubraca in the United States in December 2016 for this indication.

 

The FDA is currently reviewing on a priority review timeline our sNDA for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

 

Our MAA submitted to the European Union’s EMA for an ovarian cancer treatment indication for Rubraca is currently under review by the EMA’s CHMP.  Following a Scientific Advisory Group - Oncology meeting and an oral explanation by us before the CHMP in February 2018, the CHMP has communicated a positive trend vote for the MAA and their intention to hold a final vote on the treatment indication at their March 2018 meeting.

 

Liquidity

 

We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenue from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless and until it does, we will continue to need to raise additional cash.

 

In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including commercial planning and sales and marketing expenses associated with the launch of Rubraca in the United States and, if approved by the European Commission in Europe, funding of its development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on our current estimates, we believe that our cash, cash equivalents and available-for-sale securities will allow us to fund activities through the next 12 months.

 

F-7


 

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include our accounts and our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

 

Revenue Recognition

 

We are currently approved to sell Rubraca in the United States market.  We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers.  Our customers subsequently sell our products to patients and health care providers.  Separately, we have arrangements with certain payors and other third-parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. 

 

Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Product sales are recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns. Estimating rebates, chargebacks, discounts, product returns and other deductions requires significant judgments about future events and uncertainties, and requires us to rely heavily on assumptions, as well as historical experience. We only recognize revenue on product sales once the product is sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns.

 

For the year ended December 31, 2017, we recognized $55.5 million of product revenue. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the costs of Rubraca units recognized as revenue during the year ended December 31, 2017 were expensed prior to the December 19, 2016 FDA approval, and a minimal amount is included in cost of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories. The majority of products sales were of pre-commercialization inventory in 2017.

 

Product revenue from each of our customers who individually accounted for 10% or more of total revenues consisted of the following:

 

 

 

 

 

 

December 31, 

 

    

2017

Customer A

 

35%

Customer B

 

27%

Customer C

 

12%

Customer D

 

10%

 

Effective January 1, 2018, we adopted ASC 606, the new revenue recognition standard, using the modified retrospective method. For a complete discussion of this adoption and the accounting for net product revenue, see the Recently Issued Accounting Standards section below and Note 11, Revenue Recognition.

 

F-8


 

Fair Value of Financial Instruments

 

Cash, cash equivalents, available-for-sale securities and contingent purchase consideration are carried at fair value. Financial instruments, including other current assets and accounts payable, are carried at cost, which approximates fair value given their short-term nature (see Note 4, Fair Value Measurements). 

 

Cash, Cash Equivalents and Available-for-Sale Securities

 

We consider all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations.

 

Marketable securities are considered to be available-for-sale securities and consist of U.S. treasury securities. Available-for-sale securities are reported at fair value on the Consolidated Balance Sheets and unrealized gains and losses are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense) on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on our intent to fund current operations with these securities or to make them available for current operations.

 

A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.

 

Accounts Receivable

 

As of December 31, 2017 and 2016, we had no allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. Equipment purchased for use in manufacturing and clinical trials is evaluated to determine whether the equipment is solely beneficial for a drug candidate in the development stage or whether it has an alternative use. Equipment with an alternative use is capitalized. Leasehold improvements are amortized over the economic life of the asset or the lease term, whichever is shorter. Maintenance and repairs are expensed as incurred. The estimated useful lives of our capitalized assets are as follows:

 

 

 

 

 

 

 

Estimated

 

 

    

Useful Life

 

Computer hardware and software

 

3 to 5 years

 

Leasehold improvements

 

6 years

 

Laboratory, manufacturing and office equipment

 

5 to 7 years

 

Furniture and fixtures

 

10 years

 

 

Long-Lived Assets

 

We review long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. If the carrying value of the assets exceed their future net undiscounted cash flows, an impairment charge is recognized for the amount by which the carrying value of the assets exceeds the fair value of the assets.

 

F-9


 

Intangible Assets, Net

 

Definite-lived intangible assets related to capitalized milestones under license agreements are amortized on a straight-line basis over their remaining useful lives, which are estimated to be the remaining patent life.  If our estimate of the product’s useful life is shorter than the remaining patent life, then a shorter period is used. Amortization expense is recorded as a component of cost of sales on the Consolidated Statements of Operations and Comprehensive Loss.

 

Intangible acquired in-process research and development (“IPR&D”) assets were established as part of the acquisition of Ethical Oncology Science, S.p.A. (“EOS”) in November 2013 and were not amortized.

 

Intangible assets are evaluated for impairment at least annually in the fourth quarter or more frequently if impairment indicators exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the decision to discontinue the development of a drug, the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate, or new information regarding potential sales for the drug. In connection with any impairment assessment, the fair value of the intangible assets as of the date of assessment is compared to the carrying value of the intangible asset. Impairment losses are recognized if the carrying value of an intangible asset is both not recoverable and exceeds its fair value. During the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&D intangible assets, reducing the remaining carrying value to zero (see Note 6, Intangible Assets and Goodwill). Previously, the Company recorded an $89.6 million impairment charge to the IPR&D intangible assets during the fourth quarter of 2015.

 

Goodwill

 

Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination accounted for under the acquisition method of accounting and is not amortized, but is subject to impairment testing at least annually in the fourth quarter or when a triggering event is identified that could indicate a potential impairment. We are organized as a single reporting unit and perform impairment testing by comparing the carrying value of the reporting unit to the fair value of the Company. Goodwill was recorded as a result of the EOS acquisition.

 

Other Current Assets

 

Other current assets are comprised of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

December 31, 

 

 

    

2017

    

2016

 

Receivable from partners

 

$

 9

 

$

2,882

 

Prepaid insurance

 

 

1,926

 

 

1,234

 

Prepaid expenses - other

 

 

3,355

 

 

2,109

 

Receivable - other

 

 

2,023

 

 

364

 

Other

 

 

187

 

 

90

 

Total

 

$

7,500

 

$

6,679

 

 

F-10


 

Other Accrued Expenses

 

Other accrued expenses are comprised of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

December 31, 

 

 

    

2017

    

2016

 

Accrued personnel costs

 

$

13,889

 

$

15,850

 

Accrued interest payable

 

 

2,096

 

 

2,096

 

Income tax payable

 

 

 —

 

 

556

 

Accrued corporate legal fees and professional services

 

 

415

 

 

589

 

Accrued royalties

 

 

2,984

 

 

 —

 

Accrued sales deductions

 

 

1,008

 

 

 —

 

Payable to third party logistics provider

 

 

2,661

 

 

 —

 

Accrued expenses - other

 

 

2,830

 

 

396

 

Total

 

$

25,883

 

$

19,487

 

 

Valuation of Contingent Consideration Resulting from a Business Combination

 

Subsequent to the acquisition date, we re-measure contingent consideration arrangements at fair value each reporting period and record changes in fair value to change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss. Changes in fair value are primarily attributed to new information about the IPR&D assets, including changes in timeline and likelihood of success, and the passage of time. In the absence of new information, changes in fair value reflect only the passage of time. During the fourth quarter of 2015, we recorded a $26.9 million reduction in the fair value of the contingent purchase consideration liability due to a change in the estimated probability-weighted future discounted milestone payments, as well as the timing of such payments, for the lucitanib program.  Then, during the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At December 31, 2017, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets remained at zero due to the uncertainty of achieving any of the lucitanib regulatory milestones, and therefore the remote likelihood of future milestone payouts.

 

Research and Development Expense

 

Research and development costs are charged to expense as incurred and include, but are not limited to, salary and benefits, share-based compensation, clinical trial activities, drug development and manufacturing, companion diagnostic development and third-party service fees, including contract research organizations and investigative sites. During 2015, we completed the hiring of our U.S. sales and marketing and medical affairs organizations in preparation for the potential commercial launch of Rubraca. These costs were also included in research and development expense before the FDA approval of Rubraca.

 

Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred and are reflected on the Consolidated Balance Sheets as prepaid or accrued research and development expenses.

 

Acquired In-Process Research and Development Expense

 

We have acquired and expect to continue to acquire the rights to develop and commercialize new drug candidates. The upfront payments to acquire a new drug compound, as well as subsequent milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use.  Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to product cost of sales.

 

F-11


 

Share-Based Compensation Expense

 

Share-based compensation is recognized as expense for all share-based awards made to employees and directors and is based on estimated fair values. We determine equity-based compensation at the grant date using the Black-Scholes option pricing model. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period. Any changes to the estimated forfeiture rates are accounted for prospectively.

 

Inventory

 

Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. Prior to the regulatory approval of Rubraca, we incurred expenses for the manufacture of drug that could potentially be available to support the commercial launch of Rubraca. Until the first reporting period when regulatory approval has been received, we record all such costs as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues.

 

The active pharmaceutical ingredient in Rubraca is currently produced by a single supplier.

 

At December 31, 2017, deposit on inventory on the Consolidated Balance Sheets is a cash deposit of $20.5 million made to a manufacturer for the purchase of inventory which we expect to be converted to finished goods within the next twelve months.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject us to concentrations of credit risk are primarily cash, cash equivalents and available-for-sale securities. We maintain our cash and cash equivalent balances in the form of money market accounts with financial institutions that we believe are creditworthy. Available-for-sale securities are invested in accordance with our investment policy. The investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that we believe minimizes the exposure to concentration of credit risk. We have no financial instruments with off-balance sheet risk of accounting loss.

 

Foreign Currency

 

The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates and the results of operations are translated at the average exchange rates for the reported periods. The resulting translation adjustments are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. Transaction gains and losses are recorded to foreign currency gains (losses) on the Consolidated Statements of Operations and Comprehensive Loss. As of December 31, 2017 and 2016, approximately 1% of our total liabilities were denominated in currencies other than the functional currency.

 

Income Taxes

 

We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized. 

 

Recently Adopted Accounting Standards

 

In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" (ASU 2016-09).  ASU 2016-09 simplifies how several aspects of share-based payments are accounted for and presented in the financial statements. ASU 2016-09 is effective for public companies for annual reporting periods beginning after December 15, 2016. We adopted this ASU

F-12


 

in the first quarter of 2017. We had excess tax benefits for which a benefit could not be previously recognized of approximately $18.2 million. Upon adoption the balance of the unrecognized excess tax benefits were reversed with the impact recorded to retained earnings including any change to the valuation allowance as a result of the adoption. Due to the full valuation allowance on the U.S. deferred tax assets, there is no impact to the financial statements as a result of this adoption.

 

Recently Issued Accounting Standards

   

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, “Revenue from Contracts with Customers” and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability.  Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We have elected to apply the new standard using the modified retrospective method upon its adoption date on January 1, 2018. 

 

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. The standard also requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.

   

We have examined our revenue recognition policy specific to revenue streams from representative contracts governing product sales from Rubraca and have come to conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. We have reviewed a representative sample of contracts, including our collaboration agreements with Servier and Bristol-Myers Squibb discussed in Note 13, License Agreements, and determined the potential impact to our accounting policies, financial controls and operations. Our conclusions include recognizing revenue on product sales once the product is sold to the specialty distributor and specialty pharmacy providers. Currently, we anticipate the effects of adoption to be as described in Note 11, Revenue Recognition.

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. We plan to adopt on January 1, 2019. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.

 

In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” which clarifies the definition of a business in ASC 805. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. We adopted this standard on January 1, 2018 and the adoption resulted in no change to our consolidated financial statements and related disclosures.

   

In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting”, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which we would be required to apply modification accounting under ASC 718. Specifically, we would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is effective for annual reporting periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim

F-13


 

period. We adopted this standard on January 1, 2018 and the adoption resulted in no change to our consolidated financial statements and related disclosures.

 

 

 

 

3. Property and Equipment

 

Property and equipment consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

   

 

December 31, 

 

 

    

2017

    

2016

 

Laboratory, manufacturing and office equipment

 

$

2,853

 

$

2,555

 

Leasehold improvements

 

 

2,285

 

 

2,276

 

Furniture and fixtures

 

 

1,416

 

 

1,411

 

Computer hardware and software

 

 

1,141

 

 

855

 

Total property and equipment

 

 

7,695

 

 

7,097

 

Less: accumulated depreciation

 

 

(3,688)

 

 

(2,657)

 

Total property and equipment, net

 

$

4,007

 

$

4,440

 

 

Depreciation expense related to property and equipment was approximately $1.0 million, $1.1 million and $0.8 million for the years ended December 31, 2017, 2016 and 2015, respectively.

 

4. Fair Value Measurements

 

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:

 

Level 1:

Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.

 

 

Level 2:

Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

 

 

Level 3:

Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired with the purchase of EOS in November 2013 is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer, reducing the remaining fair value to zero. The fair value and carrying value remained at zero as of December 31, 2017.

 

The change in the fair value of Level 3 instruments is included in change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss.

   

 

F-14


 

The following table identifies our assets that were measured at fair value on a recurring basis (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

Balance

    

Level 1

    

Level 2

    

Level 3

 

December 31, 2017

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market

 

$

433,136

 

$

433,136

 

$

 —

 

$

 —

 

U.S. treasury securities

 

 

99,533

 

 

 —

 

 

99,533

 

 

 —

 

Total assets at fair value

 

$

532,669

 

$

433,136

 

$

99,533

 

$

 —

 

December 31, 2016

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market

 

$

202,361

 

$

202,361

 

$

 —

 

$

 —

 

U.S. treasury securities

 

 

49,997

 

 

 —

 

 

49,997

 

 

 —

 

Total assets at fair value

 

$

252,358

 

$

202,361

 

$

49,997

 

$

 —

 

 

There were no liabilities that were measured at fair value on a recurring basis as of December 31, 2017. There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the year ended December 31, 2017.

Financial instruments not recorded at fair value include our convertible senior notes. At December 31, 2017, the carrying amount of the convertible senior notes was $282.4 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $388.3 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the convertible senior notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 7, Convertible Senior Notes for discussion of the convertible senior notes. The carrying amounts of accounts payable and accrued expenses approximate their fair value due to their short-term maturities.

 

5. Available-for-Sale Securities

 

As of December 31, 2017, available-for-sale securities consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

    

 

    

Gross

    

Gross

    

Aggregate

 

 

 

Amortized

 

Unrealized

 

Unrealized

 

Fair

 

 

 

Cost

 

Gains

 

Losses

 

Value

 

U.S. treasury securities

 

$

99,650

 

$

 —

 

$

(117)

 

$

99,533

 

 

As of December 31, 2017, the fair value and gross unrealized losses of available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months were as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

    

Aggregate

    

Gross

 

 

 

Fair

 

Unrealized

 

 

 

Value

 

Losses

 

U.S. treasury securities

 

$

99,533

 

$

(117)

 

 

Our investments have been in an unrealized loss position for two months. Based upon our evaluation of all relevant factors, we believe that the decline in fair value of securities held at December 31, 2017 below cost is temporary, and we intend to retain our investment in these securities for a sufficient period of time to allow for recovery of the fair value.

 

As of December 31, 2017, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):

 

 

 

 

 

 

 

 

 

 

    

Amortized

    

Fair

 

 

 

Cost

 

Value

 

Due in one year or less

 

$

99,650

 

$

99,533

 

Due in one year to two years

 

 

 —

 

 

 —

 

Total

 

$

99,650

 

$

99,533

 

 

 

F-15


 

6. Inventories

 

The following table presents inventories as of December 31, 2017 and December 31, 2016 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

    

2017

    

2016

 

Work in process

 

$

24,721

 

$

 —

 

Finished goods

 

 

2,787

 

 

 —

 

Total

 

$

27,508

 

$

 —

 

 

 

 

 

 

 

 

 

 

 

 

 

At December 31, 2017, deposit on inventory on the Consolidated Balance Sheets is a cash deposit of $20.5 million made to a manufacturer for the purchase of inventory which we expect to be converted to finished goods within the next twelve months.

 

 

 

 

 

7. Intangible Assets and Goodwill

 

At December 31, 2017 and 2016, intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

 

2017

    

2016

 

Intangible asset - milestones

 

$

21,100

 

$

21,100

 

Accumulated amortization

 

 

(1,539)

 

 

(53)

 

Total intangible asset, net

 

$

19,561

 

$

21,047

 

 

The estimated useful lives of these intangibles assets extended through 2031.

 

We recorded an amortization expense of $1.5 million and $0.053 million related to capitalized milestone payments during the year ended December 31, 2017 and December 31, 2016, respectively. Estimated future amortization expense for intangible assets as of December 31, 2017 is as follows (in thousands):

 

 

 

 

 

 

 

 

 

2018

 

 

 

 

$

1,486

 

2019

 

 

 

 

 

1,486

 

2020

 

 

 

 

 

1,486

 

2021

 

 

 

 

 

1,486

 

2022

 

 

 

 

 

1,486

 

Thereafter

 

 

 

 

 

12,131

 

 

 

 

 

 

$

19,561

 

 

IPR&D assets and goodwill were established as part of the purchase accounting of EOS in November 2013, and consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

    

2017

    

2016

 

IPR&D assets:

 

 

  

 

 

  

 

Balance at beginning of period

 

$

 —

 

$

101,500

 

Impairment of intangible asset (a)

 

 

 —

 

 

(104,517)

 

Change in foreign currency gains and losses

 

 

 —

 

 

3,017

 

Balance at end of period

 

$

 —

 

$

 —

 

 

 

 

  

 

 

  

 

Goodwill:

 

 

  

 

 

  

 

Balance at beginning of period

 

$

57,192

 

$

59,327

 

Change in foreign currency gains and losses

 

 

8,025

 

 

(2,135)

 

Balance at end of period

 

$

65,217

 

$

57,192

 


F-16


 

(a)

During the second quarter of 2016, we recorded a $104.5 million impairment charge due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At December 31, 2017, the IPR&D intangible asset recorded on the Consolidated Balance Sheets was zero.

 

During the fourth quarter of 2015, we recorded an $89.6 million impairment charge due to our and our development partner’s decision to terminate the development of lucitanib for lung cancer, as well as updates to the probability-weighted discounted cash flow assumptions for the breast cancer indication.

 

These reductions were included in impairment of intangible asset on the Consolidated Statements of Operations and Comprehensive Loss.

 

As of December 31, 2017, no impairment to the carrying value of the goodwill was identified.

 

8. Convertible Senior Notes

 

On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “Notes”) resulting in net proceeds of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

 

The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year. The Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.

 

Holders may convert all or any portion of the Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

 

On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes. 

 

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the Notes, holders may require us to repurchase for cash all or any portion of the Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

 

The Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

 

In connection with the issuance of the Notes, we incurred $9.2 million of debt issuance costs. The debt issuance costs are amortized as interest expense over the expected life of the Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the Notes. As of December 31, 2017 and 2016, the

F-17


 

balance of unamortized debt issuance costs was $5.1 million and $6.4 million, respectively, and is recorded as a reduction to the convertible senior notes at the Consolidated Balance Sheets.

 

The following table sets forth total interest expense to the Notes and the milestone liability during the years ended December 31, 2017 and 2016 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

2017

    

2016

    

2015

Contractual interest expense

 

$

7,188

 

$

7,187

 

$

7,167

Accretion of interest on milestone liability

 

 

1,961

 

 

62

 

 

 —

Amortization of debt issuance costs

 

 

1,279

 

 

1,242

 

 

1,205

Total interest expense

 

$

10,428

 

$

8,491

 

$

8,372

 

 

9. Stockholders’ Equity

 

Common Stock

 

In July 2015, we sold 4,054,487 shares of our common stock in a public offering at $78.00 per share. The net proceeds from the offering were $298.5 million, after deducting underwriting discounts and commissions and offering expenses.

 

In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses.

 

In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses.

 

The holders of common stock are entitled to one vote per share on all matters to be voted upon by our stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors.

 

Accumulated Other Comprehensive Loss

 

Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities.

 

The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign Currency

 

Unrealized

 

Total Accumulated

 

 

Translation Adjustments

 

(Losses) Gains

 

Other Comprehensive Loss

Balance at December 31, 2015

 

$

(47,077)

 

$

(383)

 

$

(47,460)

Other comprehensive income (loss)

 

 

(1,693)

   

 

224

   

 

(1,469)

Total before tax

 

 

(48,770)

 

 

(159)

 

 

(48,929)

Tax effect

 

 

1,336

 

 

13

 

 

1,349

Balance at December 31, 2016

 

 

(47,434)

 

 

(146)

 

 

(47,580)

Other comprehensive income (loss)

 

 

8,735

 

 

(110)

 

 

8,625

Total before tax

 

 

(38,699)

 

 

(256)

 

 

(38,955)

Tax effect

 

 

(3,218)

 

 

 —

 

 

(3,218)

Balance at December 31, 2017

 

$

(41,917)

 

$

(256)

 

$

(42,173)

 

The other comprehensive income (loss) related to foreign currency translation adjustments was primarily due to the currency translation of the IPR&D intangible assets, goodwill and deferred income taxes (see Note 7,  Intangible Assets

F-18


 

and Goodwill). There were no reclassifications out of accumulated other comprehensive loss in the years ended December 31, 2017, 2016 and 2015.

 

10. Share-Based Compensation

 

Stock Options

 

In August 2011, our Board of Directors approved the 2011 Stock Incentive Plan (the “2011 Plan”), which became effective upon the closing of our initial public offering in November 2011. The 2011 Plan provides for the granting of incentive and nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards and other share-based awards to our employees, directors and consultants. Common shares authorized for issuance under the 2011 Plan were 9,590,378 at December 31, 2017, which represents the initial reserve of 1,250,000 shares of common stock plus 192,185 shares of common stock remaining for future grant from the 2009 Equity Incentive Plan (the “2009 Plan”), which was terminated upon the closing of our initial public offering in November 2011, and 8,148,193 new shares authorized by the Board of Directors at the annual meetings of stockholders. Future forfeitures and cancellations of options previously granted under the 2009 Plan were transferred to and also available for grant under the 2011 Plan. Stock options granted vest ratably over either a one-year period or three-year period for Board of Director grants. Employee stock options generally vest over a four-year period with 25% of the options cliff-vesting after year one and the remaining options vesting ratably over each subsequent month. All stock options expire 10 years from the date of grant.

 

Share-based compensation expense for the years ended December 31, 2017, 2016 and 2015, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

 

2017

    

2016

    

2015

 

Research and development

 

$

20,335

 

$

27,558

 

$

27,321

 

Selling, general and administrative

 

 

24,372

 

 

12,238

 

 

13,036

 

Total share-based compensation expense

 

$

44,707

 

$

39,796

 

$

40,357

 

 

We did not recognize a tax benefit related to share-based compensation expense during the years ended December 31, 2017, 2016 and 2015 as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of December 31, 2017.

 

The following table summarizes the activity relating to our options to purchase common stock:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

  

 

 

  

Weighted

  

 

 

 

 

 

 

 

Weighted

 

Average

 

Aggregate

 

 

 

 

 

Average

 

Remaining

 

Intrinsic

 

 

 

Number of

 

Exercise

 

Contractual

 

Value

 

 

 

Options

 

Price

 

Term (Years)

 

(Thousands)

 

Outstanding at December 31, 2016

 

5,520,482

 

$

42.00

 

  

 

 

  

 

Granted

 

1,048,700

 

 

66.09

 

  

 

 

  

 

Exercised

 

(465,690)

 

 

29.90

 

  

 

 

  

 

Forfeited

 

(313,757)

 

 

49.20

 

  

 

 

  

 

Outstanding at December 31, 2017 (a)

 

5,789,735

 

$

46.77

 

7.1

 

$

145,067

 

Vested and expected to vest at December 31, 2017

 

5,505,557

 

$

46.52

 

7.0

 

$

139,526

 

Vested and exercisable at December 31, 2017

 

3,481,931

 

$

44.60

 

6.1

 

$

95,463

 


(a)

Includes 33,750 performance-based stock options granted to our executives in the first quarter of 2015, which vested on approval by the FDA in December 19, 2016 to commercially distribute, sell or market Rubraca. Related stock compensation expense was recognized on that date.

 

The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $68.00 as of December 31, 2017, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.

 

F-19


 

The following table summarizes information about our stock options as of and for the years ended December 31, 2017, 2016 and 2015:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

 

2017

    

2016

    

2015

 

Weighted-average grant date fair value per share

 

$

48.79

 

$

16.62

 

$

52.70

 

Intrinsic value of options exercised

 

$

18,986,726

 

$

3,118,097

 

$

19,976,769

 

Cash received from stock option exercises

 

$

13,924,174

 

$

3,267,721

 

$

5,478,211

 

 

 

The fair value of each share-based award is estimated on the grant date using the Black-Scholes option pricing model based upon the weighted-average assumptions provided in the following table:

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Dividend yield

 

 —

 

 —

 

 —

 

Volatility (a)

 

89

%  

93

%  

72

%

Risk-free interest rate (b)

 

2.16

%  

1.77

%  

1.77

%

Expected term (years) (c)

 

5.8

 

5.8

 

6.1

 

 


(a)

Volatility: The expected volatility was estimated using our historical data.

(b)

Risk-free interest rate: The rate is based on the yield on the grant date of a zero-coupon U.S. Treasury bond whose maturity period approximates the option’s expected term.

(c)

 Expected term: The expected term of the award was estimated using our historical data.

 

The total fair value of stock options vested during the years ended December 31, 2017, 2016 and 2015 was $36.0 million, $40.8 million and $36.5 million, respectively.

 

Restricted Stock

 

During 2016, we issued restricted stock units (“RSUs”) to certain employees under the 2011 Stock Incentive Plan. The RSUs vest either (i) over two years, with 50% vesting one year from the date of grant and the remaining 50% vesting two years from the date of grant or (ii) over four years, with 25% vesting one year from the date of grant and the remaining 75% vesting ratably each subsequent quarter over the following three years, as defined in the grant agreement. Vested RSUs are payable in shares of our common stock at the end of the vesting period. RSUs are measured based on the fair value of the underlying stock on the grant date. The minimum statutory tax on the value of common stock shares  issued to employees upon vesting are paid by us through the sale of registered shares of our common stock.

 

F-20


 

The following table summarizes the activity related to our unvested RSUs:

 

 

 

 

 

 

 

 

    

 

    

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

Average

 

 

 

Number of

 

Grant Date

 

 

 

Units

 

Fair Value

 

Unvested at December 31, 2016

 

562,458

 

$

24.70

 

Granted

 

249,984

 

 

64.66

 

Vested

 

(180,912)

 

 

23.83

 

Forfeited

 

(42,001)

 

 

28.09

 

Unvested as of December 31, 2017

 

589,529

 

$

41.67

 

Expected to vest after December 31, 2017

 

513,069

 

$

41.40

 

 

Unrecognized share-based compensation expense related to non-vested options and RSUs, adjusted for expected forfeitures, was $89.4 million as of December 31, 2017. The unrecognized share-based compensation expense is expected to be recognized over the weighted-average remaining vesting period of 3.3 years.

 

Common Stock Reserved for Issuance

 

As of December 31, 2017, we reserved shares of common stock for future issuance as follows:

 

 

 

 

 

 

 

 

 

 

    

 

    

Available for

    

 

 

 

 

 

 

Grant

 

Total Shares of

 

 

 

Common Stock

 

or Future

 

Common Stock

 

 

 

Outstanding

 

Issuance

 

Reserved

 

2009 Equity Incentive Plan

 

331,213

 

 —

 

331,213

 

2011 Stock Incentive Plan

 

6,048,051

 

2,589,033

 

8,637,084

 

2011 Employee Stock Purchase Plan

 

 —

 

558,870

 

558,870

 

Total

 

6,379,264

 

3,147,903

 

9,527,167

 

 

Employee Stock Purchase Plan

 

In August 2011, our Board of Directors approved the Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan (the “Purchase Plan”). Each year, on the date of our annual meeting of stockholders and at the discretion of our board of directors, the amount of shares reserved for issuance under the Purchase Plan may be increased by up to the lesser of (1) a number of additional shares of our common stock representing 1% of our then-outstanding shares of common stock, (2) 344,828 shares of our common stock and (3) a lesser number of shares as approved by the Board. The Purchase Plan provides for consecutive six-month offering periods, during which participating employees may elect to have up to 10% of their compensation withheld and applied to the purchase of common stock at the end of each offering period. The purchase price of the common stock is 85% of the lower of the fair value of a share of common stock on the first trading date of each offering period or the fair value of a share of common stock on the last trading day of the offering period. The Purchase Plan will terminate on August 24, 2021, the tenth anniversary of the date of initial adoption of the Purchase Plan. We sold 51,681 and 110,508 shares to employees in 2017 and 2016, respectively. There were 558,870 shares available for sale under the Purchase Plan as of December 31, 2017. The weighted-average estimated grant date fair value of purchase awards under the Purchase Plan during the years ended December 31, 2017 and 2016 was $23.08 and $11.70 per share, respectively. The total share-based compensation expense recorded as a result of the Purchase Plan was approximately $1.0 million, $0.8 million and $0.9 million during the years ended December 31, 2017, 2016 and 2015, respectively.

 

F-21


 

The fair value of purchase awards granted to our employees during the years ended December 31, 2017, 2016 and 2015, respectively, was estimated using the Black-Scholes option pricing model based upon the weighted-average assumptions provided in the following table:

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Dividend yield

 

 —

 

 —

 

 —

 

Volatility (a)

 

79

%  

92

%  

71

%

Risk-free interest rate (b)

 

0.90

%  

0.40

%  

0.11

%

Expected term (years) (c)

 

0.5

 

0.5

 

0.5

 


(a)

Volatility: The expected volatility was estimated using our historical data.

(b)

Risk-free interest rate: The rate is based on the U.S. Treasury yield in effect at the time of grant with terms similar to the contractual term of the purchase right.

(c)

Expected term: The expected life of the award represents the six-month offering period for the Purchase Plan.

 

 

11. Revenue Recognition

 

Effective January 1, 2018, we adopted ASC 606, the new revenue recognition standard, using the modified retrospective method. Upon adoption, the accounting for net product revenue is as follows:

 

Product Revenue, Net

 

We are currently approved to sell Rubraca in the United States market.  We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers.  Our customers subsequently sell our products to patients and health care providers.  Separately, we have arrangements with certain payors and other third-parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. 

 

Revenue from product sales are recognized when customers obtain control of our product, which occurs at a point in time, typically upon delivery to the customers. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less.

 

Reserves for Variable Consideration

   

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, chargebacks, discounts, co-pay assistance, estimated product returns and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product.  These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customers) or a current liability (if the amount is payable to a party other than a customer).  Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.  Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract.  The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.  Actual amounts of consideration ultimately received may differ from our estimates.  If actual results in the future vary from our estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.

 

F-22


 

Rebates. Rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare coverage gap program. Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. The accrual for rebates is based on statutory discount rates and known sales to specialty pharmacy patients, or expected utilization for specialty distributor sales to healthcare providers. As we gain more historical experience, the accrual will be based solely on the expected utilization from historical data we have accumulated since the Rubraca product launch. Rebates are generally invoiced and paid quarterly in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known or estimated prior quarters’ unpaid rebates.

 

Chargebacks. Chargebacks are discounts that occur when contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service organizations and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the healthcare provider. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates and known sales to specialty distributors adjusted for the estimated utilization by healthcare providers.

 

Discounts. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts from product sales when revenue is recognized. Service fees are recorded as a selling expense when product sales occur.

 

Co-pay assistance. Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. The intent of this program is to reduce the patient’s out of pocket costs. Liabilities for co-pay assistance are based on actual program participation and estimates of program redemption using data provided by third-party administrators.

     

Returns. Consistent with industry practice, we generally offer customers a limited right of return for product that has been purchased based on the product’s expiration date, which lapses upon shipment to a patient. To date, we have had minimal product returns and we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience.

 

Currently, we only recognize revenue on product sales once the product is sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, i.e. when product is sold through the channel. Effective January 1, 2018, we will begin recognizing revenue when our customers, the specialty distributors and specialty pharmacy providers, take control of our product or when product is sold into the channel. This will have the impact of us recognizing revenue approximately two to four weeks earlier than before adopting the new standard and will also increase the significance of estimating variable consideration.

 

We used the modified retrospective method to adopt the new standard. This means that we will not restate previously issued financial statements, but will record a one-time adjustment to retained earnings of $2.3 million. This adjustment represents the sales of our product to our customers prior to January 1, 2018, that have not been sold to patients or healthcare providers, offset by related gross-to-net adjustments and other direct costs, including royalties and sales incentive compensation.

 

12. Commitments and Contingencies

 

We lease office space in Boulder, Colorado, San Francisco, California, Oakland, California, Cambridge, UK and Milan, Italy under non-cancelable operating lease agreements that expire through 2028. The lease agreements contain periodic rent increases that result in the recording deferred rent over the terms of certain leases.

 

F-23


 

In November 2017, we entered into a ten-year lease agreement for new office space in Oakland, California. Pursuant to the terms of the lease, the landlord will reimburse us for up to $2.5 million of leasehold improvement expenditures (“Tenant Improvement Allowance”). Upon completion of construction, we will record the Tenant Improvement Allowance as deferred rent, which will be amortized as a reduction to rental expense over the lease term.

 

Rental expense under these leases was $2.2 million, $2.2 million and $2.4 million for the years ended December 31, 2017, 2016 and 2015, respectively.

 

Future minimum rental commitments, by fiscal year and in the aggregate, for our operating leases are provided below (in thousands):

 

 

 

 

 

 

 

    

December 31, 

 

 

 

2017

 

2018

 

$

3,050

 

2019

 

 

3,902

 

2020

 

 

3,744

 

2021

 

 

3,855

 

2022

 

 

2,519

 

Thereafter

 

 

11,563

 

Total future minimum lease payments

 

$

28,633

 

 

Manufacture and Services Agreement Commitments

 

On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for rucaparib. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in rucaparib that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified any forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the rucaparib active ingredient. We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of December 31, 2017, $223.9 million of purchase commitments exist under the Agreement. 

 

Legal Proceedings

 

We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition.

 

Rociletinib-Related Litigation

 

Following Clovis’ regulatory announcement in November 2015 of adverse developments in its ongoing clinical trials for rociletinib, Clovis and certain of its current and former executives were named in various securities lawsuits, the largest of which was a putative class action lawsuit in the District of Colorado (the “Medina Action”) which was settled on October 26, 2017 (the “Medina Settlement”).  The open actions currently pending against Clovis are discussed below.   While other entities have threatened to bring claims relating to rociletinib and the November 2015 announcement, none have commenced litigation as of the date of this filing. 

 

On January 22, 2016, the Electrical Workers Local #357 Pension and Health & Welfare Trusts, a purported shareholder of Clovis, filed a purported class action complaint (the “Electrical Workers Complaint”) against Clovis and certain of its officers, directors, investors and underwriters in the Superior Court of the State of California, County of San Mateo (the “Electrical Workers Court”). The Electrical Workers Complaint purports to be asserted on behalf of a class of persons who purchased stock in the July 2015 Offering. The complaint asserted claims under certain provisions of the Securities Act of 1933 (the “Securities Act”) relating to a July 2015 follow-on offering of Clovis securities (the

F-24


 

“July 2015 Offering”) based on substantially similar allegations to those asserted in the Medina Action. On June 30, 2016, the Electrical Workers Plaintiffs filed an amended complaint adding new allegations (the “Amended Complaint”).

   

On July 28, 2016, the defendants filed a motion to stay the Electrical Workers action pending resolution of the Medina Action and a demurrer to the Amended Complaint. On September 23, 2016, after hearing oral argument, the Electrical Workers Court granted the motion to stay and reserved on issuing a ruling on defendants’ pending demurrer.

 

The Company believes that the claims asserted in the Electrical Workers Action are released and barred by operation of law through the Medina Settlement, and accordingly plans to seek dismissal of the Electrical Workers Action on that basis.

 

On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the offering materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages.

   

On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.

   

On January 31, 2017, Defendants filed a motion to stay the Antipodean action pending resolution of the Medina Action in the District of Colorado. Defendants also filed a motion to dismiss the Antipodean Amended Complaint on March 29, 2017.

   

On March 14, 2017, the Clovis Defendants and Antipodean participated in a mediation, which did not result in a settlement.

   

On August 8, 2017, the parties participated in a scheduled hearing on Defendants’ motion to stay and motion to dismiss before Justice Masley of the New York Supreme Court, County of New York. At the hearing, Justice Masley granted Defendants’ motion to stay. Per the Court’s August 10, 2017 order, Defendants’ motion to dismiss was held in abeyance and deemed submitted on November 1, 2017.  On November 1, 2017, the Defendants provided a status update to the Court regarding the outcome of the hearing.  The update informed the Court that Antipodean had excluded itself from the Medina Settlement, as memorialized in the final judgment entered by the Medina Court.  No date has been scheduled for argument on Defendants’ motion to dismiss.

   

The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint.  However, there can be no assurance that the defense will be successful.

   

In March 2017, two putative shareholders of the Company, Macalinao and McKenry (the “Derivative Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”).

   

On May 18, 2017, the Derivative Plaintiffs filed a Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to prior demands for inspection of the Company’s books and records served on the Company by each of Macalinao and McKenry under 8 Del. C. § 220. The Consolidated Derivative Complaint sought, among other things, an award of money damages.

   

F-25


 

On July 31, 2017, the defendants filed a motion to dismiss the Consolidated Derivative Complaint. Plaintiffs filed an opposition to the motion to dismiss on August 31, 2017, and the defendants filed a reply in further support of the motion to dismiss on September 26, 2017. No date has been scheduled for argument on Defendants’ motion to dismiss the Consolidated Derivative Complaint.

   

The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful.

   

On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages.

   

On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative Complaint. On June 20, 2017, the court granted the motion to stay.

   

The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.

 

In addition, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. The Company is continuing to cooperate with these agencies with respect to their investigations. The Medina Settlement does not resolve these inquiries and the Company cannot predict their timing or outcome.

 

Director Compensation Litigation

 

On May 10, 2017, John Solak, a purported shareholder of the Company, filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware (the “Solak Complaint”) against certain directors and an officer of the Company. The Solak Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by adopting a compensation plan that overcompensated the non-employee director defendants, in relation to companies of comparable market capitalization and size. The Solak Complaint also alleged claims of waste of corporate assets and unjust enrichment due to this allegedly wrongful compensation plan. The Solak Complaint sought, among other things, an award of money damages and the imposition of corporate governance reforms.

   

The Court has entered a number of orders extending the defendants’ time to respond to the Solak Complaint based on, among other factors, the fact that the parties are engaged in discussions in an effort to resolve the Solak action. On February 14, 2018, the parties filed a joint letter to the Court requesting that all deadlines in the action be held in abeyance while the parties engaged in final settlement discussions.

 

On February 26, 2018, the defendants entered into a stipulation of compromise and settlement with plaintiff that is intended to settle the Solak action. The proposed settlement is subject to Court approval upon the conclusion of a settlement hearing concerning the fairness of the terms of the proposed settlement, which will be scheduled following the provision of notice to shareholders of the Company.

 

In accordance with the terms of the proposed settlement, the Company will present a new non-employee director compensation policy for shareholder vote at the next annual shareholder meeting. Under the proposed new non-employee director compensation policy, annual base compensation for incumbent non-employee directors would be set at an amount between $350,000 and $425,000, which would remain in place for a period between two and five years. Additionally, the proposed policy sets annual base compensation for new non-employee directors at an amount between $525,000 and $637,500 and includes fixed annual fees for board and committee service. The proposed settlement also

F-26


 

sets forth a number of corporate governance reforms that the Company will undertake, including, enhanced proxy disclosures, the codification of the Company’s stock ownership guidelines for directors, and enhanced disclosure requirements for certain forms of director compensation. While no cash payments will be made to investors as part of the proposed settlement, plaintiff’s counsel is expected to file a fee application which the Company has agreed not to oppose up to an agreed-upon amount. The proposed settlement contains no admission of wrongdoing.

 

13. License Agreements

 

Rucaparib

 

In June 2011, we entered into a license agreement with Pfizer Inc. to obtain the exclusive global rights to develop and commercialize Rubraca. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of Rubraca, we made milestones payments of $1.4 million, which were recognized as acquired in-process research and development expense.

 

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) European Commission approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones.

 

On December 19, 2016, the FDA approved Rubraca as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated with advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was paid in the first quarter of 2017. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we have exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. These payments were recognized as intangible assets and amortized over the estimated remaining useful life of rucaparib.

 

We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize Rubraca and we are responsible for all ongoing development and commercialization costs for Rubraca. We are required to make regulatory milestone payments to Pfizer of up to an additional $69.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for Rubraca are met, which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize Rubraca.

 

The license agreement with Pfizer will remain in effect until the expiration of all of our royalty and sublicense revenue obligations to Pfizer, determined on a product-by-product and country-by-country basis, unless we elect to terminate the license agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Pfizer can terminate the agreement, resulting in a loss of our rights to Rubraca and an obligation to assign or license to Pfizer any intellectual property rights or other rights we may have in Rubraca, including our regulatory filings, regulatory approvals, patents and trademarks for Rubraca.

 

In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with Rubraca under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of Rubraca for the uses claimed by these patents. Pursuant to the terms of the license agreement, we made an upfront payment of $0.25 million upon execution of the agreement. During the second quarter of 2016, we made a milestone payment of $0.3 million to AstraZeneca upon the NDA submission for Rubraca. These payments were recognized as acquired in-process research and development expense. The FDA approval of Rubraca on December 19, 2016 resulted in a final $0.35 million milestone payment to AstraZeneca as required by the license agreement. This payment was recognized in

F-27


 

intangible assets and amortized over the estimated remaining useful life of Rubraca. AstraZeneca also receives royalties on net sales of Rubraca.

 

Lucitanib

 

In connection with our acquisition of EOS in November 2013, we gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for upfront milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments.

 

In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product candidate containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib.

 

In the first quarter of 2014, we recognized acquired in-process research and development expense of $3.4 million, which represents 25% of the sublicense agreement consideration of $13.6 million received from Servier upon the end of opposition and appeal of the lucitanib patent by the European Patent Office.

 

The license agreement with Advenchen will remain in effect until the expiration of all of our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in a loss of our rights to lucitanib.

 

In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an upfront payment of €45.0 million. We are entitled to receive additional payments upon achievement of specified development, regulatory and commercial milestones up to €100.0 million in the aggregate, €10.0 million of which was received in the first quarter of 2014. In addition, we are entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, which, in the aggregate, could total €250.0 million. We are also entitled to receive royalties at percentage rates ranging from low to mid-teens on sales of lucitanib by Servier.

 

The development, regulatory and commercial milestones represent non-refundable amounts that would be paid by Servier to us if certain milestones are achieved in the future. These milestones, if achieved, are substantive as they relate solely to past performance, are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of our performance, which are reasonable relative to the other deliverables and terms of the arrangement, and are unrelated to the delivery of any further elements under the arrangement.

 

We and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for all of the global development costs for lucitanib up to €80.0 million. Cumulative global development costs in excess of €80.0 million, if any, will be shared equally between us and Servier. During the second quarter of 2016, we and Servier agreed to discontinue the development of lucitanib for breast cancer. We are continuing to evaluate what, if any, further development of lucitanib will be pursued. During 2017, we completed the committed on-going development activities in 2017 and received full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations and Comprehensive Loss.

 

We recorded a $0.0 and $1.3 million receivable at December 31, 2017 and 2016, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. During the years ending December 31, 2017, 2016 and 2015, we incurred ($0.2) million,

F-28


 

$7.7 million and $13.7 million, respectively, in research and development costs and recorded reductions in research and development expense of $1.0 million, $9.0 million and $11.8 million, respectively, for reimbursable development costs due from Servier.

 

Rociletinib

 

In May 2010, we entered into an exclusive worldwide license agreement with Celgene to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor (“EGFR”) gene product. Rociletinib was identified as the lead inhibitor candidate under the license agreement. We are responsible for all non-clinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib.

 

We made an upfront payment of $2.0 million upon execution of the license agreement, a $4.0 million milestone payment in the first quarter of 2012 upon the acceptance by the FDA of our Investigational New Drug application for rociletinib and a $5.0 million milestone payment in the first quarter of 2014 upon initiation of the Phase II study for rociletinib. In the third quarter of 2015, we made milestone payments totaling $12.0 million upon acceptance of the NDA and MAA for rociletinib by the FDA and EMA, respectively. We recognized all payments prior to commercial approval as acquired in-process research and development expense.

 

During the second quarter of 2016, we received a CRL from the FDA for the rociletinib NDA. We terminated enrollment in all sponsored clinical studies, although we continue to provide drug to patients whose clinicians recommend continuing rociletinib therapy. We are continuing analyses of rociletinib data to determine whether certain populations of patients may represent an opportunity for a partner committed to investing in further clinical development.

We are obligated to pay royalties at percentage rates ranging from mid-single digits to low teens based on the volume of annual net sales achieved. We are required to pay up to an additional aggregate of $98.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are required to pay up to an aggregate of $120.0 million in sales milestone payments if certain annual sales targets are achieved, which relate to annual sales targets of $500.0 million and above.

14. Net Loss Per Common Share

 

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

 

The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

 

2017

    

2016

    

2015

 

Common shares under option

 

4,260

 

3,398

 

2,031

 

Convertible senior notes

 

4,646

 

4,646

 

4,646

 

Total potential dilutive shares

 

8,906

 

8,044

 

6,677

 

 

 

F-29


 

15. Income Taxes

 

We are subject to U.S. federal, state and foreign income tax.  The geographical components of income (loss) before income taxes consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Domestic

 

$

(351,338)

 

$

(277,776)

 

$

(290,342)

 

Foreign

 

 

1,363

  

 

(103,395)

 

 

(91,595)

  

Total loss before income taxes

 

$

(349,975)

 

$

(381,171)

 

$

(381,937)

 

 

The income tax provision consists of the following current and deferred tax (benefit) expense amounts (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

 

2015

 

Current tax:

 

 

 

  

 

 

 

 

 

 

U.S. Federal & State

 

$

 —

 

$

 —

 

$

 —

 

Foreign

 

 

(360)

  

 

64

 

 

 —

 

Total current (benefit) expense

 

 

(360)

 

 

64

 

 

 —

 

Deferred tax:

 

 

 

  

 

 

 

 

 

 

U.S. Federal & State

 

 

(3,218)

 

 

 —

 

 

 —

 

Foreign

 

 

 —

  

 

(32,098)

 

 

(29,076)

 

Total deferred (benefit)

 

 

(3,218)

 

 

(32,098)

 

 

(29,076)

 

Total income tax (benefit)

 

$

(3,578)

 

$

(32,034)

 

$

(29,076)

 

 

A reconciliation of the U.S. federal statutory income tax rate to our effective tax rate is provided below:

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Federal income tax benefit at statutory rate

 

(34.0)

%  

(34.0)

%  

(34.0)

%

State income tax benefit, net of federal benefit

 

(3.2)

 

(3.6)

 

(3.0)

 

Tax credits

 

(1.2)

 

(10.8)

 

(13.6)

 

Limitation on future foreign tax credits

 

 —

 

(5.9)

 

(5.0)

 

Change in uncertain tax positions

 

0.2

 

4.2

 

 —

 

Other

 

(1.1)

 

2.3

 

0.4

 

Tax impact of Tax Cuts and Jobs Act of 2017

 

46.4

 

 —

 

 —

 

Change in valuation allowance

 

(8.1)

 

39.4

 

47.6

 

Effective income tax rate

 

(1.0)

%  

(8.4)

%  

(7.6)

%

 

F-30


 

The significant components of our deferred tax assets and liabilities are as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

    

2017

    

2016

 

Deferred tax assets:

 

 

   

  

 

 

  

Net operating loss carryforward

 

$

272,710

 

$

275,898

  

Tax credit carryforwards

 

 

222,150

 

 

217,948

  

Intangible assets

 

 

29,900

 

 

42,745

  

Share-based compensation expense

 

 

27,844

 

 

31,390

  

Foreign currency translation

 

 

3,012

 

 

10,510

  

Product acquisition costs

 

 

5,881

 

 

9,764

  

Accrued liabilities and other

 

 

3,879

 

 

5,384

  

Total deferred tax assets

 

 

565,376

 

 

593,639

  

Valuation allowance

 

 

(564,122)

 

 

(592,423)

  

Deferred tax assets, net of valuation allowance

 

 

1,254

 

 

1,216

  

Deferred tax liabilities:

 

 

 

 

 

 

  

Prepaid expenses and other

 

 

(1,254)

 

 

(1,216)

  

Total deferred tax liabilities

 

 

(1,254)

 

 

(1,216)

  

Net deferred tax liability

 

$

 —

 

$

 —

  

 

On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (the “Act”), a tax reform bill which, among other items, reduces the current corporate federal income tax rate to 21% from 35%. The rate reduction is effective January 1, 2018. We believe the Act will cause us to revalue our deferred tax assets and liabilities to the lower federal tax rate. Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through income tax expense.

 

Pursuant to the SEC Staff Accounting Bulletin ("SAB") No. 118, "Income Tax Accounting Implications of the Tax Cuts and Jobs Act" ("SAB 118"), we may select one of three scenarios to determine a reasonable estimate arising from the Tax Act. Those scenarios are (i) a final estimate which effectively closes the measurement window; (ii) a reasonable estimate leaving the measurement window open for future revisions; and (iii) no estimate as the law is still being analyzed. We were able to provide a reasonable estimate for the revaluation of deferred taxes by recording a net tax provision of $162.2 million in the period ending December 31, 2017, which is offset by a change in valuation allowance with no net impact to tax expense. Other impacts of the Act including, but not limited to, provisional transition tax, expensing of qualified property and interest limitations are not expected to have a material impact to our financial statement presentation or disclosures. The final impact of the Act may be different from the provisional amounts reported due to changes in interpretations and assumptions of the current guidance available as well as the issuance of new regulatory guidance in the future. We anticipate the full financial impact will be determined at the time our 2017 U.S. corporate income tax return is filed in 2018.

   

The realization of deferred tax assets is dependent upon a number of factors including future earnings, the timing and amount of which is uncertain. A valuation allowance was established for the net deferred tax asset balance due to management’s belief that the realization of these assets is not likely to occur in the foreseeable future. We recorded a net decrease to the valuation allowance of $28.3 million for the year ended December 31, 2017, due to the revaluation of our net deferred tax assets resulting from the reduction to the corporate federal tax rate to 21% offset by the growth in net operating losses and credit carryforwards during the year. The increase of $143.3 million recorded to our valuation allowance during the year ended December 31, 2016 was due primarily to the increase in net operating loss and tax credit carryforwards.

 

In addition, the Company recognizes tax benefits if it is more likely than not to be sustained under audit by the relevant taxing authority based on technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained during audit. If the threshold is met, the tax benefit is measured and recognized at the largest amount above the greater than 50% likelihood threshold at time of settlement. The balance of unrecognized tax benefits at December 31, 2017 of $24.5 million, if recognized, would not impact the Company’s effective tax rate as

F-31


 

long as they remain subject to a full valuation allowance. The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

 

2017

2016

 

Balance at beginning of year

 

$

24,075

 

$

 —

 

Additions related to prior periods tax positions

 

 

 —

 

 

17,844

 

Additions related to current period tax positions

 

 

437

 

 

6,231

 

Settlements with tax authorities

 

 

 —

 

 

 —

 

Expiration of statute of limitations

 

 

 —

 

 

 —

 

Balance at end of year

 

$

24,512

 

$

24,075

 

 

As of December 31, 2017, we had approximately $1.0 billion, $1.2 billion and $0.4 million of U.S. federal, state and foreign net operating loss carryforwards, respectively. The U.S. federal net operating losses will expire from 2029 to 2037 if not utilized and the U.S state net operating losses will expire from 2024 to 2037 if not utilized.  We have research and development and orphan drug tax credit carryforwards of $245.1 million that will expire from 2029 through 2037 if not utilized.

 

We believe that a change in ownership as defined under Section 382 of the U.S. Internal Revenue Code occurred as a result of our public offering of common stock completed in April 2012. Future utilization of the federal net operating losses (“NOL”) and tax credit carryforwards accumulated from inception to the change in ownership date will be subject to annual limitations to offset future taxable income. At this time, we do not believe this limitation will prevent the utilization of the federal NOL or credit carryforward prior to expiration. It is possible that a change in ownership will occur in the future, which will limit the NOL amounts generated since the last estimated change. Our federal and state income taxes for the period from inception to December 31, 2017 remain open to an audit. Our foreign subsidiaries are also subject to tax audits by tax authorities in the jurisdictions where they operate for the periods from December 31, 2011 to December 31, 2017.

 

We may be assessed interest and penalties related to the settlement of tax positions and such amounts will be recognized within income tax expense when assessed. To date, no interest and penalties have been recognized.

 

16. Employee Benefit Plans

 

We maintain a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code for our U.S. employees. The plan allows eligible employees to defer, at the employee’s discretion, pretax compensation up to the IRS annual limits. We matched contributions up to 4% of the eligible employee’s compensation or the maximum amount permitted by law. Total expense for contributions made to U.S. employees was approximately $1.9 million, $1.6 million and $0.8 million for the years ended December 31, 2017, 2016 and 2015, respectively. Our international employees participate in retirement plans or postretirement life insurance plans governed by the local laws in effect for the country in which they reside. We made contributions to the retirement plans or postretirement life insurance plans of international employees of approximately $0.3 million, $0.2 million and $0.2 million for the years ended December 31, 2017, 2016 and 2015, respectively.

F-32


 

17. Quarterly Information (Unaudited)

 

The results of operations on a quarterly basis for the years ended December 31, 2017 and 2016 were as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

March 31, 

  

June 30, 

  

September 30, 

  

December 31, 

  

March 31, 

  

June 30, 

  

September 30, 

  

December 31, 

 

 

 

2017

 

2017

 

2017

 

2017

 

2016

 

2016  (1)

 

2016

 

2016

 

Revenues:

 

 

`

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

Product revenue, net

 

$

7,045

 

$

14,620

 

$

16,806

 

$

17,040

 

$

 —

 

$

 —

 

$

 —

 

$

78

 

Operating expenses:

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

Cost of sales - product

 

 

1,163

 

 

2,730

 

 

3,026

 

 

3,332

 

 

 —

 

 

 —

 

 

 —

 

 

70

 

Cost of sales - intangible asset amortization

 

 

372

 

 

372

 

 

372

 

 

370

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

Research and development

 

 

32,447

 

 

33,108

 

 

38,924

 

 

38,019

 

 

74,608

 

 

67,729

 

 

54,338

 

 

54,454

 

Selling, general and administrative

 

 

29,224

 

 

36,149

 

 

35,011

 

 

38,523

 

 

9,827

 

 

9,552

 

 

9,162

 

 

12,190

 

Acquired in-process research and development

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

300

 

 

500

 

 

500

 

Impairment of intangible asset

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

104,517

 

 

 —

 

 

 —

 

Change in fair value of contingent purchase consideration

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

516

 

 

(25,452)

 

 

 —

 

 

 —

 

 Total expenses

 

 

63,206

 

 

72,359

 

 

77,333

 

 

80,244

 

 

84,951

 

 

156,646

 

 

64,000

 

 

67,214

 

Operating loss

 

 

(56,161)

 

 

(57,739)

 

 

(60,527)

 

 

(63,204)

 

 

(84,951)

 

 

(156,646)

 

 

(64,000)

 

 

(67,136)

 

Other income (expense):

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

Interest expense

 

 

(2,581)

 

 

(2,598)

 

 

(2,618)

 

 

(2,631)

 

 

(2,104)

 

 

(2,106)

 

 

(2,108)

 

 

(2,173)

 

Foreign currency gain (loss)

 

 

(159)

 

 

76

 

 

(44)

 

 

45

 

 

(551)

 

 

183

 

 

(66)

 

 

(146)

 

Legal settlement loss

 

 

 —

 

 

(117,000)

 

 

 —

 

 

11,523

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

Other income (expense)

 

 

354

 

 

594

 

 

1,291

 

 

1,404

 

 

25

 

 

196

 

 

252

 

 

160

 

Other income (expense), net

 

 

(2,386)

 

 

(118,928)

 

 

(1,371)

 

 

10,341

 

 

(2,630)

 

 

(1,727)

 

 

(1,922)

 

 

(2,159)

 

Loss before income taxes

 

 

(58,547)

 

 

(176,667)

 

 

(61,898)

 

 

(52,863)

 

 

(87,581)

 

 

(158,373)

 

 

(65,922)

 

 

(69,295)

 

Income tax (expense) benefit

 

 

83

 

 

1,281

 

 

1,234

 

 

980

 

 

4,181

 

 

29,059

 

 

227

 

 

(1,433)

 

Net loss

 

$

(58,464)

 

$

(175,386)

 

$

(60,664)

 

$

(51,883)

 

$

(83,400)

 

$

(129,314)

 

$

(65,695)

 

$

(70,728)

 

Basic and diluted net loss per common share

 

$

(1.33)

 

$

(3.88)

 

$

(1.24)

 

$

(1.04)

 

$

(2.17)

 

$

(3.37)

 

$

(1.70)

 

$

(1.83)

 

Basic and diluted weighted average common shares outstanding

 

 

44,039

 

 

45,176

 

 

48,917

 

 

49,973

 

 

38,360

 

 

38,389

 

 

38,538

 

 

38,624

 


(1)

In the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&D intangible asset related to our lucitanib product candidate.

 

 

F-33


EX-12.1 2 clvs-20171231ex1212dd759.htm EX-12.1 clvs_Ex12_1

Exhibit 12.1

Clovis Oncology, Inc.

Computation of Deficiency of Earnings to Fixed Charges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31,

 

 

 

2017

 

 

2016

 

 

2015

 

 

2014

 

 

2013

 

 

 

 

Earnings (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

$

(349,975)

 

 

$

(381,171)

 

 

$

(381,937)

 

 

$

(157,723)

 

 

$

(84,480)

 

Fixed charges (from below)

 

 

10,988

 

 

 

9,119

 

 

 

8,824

 

 

 

2,698

 

 

 

85

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total loss

 

$

(338,987)

 

 

$

(372,052)

 

 

$

(373,113)

 

 

$

(155,025)

 

 

$

(84,395)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fixed charges:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

$

9,148

 

 

$

7,249

 

 

$

7,167

 

 

$

2,236 

 

 

$

 

 

Amortization of debt issuance costs

 

 

1,279

 

 

 

1,242

 

 

 

1,205

 

 

 

368 

 

 

 

 

 

Interest portion of rent expense

 

 

561

 

 

 

628

 

 

 

452

 

 

 

94

 

 

 

85

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total fixed charges

 

$

10,988

 

 

$

9,119

 

 

$

8,824

 

 

$

2,698

 

 

$

85

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Coverage deficiency

 

$

349,975

 

 

$

381,171

 

 

$

381,937

 

 

$

157,723

 

 

$

84,480

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


EX-23.1 3 clvs-20171231ex231509864.htm EX-23.1 clvs_Ex23_1

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the following Registration Statements:

 

(1) Registration Statements (Form S-3 Nos. 333-211947 and 333-215400) of Clovis Oncology, Inc., and

 

(2) Registration Statements (Form S-8 Nos. 333-219046, 333-211948, 333-178283, 333-182278, 333-190565, 333-198022, and 333-206193) pertaining to the 2009 Equity Incentive Plan, 2011 Stock Incentive Plan and 2011 Employee Stock Purchase Plan of Clovis Oncology, Inc.;

 

of our reports dated February 26, 2018, with respect to the consolidated financial statements of Clovis Oncology, Inc., and the effectiveness of internal control over financial reporting of Clovis Oncology, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2017.

 

/s/ Ernst & Young LLP

 

Denver, Colorado

February 27, 2018


EX-31.1 4 clvs-20171231ex3111fe53e.htm EX-31.1 clvs_Ex31_1

Exhibit 31.1

 

I, Patrick J. Mahaffy, certify that:

 

1.

I have reviewed this annual report on Form 10-K of Clovis Oncology, Inc. for the year ended December 31, 2017;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 27, 2018 

 

/s/ PATRICK J. MAHAFFY

 

Patrick J. Mahaffy

President and Chief Executive Officer

 

 


EX-31.2 5 clvs-20171231ex3126aa7a0.htm EX-31.2 clvs_Ex31_2

Exhibit 31.2

 

I, Daniel W. Muehl, certify that:

 

1.

I have reviewed this annual report on Form 10-K of Clovis Oncology, Inc. for the year ended December 31, 2017;  

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 27, 2018 

 

/s/ DANIEL W. MUEHL

 

Daniel W. Muehl

Senior Vice President of Finance and

Principal Financial and Accounting Officer

 

 


EX-32.1 6 clvs-20171231ex32156c0fa.htm EX-32.1 clvs_Ex32_1

Exhibit 32.1

 

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Annual Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission (the “Report”), Patrick J. Mahaffy, as Chief Executive Officer of the Company, does hereby certify, pursuant to §906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. §1350), that to his knowledge:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: February 27, 2018

 

/s/ PATRICK J. MAHAFFY

 

Patrick J. Mahaffy

President and Chief Executive Officer

 

 


EX-32.2 7 clvs-20171231ex3222b5bda.htm EX-32.2 clvs_Ex32_2

Exhibit 32.2

 

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Annual Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission (the “Report”), Daniel W. Muehl, as Senior Vice President of Finance and Principal Financial and Accounting Officer of the Company, does hereby certify, pursuant to §906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. §1350), that to his knowledge:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: February 27, 2018

 

/s/ DANIEL W. MUEHL

 

Daniel W. Muehl

Senior Vice President of Finance and

Principal Financial and Accounting Officer

 

 


GRAPHIC 8 clvs20171231x10k001.jpg GRAPHIC begin 644 clvs20171231x10k001.jpg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�_\ P.B_^*K\J\48KB_U?C_/^'_!/!_XC/7_ .@6/_@3_P C]5/^%E^& M_P#H8-#_ / Z+_XJC_A9?AO_ *�_\ P.B_^*K\J\48H_U?C_/^'_!#_B,] M?_H%C_X$_P#(_53_ (67X;_Z�__ Z+_P"*H_X67X;_ .A@T/\ \#HO_BJ_ M*O%&*/\ 5^/\_P"'_!#_ (C/7_Z!8_\ @3_R/U4_X67X;_Z�__ .B_P#B MJ/\ A9?AO_H8-#_\#HO_ (JORKQ1BC_5^/\ /^'_ 0_XC/7_P"@6/\ X$_\ MC]5/^%E^&_\ H8-#_P# Z+_XJC_A9?AO_H8-#_\ Z+_ .*K\J\48H_U?C_/ M^'_!#_B,]?\ Z!8_^!/_ "/U4_X67X;_ .A@T/\ \#HO_BJ/^%E^&_\ H8-# M_P# Z+_XJORKQ1BC_5^/\_X?\$/^(SU_^@6/_@3_ ,C]5/\ A9?AO_H8-#_\ M#HO_ (JC_A9?AO\ Z�_P#P.B_^*K\J\48H_P!7X_S_ (?\$/\ B,]?_H%C M_P"!/_(_53_A9?AO_H8-#_\ Z+_ .*H_P"%E^&_^A@T/_P.B_\ BJ_*O%&* M/]7X_P _X?\ !#_B,]?_ *!8_P#@3_R/U4_X67X;_P"A@T/_ ,#HO_BJ/^%E M^&_^A@T/_P #HO\ XJORKQ1BC_5^/\_X?\$/^(SU_P#H%C_X$_\ (_53_A9? MAO\ Z�_P#P.B_^*H_X67X;_P"A@T/_ ,#HO_BJ_*O%&*/]7X_S_A_P0_XC M/7_Z!8_^!/\ R/U4_P"%E^&_^A@T/_P.B_\ BJ/^%E^&_P#H8-#_ / Z+_XJ MORKQ1BC_ %?C_/\ A_P0_P"(SU_^@6/_ ($_\C]5/^%E^&_^A@T/_P #HO\ MXJC_ (67X;_Z�__ Z+_P"*K\J\48H_U?C_ #_A_P $/^(SU_\ H%C_ .!/ M_(_53_A9?AO_ *�_\ P.B_^*H_X67X;_Z�__ .B_P#BJ_*O%&*/]7X_ MS_A_P0_XC/7_ .@6/_@3_P C]5/^%E^&_P#H8-#_ / Z+_XJC_A9?AO_ *&# M0_\ P.B_^*K\J\48H_U?C_/^'_!#_B,]?_H%C_X$_P#(_53_ (67X;_Z�_ M_ Z+_P"*H_X67X;_ .A@T/\ \#HO_BJ_*O%&*/\ 5^/\_P"'_!#_ (C/7_Z! M8_\ @3_R/U4_X67X;_Z�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�_P#P.B_^*K\J\48H_P!7X_S_ (?\$/\ MB-%?_H%C_P"!/_(_53_A9?AO_H8-#_\ Z+_ .*H_P"%E^&_^A@T/_P.B_\ MBJ_*O%&*/]7X_P _X?\ !#_B-%?_ *!8_P#@3_R/U4_X67X;_P"A@T/_ ,#H MO_BJ/^%E^&_^A@T/_P #HO\ XJORKQ1BC_5^/\_X?\$/^(T5_P#H%C_X$_\ M(_53_A9?AO\ Z�_P#P.B_^*H_X67X;_P"A@T/_ ,#HO_BJ_*O%&*/]7X_S M_A_P0_XC17_Z!8_^!/\ R/U4_P"%E^&_^A@T/_P.B_\ BJ/^%E^&_P#H8-#_ M / Z+_XJORKQ1BC_ %?C_/\ A_P0_P"(T5_^@6/_ ($_\C]5/^%E^&_^A@T/ M_P #HO\ XJC_ (67X;_Z�__ Z+_P"*K\J\48H_U?C_ #_A_P $/^(T5_\ MH%C_ .!/_(_53_A9?AO_ *�_\ P.B_^*H_X67X;_Z�__ .B_P#BJ_*O M%&*/]7X_S_A_P0_XC17_ .@6/_@3_P C]5/^%E^&_P#H8-#_ / Z+_XJC_A9 M?AO_ *�_\ P.B_^*K\J\4A'%'^K\?Y_P /^"+_ (C17_Z!8_\ @;_R/V/\ M#?%+PROAR+/B+0A\S?\ +_%ZG_:K8_X6IX7_ .ACT'_P/B_^*K\>_#Z#^S$X M[G^=7=@I?ZMP_G?W?\$QEXY8B+M]4C_X&_\ Y$_4OXD_%#PS)/:[?$6AGY6_ MY?XO;_:KF?\ A9?AO_H8-#_\#HO_ (JOS \4C]Y#]#65BC_5V"TYW]W_ 36 M/C5B)+F^JQ_\#?\ \B?JI_PLOPW_ -#!H?\ X'1?_%4?\++\-_\ 0P:'_P"! MT7_Q5?E7BC%/_5^/\_X?\$K_ (C17_Z!8_\ @3_R/U4_X67X;_Z�__ .B M_P#BJ/\ A9?AO_H8-#_\#HO_ (JORKQ1BC_5^/\ /^'_ 0_XC17_P"@6/\ MX$_\C]5/^%E^&_\ H8-#_P# Z+_XJC_A9?AO_H8-#_\ Z+_ .*K\J\48H_U M?C_/^'_!#_B-%?\ Z!8_^!/_ "/U4_X67X;_ .A@T/\ \#HO_BJ/^%E^&_\ MH8-#_P# Z+_XJORKQ1BC_5^/\_X?\$/^(T5_^@6/_@3_ ,C]5/\ A9?AO_H8 M-#_\#HO_ (JC_A9?AO\ Z�_P#P.B_^*K\J\48H_P!7X_S_ (?\$/\ B-%? M_H%C_P"!/_(_53_A9?AO_H8-#_\ Z+_ .*H_P"%E^&_^A@T/_P.B_\ BJ_* MO%&*/]7X_P _X?\ !#_B-%?_ *!8_P#@3_R/U4_X67X;_P"A@T/_ ,#HO_BJ M/^%E^&_^A@T/_P #HO\ XJORKQ1BC_5^/\_X?\$/^(T5_P#H%C_X$_\ (_53 M_A9?AO\ Z�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end GRAPHIC 9 clvs20171231x10k002.jpg GRAPHIC begin 644 clvs20171231x10k002.jpg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end EX-101.INS 10 clvs-20171231.xml EX-101.INS 0001466301 us-gaap:ConvertibleDebtMember 2016-12-31 0001466301 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0001466301 us-gaap:RetainedEarningsMember 2017-12-31 0001466301 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001466301 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001466301 us-gaap:RetainedEarningsMember 2016-12-31 0001466301 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001466301 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001466301 us-gaap:RetainedEarningsMember 2015-12-31 0001466301 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001466301 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001466301 us-gaap:RetainedEarningsMember 2014-12-31 0001466301 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001466301 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0001466301 2017-01-31 0001466301 2015-07-31 0001466301 us-gaap:PerformanceSharesMember us-gaap:ExecutiveOfficerMember 2015-01-01 2015-03-31 0001466301 clvs:EmployeeStockPurchasePlansMember 2017-01-01 2017-12-31 0001466301 clvs:EmployeeStockPurchasePlansMember 2016-01-01 2016-12-31 0001466301 clvs:EmployeeStockPurchasePlansMember 2015-01-01 2015-12-31 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001466301 clvs:StockIncentivePlanTwentyElevenMember us-gaap:MinimumMember us-gaap:DirectorMember 2017-01-01 2017-12-31 0001466301 clvs:StockIncentivePlanTwentyElevenMember us-gaap:MaximumMember us-gaap:DirectorMember 2017-01-01 2017-12-31 0001466301 clvs:StockIncentivePlanTwentyElevenMember 2017-01-01 2017-12-31 0001466301 clvs:StockIncentivePlanTwentyElevenMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-01-01 2016-12-31 0001466301 clvs:StockIncentivePlanTwentyElevenMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2016-01-01 2016-12-31 0001466301 clvs:StockIncentivePlanTwentyElevenMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-01-01 2016-12-31 0001466301 clvs:StockIncentivePlanTwentyElevenMember clvs:ShareBasedCompensationAwardTrancheFourMember 2016-01-01 2016-12-31 0001466301 clvs:StockIncentivePlanTwentyElevenMember 2016-01-01 2016-12-31 0001466301 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001466301 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2017-12-31 0001466301 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001466301 clvs:AdvenchenLaboratoriesLLCMember clvs:LicenseAgreementsLucitanibMember us-gaap:LicenseAgreementTermsMember 2014-01-01 2014-03-31 0001466301 us-gaap:MachineryAndEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001466301 us-gaap:MachineryAndEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001466301 clvs:ComputerHardwareAndSoftwareMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001466301 clvs:ComputerHardwareAndSoftwareMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001466301 us-gaap:LeaseholdImprovementsMember 2017-01-01 2017-12-31 0001466301 us-gaap:FurnitureAndFixturesMember 2017-01-01 2017-12-31 0001466301 us-gaap:MachineryAndEquipmentMember 2017-12-31 0001466301 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001466301 us-gaap:FurnitureAndFixturesMember 2017-12-31 0001466301 clvs:ComputerHardwareAndSoftwareMember 2017-12-31 0001466301 us-gaap:MachineryAndEquipmentMember 2016-12-31 0001466301 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001466301 us-gaap:FurnitureAndFixturesMember 2016-12-31 0001466301 clvs:ComputerHardwareAndSoftwareMember 2016-12-31 0001466301 2017-06-01 2017-06-30 0001466301 2017-01-01 2017-01-31 0001466301 2015-07-01 2015-07-31 0001466301 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001466301 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0001466301 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0001466301 us-gaap:StateAndLocalJurisdictionMember 2017-12-31 0001466301 us-gaap:ForeignCountryMember 2017-12-31 0001466301 us-gaap:DomesticCountryMember 2017-12-31 0001466301 us-gaap:MinimumMember clvs:FutureDirectorMember 2017-01-01 2017-12-31 0001466301 us-gaap:MaximumMember clvs:FutureDirectorMember 2017-01-01 2017-12-31 0001466301 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001466301 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001466301 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001466301 2017-11-01 2017-11-30 0001466301 2017-11-30 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2016-06-30 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2017-12-31 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2016-12-31 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2015-12-31 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2017-01-01 2017-12-31 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2016-04-01 2016-06-30 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2016-01-01 2016-12-31 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2015-10-01 2015-12-31 0001466301 clvs:EthicalOncologyScienceSpAMember 2017-01-01 2017-12-31 0001466301 clvs:EthicalOncologyScienceSpAMember 2016-01-01 2016-12-31 0001466301 clvs:EthicalOncologyScienceSpAMember 2017-12-31 0001466301 clvs:EthicalOncologyScienceSpAMember 2016-12-31 0001466301 clvs:EthicalOncologyScienceSpAMember 2015-12-31 0001466301 us-gaap:LicensingAgreementsMember 2017-12-31 0001466301 us-gaap:LicensingAgreementsMember 2016-12-31 0001466301 us-gaap:ScenarioForecastMember 2018-01-01 2018-12-31 0001466301 us-gaap:MaximumMember 2017-01-01 2017-12-31 0001466301 us-gaap:ForeignPlanMember 2017-01-01 2017-12-31 0001466301 country:US 2017-01-01 2017-12-31 0001466301 us-gaap:ForeignPlanMember 2016-01-01 2016-12-31 0001466301 country:US 2016-01-01 2016-12-31 0001466301 us-gaap:ForeignPlanMember 2015-01-01 2015-12-31 0001466301 country:US 2015-01-01 2015-12-31 0001466301 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2017-12-31 0001466301 us-gaap:ConvertibleDebtMember 2014-09-09 2014-09-09 0001466301 us-gaap:ConvertibleDebtMember 2014-09-09 0001466301 us-gaap:ConvertibleDebtMember 2017-12-31 0001466301 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember clvs:CustomerMember 2017-01-01 2017-12-31 0001466301 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember clvs:CustomerDMember 2017-01-01 2017-12-31 0001466301 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember clvs:CustomerCMember 2017-01-01 2017-12-31 0001466301 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember clvs:CustomerBMember 2017-01-01 2017-12-31 0001466301 us-gaap:CommonStockMember 2017-12-31 0001466301 us-gaap:CommonStockMember 2016-12-31 0001466301 us-gaap:CommonStockMember 2015-12-31 0001466301 us-gaap:CommonStockMember 2014-12-31 0001466301 2014-12-31 0001466301 2016-06-30 0001466301 us-gaap:USTreasurySecuritiesMember 2017-01-01 2017-12-31 0001466301 us-gaap:USTreasurySecuritiesMember 2017-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001466301 us-gaap:USTreasurySecuritiesMember 2017-12-31 0001466301 us-gaap:MoneyMarketFundsMember 2017-12-31 0001466301 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001466301 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001466301 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001466301 us-gaap:USTreasurySecuritiesMember 2016-12-31 0001466301 us-gaap:MoneyMarketFundsMember 2016-12-31 0001466301 us-gaap:FairValueInputsLevel3Member 2016-12-31 0001466301 us-gaap:FairValueInputsLevel2Member 2016-12-31 0001466301 us-gaap:FairValueInputsLevel1Member 2016-12-31 0001466301 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001466301 us-gaap:ConvertibleDebtSecuritiesMember 2017-01-01 2017-12-31 0001466301 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001466301 us-gaap:ConvertibleDebtSecuritiesMember 2016-01-01 2016-12-31 0001466301 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0001466301 us-gaap:ConvertibleDebtSecuritiesMember 2015-01-01 2015-12-31 0001466301 us-gaap:LicensingAgreementsMember 2017-01-01 2017-12-31 0001466301 us-gaap:LicensingAgreementsMember 2016-01-01 2016-12-31 0001466301 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0001466301 clvs:EmployeeStockPurchasePlanTwentyElevenMember 2017-01-01 2017-12-31 0001466301 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-12-31 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-12-31 0001466301 clvs:EmployeeStockPurchasePlanTwentyElevenMember 2016-01-01 2016-12-31 0001466301 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-12-31 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-12-31 0001466301 clvs:EmployeeStockPurchasePlanTwentyElevenMember 2015-01-01 2015-12-31 0001466301 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001466301 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0001466301 2015-12-31 0001466301 clvs:LicenseAgreementsLucitanibMember 2017-12-31 0001466301 clvs:LicenseAgreementsLucitanibMember 2016-12-31 0001466301 2017-06-30 0001466301 2018-02-21 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2017-01-01 2017-03-31 0001466301 clvs:LicenseAgreementsLicensorAstraZenecaUKLtdMember clvs:LicenseAgreementsRucaparibMember 2016-12-19 2016-12-19 0001466301 clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:RegulatoryMilestonePaymentMember clvs:LicenseAgreementsRociletinibMember 2016-07-01 2016-09-30 0001466301 clvs:LicenseAgreementsLicensorAstraZenecaUKLtdMember clvs:LicenseAgreementsRucaparibMember 2016-04-01 2016-06-30 0001466301 clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:RegulatoryMilestonePaymentMember clvs:LicenseAgreementsRociletinibMember 2014-01-01 2014-03-31 0001466301 clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:RegulatoryMilestonePaymentMember clvs:LicenseAgreementsRociletinibMember 2012-01-01 2012-03-31 0001466301 clvs:LicenseAgreementsLucitanibMember 2017-01-01 2017-12-31 0001466301 clvs:LicenseAgreementsLucitanibMember 2016-01-01 2016-12-31 0001466301 clvs:LicenseAgreementsLucitanibMember 2015-01-01 2015-12-31 0001466301 clvs:AdvenchenLaboratoriesLLCMember clvs:LicenseAgreementsLucitanibMember us-gaap:LicenseAgreementTermsMember 2008-10-01 2008-10-31 0001466301 us-gaap:StateAndLocalJurisdictionMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001466301 us-gaap:StateAndLocalJurisdictionMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001466301 us-gaap:DomesticCountryMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001466301 us-gaap:DomesticCountryMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001466301 us-gaap:MinimumMember us-gaap:DirectorMember 2017-01-01 2017-12-31 0001466301 us-gaap:MaximumMember us-gaap:DirectorMember 2017-01-01 2017-12-31 0001466301 2017-03-01 2017-03-31 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember us-gaap:MinimumMember 2016-12-19 2016-12-19 0001466301 clvs:LicenseAgreementsLucitanibMember us-gaap:MaximumMember us-gaap:LicenseAgreementTermsMember 2017-01-01 2017-12-31 0001466301 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001466301 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001466301 clvs:LicenseAgreementsLucitanibMember us-gaap:LicenseAgreementTermsMember 2014-01-01 2014-03-31 0001466301 clvs:LicenseAgreementsLucitanibMember us-gaap:LicenseAgreementTermsMember 2012-09-01 2012-09-30 0001466301 clvs:LicenseAgreementsLicensorAstraZenecaUKLtdMember clvs:LicenseAgreementsRucaparibMember 2012-04-01 2012-04-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember us-gaap:LicenseAgreementTermsMember 2011-06-01 2011-06-30 0001466301 clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:LicenseAgreementsRociletinibMember 2010-05-01 2010-05-31 0001466301 clvs:EmployeeStockPurchasePlanTwentyElevenMember 2011-08-31 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001466301 clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:LicenseAgreementsRociletinibMember 2017-01-01 2017-12-31 0001466301 clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:RegulatoryMilestonePaymentMember clvs:LicenseAgreementsRociletinibMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001466301 us-gaap:AccountingStandardsUpdate201609Member 2017-01-01 2017-12-31 0001466301 clvs:EmployeeStockPurchasePlanTwentyElevenMember 2011-08-01 2011-08-31 0001466301 clvs:SemiAnnualPaymentSecondPaymentMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-12-31 0001466301 clvs:SemiAnnualPaymentFirstPaymentMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-12-31 0001466301 us-gaap:ConvertibleDebtMember 2017-01-01 2017-12-31 0001466301 clvs:StockIncentivePlanTwentyElevenMember 2017-12-31 0001466301 clvs:EquityIncentivePlanTwentyZeroNineMember 2017-12-31 0001466301 clvs:EmployeeStockPurchasePlanTwentyElevenMember 2017-12-31 0001466301 2017-10-01 2017-12-31 0001466301 2017-07-01 2017-09-30 0001466301 2017-04-01 2017-06-30 0001466301 2017-01-01 2017-03-31 0001466301 2016-10-01 2016-12-31 0001466301 2016-07-01 2016-09-30 0001466301 2016-04-01 2016-06-30 0001466301 2016-01-01 2016-03-31 0001466301 2015-10-01 2015-12-31 0001466301 clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:RegulatoryMilestonePaymentMember clvs:LicenseAgreementsRociletinibMember us-gaap:MaximumMember 2017-12-31 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember us-gaap:MaximumMember 2017-12-31 0001466301 clvs:LicenseAgreementsLucitanibMember us-gaap:MaximumMember us-gaap:LicenseAgreementTermsMember 2017-12-31 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2017-01-01 2017-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-12-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-12-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-12-31 0001466301 2017-12-31 0001466301 2016-12-31 0001466301 2017-01-01 2017-12-31 0001466301 2016-01-01 2016-12-31 0001466301 2015-01-01 2015-12-31 clvs:segment clvs:D iso4217:USD xbrli:shares clvs:Vote clvs:shareholder xbrli:pure clvs:item xbrli:shares iso4217:EUR iso4217:USD 0 62000 1961000 589000 415000 35198000 18465000 0 1008000 -48929000 -159000 -48770000 -38955000 -256000 -38699000 0 21100000 0 0 0 1100000 20000000 100000000 170000000 250000000 120000000 0 0 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Cash, Cash Equivalents and Available-for-Sale Securities </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We consider all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S.&nbsp;government and U.S.&nbsp;government agency obligations.&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Marketable securities are considered to be available-for-sale securities and consist of U.S. treasury securities. Available-for-sale securities are reported at fair value on the Consolidated Balance Sheets and unrealized gains and losses are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense) on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on our intent to fund current operations with these securities or to make them available for current operations. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.</font> </p><div /></div> </div> 24611000 -26900000 -516000 24936000 25452000 0 0 0 0 0 0 0 6379264 0 331213 6048051 0 0 70000 0 0 70000 1163000 10251000 2730000 3026000 3332000 2 --03-15 --09-15 1.00 0 22022000 20062000 0 23000000 42745000 29900000 0 20461000 0.000 0.042 0.002 P6M 18200000 69750000 98000000 500000000 250000000 0 0 20461000 -14122000 15364000 17297000 0.01 344828 1250000 2000000 7000000 250000 45000000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">13. License Agreements </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Rucaparib </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In June 2011, we entered into a license agreement with Pfizer Inc. to obtain the exclusive global rights to develop and commercialize Rubraca. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0&nbsp;million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of Rubraca, we made milestones payments of $1.4 million, which were recognized as acquired in-process research and development expense. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">st</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Indication in US and (ii) European Commission approval of an MAA for 1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">st</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">On December 19, 2016, the FDA approved Rubraca as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated with advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was paid in the first quarter of 2017. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we have exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. These payments were recognized as intangible assets and amortized over the estimated remaining useful life of rucaparib.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize Rubraca and we are responsible for all ongoing development and commercialization costs for Rubraca. We are required to make regulatory milestone payments to Pfizer of up to an additional $69.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for Rubraca are met, which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0&nbsp;million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize Rubraca.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The license agreement with Pfizer will remain in effect until the expiration of all of our royalty and sublicense revenue obligations to Pfizer, determined on a product-by-product and country-by-country basis, unless we elect to terminate the license agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Pfizer can terminate the agreement, resulting in a loss of our rights to Rubraca and an obligation to assign or license to Pfizer any intellectual property rights or other rights we may have in Rubraca, including our regulatory filings, regulatory approvals, patents and trademarks for Rubraca. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with Rubraca under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of Rubraca for the uses claimed by these patents. Pursuant to the terms of the license agreement, we made an upfront payment of $0.25 million upon execution of the agreement. During the second quarter of 2016, we made a milestone payment of $0.3 million to AstraZeneca upon the NDA submission for Rubraca. These payments were recognized as acquired in-process research and development expense. The FDA approval of Rubraca on December 19, 2016 resulted in a final $0.35 million milestone payment to AstraZeneca as required by the license agreement. This payment was recognized in intangible assets and amortized over the estimated remaining useful life of Rubraca. AstraZeneca also receives royalties on net sales of Rubraca.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Lucitanib </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In connection with our acquisition of EOS in November 2013, we gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (&#x201C;Advenchen&#x201D;). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for upfront milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product candidate containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In the first quarter of 2014, we recognized acquired in-process research and development expense of $3.4 million, which represents 25% of the sublicense agreement consideration of $13.6&nbsp;million received from Servier upon the end of opposition and appeal of the lucitanib patent by the European Patent Office. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The license agreement with Advenchen will remain in effect until the expiration of all of our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in a loss of our rights to lucitanib.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an upfront payment of &#x20AC;45.0 million. We are entitled to receive additional payments upon achievement of specified development, regulatory and commercial milestones up to &#x20AC;100.0&nbsp;million in the aggregate, &#x20AC;10.0 million of which was received in the first quarter of 2014. In addition, we are entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, which, in the aggregate, could total &#x20AC;250.0&nbsp;million. We are also entitled to receive royalties at percentage rates ranging from low to mid-teens on sales of lucitanib by Servier. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The development, regulatory and commercial milestones represent non-refundable amounts that would be paid by Servier to us if certain milestones are achieved in the future. These milestones, if achieved, are substantive as they relate solely to past performance, are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of our performance, which are reasonable relative to the other deliverables and terms of the arrangement, and are unrelated to the delivery of any further elements under the arrangement. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for all of the global development costs for lucitanib up to &#x20AC;80.0&nbsp;million. Cumulative global development costs in excess of &#x20AC;80.0&nbsp;million, if any, will be shared equally between us and Servier. During the second quarter of 2016, we and Servier agreed to discontinue the development of lucitanib for breast cancer. We are continuing to evaluate what, if any, further development of lucitanib will be pursued. During 2017, we completed the committed on-going development activities in 2017 and received full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations and Comprehensive Loss. </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We recorded a $</font><font style="display:inline;">0.0</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and $1.3 million receivable at December&nbsp;31, 2017 and 2016, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. During the years ending December 31, 2017, 2016 and 2015, we incurred ($0.2) million, $7.7 million and $13.7 million, respectively, in research and development costs and recorded reductions in research and development expense of $1.0 million, $9.0 million and $11.8 million, respectively, for reimbursable development costs due from Servier.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Rociletinib</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In May 2010, we entered into an exclusive worldwide license agreement with Celgene to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor (&#x201C;EGFR&#x201D;) gene product. Rociletinib was identified as the lead inhibitor candidate under the license agreement. We are responsible for all non-clinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We made an upfront payment of $2.0 million upon execution of the license agreement, a $4.0 million milestone payment in the first quarter of 2012 upon the acceptance by the FDA of our Investigational New Drug application for rociletinib and a $5.0 million milestone payment in the first quarter of 2014 upon initiation of the Phase II study for rociletinib. In the third quarter of 2015, we made milestone payments totaling $12.0 million upon acceptance of the NDA and MAA for rociletinib by the FDA and EMA, respectively. We recognized all payments prior to commercial approval as acquired in-process research and development expense.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">During the second quarter of 2016, we received a CRL from the FDA for the rociletinib NDA. We terminated enrollment in all sponsored clinical studies, although we continue to provide drug to patients whose clinicians recommend continuing rociletinib therapy. We are continuing analyses of rociletinib data to determine whether certain populations of patients may represent an opportunity for a partner committed to investing in further clinical development.</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We are obligated to pay royalties at percentage rates ranging from mid-single digits to low teens based on the volume of annual net sales achieved. We are required to pay up to an additional aggregate of $98.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are required to pay up to an aggregate of $120.0 million in sales milestone payments if certain annual sales targets are achieved, which relate to annual sales targets of $500.0 million and above.</font> </p><div /></div> </div> 13600000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Liquidity </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenue from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless and until it does, we will continue to need to raise additional cash. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including commercial planning and sales and marketing expenses associated with the launch of Rubraca in the United States and, if approved by the European Commission in Europe, funding of its development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on our current estimates, we believe that our cash, cash equivalents and available-for-sale securities will allow us to fund activities through the next 12 months</font><font style="display:inline;">.</font> </p><div /></div> </div> 105478000 105477000 1000 1472324 80000000 P2M 1400000 2 P12M P18M P12M 2 1 P5Y P2Y 2028 2037 2029 2037 2024 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Other Accrued Expenses </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Other accrued expenses are comprised of the following (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued personnel costs</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 13,889</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 15,850</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued interest payable</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,096</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,096</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Income tax payable</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 556</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued corporate legal fees and professional services</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 415</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 589</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued royalties</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,984</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued sales deductions</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,008</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Payable to third party logistics provider</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,661</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued expenses - other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,830</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 396</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 25,883</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 19,487</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Other Current Assets </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Other current assets are comprised of the following (in thousands): </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Receivable from partners</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;9</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,882</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Prepaid insurance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,926</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,234</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Prepaid expenses - other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,355</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,109</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Receivable - other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,023</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 364</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 187</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 90</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 7,500</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 6,679</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 10000000 0 0 2515000 0.25 0.01 0.01 <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The estimated useful lives of our capitalized assets are as follows: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Estimated</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Useful&nbsp;Life</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Computer hardware and software</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">3&nbsp;to&nbsp;5&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Leasehold improvements</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">6&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Laboratory, manufacturing and office equipment</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">5 to 7&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Furniture and fixtures</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">10&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Recently Adopted Accounting Standards</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" (ASU 2016-09).&nbsp;&nbsp;ASU 2016-09 simplifies how several aspects of share-based payments are accounted for and presented in the financial statements. ASU 2016-09 is effective for public companies for annual reporting periods beginning after December 15, 2016. We adopted this ASU in the first quarter of 2017. We had excess tax benefits for which a benefit could not be previously recognized of approximately $18.2 million. Upon adoption the balance of the unrecognized excess tax benefits were reversed with the impact recorded to retained earnings including any change to the valuation allowance as a result of the adoption. Due to the full valuation allowance on the U.S. deferred tax assets, there is no impact to the financial statements as a result of this adoption.</font> </p><div /></div> </div> 11800000 9000000 1000000 200000 4000000 5000000 300000 12000000 350000 750000 <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017, we reserved shares of common stock for future issuance as follows: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Available&nbsp;for</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Grant</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Total&nbsp;Shares&nbsp;of</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Common Stock</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">or&nbsp;Future</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Common&nbsp;Stock</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Outstanding</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Issuance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Reserved</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2009 Equity Incentive Plan</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 331,213</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 331,213</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2011 Stock Incentive Plan</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 6,048,051</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,589,033</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,637,084</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2011 Employee Stock Purchase Plan</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 558,870</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 558,870</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 6,379,264</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,147,903</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 9,527,167</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 513069 41.40 0 175000 12170000 9527167 558870 331213 8637084 68.00 162200000 0.000 0.000 0.464 2021-08-24 0 2661000 false --12-31 FY 2017 2017-12-31 10-K 0001466301 50573183 Yes Large Accelerated Filer 4220084525 Clovis Oncology, Inc. No Yes CLVS 2882000 1300000 9000 0 10912000 15147000 121000 6181000 -1400000 -211000 -354000 19487000 25883000 0 2984000 2657000 3688000 -47460000 -383000 -47077000 -47580000 -146000 -47434000 -42173000 -256000 -41917000 1174950000 1887198000 40357000 40357000 39796000 39796000 44707000 44707000 17741000 40357000 900000 27321000 13036000 39796000 800000 27558000 12238000 44707000 1000000 20335000 24372000 0 0 1205000 1242000 1279000 53000 1500000 6677000 4646000 2031000 8044000 4646000 3398000 8906000 4646000 4260000 364557000 735230000 279410000 626940000 252358000 202361000 49997000 0 202361000 49997000 202361000 0 0 0 49997000 0 532669000 433136000 99533000 0 433136000 99533000 433136000 0 0 0 99533000 0 0 117000 99650000 99650000 <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017, the fair value and gross unrealized losses of available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months were as follows (in thousands):</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Aggregate</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Gross</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Value</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Losses</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">U.S. treasury securities</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,533</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (117)</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 117000 99533000 49997000 99533000 99650000 99533000 99533000 99533000 <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Amortized</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Cost</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Value</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Due in one year or less</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,650</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,533</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Due in one year to two years</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,650</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,533</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Basis of Presentation </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201C;U.S. GAAP&#x201D;). The consolidated financial statements include our accounts and our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&nbsp;</font> </p><div /></div> </div> -27792000 -24661000 0 0 0 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Valuation of Contingent Consideration Resulting from a Business Combination </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Subsequent to the acquisition date, we re-measure contingent consideration arrangements at fair value each reporting period and record changes in fair value to change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss. Changes in fair value are primarily attributed to new information about the IPR&amp;D assets, including changes in timeline and likelihood of success, and the passage of time. In the absence of new information, changes in fair value reflect only the passage of time. During the fourth quarter of 2015, we recorded a $26.9 million reduction in the fair value of the contingent purchase consideration liability due to a change in the estimated probability-weighted future discounted milestone payments, as well as the timing of such payments, for the lucitanib program.&nbsp;&nbsp;Then, during the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner&#x2019;s decision to discontinue the development of lucitanib for breast cancer. At December 31, 2017, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets remained at zero due to the uncertainty of achieving any of the lucitanib regulatory milestones, and therefore the remote likelihood of future milestone payouts.</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">CLOVIS ONCOLOGY, INC. </font> </p> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS <a name="NOTESTOCONSOLIDATED_327779"></a></font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">1. Nature of Business </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. We have and intend to continue to license or acquire rights to oncology compounds in all stages of clinical development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Our marketed product Rubraca&#xAE; (rucaparib) is approved on an accelerated basis in the United States by the FDA as monotherapy for the treatment of patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. We launched Rubraca in the United States in December 2016 for this indication. </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The FDA is currently reviewing on a priority review timeline our sNDA for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Our MAA submitted to the European Union&#x2019;s EMA for an ovarian cancer treatment indication for Rubraca is currently under review by the EMA&#x2019;s CHMP.&nbsp;&nbsp;Following a&nbsp;Scientific Advisory Group&nbsp;- Oncology meeting and an oral explanation by us before the CHMP in February 2018, the CHMP has communicated a positive trend vote for the MAA and their intention to hold a final vote on the treatment indication at their March 2018 meeting.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Liquidity </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenue from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless and until it does, we will continue to need to raise additional cash. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including commercial planning and sales and marketing expenses associated with the launch of Rubraca in the United States and, if approved by the European Commission in Europe, funding of its development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on our current estimates, we believe that our cash, cash equivalents and available-for-sale securities will allow us to fund activities through the next 12 months</font><font style="display:inline;">.</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 482677000 278756000 216186000 464198000 -203921000 -62570000 248012000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12. Commitments and Contingencies </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We lease office space in Boulder, Colorado, San&nbsp;Francisco, California, Oakland, California, Cambridge, UK and Milan, Italy under non-cancelable operating lease agreements that expire through 2028. The lease agreements contain periodic rent increases that result in the recording deferred rent over the terms of certain leases.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In November 2017, we entered into a ten-year lease agreement for new office space in Oakland, California. Pursuant to the terms of the lease, the landlord will reimburse us for up to $2.5 million of leasehold improvement expenditures (&#x201C;Tenant Improvement Allowance&#x201D;). Upon completion of construction, we will record the Tenant Improvement Allowance as deferred rent, which will be amortized as a reduction to rental expense over the lease term.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Rental expense under these leases was $2.2 million, $2.2 million and $2.4 million for the years ended December 31, 2017, 2016 and 2015, respectively.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Future minimum rental commitments, by fiscal year and in the aggregate, for our operating leases are provided below (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2018</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,050</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2019</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,902</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2020</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,744</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2021</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,855</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2022</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,519</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Thereafter</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 11,563</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total future minimum lease payments</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 28,633</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Manufacture and Services Agreement Commitments </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">On October 3, 2016, we entered into a Manufacturing and Services Agreement (the &#x201C;Agreement&#x201D;) with a non-exclusive third-party supplier for the production of the active ingredient for rucaparib. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in rucaparib that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified any forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the rucaparib active ingredient. We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of December 31, 2017, $223.9 million of purchase commitments exist under the Agreement.&nbsp; </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Legal Proceedings</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition.</font> </p> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Rociletinib-Related Litigation</font> </p> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Following Clovis&#x2019; regulatory announcement in November 2015 of adverse developments in its ongoing clinical trials for rociletinib, Clovis and certain of its current and former executives were named in various securities lawsuits, the largest of which was a putative class action lawsuit in the District of Colorado (the &#x201C;Medina Action&#x201D;) which was settled on October 26, 2017 (the &#x201C;Medina Settlement&#x201D;).&nbsp;&nbsp;The open actions currently pending against Clovis are discussed below.&nbsp;&nbsp;&nbsp;While other entities have threatened to bring claims relating to rociletinib and the November 2015 announcement, none have commenced litigation as of the date of this filing.&nbsp; </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">On January 22, 2016, the Electrical Workers Local #357 Pension and Health &amp; Welfare Trusts, a purported shareholder of Clovis, filed a purported class action complaint (the &#x201C;Electrical Workers Complaint&#x201D;) against Clovis and certain of its officers, directors, investors and underwriters in the Superior Court of the State of California, County of San Mateo (the &#x201C;Electrical Workers Court&#x201D;). The Electrical Workers Complaint purports to be asserted on behalf of a class of persons who purchased stock in the July 2015 Offering. The complaint asserted claims under certain provisions of the Securities Act of 1933 (the &#x201C;Securities Act&#x201D;) relating to a July 2015 follow-on offering of Clovis securities (the &#x201C;July 2015 Offering&#x201D;) based on substantially similar allegations to those asserted in the Medina Action. On June 30, 2016, the Electrical Workers Plaintiffs filed an amended complaint adding new allegations (the &#x201C;Amended Complaint&#x201D;). </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">On July 28, 2016, the defendants filed a motion to stay the Electrical Workers action pending resolution of the Medina Action and a demurrer to the Amended Complaint. On September 23, 2016, after hearing oral argument, the Electrical Workers Court granted the motion to stay and reserved on issuing a ruling on defendants&#x2019; pending demurrer. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">The Company believes that the claims asserted in the Electrical Workers Action are released and barred by operation of law through the Medina Settlement, and accordingly plans to seek dismissal of the Electrical Workers Action on that basis. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">On November 10, 2016, Antipodean Domestic Partners (&#x201C;Antipodean&#x201D;) filed a complaint (the &#x201C;Antipodean Complaint&#x201D;) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the offering materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib&#x2019;s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the &#x201C;Antipodean Amended Complaint&#x201D;) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">On January 31, 2017, Defendants filed a motion to stay the Antipodean action pending resolution of the Medina Action in the District of Colorado. Defendants also filed a motion to dismiss the Antipodean Amended Complaint on March 29, 2017. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">On March 14, 2017, the Clovis Defendants and Antipodean participated in a mediation, which did not result in a settlement. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">On August 8, 2017, the parties participated in a scheduled hearing on Defendants&#x2019; motion to stay and motion to dismiss before Justice Masley of the New York Supreme Court, County of New York. At the hearing, Justice Masley granted Defendants&#x2019; motion to stay. Per the Court&#x2019;s August 10, 2017 order, Defendants&#x2019; motion to dismiss was held in abeyance and deemed submitted on November 1, 2017.&nbsp;&nbsp;On November 1, 2017, the Defendants provided a status update to the Court regarding the outcome of the hearing.&nbsp;&nbsp;The update informed the Court that Antipodean had excluded itself from the Medina Settlement, as memorialized in the final judgment entered by the Medina Court.&nbsp;&nbsp;No date has been scheduled for argument on Defendants&#x2019; motion to dismiss. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint.&nbsp;&nbsp;However, there can be no assurance that the defense will be successful. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp; </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">In March 2017, two putative shareholders of the Company, Macalinao and McKenry (the &#x201C;Derivative Plaintiffs&#x201D;), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the &#x201C;Consolidated Derivative Action&#x201D;). </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">On May 18, 2017, the Derivative Plaintiffs filed a Consolidated Verified Shareholder Derivative Complaint (the &#x201C;Consolidated Derivative Complaint&#x201D;). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company&#x2019;s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to prior demands for inspection of the Company&#x2019;s books and records served on the Company by each of Macalinao and McKenry under 8 Del. C.&nbsp;&#xA7; 220. The Consolidated Derivative Complaint sought, among other things, an award of money damages. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">On July 31, 2017, the defendants filed a motion to dismiss the Consolidated Derivative Complaint. Plaintiffs filed an opposition to the motion to dismiss on August 31, 2017, and the defendants filed a reply in further support of the motion to dismiss on September 26, 2017. No date has been scheduled for argument on Defendants&#x2019; motion to dismiss the Consolidated Derivative Complaint. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp; </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the &#x201C;Guo Complaint&#x201D;) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company&#x2019;s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company&#x2019;s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative Complaint. On June 20, 2017, the court granted the motion to stay. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful. </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">In addition, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission and the U.S. Department of Justice, relating to the Company&#x2019;s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. The Company is continuing to cooperate with these agencies with respect to their investigations. The Medina Settlement does not resolve these inquiries and the Company cannot predict their timing or outcome.</font> </p> <p style="margin:0pt;text-indent:24.5pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Director Compensation Litigation</font> </p> <p style="margin:0pt;text-indent:24.5pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">On May 10, 2017, John Solak, a purported shareholder of the Company, filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware (the &#x201C;Solak Complaint&#x201D;) against certain directors and an officer of the Company. The Solak Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by adopting a compensation plan that overcompensated the non-employee director defendants, in relation to companies of comparable market capitalization and size. The Solak Complaint also alleged claims of waste of corporate assets and unjust enrichment due to this allegedly wrongful compensation plan. The Solak Complaint sought, among other things, an award of money damages and the imposition of corporate governance reforms. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The Court has entered a number of orders extending the defendants&#x2019; time to respond to the Solak Complaint based on, among other factors, the fact that the parties are engaged in discussions in an effort to resolve the Solak action. On February 14, 2018, the parties filed a joint letter to the Court requesting that all deadlines in the action be held in abeyance while the parties engaged in final settlement discussions.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">On February 26, 2018, the defendants entered into a stipulation of compromise and settlement with plaintiff that is intended to settle the Solak action. The proposed settlement is subject to Court approval upon the conclusion of a settlement hearing concerning the fairness of the terms of the proposed settlement, which will be scheduled following the provision of notice to shareholders of the Company.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In accordance with the terms of the proposed settlement, the Company will present a new non-employee director compensation policy for shareholder vote at the next annual shareholder meeting. Under the proposed new non-employee director compensation policy, annual base compensation for incumbent non-employee directors would be set at an amount between $350,000 and $425,000, which would remain in place for a period between two and five years. Additionally, the proposed policy sets annual base compensation for new non-employee directors at an amount between $525,000 and $637,500 and includes fixed annual fees for board and committee service. The proposed settlement also sets forth a number of corporate governance reforms that the Company will undertake, including, enhanced proxy disclosures, the codification of the Company&#x2019;s stock ownership guidelines for directors, and enhanced disclosure requirements for certain forms of director compensation. While no cash payments will be made to investors as part of the proposed settlement, plaintiff&#x2019;s counsel is expected to file a fee application which the Company has agreed not to oppose up to an agreed-upon amount. The proposed settlement contains no admission of wrongdoing.</font> </p><div /></div> </div> 3147903 558870 0 2589033 0.001 0.001 100000000 100000000 38724090 50565119 33977187 38359454 38724090 38724090 50565119 50565151 39000 51000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16. Employee Benefit Plans </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We maintain a retirement plan, which is qualified under section&nbsp;401(k) of the Internal Revenue Code for our U.S.&nbsp;employees. The plan allows eligible employees to defer, at the employee&#x2019;s discretion, pretax compensation up to the IRS annual limits. We matched contributions up to 4% of the eligible employee&#x2019;s compensation or the maximum amount permitted by law. Total expense for contributions made to U.S.&nbsp;employees was approximately $</font><font style="display:inline;">1.9</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> million, $1.6 million and $0.8</font><font style="display:inline;"> million</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> for the years ended December 31, 2017, 2016 and 2015, respectively. Our international employees participate in retirement plans or postretirement life insurance plans governed by the local laws in effect for the country in which they reside. We made contributions to the retirement plans or postretirement life insurance plans of international employees of approximately $</font><font style="display:inline;">0.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> million, $0.2 million and $0.2 million for the years ended December 31, 2017, 2016 and 2015, respectively.</font> </p><div /></div> </div> -375873000 -349257000 -340990000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Concentration of Credit Risk </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Financial instruments that potentially subject us to concentrations of credit risk are primarily cash, cash equivalents and available-for-sale securities. We maintain our cash and cash equivalent balances in the form of money market accounts with financial institutions that we believe are creditworthy. Available-for-sale securities are invested in accordance with our investment policy. The investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that we believe minimizes the exposure to concentration of credit risk. We have no financial instruments with off-balance sheet risk of accounting loss.</font> </p><div /></div> </div> 0.27 0.12 0.10 0.35 281126000 282406000 282400000 0 0 0 0 0 0 372000 1486000 372000 372000 370000 0 0 0 0 64000 -360000 0 64000 -360000 61.88 16.1616 30 1.50 20 287500000 388300000 0.025 2021-09-15 2018-09-15 1.00 P7Y 0 0 -3218000 9200000 -29076000 -32098000 0 -29076000 -32098000 -3218000 1216000 1254000 1406000 3671000 9764000 5881000 593639000 565376000 1216000 1254000 275898000 272710000 217948000 222150000 31390000 27844000 5384000 3879000 10510000 3012000 592423000 564122000 0 0 1216000 1254000 800000 200000 1600000 200000 1900000 300000 0.04 800000 1100000 1000000 761000 1141000 2504000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">10. Share-Based Compensation </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Stock Options </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:11pt;text-indent:12.25pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;"> In August 2011, our Board of Directors approved the 2011 Stock Incentive Plan (the &#x201C;2011 Plan&#x201D;), which became effective upon the closing of our initial public offering in November 2011. The 2011 Plan provides for the granting of incentive and nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards and other share-based awards to our employees, directors and consultants. Common shares authorized for issuance under the 2011 Plan were 9,590,378 at December&nbsp;31, 2017, which represents the initial reserve of 1,250,000 shares of common stock plus 192,185 shares of common stock remaining for future grant from the 2009 Equity Incentive Plan (the &#x201C;2009 Plan&#x201D;), which was terminated upon the closing of our initial public offering in November 2011, and 8,148,193 new shares authorized by the Board of Directors at the annual meetings of stockholders. Future forfeitures and cancellations of options previously granted under the 2009 Plan were transferred to and also available for grant under the 2011 Plan. Stock options granted vest ratably over either a one-year period or three-year period for Board of Director grants. Employee stock options generally vest over a four-year period with 25% of the options cliff-vesting after year one and the remaining options vesting ratably over each subsequent month. All stock options expire 10 years from the date of grant.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Share-based compensation expense for the years ended December 31, 2017, 2016 and 2015, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 86.80%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:31.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Research and development </font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 20,335</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 27,558</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 27,321</font></p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Selling, general and administrative</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24,372</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 12,238</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 13,036</font></p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total share-based compensation expense</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 44,707</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 39,796</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 40,357</font></p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We did not recognize a tax&nbsp;benefit related to share-based compensation expense during the years ended December 31, 2017, 2016 and 2015 as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of December&nbsp;31, 2017.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table summarizes the activity relating to our options to purchase common stock: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Weighted</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:06.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Weighted</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Average</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Aggregate</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:06.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Average</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Remaining</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Intrinsic</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:06.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Exercise</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Contractual</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Value</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Options</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:06.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Price</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Term&nbsp;(Years)</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Thousands)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding at December&nbsp;31,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 5,520,482</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 42.00</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Granted </font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 1,048,700</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 66.09</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Exercised</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (465,690)</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 29.90</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Forfeited</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (313,757)</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 49.20</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding at December&nbsp;31,&nbsp;2017 (a)</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 5,789,735</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 46.77</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 7.1</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 145,067</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vested and expected to vest at December&nbsp;31,&nbsp;2017</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 5,505,557</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 46.52</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 7.0</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 139,526</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vested and exercisable at December&nbsp;31,&nbsp;2017</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 3,481,931</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 44.60</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 6.1</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 95,463</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (a)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Includes 33,750 performance-based stock options granted to our executives in the first quarter of 2015</font><font style="display:inline;">, which vested on approval by the FDA in December 19, 2016 to commercially distribute, sell or market Rubraca.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Related stock compensation expense was recognized on that date.</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $68.00 as of December&nbsp;31, 2017, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table summarizes information about our stock options as of and for the years ended December&nbsp;31, 2017, 2016 and 2015: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:45.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Weighted-average grant date fair value per share</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 48.79</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 16.62</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 52.70</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Intrinsic value of options exercised</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 18,986,726</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,118,097</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 19,976,769</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Cash received from stock option exercises</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 13,924,174</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,267,721</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 5,478,211</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The fair value of each share-based award is estimated on the grant date using the Black-Scholes option pricing model based upon the weighted-average assumptions provided in the following table: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:25.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Dividend yield</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Volatility (a)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 89</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 93</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 72</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Risk-free interest rate (b)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2.16</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1.77</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1.77</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Expected term (years) (c)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 5.8</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 5.8</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 6.1</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (a)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Volatility</font><font style="display:inline;font-family:Times New Roman,Times,serif;">: The expected volatility was estimated using our historical data.</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (b)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Risk-free interest rate:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The rate is based on the yield on the grant date of a zero-coupon U.S. Treasury bond whose maturity period approximates the option&#x2019;s expected term.</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (c)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Expected term:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The expected term of the award was estimated using our historical data.</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The total fair value of stock options vested during the years ended December 31, 2017, 2016 and 2015 was $</font><font style="display:inline;">36.0</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> million, $40.8 million and $36.5 million, respectively. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Restricted Stock</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">During 2016, we issued restricted stock units (&#x201C;RSUs&#x201D;) to certain employees under the 2011 Stock Incentive Plan. The RSUs vest either (i) over two years, with 50% vesting one year from the date of grant and the remaining 50% vesting two years from the date of grant or (ii) over four years, with 25% vesting one year from the date of grant and the remaining 75% vesting ratably each subsequent quarter over the following three years, as defined in the grant agreement. Vested RSUs are payable in shares of our common stock at the end of the vesting period. RSUs are measured based on the fair value of the underlying stock on the grant date. The minimum statutory tax on the value of common stock shares&nbsp;&nbsp;issued to employees upon vesting are paid by us through the sale of registered shares of our common stock.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table summarizes the activity related to our unvested RSUs:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Grant Date</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Units</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Fair Value</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Unvested at December&nbsp;31,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 562,458</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24.70</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Granted </font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 249,984</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 64.66</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Vested </font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (180,912)</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 23.83</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Forfeited</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (42,001)</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 28.09</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Unvested as of December&nbsp;31,&nbsp;2017</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 589,529</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 41.67</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Expected to vest after December&nbsp;31,&nbsp;2017</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 513,069</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 41.40</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Unrecognized share-based compensation expense related to non-vested options and RSUs, adjusted for expected forfeitures, was $89.4 million as of December&nbsp;31, 201</font><font style="display:inline;">7</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. The unrecognized share-based compensation expense is expected to be recognized over the weighted-average remaining vesting period of 3.3&nbsp;years.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Common Stock Reserved for Issuance </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017, we reserved shares of common stock for future issuance as follows: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Available&nbsp;for</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Grant</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Total&nbsp;Shares&nbsp;of</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Common Stock</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">or&nbsp;Future</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Common&nbsp;Stock</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Outstanding</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Issuance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Reserved</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2009 Equity Incentive Plan</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 331,213</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 331,213</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2011 Stock Incentive Plan</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 6,048,051</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,589,033</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,637,084</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2011 Employee Stock Purchase Plan</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 558,870</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 558,870</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 6,379,264</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,147,903</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 9,527,167</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Employee Stock Purchase Plan </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In August 2011, our Board of Directors approved the Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan (the &#x201C;Purchase Plan&#x201D;). Each year, on the date of our annual meeting of stockholders and at the discretion of our board of directors, the amount of shares reserved for issuance under the Purchase Plan may be increased by up to the lesser of (1)&nbsp;a number of additional shares of our common stock representing 1% of our then-outstanding shares of common stock, (2)&nbsp;344,828 shares of our common stock and (3)&nbsp;a lesser number of shares as approved by the Board. The Purchase Plan provides for consecutive six-month offering periods, during which participating employees may elect to have up to 10% of their compensation withheld and applied to the purchase of common stock at the end of each offering period. The purchase price of the common stock is 85% of the lower of the fair value of a share of common stock on the first trading date of each offering period or the fair value of a share of common stock on the last trading day of the offering period. The Purchase Plan will terminate on August&nbsp;24, 2021, the tenth anniversary of the date of initial adoption of the Purchase Plan. We sold 51,681 and 110,508 shares to employees in 2017 and 2016, respectively. There were 558,870 shares available for sale under the Purchase Plan as of December&nbsp;31, 2017. The weighted-average estimated grant date fair value of purchase awards under the Purchase Plan during the years ended December&nbsp;31, 2017 and 2016 was $23.08 and $11.70 per share, respectively. The total share-based compensation expense recorded as a result of the Purchase Plan was approximately $</font><font style="display:inline;">1.0</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> million, $0.8 million and $0.9 million during the years ended December 31, 2017, 2016 and 2015, respectively. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The fair value of purchase awards granted to our employees during the years ended December 31, 2017, 2016 and 2015, respectively, was estimated using the Black-Scholes option pricing model based upon the weighted-average assumptions provided in the following table: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:26.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Dividend yield</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Volatility (a)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 79</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 92</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 71</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Risk-free interest rate (b)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.90</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.40</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.11</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expected term (years) (c)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.5</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.5</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.5</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (a)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Volatility</font><font style="display:inline;font-family:Times New Roman,Times,serif;">: The expected volatility was estimated using our historical data.</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (b)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Risk-free interest rate:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The rate is based on the U.S. Treasury yield in effect at the time of grant with terms similar to the contractual term of the purchase right. </font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (c)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Expected term:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The expected life of the award represents the six-month offering period for the Purchase Plan.</font></p></td></tr></table></div> <p style="margin:5pt 0pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table summarizes information about our stock options as of and for the years ended December&nbsp;31, 2017, 2016 and 2015: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:45.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Weighted-average grant date fair value per share</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 48.79</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 16.62</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 52.70</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Intrinsic value of options exercised</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 18,986,726</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,118,097</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 19,976,769</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:53.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Cash received from stock option exercises</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 13,924,174</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,267,721</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 5,478,211</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> -9.79 -2.17 -9.07 -3.37 -1.70 -1.83 -1.33 -7.36 -3.88 -1.24 -1.04 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">14. Net Loss Per Common Share </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):</font> </p> <p style="margin:0pt;text-indent:23.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:28.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Common shares under option</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,260</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 3,398</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 2,031</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Convertible senior notes</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,646</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,646</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,646</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total potential dilutive shares</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 8,906</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 8,044</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 6,677</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> -0.076 -0.084 -0.010 0.340 0.340 0.340 0.35 0.21 0.476 0.394 -0.081 0.004 0.023 -0.011 0.030 0.036 0.032 0.136 0.108 0.012 0.050 0.059 0.000 -757000 -365000 943000 15850000 13889000 89400000 P3Y3M18D 0 0 0 0 0 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">4. Fair Value Measurements </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:09.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Level&nbsp;1:</font></p> </td> <td valign="top" style="width:90.18%;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Quoted prices in active markets for identical assets or liabilities. Our Level&nbsp;1 assets consist of money market investments. We do not have Level 1 liabilities.</font></p> </td> </tr> <tr> <td valign="top" style="width:09.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:90.18%;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:09.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Level&nbsp;2:</font></p> </td> <td valign="top" style="width:90.18%;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Observable inputs other than Level&nbsp;1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.</font></p> </td> </tr> <tr> <td valign="top" style="width:09.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:90.18%;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:09.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Level&nbsp;3:</font></p> </td> <td valign="top" style="width:90.18%;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired with the purchase of EOS in November 2013 is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner&#x2019;s decision to discontinue the development of lucitanib for breast cancer, reducing the remaining fair value to zero. The fair value and carrying value remained at zero as of December 31, 2017.</font></p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The change in the fair value of Level 3 instruments is included in change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss. </font></p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp; &nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table identifies our assets that were measured at fair value on a recurring basis (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Balance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Level&nbsp;1</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Level&nbsp;2</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Level&nbsp;3</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">December&nbsp;31,&nbsp;2017</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Assets:</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Money market</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 433,136</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 433,136</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">U.S. treasury securities</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 99,533</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 99,533</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total assets at fair value</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 532,669</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 433,136</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 99,533</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">December&nbsp;31,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Assets:</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Money market</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 202,361</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 202,361</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">U.S. treasury securities</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 49,997</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 49,997</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total assets at fair value</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 252,358</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 202,361</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 49,997</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">There were no liabilities that were measured at fair value on a recurring basis as of December 31, 2017. There were no transfers between the Level 1&nbsp;and Level 2 categories or into or out of the Level 3 category during the year ended December 31, 2017.</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Financial instruments not recorded at fair value include our convertible senior notes. At December 31, 2017, the carrying amount of the convertible senior notes was $282.4 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $388.3 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the convertible senior notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 7, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Convertible Senior Notes</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> for discussion of the convertible senior notes. The carrying amounts of accounts payable and accrued expenses approximate their fair value due to their short-term maturities.</font> </p><div /></div> </div> 0 0 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:09.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Level&nbsp;1:</font></p> </td> <td valign="top" style="width:90.18%;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Quoted prices in active markets for identical assets or liabilities. Our Level&nbsp;1 assets consist of money market investments. We do not have Level 1 liabilities.</font></p> </td> </tr> <tr> <td valign="top" style="width:09.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:90.18%;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:09.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Level&nbsp;2:</font></p> </td> <td valign="top" style="width:90.18%;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Observable inputs other than Level&nbsp;1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.</font></p> </td> </tr> <tr> <td valign="top" style="width:09.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:90.18%;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:09.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Level&nbsp;3:</font></p> </td> <td valign="top" style="width:90.18%;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired with the purchase of EOS in November 2013 is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner&#x2019;s decision to discontinue the development of lucitanib for breast cancer, reducing the remaining fair value to zero. The fair value and carrying value remained at zero as of December 31, 2017.</font></p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The change in the fair value of Level 3 instruments is included in change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss. </font></p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp; &nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 0 0 0 0 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Fair Value of Financial Instruments </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Cash, cash equivalents, available-for-sale securities and contingent purchase consideration are carried at fair value. Financial instruments, including other current assets and accounts payable, are carried at cost, which approximates fair value given their short-term nature (see Note 4, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Fair Value Measurements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">). &nbsp; &nbsp;</font> </p><div /></div> </div> 53000 1539000 12131000 1486000 1486000 1486000 1486000 1486000 21100000 21100000 21047000 19561000 2740000 -551000 -580000 183000 -66000 -146000 -159000 -82000 76000 -44000 45000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Foreign Currency </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates and the results of operations are translated at the average exchange rates for the reported periods. The resulting translation adjustments are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. Transaction gains and losses are recorded to foreign currency gains (losses) on the Consolidated Statements of Operations and Comprehensive Loss. As of December 31, 2017 and 2016, approximately 1% of our total liabilities were denominated in currencies other than the functional currency.</font> </p><div /></div> </div> -39000 -105000 0 0 0 0 0 0 0 0 -105477000 -117000000 0 11523000 59327000 57192000 57192000 65217000 65217000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">7. Intangible Assets and Goodwill </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">At December 31, 2017 and 2016, intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.46%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;"> <font style="display:inline;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Intangible asset - milestones</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 21,100</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 21,100</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accumulated amortization</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,539)</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (53)</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total intangible asset, net</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 19,561</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 21,047</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The estimated useful lives of these intangibles assets extended through 2031.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We recorded an amortization expense of $1.5 million and $0.053 million related to capitalized milestone payments during the year ended December 31, 2017 and December 31, 2016, respectively. &nbsp;Estimated future amortization expense for intangible assets as of December 31, 2017 is as follows (in thousands):</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2018</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,486</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2019</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,486</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2020</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,486</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2021</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,486</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2022</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,486</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Thereafter</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 12,131</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;"> <font style="display:inline;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 19,561</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">IPR&amp;D assets and goodwill were established as part of the purchase accounting of EOS in November 2013, and consisted of the following (in thousands):</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 82.74%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:23.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">IPR&amp;D assets:</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at beginning of period</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 101,500</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Impairment of intangible asset (a)</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (104,517)</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Change in foreign currency gains and losses</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,017</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at end of period</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">Goodwill:</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at beginning of period</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 57,192</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 59,327</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Change in foreign currency gains and losses</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,025</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (2,135)</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at end of period</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 65,217</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 57,192</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (a)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">During the second quarter of 2016, we recorded a $104.5 million impairment charge due to our and our development partner&#x2019;s decision to discontinue the development of lucitanib for breast cancer. At December 31, 2017, the IPR&amp;D intangible asset recorded on the Consolidated Balance Sheets was zero.</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">During the fourth quarter of 2015, we recorded an $89.6 million impairment charge due to our and our development partner&#x2019;s decision to terminate the development of lucitanib for lung cancer, as well as updates to the probability-weighted discounted cash flow assumptions for the breast cancer indication.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">These reductions were included in impairment of intangible asset on the Consolidated Statements of Operations and Comprehensive Loss.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017, no impairment to the carrying value of the goodwill was identified.</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Goodwill </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination accounted for under the acquisition method of accounting and is not amortized, but is subject to impairment testing at least annually in the fourth quarter or when a triggering event is identified that could indicate a potential impairment. We are organized as a single reporting unit and perform impairment testing by comparing the carrying value of the reporting unit to the fair value of the Company. Goodwill was recorded as a result of the EOS acquisition.&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Intangible Assets, Net </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Definite-lived intangible assets related to capitalized milestones under license agreements are amortized on a straight-line basis over their remaining useful lives, which are estimated to be the remaining patent life.&nbsp;&nbsp;If our estimate of the product&#x2019;s useful life is shorter than the remaining patent life, then a shorter period is used. Amortization expense is recorded as a component of cost of sales on the Consolidated Statements of Operations and Comprehensive Loss. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Intangible acquired in-process research and development (&#x201C;IPR&amp;D&#x201D;) assets were established as part of the acquisition of Ethical Oncology Science, S.p.A. (&#x201C;EOS&#x201D;) in November 2013 and were not amortized. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Intangible assets are evaluated for impairment at least annually in the fourth quarter or more frequently if impairment indicators exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the decision to discontinue the development of a drug, the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate, or new information regarding potential sales for the drug. In connection with any impairment assessment, the fair value of the intangible assets as of the date of assessment is compared to the carrying value of the intangible asset. Impairment losses are recognized if the carrying value of an intangible asset is both not recoverable and exceeds its fair value. During the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&amp;D intangible assets, reducing the remaining carrying value to zero (see Note 6, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Intangible Assets and Goodwill</font><font style="display:inline;font-family:Times New Roman,Times,serif;">). Previously, the Company recorded an $89.6 million impairment charge to the IPR&amp;D intangible assets during the fourth quarter of 2015. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> -2135000 8025000 0 89557000 89600000 0 104517000 104517000 104517000 104500000 0 0 0 0 0 0 0 0 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Long-Lived Assets </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We review long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate. If the carrying value of the assets exceed their future net undiscounted cash flows, an impairment charge is recognized for the amount by which the carrying value of the assets exceeds the fair value of the assets.</font> </p><div /></div> </div> -290342000 -277776000 -351338000 -381937000 -87581000 -381171000 -158373000 -65922000 -69295000 -58547000 -349975000 -176667000 -61898000 -52863000 -91595000 -103395000 1363000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">15. Income Taxes</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We are subject to U.S. federal, state and foreign income tax.&nbsp;&nbsp;The geographical components of income (loss) before income taxes consisted of the following (in thousands):</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:40.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Domestic</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (351,338)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (277,776)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (290,342)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Foreign</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,363</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (103,395)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (91,595)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total loss before income taxes</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (349,975)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (381,171)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (381,937)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The income tax provision consists of the following current and deferred tax (benefit) expense amounts (in thousands):</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.60%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:33.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Current tax:</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">U.S. Federal &amp; State</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Foreign</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (360)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 64</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total current (benefit) expense</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (360)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 64</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Deferred tax:</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">U.S. Federal &amp; State</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3,218)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Foreign</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (32,098)</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (29,076)</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total deferred (benefit)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3,218)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (32,098)</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (29,076)</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total income tax (benefit)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3,578)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (32,034)</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (29,076)</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">A reconciliation of the U.S. federal statutory income tax rate to our effective tax rate is provided below:</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:27.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Federal income tax benefit at statutory rate</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (34.0)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (34.0)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (34.0)</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">State income tax benefit, net of federal benefit</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3.2)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3.6)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3.0)</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Tax credits</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1.2)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (10.8)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (13.6)</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Limitation on future foreign tax credits</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (5.9)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (5.0)</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Change in uncertain tax positions</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 0.2</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 4.2</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1.1)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2.3</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 0.4</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Tax impact of Tax Cuts and Jobs Act of 2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 46.4</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Change in valuation allowance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (8.1)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 39.4</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 47.6</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Effective income tax rate</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1.0)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (8.4)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (7.6)</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The significant components of our deferred tax assets and liabilities are as follows (in thousands): </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:26.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Deferred tax assets:</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;&nbsp; </font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp; </font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Net operating loss carryforward</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 272,710</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 275,898</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Tax credit carryforwards</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 222,150</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 217,948</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Intangible assets</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 29,900</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 42,745</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Share-based compensation expense</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 27,844</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 31,390</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Foreign currency translation</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,012</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 10,510</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Product acquisition costs</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 5,881</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 9,764</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued liabilities and other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,879</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 5,384</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total deferred tax assets</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 565,376</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 593,639</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Valuation allowance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (564,122)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (592,423)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Deferred tax assets, net of valuation allowance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,254</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,216</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Deferred tax liabilities:</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Prepaid expenses and other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,254)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,216)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total deferred tax liabilities</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,254)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,216)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Net deferred tax liability</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (the &#x201C;Act&#x201D;), a tax reform bill which, among other items, reduces the current corporate federal income tax rate to 21% from 35%. The rate reduction is effective January 1, 2018. We believe the Act will cause us to revalue our deferred tax assets and liabilities to the lower federal tax rate. Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through income tax expense.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Pursuant to the SEC Staff Accounting Bulletin ("SAB") No. 118, "Income Tax Accounting Implications of the Tax Cuts and Jobs Act" ("SAB 118"), we may select one of three scenarios to determine a reasonable estimate arising from the Tax Act. Those scenarios are (i) a final estimate which effectively closes the measurement window; (ii) a reasonable estimate leaving the measurement window open for future revisions; and (iii) no estimate as the law is still being analyzed. We were able to provide a reasonable estimate for the revaluation of deferred taxes by recording a net tax provision of $162.2 million in the period ending December 31, 2017, which is offset by a change in valuation allowance with no net impact to tax expense. Other impacts of the Act including, but not limited to, provisional transition tax, expensing of qualified property and interest limitations are not expected to have a material impact to our financial statement presentation or disclosures. The final impact of the Act may be different from the provisional amounts reported due to changes in interpretations and assumptions of the current guidance available as well as the issuance of new regulatory guidance in the future. We anticipate the full financial impact will be determined at the time our 2017 U.S. corporate income tax return is filed in 2018.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The realization of deferred tax assets is dependent upon a number of factors including future earnings, the timing and amount of which is uncertain. A valuation allowance was established for the net deferred tax asset balance due to management&#x2019;s belief that the realization of these assets is not likely to occur in the foreseeable future. We recorded a net decrease to the valuation allowance of $28.3 million for the year ended December 31, 2017, due to the revaluation of our net deferred tax assets resulting from the reduction to the corporate federal tax rate to 21% offset by the growth in net operating losses and credit carryforwards during the year. The increase of $143.3 million recorded to our valuation allowance during the year ended December 31, 2016 was due primarily to the increase in net operating loss and tax credit carryforwards.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In addition, the Company recognizes tax benefits if it is more likely than not to be sustained under audit by the relevant taxing authority based on technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained during audit. If the threshold is met, the tax benefit is measured and recognized at the largest amount above the greater than 50% likelihood threshold at time of settlement. The balance of unrecognized tax benefits at December 31, 2017 of $24.5 million, if recognized, would not impact the Company&#x2019;s effective tax rate as long as they remain subject to a full valuation allowance. The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:23.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td colspan="2" valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at beginning of year</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24,075</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Additions related to prior periods tax positions</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 17,844</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Additions related to current period tax positions</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 437</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 6,231</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Settlements with tax authorities</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Expiration of statute of limitations</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at end of year</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24,512</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24,075</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017, we had approximately $1.0 billion, $1.2 billion and $0.4 million of U.S.&nbsp;federal, state and foreign net operating loss carryforwards, respectively. The U.S. federal net operating losses will expire from 2029 to 2037 if not utilized and the U.S state net operating losses will expire from 2024 to 2037 if not utilized.&nbsp;&nbsp;We have research and development and orphan drug tax credit carryforwards of $245.1 million that will expire from 2029 through 2037 if not utilized. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We believe that a change in ownership as defined under Section&nbsp;382 of the U.S. Internal Revenue Code occurred as a result of our public offering of common stock completed in April 2012. Future utilization of the federal net operating losses (&#x201C;NOL&#x201D;) and tax credit carryforwards accumulated from inception to the change in ownership date will be subject to annual limitations to offset future taxable income. At this time, we do not believe this limitation will prevent the utilization of the federal NOL or credit carryforward prior to expiration. It is possible that a change in ownership will occur in the future, which will limit the NOL amounts generated since the last estimated change. Our federal and state income taxes for the period from inception to December&nbsp;31, 2017 remain open to an audit. Our foreign subsidiaries are also subject to tax audits by tax authorities in the jurisdictions where they operate for the periods from December 31, 2011 to December 31, 2017.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We may be assessed interest and penalties related to the settlement of tax positions and such amounts will be recognized within income tax expense when assessed. To date, no interest and penalties have been recognized.</font> </p><div /></div> </div> -29076000 -4181000 -32034000 -29059000 -227000 1433000 -83000 -3578000 -1281000 -1234000 -980000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Income Taxes</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.&nbsp;</font> </p><div /></div> </div> 8105000 -1544000 5637000 0 121000 6061000 -28874000 -31771000 -3218000 0 0 27508000 5295000 7867000 6556000 4380000 -1039000 6476000 101500000 0 0 3017000 0 0 21047000 19561000 8372000 2104000 8491000 2106000 2108000 2173000 2581000 10428000 2598000 2618000 2631000 7167000 7187000 7188000 <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table sets forth total interest expense to the Notes and the milestone liability during the years ended December&nbsp;31, 2017 and 2016 (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:31.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Contractual interest expense</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 7,188</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 7,187</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 7,167</font></p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accretion of interest on milestone liability</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,961</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 62</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Amortization of debt issuance costs</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,279</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,242</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,205</font></p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total interest expense</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 10,428</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,491</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,372</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 7307000 7188000 7188000 2096000 2096000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">6. Inventories</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table presents inventories as of December 31, 2017 and December 31, 2016 (in thousands):</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Work in process</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24,721</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Finished goods</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,787</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 27,508</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">At December 31, 2017, deposit on inventory on the Consolidated Balance Sheets is a cash deposit of $20.5 million made to a manufacturer for the purchase of inventory which we expect to be converted to finished goods within the next twelve months.</font> </p><div /></div> </div> 0 2787000 0 27508000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Inventory</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. Prior to the regulatory approval of Rubraca, we incurred expenses for the manufacture of drug that could potentially be available to support the commercial launch of Rubraca. Until the first reporting period when regulatory approval has been received, we record all such costs as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The active pharma</font><font style="display:inline;">ceutical ingredient in Rubraca is currently produced by a single supplier.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">At December 31, 2017, deposit on inventory on the Consolidated Balance Sheets is a cash deposit of $20.5 million made to a manufacturer for the purchase of inventory which we expect to be converted to finished goods within the next twelve months.</font> </p><div /></div> </div> 0 24721000 <div> <div> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">5. Available-for-Sale Securities</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017, available-for-sale securities consisted of the following (in thousands):</font> </p> <p style="margin:0pt;text-indent:24.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:45.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Gross</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Gross</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Aggregate</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:45.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Amortized</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:45.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Cost</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Gains</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Losses</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Value</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:45.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">U.S. treasury securities</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,650</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (117)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,533</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017, the fair value and gross unrealized losses of available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months were as follows (in thousands):</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Aggregate</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Gross</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Value</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Losses</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">U.S. treasury securities</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,533</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (117)</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Our investments have been in an unrealized loss position for two months. Based upon our evaluation of all relevant factors, we believe that the decline in fair value of securities held at December 31, 2017 below cost is temporary, and we intend to retain our investment in these securities for a sufficient period of time to allow for recovery of the fair value.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Amortized</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Cost</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Value</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Due in one year or less</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,650</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,533</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Due in one year to two years</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,650</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,533</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> 2400000 2200000 2200000 2500000 P10Y 368191000 367594000 364557000 735230000 65597000 81517000 0 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8. Convertible Senior Notes </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">On September&nbsp;9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the &#x201C;Notes&#x201D;) resulting in net proceeds of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The Notes are senior unsecured obligations and bear interest at a rate of 2.5%&nbsp;per year, payable semi-annually in arrears on March&nbsp;15 and September&nbsp;15 of each year. The Notes will mature on September&nbsp;15, 2021, unless earlier converted, redeemed or repurchased. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Holders may convert all or any portion of the Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the Notes in connection with such a corporate event or during the related redemption period in certain circumstances. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">On or after September&nbsp;15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes. &nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the Notes, holders may require us to repurchase for cash all or any portion of the Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In connection with the issuance of the Notes, we incurred $9.2 million of debt issuance costs. The debt issuance costs are amortized as interest expense over the expected life of the Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the Notes. As of December 31, 2017 and 2016, the balance of unamortized debt issuance costs was $5.1 million and $6.4 million, respectively, and is recorded as a reduction to the convertible senior notes at the Consolidated Balance Sheets.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table sets forth total interest expense to the Notes and the milestone liability during the years ended December&nbsp;31, 2017 and 2016 (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:31.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Contractual interest expense</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 7,188</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 7,187</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 7,167</font></p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accretion of interest on milestone liability</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,961</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 62</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Amortization of debt issuance costs</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,279</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,242</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,205</font></p> </td> </tr> <tr> <td valign="bottom" style="width:67.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total interest expense</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 10,428</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,491</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,372</font></p> </td> </tr> </table></div> <p style="margin:5pt 0pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> 304480000 5176000 562075000 -254578000 199299000 -54102000 -253066000 -266680000 -260904000 -352861000 -352861000 -83400000 -349137000 -349137000 -129314000 -65695000 -70728000 -58464000 -346397000 -346397000 -175386000 -60664000 -51883000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Recently Issued Accounting Standards </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued ASU No. 2014-09, &#x201C;Revenue from Contracts with Customers&#x201D; and has subsequently issued several supplemental and/or clarifying ASUs (collectively, &#x201C;ASC 606&#x201D;). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability.&nbsp;&nbsp;Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We have elected to apply the new standard using the modified retrospective method upon its adoption date on January 1, 2018.&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. The standard also requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We have examined our revenue recognition policy specific to revenue streams from representative contracts governing product sales from Rubraca and have come to conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. We have reviewed a representative sample of contracts, including our collaboration agreements with Servier and Bristol-Myers Squibb discussed in Note 13, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">License Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, and determined the potential impact to our accounting policies, financial controls and operations. Our conclusions include recognizing revenue on product sales once the product is sold to the specialty distributor and specialty pharmacy providers. Currently, we anticipate the effects of adoption to be as described in Note 11, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Revenue Recognition</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In February 2016, the FASB issued ASU No. 2016-02, &#x201C;Leases (Topic 842),&#x201D; which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. We plan to adopt on January 1, 2019. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In January 2017, the FASB issued ASU No. 2017-01, &#x201C;Clarifying the Definition of a Business,&#x201D; which clarifies the definition of a business in ASC 805. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. We adopted this standard on January 1, 2018 and the adoption resulted in no change to our consolidated financial statements and related disclosures. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In May 2017, the FASB issued ASU 2017-09, &#x201C;Compensation &#x2013; Stock Compensation (Topic 718): Scope of Modification Accounting&#x201D;, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which we would be required to apply modification accounting under ASC 718. Specifically, we would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is effective for annual reporting periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. We adopted this standard on January 1, 2018 and the adoption resulted in no change to our consolidated financial statements and related disclosures.</font> </p><div /></div> </div> -5216000 -2630000 -8438000 -1727000 -1922000 -2159000 -2386000 -112344000 -118928000 -1371000 10341000 1 637500 425000 525000 350000 376721000 84951000 372811000 156646000 64000000 67214000 63206000 293142000 72359000 77333000 80244000 -376721000 -84951000 -372733000 -156646000 -64000000 -67136000 -56161000 -237631000 -57739000 -60527000 -63204000 28633000 3050000 2519000 3855000 3744000 3902000 11563000 1000000000 400000 1200000000 396000 2830000 6679000 7500000 90000 187000 2468000 19505000 -1469000 224000 -1693000 8625000 -110000 8735000 -22629000 -22629000 -357000 -357000 5517000 5517000 -23012000 -120000 5407000 1349000 13000 1336000 -3218000 0 -3218000 -383000 -383000 237000 237000 -110000 -110000 416000 25000 633000 196000 252000 160000 354000 3643000 594000 1291000 1404000 364000 2023000 392540000 0 263500000 3035000 766000 487000 0.001 0.001 10000000 10000000 0 0 0 0 2109000 3355000 6427000 1559000 1234000 1926000 278300000 298509000 298500000 0 221200000 545838000 324600000 5971000 5176000 16237000 140997000 200000000 213500000 0 65000 0 5478211 3267721 13924174 -352861000 -349137000 -346397000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">3. Property and Equipment </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Property and equipment consisted of the following (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;"> &nbsp; &nbsp;</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Laboratory, manufacturing and office equipment</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 2,853</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 2,555</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Leasehold improvements</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 2,285</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 2,276</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Furniture and fixtures</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 1,416</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 1,411</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Computer hardware and software</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 1,141</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 855</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total property and equipment</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 7,695</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 7,097</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Less: accumulated depreciation</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (3,688)</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (2,657)</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total property and equipment, net</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,007</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,440</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Depreciation expense related to property and equipment was approximately $</font><font style="display:inline;">1.0</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> million, $1.1 million and $0.8 million for the years ended December 31, 2017, 2016 and 2015, respectively.</font> </p><div /></div> </div> 7097000 855000 1411000 2276000 2555000 7695000 1141000 1416000 2285000 2853000 4440000 4007000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Property and Equipment </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Property and equipment are stated at cost, less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. Equipment purchased for use in manufacturing and clinical trials is evaluated to determine whether the equipment is solely beneficial for a drug candidate in the development stage or whether it has an alternative use. Equipment with an alternative use is capitalized. Leasehold improvements are amortized over the economic life of the asset or the lease term, whichever is shorter. Maintenance and repairs are expensed as incurred. The estimated useful lives of our capitalized assets are as follows: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Estimated</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Useful&nbsp;Life</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Computer hardware and software</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">3&nbsp;to&nbsp;5&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Leasehold improvements</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">6&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Laboratory, manufacturing and office equipment</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">5 to 7&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Furniture and fixtures</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">10&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Property and equipment consisted of the following (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;"> &nbsp; &nbsp;</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Laboratory, manufacturing and office equipment</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 2,853</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 2,555</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Leasehold improvements</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 2,285</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 2,276</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Furniture and fixtures</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 1,416</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 1,411</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Computer hardware and software</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 1,141</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 855</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total property and equipment</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 7,695</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 7,097</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Less: accumulated depreciation</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (3,688)</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (2,657)</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total property and equipment, net</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,007</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,440</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> P10Y P6Y P5Y P3Y P7Y P5Y 223900000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17. Quarterly Information (Unaudited) </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The results of operations on a quarterly basis for the years ended December&nbsp;31, 2017 and 2016 were as follows (in thousands): </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">March&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">June&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">March&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">June&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016 &nbsp;(1)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Revenues:</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">`</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Product revenue, net</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 7,045</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 14,620</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 16,806</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 17,040</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 78</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Operating expenses:</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Cost of sales - product</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 1,163</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 2,730</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 3,026</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 3,332</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 70</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Cost of sales - intangible asset amortization</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 372</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 372</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 372</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 370</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Research and development</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 32,447</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 33,108</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,924</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,019</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 74,608</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 67,729</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 54,338</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 54,454</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Selling, general and administrative</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 29,224</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 36,149</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 35,011</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,523</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 9,827</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 9,552</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 9,162</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 12,190</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Acquired in-process research and development</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 300</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 500</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 500</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Impairment of intangible asset</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 104,517</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Change in fair value of contingent purchase consideration</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 516</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (25,452)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;Total expenses</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 63,206</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 72,359</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 77,333</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 80,244</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 84,951</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 156,646</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 64,000</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 67,214</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Operating loss</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (56,161)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (57,739)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (60,527)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (63,204)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (84,951)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (156,646)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (64,000)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (67,136)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Other income (expense):</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Interest expense</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,581)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,598)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,618)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,631)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,104)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,106)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,108)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,173)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Foreign currency gain (loss)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (159)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 76</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (44)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 45</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (551)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 183</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (66)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (146)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Legal settlement loss</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (117,000)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 11,523</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Other income (expense)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 354</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 594</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 1,291</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 1,404</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 25</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 196</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 252</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 160</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Other income (expense), net</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,386)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (118,928)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1,371)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 10,341</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,630)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1,727)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1,922)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,159)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Loss before income taxes</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (58,547)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (176,667)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (61,898)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (52,863)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (87,581)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (158,373)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (65,922)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (69,295)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Income tax (expense) benefit</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 83</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 1,281</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 1,234</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 980</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 4,181</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 29,059</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 227</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1,433)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Net loss</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (58,464)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (175,386)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (60,664)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (51,883)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (83,400)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (129,314)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (65,695)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (70,728)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Basic and diluted net loss per common share</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1.33)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (3.88)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1.24)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1.04)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2.17)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (3.37)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1.70)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1.83)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Basic and diluted weighted average common shares outstanding</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 44,039</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 45,176</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 48,917</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 49,973</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,360</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,389</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,538</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,624</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (1)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;">In the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&amp;D intangible asset related to our lucitanib product candidate.</font></p></td></tr></table></div><div /></div> </div> 0 0 0 3400000 12000000 0 1300000 300000 500000 500000 0 0 0 0 0 269251000 13700000 74608000 251129000 7700000 67729000 54338000 54454000 32447000 142498000 33108000 38924000 38019000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Research and Development Expense </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Research and development costs are charged to expense as incurred and include, but are not limited to, salary and benefits, share-based compensation, clinical trial activities, drug development and manufacturing, companion diagnostic development and third-party service fees, including contract research organizations and investigative sites. During 2015, we completed the hiring of our U.S. sales and marketing and medical affairs organizations in preparation for the potential commercial launch of Rubraca. These costs were also included in research and development expense before the FDA approval of Rubraca.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred and are reflected on the Consolidated Balance Sheets as prepaid or accrued research and development expenses. </font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Acquired In-Process Research and Development Expense </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We have acquired and expect to continue to acquire the rights to develop and commercialize new drug candidates. The upfront payments to acquire a new drug compound, as well as subsequent milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use.&nbsp;&nbsp;Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to product cost of sales.</font> </p><div /></div> </div> 6697 180912 -57000 -57000 -1131043000 -1477440000 2300000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">11. Revenue Recognition</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Effective January 1, 2018, </font><font style="display:inline;">we adopted ASC 606, the new revenue recognition standard, using the modified retrospective method. Upon adoption, the accounting for net product revenue is as follows:</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Product Revenue, Net</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We are currently approved to sell Rubraca in the United States market.&nbsp;&nbsp;We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. &nbsp;Our customers subsequently sell our products to patients and health care providers. &nbsp;Separately, we have arrangements with certain payors and other third-parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts.&nbsp; </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Revenue from product sales are recognized when customers obtain control of our product, which occurs at a point in time, typically upon delivery to the customers. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Reserves for Variable Consideration </font> </p> <p style="margin:0pt;text-indent:36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, chargebacks, discounts, co-pay assistance, estimated product returns and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product.&nbsp;&nbsp;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customers) or a current liability (if the amount is payable to a party other than a customer).&nbsp;&nbsp;Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.&nbsp;&nbsp;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract.&nbsp;&nbsp;The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&nbsp;&nbsp;Actual amounts of consideration ultimately received may differ from our estimates.&nbsp;&nbsp;If actual results in the future vary from our estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Rebates. </font><font style="display:inline;color:#000000;">Rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare coverage gap program. Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. We</font><font style="display:inline;color:#000000;background-color: #FFFFFF;"> estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix.&nbsp;</font><font style="display:inline;color:#000000;">The accrual for rebates is based on statutory discount rates and known sales to specialty pharmacy patients, or expected utilization for specialty distributor sales to healthcare providers. As we gain more historical experience, the accrual will be based solely on the expected utilization from historical data we have accumulated since the Rubraca product launch. Rebates are generally invoiced and paid quarterly in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known or estimated prior quarters&#x2019; unpaid rebates.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Chargebacks. </font><font style="display:inline;color:#000000;">Chargebacks are discounts that occur when contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service organizations and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the healthcare provider. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates and known sales to specialty distributors adjusted for the estimated utilization by healthcare providers.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Discounts.</font><font style="display:inline;color:#000000;"> Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts from product sales when revenue is recognized. Service fees are recorded as a selling expense when product sales occur.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Co-pay assistance.</font><font style="display:inline;color:#000000;"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. The intent of this program is to reduce the patient&#x2019;s out of pocket costs. Liabilities for co-pay assistance are based on actual program participation and estimates of program redemption using data provided by third-party administrators.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp; &nbsp; &nbsp; </font> </p> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Returns.</font><font style="display:inline;color:#000000;"> Consistent with industry practice, we generally offer customers a limited right of return for product that has been purchased based on the product&#x2019;s expiration date, which lapses upon shipment to a patient. To date, we have had minimal product returns and we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Currently, we only recognize revenue on product sales once the product is sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, i.e. when product is sold through the channel. Effective January 1, 2018, we will begin recognizing revenue when our customers, the specialty distributors and specialty pharmacy providers, take control of our product or when product is sold into the channel. This will have the impact of us recognizing revenue approximately two to four weeks earlier than before adopting the new standard and will also increase the significance of estimating variable consideration. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We used the modified retrospective method to adopt the new standard. This means that we will not restate previously issued financial statements, but will record a one-time adjustment to retained earnings of $2.3 million. This adjustment represents the sales of our product to our customers prior to January 1, 2018, that have not been sold to patients or healthcare providers, offset by related gross-to-net adjustments and other direct costs, including royalties and sales incentive compensation.</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Revenue Recognition </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We are currently approved to sell Rubraca in the United States market.&nbsp;&nbsp;We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. &nbsp;Our customers subsequently sell our products to patients and health care providers. &nbsp;Separately, we have arrangements with certain payors and other third-parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts.&nbsp; </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Product sales are recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns. Estimating rebates, chargebacks, discounts, product returns and other deductions requires significant judgments about future events and uncertainties, and requires us to rely heavily on assumptions, as well as historical experience. We only recognize revenue on product sales once the product is sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">For the year ended December 31, 2017, we recognized $55.5 million of product revenue. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the costs of Rubraca units recognized as revenue during the year ended December 31, 2017 were expensed prior to the December 19, 2016 FDA approval, and a minimal amount is included in cost of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories. The majority of products sales were of pre-commercialization inventory in 2017.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Product revenue from each of our customers who individually accounted for 10% or more of total revenues consisted of the following:</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer A</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">35%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer B</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">27%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer C</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">12%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer D</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">10%</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Effective January 1, 2018, </font><font style="display:inline;">we adopted ASC 606, the new revenue recognition standard, using the modified retrospective method. For a complete discussion of this adoption and the accounting for net product revenue, see the </font><font style="display:inline;font-style:italic;">Recently Issued Accounting Standards </font><font style="display:inline;">section below and Note 11, </font><font style="display:inline;font-style:italic;">Revenue Recognition</font><font style="display:inline;">.</font> </p><div /></div> </div> 0 0 78000 0 0 78000 7045000 55511000 14620000 16806000 17040000 <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Other accrued expenses are comprised of the following (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued personnel costs</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 13,889</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 15,850</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued interest payable</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,096</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,096</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Income tax payable</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 556</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued corporate legal fees and professional services</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 415</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 589</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued royalties</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,984</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued sales deductions</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,008</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Payable to third party logistics provider</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,661</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued expenses - other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,830</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 396</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 25,883</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 19,487</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.78%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Foreign Currency</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:23.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Total Accumulated</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Translation Adjustments</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">(Losses) Gains</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:23.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Other Comprehensive Loss</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at December 31, 2015</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (47,077)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (383)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (47,460)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Other comprehensive income (loss) </font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,693)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Calibri;color:#000000;">&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 224</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Calibri;color:#000000;">&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,469)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total before tax</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (48,770)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (159)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (48,929)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Tax effect</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,336</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 13</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,349</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at December 31, 2016</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (47,434)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (146)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (47,580)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Other comprehensive income (loss) </font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,735</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (110)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,625</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total before tax</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (38,699)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (256)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (38,955)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Tax effect</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3,218)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3,218)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at December 31, 2017</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (41,917)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (256)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (42,173)</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):</font> </p> <p style="margin:0pt;text-indent:23.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:28.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Common shares under option</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,260</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 3,398</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 2,031</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Convertible senior notes</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,646</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,646</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 4,646</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total potential dilutive shares</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 8,906</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 8,044</font></p> </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 6,677</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017, available-for-sale securities consisted of the following (in thousands):</font> </p> <p style="margin:0pt;text-indent:24.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:45.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Gross</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Gross</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Aggregate</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:45.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Amortized</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:45.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Cost</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Gains</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Losses</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Value</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:45.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">U.S. treasury securities</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,650</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (117)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 99,533</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.60%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:33.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Current tax:</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">U.S. Federal &amp; State</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Foreign</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (360)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 64</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total current (benefit) expense</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (360)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 64</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Deferred tax:</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">U.S. Federal &amp; State</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3,218)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Foreign</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (32,098)</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (29,076)</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total deferred (benefit)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3,218)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (32,098)</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (29,076)</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total income tax (benefit)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3,578)</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (32,034)</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (29,076)</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:26.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Deferred tax assets:</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;&nbsp; </font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp; </font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Net operating loss carryforward</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 272,710</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 275,898</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Tax credit carryforwards</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 222,150</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 217,948</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Intangible assets</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 29,900</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 42,745</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Share-based compensation expense</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 27,844</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 31,390</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Foreign currency translation</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,012</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 10,510</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Product acquisition costs</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 5,881</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 9,764</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued liabilities and other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,879</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 5,384</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total deferred tax assets</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 565,376</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 593,639</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Valuation allowance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (564,122)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (592,423)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Deferred tax assets, net of valuation allowance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,254</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,216</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Deferred tax liabilities:</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Prepaid expenses and other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,254)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,216)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total deferred tax liabilities</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,254)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,216)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Net deferred tax liability</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:27.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Federal income tax benefit at statutory rate</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (34.0)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (34.0)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (34.0)</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">State income tax benefit, net of federal benefit</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3.2)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3.6)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3.0)</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Tax credits</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1.2)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (10.8)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (13.6)</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Limitation on future foreign tax credits</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (5.9)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (5.0)</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Change in uncertain tax positions</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 0.2</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 4.2</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1.1)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2.3</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 0.4</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Tax impact of Tax Cuts and Jobs Act of 2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 46.4</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Change in valuation allowance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (8.1)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 39.4</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 47.6</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Effective income tax rate</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1.0)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (8.4)</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (7.6)</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Share-based compensation expense for the years ended December 31, 2017, 2016 and 2015, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 86.80%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:31.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Research and development </font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 20,335</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 27,558</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 27,321</font></p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Selling, general and administrative</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24,372</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 12,238</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 13,036</font></p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:66.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total share-based compensation expense</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 44,707</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 39,796</font></p> </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 40,357</font></p> </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table identifies our assets that were measured at fair value on a recurring basis (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Balance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Level&nbsp;1</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Level&nbsp;2</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Level&nbsp;3</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">December&nbsp;31,&nbsp;2017</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Assets:</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Money market</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 433,136</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 433,136</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">U.S. treasury securities</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 99,533</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 99,533</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total assets at fair value</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 532,669</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 433,136</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 99,533</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">December&nbsp;31,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Assets:</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Money market</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 202,361</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 202,361</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">U.S. treasury securities</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 49,997</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 49,997</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:52.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total assets at fair value</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 252,358</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 202,361</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 49,997</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Estimated future amortization expense for intangible assets as of December 31, 2017 is as follows (in thousands):</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2018</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,486</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2019</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,486</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2020</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,486</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2021</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,486</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2022</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,486</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Thereafter</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 12,131</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;"> <font style="display:inline;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 19,561</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">At December 31, 2017 and 2016, intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.46%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;"> <font style="display:inline;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Intangible asset - milestones</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 21,100</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 21,100</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accumulated amortization</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,539)</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (53)</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total intangible asset, net</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 19,561</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 21,047</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Future minimum rental commitments, by fiscal year and in the aggregate, for our operating leases are provided below (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2018</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,050</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2019</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,902</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2020</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,744</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2021</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,855</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">2022</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,519</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Thereafter</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 11,563</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total future minimum lease payments</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 28,633</font></p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:40.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Domestic</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (351,338)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (277,776)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (290,342)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Foreign</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,363</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (103,395)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (91,595)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:56.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total loss before income taxes</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (349,975)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (381,171)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (381,937)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">IPR&amp;D assets and goodwill were established as part of the purchase accounting of EOS in November 2013, and consisted of the following (in thousands):</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 82.74%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:23.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">IPR&amp;D assets:</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at beginning of period</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 101,500</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Impairment of intangible asset (a)</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (104,517)</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Change in foreign currency gains and losses</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,017</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at end of period</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">Goodwill:</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at beginning of period</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 57,192</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 59,327</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Change in foreign currency gains and losses</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,025</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (2,135)</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at end of period</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 65,217</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 57,192</font></p> </td> <td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (a)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">During the second quarter of 2016, we recorded a $104.5 million impairment charge due to our and our development partner&#x2019;s decision to discontinue the development of lucitanib for breast cancer. At December 31, 2017, the IPR&amp;D intangible asset recorded on the Consolidated Balance Sheets was zero.</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">During the fourth quarter of 2015, we recorded an $89.6 million impairment charge due to our and our development partner&#x2019;s decision to terminate the development of lucitanib for lung cancer, as well as updates to the probability-weighted discounted cash flow assumptions for the breast cancer indication.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">These reductions were included in impairment of intangible asset on the Consolidated Statements of Operations and Comprehensive Loss.</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table presents inventories as of December 31, 2017 and December 31, 2016 (in thousands):</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Work in process</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24,721</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Finished goods</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,787</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 27,508</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Other current assets are comprised of the following (in thousands): </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Receivable from partners</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;9</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,882</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Prepaid insurance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,926</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,234</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Prepaid expenses - other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,355</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,109</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Receivable - other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,023</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 364</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 187</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 90</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 7,500</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 6,679</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The results of operations on a quarterly basis for the years ended December&nbsp;31, 2017 and 2016 were as follows (in thousands): </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">March&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">June&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">March&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">June&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016 &nbsp;(1)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Revenues:</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">`</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Product revenue, net</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 7,045</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 14,620</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 16,806</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 17,040</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 78</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Operating expenses:</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Cost of sales - product</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 1,163</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 2,730</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 3,026</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 3,332</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 70</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Cost of sales - intangible asset amortization</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 372</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 372</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 372</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 370</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Research and development</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 32,447</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 33,108</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,924</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,019</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 74,608</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 67,729</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 54,338</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 54,454</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Selling, general and administrative</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 29,224</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 36,149</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 35,011</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,523</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 9,827</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 9,552</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 9,162</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 12,190</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Acquired in-process research and development</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 300</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 500</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 500</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Impairment of intangible asset</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 104,517</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Change in fair value of contingent purchase consideration</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 516</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (25,452)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;Total expenses</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 63,206</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 72,359</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 77,333</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 80,244</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 84,951</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 156,646</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 64,000</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 67,214</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Operating loss</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (56,161)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (57,739)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (60,527)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (63,204)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (84,951)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (156,646)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (64,000)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (67,136)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Other income (expense):</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Interest expense</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,581)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,598)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,618)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,631)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,104)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,106)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,108)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,173)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Foreign currency gain (loss)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (159)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 76</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (44)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 45</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (551)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 183</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (66)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (146)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Legal settlement loss</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (117,000)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 11,523</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Other income (expense)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 354</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 594</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 1,291</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 1,404</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 25</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 196</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 252</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 160</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Other income (expense), net</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,386)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (118,928)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1,371)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 10,341</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,630)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1,727)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1,922)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2,159)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Loss before income taxes</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (58,547)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (176,667)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (61,898)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (52,863)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (87,581)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (158,373)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (65,922)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (69,295)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Income tax (expense) benefit</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 83</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 1,281</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 1,234</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 980</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 4,181</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 29,059</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 227</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1,433)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Net loss</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (58,464)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (175,386)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (60,664)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (51,883)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (83,400)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (129,314)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (65,695)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (70,728)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Basic and diluted net loss per common share</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1.33)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (3.88)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1.24)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1.04)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (2.17)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (3.37)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1.70)</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> (1.83)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:20.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">Basic and diluted weighted average common shares outstanding</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 44,039</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 45,176</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 48,917</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 49,973</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,360</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,389</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,538</font></p> </td> <td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;"> 38,624</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (1)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;">In the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&amp;D intangible asset related to our lucitanib product candidate.</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table summarizes the activity relating to our options to purchase common stock: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Weighted</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:06.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Weighted</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Average</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Aggregate</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:06.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Average</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Remaining</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Intrinsic</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:06.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Exercise</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Contractual</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Value</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Options</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:06.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Price</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Term&nbsp;(Years)</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Thousands)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding at December&nbsp;31,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 5,520,482</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 42.00</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Granted </font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 1,048,700</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 66.09</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Exercised</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (465,690)</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 29.90</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Forfeited</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> (313,757)</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 49.20</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding at December&nbsp;31,&nbsp;2017 (a)</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 5,789,735</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 46.77</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 7.1</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 145,067</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vested and expected to vest at December&nbsp;31,&nbsp;2017</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 5,505,557</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 46.52</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 7.0</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 139,526</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vested and exercisable at December&nbsp;31,&nbsp;2017</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 3,481,931</font></p> </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 44.60</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 6.1</font></p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 95,463</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.25pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (a)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Includes 33,750 performance-based stock options granted to our executives in the first quarter of 2015</font><font style="display:inline;">, which vested on approval by the FDA in December 19, 2016 to commercially distribute, sell or market Rubraca.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Related stock compensation expense was recognized on that date.</font></p></td></tr></table></div><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The fair value of purchase awards granted to our employees during the years ended December 31, 2017, 2016 and 2015, respectively, was estimated using the Black-Scholes option pricing model based upon the weighted-average assumptions provided in the following table: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:26.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Dividend yield</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Volatility (a)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 79</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 92</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 71</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Risk-free interest rate (b)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.90</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.40</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.11</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expected term (years) (c)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.5</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.5</font></p> </td> <td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> 0.5</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (a)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Volatility</font><font style="display:inline;font-family:Times New Roman,Times,serif;">: The expected volatility was estimated using our historical data.</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (b)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Risk-free interest rate:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The rate is based on the U.S. Treasury yield in effect at the time of grant with terms similar to the contractual term of the purchase right. </font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (c)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Expected term:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The expected life of the award represents the six-month offering period for the Purchase Plan.</font></p></td></tr></table></div><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The fair value of each share-based award is estimated on the grant date using the Black-Scholes option pricing model based upon the weighted-average assumptions provided in the following table: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:25.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Dividend yield</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Volatility (a)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 89</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 93</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 72</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Risk-free interest rate (b)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2.16</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1.77</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1.77</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Expected term (years) (c)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 5.8</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 5.8</font></p> </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 6.1</font></p> </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (a)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Volatility</font><font style="display:inline;font-family:Times New Roman,Times,serif;">: The expected volatility was estimated using our historical data.</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (b)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Risk-free interest rate:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The rate is based on the yield on the grant date of a zero-coupon U.S. Treasury bond whose maturity period approximates the option&#x2019;s expected term.</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-size:10pt;line-height:100%;font-family:Times New Roman,Times,serif;;"> (c)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Expected term:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The expected term of the award was estimated using our historical data.</font></p></td></tr></table></div><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:23.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year ended December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td colspan="2" valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at beginning of year</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24,075</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Additions related to prior periods tax positions</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 17,844</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Additions related to current period tax positions</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 437</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 6,231</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Settlements with tax authorities</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Expiration of statute of limitations</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at end of year</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24,512</font></p> </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24,075</font></p> </td> <td valign="bottom" style="width:00.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The following table summarizes the activity related to our unvested RSUs:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Grant Date</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Units</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Fair Value</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Unvested at December&nbsp;31,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 562,458</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 24.70</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Granted </font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 249,984</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 64.66</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Vested </font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (180,912)</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 23.83</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt 0.05pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Forfeited</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (42,001)</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 28.09</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Unvested as of December&nbsp;31,&nbsp;2017</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 589,529</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 41.67</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:74.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Expected to vest after December&nbsp;31,&nbsp;2017</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 513,069</font></p> </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 41.40</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer A</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">35%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer B</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">27%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer C</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">12%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer D</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">10%</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 30524000 9827000 40731000 9552000 9162000 12190000 29224000 138907000 36149000 35011000 38523000 40357000 39796000 44707000 P4Y P3Y P1Y P1Y P2Y P4Y P3Y P1Y 0.75 0.50 0.25 0.50 0.25 42001 28.09 249984 64.66 562458 589529 24.70 41.67 180912 11.70 23.08 23.83 P10Y 0.0000 0.00 0.0000 0.00 0.0000 0.00 P6Y1M6D P6M P5Y9M18D P6M P5Y9M18D P6M 0.72 0.71 0.93 0.92 0.89 0.79 0.0177 0.0011 0.0177 0.0040 0.0216 0.0090 0.10 8148193 9590378 558870 192185 19976769 3118097 18986726 313757 33750 1048700 52.70 16.62 48.79 145067000 5520482 5789735 42.00 46.77 P7Y1M6D 95463000 3481931 44.60 P6Y1M6D 139526000 5505557 46.52 P7Y 36500000 40800000 36000000 0.85 29.90 49.20 66.09 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Share-Based Compensation Expense </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Share-based compensation is recognized as expense for all share-based awards made to employees and directors and is based on estimated fair values. We determine equity-based compensation at the grant date using the Black-Scholes option pricing model. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period. Any changes to the estimated forfeiture rates are accounted for prospectively. </font> </p><div /></div> </div> 78.00 41.00 88.00 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">2. Summary of Significant Accounting Policies </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Basis of Presentation </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201C;U.S. GAAP&#x201D;). The consolidated financial statements include our accounts and our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Use of Estimates </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The preparation of financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Revenue Recognition </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We are currently approved to sell Rubraca in the United States market.&nbsp;&nbsp;We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. &nbsp;Our customers subsequently sell our products to patients and health care providers. &nbsp;Separately, we have arrangements with certain payors and other third-parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts.&nbsp; </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Product sales are recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns. Estimating rebates, chargebacks, discounts, product returns and other deductions requires significant judgments about future events and uncertainties, and requires us to rely heavily on assumptions, as well as historical experience. We only recognize revenue on product sales once the product is sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">For the year ended December 31, 2017, we recognized $55.5 million of product revenue. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the costs of Rubraca units recognized as revenue during the year ended December 31, 2017 were expensed prior to the December 19, 2016 FDA approval, and a minimal amount is included in cost of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories. The majority of products sales were of pre-commercialization inventory in 2017.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Product revenue from each of our customers who individually accounted for 10% or more of total revenues consisted of the following:</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer A</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">35%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer B</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">27%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer C</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">12%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Customer D</font></p> </td> <td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:27.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">10%</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Effective January 1, 2018, </font><font style="display:inline;">we adopted ASC 606, the new revenue recognition standard, using the modified retrospective method. For a complete discussion of this adoption and the accounting for net product revenue, see the </font><font style="display:inline;font-style:italic;">Recently Issued Accounting Standards </font><font style="display:inline;">section below and Note 11, </font><font style="display:inline;font-style:italic;">Revenue Recognition</font><font style="display:inline;">.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Fair Value of Financial Instruments </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Cash, cash equivalents, available-for-sale securities and contingent purchase consideration are carried at fair value. Financial instruments, including other current assets and accounts payable, are carried at cost, which approximates fair value given their short-term nature (see Note 4, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Fair Value Measurements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">). &nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Cash, Cash Equivalents and Available-for-Sale Securities </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We consider all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S.&nbsp;government and U.S.&nbsp;government agency obligations.&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Marketable securities are considered to be available-for-sale securities and consist of U.S. treasury securities. Available-for-sale securities are reported at fair value on the Consolidated Balance Sheets and unrealized gains and losses are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense) on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on our intent to fund current operations with these securities or to make them available for current operations. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Accounts Receivable</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017 and 2016, we had no allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Property and Equipment </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Property and equipment are stated at cost, less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. Equipment purchased for use in manufacturing and clinical trials is evaluated to determine whether the equipment is solely beneficial for a drug candidate in the development stage or whether it has an alternative use. Equipment with an alternative use is capitalized. Leasehold improvements are amortized over the economic life of the asset or the lease term, whichever is shorter. Maintenance and repairs are expensed as incurred. The estimated useful lives of our capitalized assets are as follows: </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Estimated</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Useful&nbsp;Life</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Computer hardware and software</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">3&nbsp;to&nbsp;5&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Leasehold improvements</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">6&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Laboratory, manufacturing and office equipment</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">5 to 7&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:83.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Furniture and fixtures</font></p> </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">10&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Long-Lived Assets </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We review long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate. If the carrying value of the assets exceed their future net undiscounted cash flows, an impairment charge is recognized for the amount by which the carrying value of the assets exceeds the fair value of the assets.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Intangible Assets, Net </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Definite-lived intangible assets related to capitalized milestones under license agreements are amortized on a straight-line basis over their remaining useful lives, which are estimated to be the remaining patent life.&nbsp;&nbsp;If our estimate of the product&#x2019;s useful life is shorter than the remaining patent life, then a shorter period is used. Amortization expense is recorded as a component of cost of sales on the Consolidated Statements of Operations and Comprehensive Loss. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Intangible acquired in-process research and development (&#x201C;IPR&amp;D&#x201D;) assets were established as part of the acquisition of Ethical Oncology Science, S.p.A. (&#x201C;EOS&#x201D;) in November 2013 and were not amortized. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Intangible assets are evaluated for impairment at least annually in the fourth quarter or more frequently if impairment indicators exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the decision to discontinue the development of a drug, the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate, or new information regarding potential sales for the drug. In connection with any impairment assessment, the fair value of the intangible assets as of the date of assessment is compared to the carrying value of the intangible asset. Impairment losses are recognized if the carrying value of an intangible asset is both not recoverable and exceeds its fair value. During the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&amp;D intangible assets, reducing the remaining carrying value to zero (see Note 6, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Intangible Assets and Goodwill</font><font style="display:inline;font-family:Times New Roman,Times,serif;">). Previously, the Company recorded an $89.6 million impairment charge to the IPR&amp;D intangible assets during the fourth quarter of 2015. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Goodwill </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination accounted for under the acquisition method of accounting and is not amortized, but is subject to impairment testing at least annually in the fourth quarter or when a triggering event is identified that could indicate a potential impairment. We are organized as a single reporting unit and perform impairment testing by comparing the carrying value of the reporting unit to the fair value of the Company. Goodwill was recorded as a result of the EOS acquisition.&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Other Current Assets </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Other current assets are comprised of the following (in thousands): </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Receivable from partners</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;9</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,882</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Prepaid insurance</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,926</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,234</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Prepaid expenses - other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 3,355</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,109</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Receivable - other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,023</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 364</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 187</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 90</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 7,500</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 6,679</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Other Accrued Expenses </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Other accrued expenses are comprised of the following (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued personnel costs</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 13,889</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 15,850</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued interest payable</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,096</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,096</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Income tax payable</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 556</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued corporate legal fees and professional services</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 415</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 589</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued royalties</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,984</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued sales deductions</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,008</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Payable to third party logistics provider</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,661</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Accrued expenses - other</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 2,830</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 396</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 25,883</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 19,487</font></p> </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Valuation of Contingent Consideration Resulting from a Business Combination </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Subsequent to the acquisition date, we re-measure contingent consideration arrangements at fair value each reporting period and record changes in fair value to change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss. Changes in fair value are primarily attributed to new information about the IPR&amp;D assets, including changes in timeline and likelihood of success, and the passage of time. In the absence of new information, changes in fair value reflect only the passage of time. During the fourth quarter of 2015, we recorded a $26.9 million reduction in the fair value of the contingent purchase consideration liability due to a change in the estimated probability-weighted future discounted milestone payments, as well as the timing of such payments, for the lucitanib program.&nbsp;&nbsp;Then, during the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner&#x2019;s decision to discontinue the development of lucitanib for breast cancer. At December 31, 2017, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets remained at zero due to the uncertainty of achieving any of the lucitanib regulatory milestones, and therefore the remote likelihood of future milestone payouts.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Research and Development Expense </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Research and development costs are charged to expense as incurred and include, but are not limited to, salary and benefits, share-based compensation, clinical trial activities, drug development and manufacturing, companion diagnostic development and third-party service fees, including contract research organizations and investigative sites. During 2015, we completed the hiring of our U.S. sales and marketing and medical affairs organizations in preparation for the potential commercial launch of Rubraca. These costs were also included in research and development expense before the FDA approval of Rubraca.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred and are reflected on the Consolidated Balance Sheets as prepaid or accrued research and development expenses. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Acquired In-Process Research and Development Expense </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We have acquired and expect to continue to acquire the rights to develop and commercialize new drug candidates. The upfront payments to acquire a new drug compound, as well as subsequent milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use.&nbsp;&nbsp;Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to product cost of sales.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Share-Based Compensation Expense </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Share-based compensation is recognized as expense for all share-based awards made to employees and directors and is based on estimated fair values. We determine equity-based compensation at the grant date using the Black-Scholes option pricing model. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period. Any changes to the estimated forfeiture rates are accounted for prospectively. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Inventory</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. Prior to the regulatory approval of Rubraca, we incurred expenses for the manufacture of drug that could potentially be available to support the commercial launch of Rubraca. Until the first reporting period when regulatory approval has been received, we record all such costs as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The active pharma</font><font style="display:inline;">ceutical ingredient in Rubraca is currently produced by a single supplier.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">At December 31, 2017, deposit on inventory on the Consolidated Balance Sheets is a cash deposit of $20.5 million made to a manufacturer for the purchase of inventory which we expect to be converted to finished goods within the next twelve months.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Concentration of Credit Risk </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Financial instruments that potentially subject us to concentrations of credit risk are primarily cash, cash equivalents and available-for-sale securities. We maintain our cash and cash equivalent balances in the form of money market accounts with financial institutions that we believe are creditworthy. Available-for-sale securities are invested in accordance with our investment policy. The investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that we believe minimizes the exposure to concentration of credit risk. We have no financial instruments with off-balance sheet risk of accounting loss.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Foreign Currency </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates and the results of operations are translated at the average exchange rates for the reported periods. The resulting translation adjustments are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. Transaction gains and losses are recorded to foreign currency gains (losses) on the Consolidated Statements of Operations and Comprehensive Loss. As of December 31, 2017 and 2016, approximately 1% of our total liabilities were denominated in currencies other than the functional currency.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Income Taxes</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Recently Adopted Accounting Standards</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" (ASU 2016-09).&nbsp;&nbsp;ASU 2016-09 simplifies how several aspects of share-based payments are accounted for and presented in the financial statements. ASU 2016-09 is effective for public companies for annual reporting periods beginning after December 15, 2016. We adopted this ASU in the first quarter of 2017. We had excess tax benefits for which a benefit could not be previously recognized of approximately $18.2 million. Upon adoption the balance of the unrecognized excess tax benefits were reversed with the impact recorded to retained earnings including any change to the valuation allowance as a result of the adoption. Due to the full valuation allowance on the U.S. deferred tax assets, there is no impact to the financial statements as a result of this adoption.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Recently Issued Accounting Standards </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued ASU No. 2014-09, &#x201C;Revenue from Contracts with Customers&#x201D; and has subsequently issued several supplemental and/or clarifying ASUs (collectively, &#x201C;ASC 606&#x201D;). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability.&nbsp;&nbsp;Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We have elected to apply the new standard using the modified retrospective method upon its adoption date on January 1, 2018.&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. The standard also requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp; &nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">We have examined our revenue recognition policy specific to revenue streams from representative contracts governing product sales from Rubraca and have come to conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. We have reviewed a representative sample of contracts, including our collaboration agreements with Servier and Bristol-Myers Squibb discussed in Note 13, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">License Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, and determined the potential impact to our accounting policies, financial controls and operations. Our conclusions include recognizing revenue on product sales once the product is sold to the specialty distributor and specialty pharmacy providers. Currently, we anticipate the effects of adoption to be as described in Note 11, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Revenue Recognition</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In February 2016, the FASB issued ASU No. 2016-02, &#x201C;Leases (Topic 842),&#x201D; which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. We plan to adopt on January 1, 2019. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In January 2017, the FASB issued ASU No. 2017-01, &#x201C;Clarifying the Definition of a Business,&#x201D; which clarifies the definition of a business in ASC 805. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. We adopted this standard on January 1, 2018 and the adoption resulted in no change to our consolidated financial statements and related disclosures. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp; &nbsp;</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In May 2017, the FASB issued ASU 2017-09, &#x201C;Compensation &#x2013; Stock Compensation (Topic 718): Scope of Modification Accounting&#x201D;, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which we would be required to apply modification accounting under ASC 718. Specifically, we would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is effective for annual reporting periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. We adopted this standard on January 1, 2018 and the adoption resulted in no change to our consolidated financial statements and related disclosures.</font> </p><div /></div> </div> 331630000 -24448000 785089000 34000 -429045000 300650000 -47460000 1129978000 38000 -781906000 -3634000 -47580000 1174950000 39000 -1131043000 367636000 -42173000 1887198000 51000 -1477440000 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">9. Stockholders&#x2019; Equity </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Common Stock </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;"> In July 2015, we sold 4,054,487 shares of our common stock in a public offering at $78.00 per share. The net proceeds from the offering were $298.5 million, after deducting underwriting discounts and commissions and offering expenses.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.</font><font style="display:inline;">2</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> million, after deducting underwriting discounts and commissions and offering expenses.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The holders of common stock are entitled to one vote per share on all matters to be voted upon by our stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors. </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Accumulated Other Comprehensive Loss </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary&#x2019;s functional currency, and unrealized gains and losses on available-for-sale securities.</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands): </font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.78%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Foreign Currency</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:23.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Total Accumulated</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Translation Adjustments</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">(Losses) Gains</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:23.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Other Comprehensive Loss</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at December 31, 2015</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (47,077)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (383)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (47,460)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Other comprehensive income (loss) </font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,693)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Calibri;color:#000000;">&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 224</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Calibri;color:#000000;">&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (1,469)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total before tax</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (48,770)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (159)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (48,929)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Tax effect</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,336</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 13</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 1,349</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at December 31, 2016</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (47,434)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (146)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (47,580)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Other comprehensive income (loss) </font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,735</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (110)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> 8,625</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Total before tax</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (38,699)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (256)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (38,955)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Tax effect</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3,218)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (3,218)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">Balance at December 31, 2017</font></p> </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (41,917)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (256)</font></p> </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:22.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;"> (42,173)</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The other comprehensive income (loss) related to foreign currency translation adjustments was primarily due to the currency translation of the IPR&amp;D intangible assets, goodwill and deferred income taxes (see Note 7, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Intangible Assets and Goodwill</font><font style="display:inline;font-family:Times New Roman,Times,serif;">). There were no reclassifications out of accumulated other comprehensive loss in the years ended December 31, 2017, 2016 and 2015. </font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Accumulated Other Comprehensive Loss </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary&#x2019;s functional currency, and unrealized gains and losses on available-for-sale securities.</font> </p><div /></div> </div> 32021 110508 110508 51681 51681 4054487 4054487 5750000 9670454 3920454 295759 247431 465690 465690 493000 493000 1965000 1965000 2312000 2312000 298509000 298505000 4000 545838000 545828000 10000 5534000 5534000 3269000 3268000 1000 13925000 13924000 1000 245100000 556000 0 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Accounts Receivable</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2017 and 2016, we had no allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.</font> </p><div /></div> </div> 6400000 5100000 0 24075000 24512000 6231000 437000 17844000 0 0 <div> <div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Use of Estimates </font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;">The preparation of financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font> </p><div /></div> </div> 143300000 -28300000 36026000 38360000 38478000 38389000 38538000 38624000 44039000 47047000 45176000 48917000 49973000 EX-101.SCH 11 clvs-20171231.xsd EX-101.SCH 00100 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Summary of Significant Accounting Policies - Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40205 - Disclosure - Summary of Significant Accounting Policies - Other Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Intangible Assets and Goodwill - Capitalized Milestones (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Convertible Senior Notes - Schedule of Total Interest Expense Recognized Related to Notes (Details) link:presentationLink link:calculationLink link:definitionLink 41008 - Disclosure - Share-Based Compensation - Reserved Shares of Common Stock for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Commitments and Contingencies - Future Minimum Rental Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41502 - Disclosure - Income Taxes - Current and Deferred Tax (Benefit) Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 41503 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 41504 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - Quarterly Information (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statements of Stockholders’ Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - Consolidated Statements of Stockholders’ Equity (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Available-for-Sale Securities link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Convertible Senior Notes link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - Quarterly Information (Unaudited) link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Available-for-Sale Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Convertible Senior Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 31703 - Disclosure - Quarterly Information (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies - Product revenue from customers (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Property and Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Available-for-Sale Securities - Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40704 - Disclosure - Intangible Assets and Goodwill - Summary of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 40705 - Disclosure - Intangible Assets and Goodwill - Summary of IPR&D Assets and Goodwill (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Convertible Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Stockholders' Equity - Component of Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Share-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Share-Based Compensation - Summary of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41004 - Disclosure - Share-Based Compensation - Summary of Stock Options Activity (Parenthetical) (Performance Shares) (Details) link:presentationLink link:calculationLink link:definitionLink 41005 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) link:presentationLink link:calculationLink link:definitionLink 41006 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions Used to Estimate Fair Value of Purchase Awards Granted (Details) link:presentationLink link:calculationLink link:definitionLink 41007 - Disclosure - Share-Based Compensation - Summary of Activity Relating to Company's Unvested Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 41505 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41506 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Employee Benefit Plans - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 clvs-20171231_cal.xml EX-101.CAL EX-101.DEF 13 clvs-20171231_def.xml EX-101.DEF EX-101.LAB 14 clvs-20171231_lab.xml EX-101.LAB EX-101.PRE 15 clvs-20171231_pre.xml EX-101.PRE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2017
Feb. 21, 2018
Jun. 30, 2017
Document And Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2017    
Document Fiscal Year Focus 2017    
Document Fiscal Period Focus FY    
Trading Symbol CLVS    
Entity Registrant Name Clovis Oncology, Inc.    
Entity Central Index Key 0001466301    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer Yes    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Large Accelerated Filer    
Entity Common Stock, Shares Outstanding   50,573,183  
Entity Public Float     $ 4,220,084,525
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Revenues:      
Product revenue, net $ 55,511 $ 78 $ 0
Operating expenses:      
Cost of sales - product 10,251 70 0
Cost of sales - intangible asset amortization 1,486 0 0
Research and development 142,498 251,129 269,251
Selling, general and administrative 138,907 40,731 30,524
Acquired in-process research and development 0 1,300 12,000
Impairment of intangible asset 0 104,517 89,557
Change in fair value of contingent purchase consideration 0 (24,936) (24,611)
Total expenses 293,142 372,811 376,721
Operating loss (237,631) (372,733) (376,721)
Other income (expense):      
Interest expense (10,428) (8,491) (8,372)
Foreign currency gain (loss) (82) (580) 2,740
Legal settlement loss (105,477) 0 0
Other income 3,643 633 416
Other income (expense), net (112,344) (8,438) (5,216)
Loss before income taxes (349,975) (381,171) (381,937)
Income tax benefit 3,578 32,034 29,076
Net loss (346,397) (349,137) (352,861)
Other comprehensive income (loss):      
Foreign currency translation adjustments, net of tax 5,517 (357) (22,629)
Net unrealized gain (loss) on available-for-sale securities, net of tax (110) 237 (383)
Other comprehensive income (loss) 5,407 (120) (23,012)
Comprehensive loss $ (340,990) $ (349,257) $ (375,873)
Loss per basic and diluted common share:      
Basic and diluted net loss per common share $ (7.36) $ (9.07) $ (9.79)
Basic and diluted weighted average common shares outstanding 47,047 38,478 36,026
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 464,198 $ 216,186
Accounts receivable, net 6,181 121
Inventories 27,508 0
Available-for-sale securities 99,533 49,997
Prepaid research and development expenses 1,559 6,427
Deposit on inventory 20,461 0
Other current assets 7,500 6,679
Total current assets 626,940 279,410
Property and equipment, net 4,007 4,440
Intangible assets, net 19,561 21,047
Goodwill 65,217 57,192
Other assets 19,505 2,468
Total assets 735,230 364,557
Current liabilities:    
Accounts payable 15,147 10,912
Accrued research and development expenses 18,465 35,198
Milestone liability 22,022 0
Other accrued expenses 25,883 19,487
Total current liabilities 81,517 65,597
Milestone liability 0 20,062
Convertible senior notes 282,406 281,126
Deferred rent, long-term 3,671 1,406
Total liabilities 367,594 368,191
Commitments and contingencies (Note 14)
Stockholders' equity (deficit):    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2017 and December 31, 2016
Common stock, $0.001 par value per share, 100,000,000 shares authorized at December 31, 2017 and December 31, 2016; 50,565,119 and 38,724,090 shares issued and outstanding at December 31, 2017 and December 31, 2016 respectively 51 39
Additional paid-in capital 1,887,198 1,174,950
Accumulated other comprehensive loss (42,173) (47,580)
Accumulated deficit (1,477,440) (1,131,043)
Total stockholders' equity (deficit) 367,636 (3,634)
Total liabilities and stockholders' equity (deficit) $ 735,230 $ 364,557
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2017
Dec. 31, 2016
Consolidated Balance Sheets    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 50,565,119 38,724,090
Common stock, shares outstanding 50,565,119 38,724,090
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total
Beginning Balance at Dec. 31, 2014 $ 34 $ 785,089 $ (24,448) $ (429,045) $ 331,630
Beginning Balance (in shares) at Dec. 31, 2014 33,977,187        
Issuance of common stock, net of issuance costs $ 4 298,505     298,509
Issuance of common stock, net of issuance costs (in shares) 4,054,487        
Issuance of common stock under employee stock purchase plan   493     493
Issuance of common stock under employee stock purchase plan (in shares) 32,021        
Exercise of stock options   5,534     5,534
Exercise of stock options (in shares) 295,759        
Share-based compensation expense   40,357     40,357
Net unrealized gain (loss) on available-for-sale securities     (383)   (383)
Foreign currency translation adjustments     (22,629)   (22,629)
Net loss       (352,861) (352,861)
Ending Balance at Dec. 31, 2015 $ 38 1,129,978 (47,460) (781,906) 300,650
Ending Balance (in shares) at Dec. 31, 2015 38,359,454        
Issuance of common stock under employee stock purchase plan   1,965     1,965
Issuance of common stock under employee stock purchase plan (in shares) 110,508        
Exercise of stock options $ 1 3,268     3,269
Exercise of stock options (in shares) 247,431        
Issuance of common stock from vesting of restricted stock units, net of shares withheld for taxes   (57)     (57)
Issuance of common stock from vesting of restricted stock units, net of shares withheld for taxes (in shares) 6,697        
Share-based compensation expense   39,796     39,796
Net unrealized gain (loss) on available-for-sale securities     237   237
Foreign currency translation adjustments     (357)   (357)
Net loss       (349,137) (349,137)
Ending Balance at Dec. 31, 2016 $ 39 1,174,950 (47,580) (1,131,043) $ (3,634)
Ending Balance (in shares) at Dec. 31, 2016 38,724,090       38,724,090
Issuance of common stock, net of issuance costs $ 10 545,828     $ 545,838
Issuance of common stock, net of issuance costs (in shares) 9,670,454        
Issuance of common stock under employee stock purchase plan   2,312     2,312
Issuance of common stock under employee stock purchase plan (in shares) 51,681        
Exercise of stock options $ 1 13,924     $ 13,925
Exercise of stock options (in shares) 465,690       465,690
Issuance of common stock from vesting of restricted stock units, net of shares withheld for taxes (in shares) 180,912        
Share-based compensation expense   44,707     $ 44,707
Legal settlement $ 1 105,477     105,478
Legal settlement (in shares) 1,472,324        
Net unrealized gain (loss) on available-for-sale securities     (110)   (110)
Foreign currency translation adjustments     5,517   5,517
Net loss       (346,397) (346,397)
Ending Balance at Dec. 31, 2017 $ 51 $ 1,887,198 $ (42,173) $ (1,477,440) $ 367,636
Ending Balance (in shares) at Dec. 31, 2017 50,565,151       50,565,119
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Stockholders’ Equity (Deficit) (Parenthetical)
$ in Thousands
12 Months Ended
Dec. 31, 2015
USD ($)
Consolidated Statements of Stockholders' (Deficit) Equity  
Issuance of stock, issuance costs $ 17,741
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Operating activities      
Net loss $ (346,397) $ (349,137) $ (352,861)
Adjustments to reconcile net loss to net cash used in operating activities:      
Share-based compensation expense 44,707 39,796 40,357
Depreciation and amortization 2,504 1,141 761
Amortization of premiums and discounts on available-for-sale securities 354 211 1,400
Amortization of debt issuance costs 1,279 1,242 1,205
Legal settlement loss 105,477 0 0
Impairment of intangible asset 0 104,517 89,557
Change in fair value of contingent purchase consideration 0 (24,661) (27,792)
Loss on disposal of property and equipment 0 105 39
Deferred income taxes (3,218) (31,771) (28,874)
Changes in operating assets and liabilities:      
Accounts receivable (6,061) (121) 0
Inventory (27,508) 0 0
Prepaid and accrued research and development expenses (17,297) (15,364) 14,122
Deposit on inventory (20,461) 0 0
Other operating assets (6,476) 1,039 (4,380)
Accounts payable 5,637 (1,544) 8,105
Other accrued expenses 6,556 7,867 5,295
Net cash used in operating activities (260,904) (266,680) (253,066)
Investing activities      
Purchases of property and equipment (487) (766) (3,035)
Proceeds from sale of property and equipment 0 65 0
Deposits for purchases of property and equipment (2,515) 0 0
Purchases of available-for-sale securities (263,500) 0 (392,540)
Sales of available-for-sale securities 213,500 200,000 140,997
Acquired in-process research and development - milestone payment (1,100) 0 0
Net cash (used in) provided by investing activities (54,102) 199,299 (254,578)
Financing activities      
Proceeds from the sale of common stock, net of issuance costs 545,838 0 298,509
Proceeds from the exercise of stock options and employee stock purchases 16,237 5,176 5,971
Net cash provided by financing activities 562,075 5,176 304,480
Effect of exchange rate changes on cash and cash equivalents 943 (365) (757)
Increase (decrease) in cash and cash equivalents 248,012 (62,570) (203,921)
Cash and cash equivalents at beginning of period 216,186 278,756 482,677
Cash and cash equivalents at end of period 464,198 216,186 278,756
Supplemental disclosure of cash flow information:      
Cash paid for interest 7,188 7,188 7,307
Non-cash investing and financing activities:      
Acquired in-process research and development - milestone not paid as of period end 0 21,100 0
Vesting of restricted stock units $ 12,170 $ 175 $ 0
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Nature of Business
12 Months Ended
Dec. 31, 2017
Nature of Business  
Nature of Business

 

CLOVIS ONCOLOGY, INC.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

1. Nature of Business

 

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. We have and intend to continue to license or acquire rights to oncology compounds in all stages of clinical development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities.

 

Our marketed product Rubraca® (rucaparib) is approved on an accelerated basis in the United States by the FDA as monotherapy for the treatment of patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. We launched Rubraca in the United States in December 2016 for this indication.

 

The FDA is currently reviewing on a priority review timeline our sNDA for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

 

Our MAA submitted to the European Union’s EMA for an ovarian cancer treatment indication for Rubraca is currently under review by the EMA’s CHMP.  Following a Scientific Advisory Group - Oncology meeting and an oral explanation by us before the CHMP in February 2018, the CHMP has communicated a positive trend vote for the MAA and their intention to hold a final vote on the treatment indication at their March 2018 meeting.

 

Liquidity

 

We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenue from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless and until it does, we will continue to need to raise additional cash.

 

In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including commercial planning and sales and marketing expenses associated with the launch of Rubraca in the United States and, if approved by the European Commission in Europe, funding of its development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on our current estimates, we believe that our cash, cash equivalents and available-for-sale securities will allow us to fund activities through the next 12 months.

 

XML 24 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2017
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include our accounts and our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. 

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

 

Revenue Recognition

 

We are currently approved to sell Rubraca in the United States market.  We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers.  Our customers subsequently sell our products to patients and health care providers.  Separately, we have arrangements with certain payors and other third-parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. 

 

Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Product sales are recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns. Estimating rebates, chargebacks, discounts, product returns and other deductions requires significant judgments about future events and uncertainties, and requires us to rely heavily on assumptions, as well as historical experience. We only recognize revenue on product sales once the product is sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns.

 

For the year ended December 31, 2017, we recognized $55.5 million of product revenue. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the costs of Rubraca units recognized as revenue during the year ended December 31, 2017 were expensed prior to the December 19, 2016 FDA approval, and a minimal amount is included in cost of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories. The majority of products sales were of pre-commercialization inventory in 2017.

 

Product revenue from each of our customers who individually accounted for 10% or more of total revenues consisted of the following:

 

 

 

 

 

 

December 31, 

 

    

2017

Customer A

 

35%

Customer B

 

27%

Customer C

 

12%

Customer D

 

10%

 

Effective January 1, 2018, we adopted ASC 606, the new revenue recognition standard, using the modified retrospective method. For a complete discussion of this adoption and the accounting for net product revenue, see the Recently Issued Accounting Standards section below and Note 11, Revenue Recognition.

 

Fair Value of Financial Instruments

 

Cash, cash equivalents, available-for-sale securities and contingent purchase consideration are carried at fair value. Financial instruments, including other current assets and accounts payable, are carried at cost, which approximates fair value given their short-term nature (see Note 4, Fair Value Measurements).    

 

Cash, Cash Equivalents and Available-for-Sale Securities

 

We consider all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations. 

 

Marketable securities are considered to be available-for-sale securities and consist of U.S. treasury securities. Available-for-sale securities are reported at fair value on the Consolidated Balance Sheets and unrealized gains and losses are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense) on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on our intent to fund current operations with these securities or to make them available for current operations.

 

A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.

 

Accounts Receivable

 

As of December 31, 2017 and 2016, we had no allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. Equipment purchased for use in manufacturing and clinical trials is evaluated to determine whether the equipment is solely beneficial for a drug candidate in the development stage or whether it has an alternative use. Equipment with an alternative use is capitalized. Leasehold improvements are amortized over the economic life of the asset or the lease term, whichever is shorter. Maintenance and repairs are expensed as incurred. The estimated useful lives of our capitalized assets are as follows:

 

 

 

 

 

 

 

Estimated

 

 

    

Useful Life

 

Computer hardware and software

 

3 to 5 years

 

Leasehold improvements

 

6 years

 

Laboratory, manufacturing and office equipment

 

5 to 7 years

 

Furniture and fixtures

 

10 years

 

 

Long-Lived Assets

 

We review long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. If the carrying value of the assets exceed their future net undiscounted cash flows, an impairment charge is recognized for the amount by which the carrying value of the assets exceeds the fair value of the assets.

 

Intangible Assets, Net

 

Definite-lived intangible assets related to capitalized milestones under license agreements are amortized on a straight-line basis over their remaining useful lives, which are estimated to be the remaining patent life.  If our estimate of the product’s useful life is shorter than the remaining patent life, then a shorter period is used. Amortization expense is recorded as a component of cost of sales on the Consolidated Statements of Operations and Comprehensive Loss.

 

Intangible acquired in-process research and development (“IPR&D”) assets were established as part of the acquisition of Ethical Oncology Science, S.p.A. (“EOS”) in November 2013 and were not amortized.

 

Intangible assets are evaluated for impairment at least annually in the fourth quarter or more frequently if impairment indicators exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the decision to discontinue the development of a drug, the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate, or new information regarding potential sales for the drug. In connection with any impairment assessment, the fair value of the intangible assets as of the date of assessment is compared to the carrying value of the intangible asset. Impairment losses are recognized if the carrying value of an intangible asset is both not recoverable and exceeds its fair value. During the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&D intangible assets, reducing the remaining carrying value to zero (see Note 6, Intangible Assets and Goodwill). Previously, the Company recorded an $89.6 million impairment charge to the IPR&D intangible assets during the fourth quarter of 2015.

 

Goodwill

 

Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination accounted for under the acquisition method of accounting and is not amortized, but is subject to impairment testing at least annually in the fourth quarter or when a triggering event is identified that could indicate a potential impairment. We are organized as a single reporting unit and perform impairment testing by comparing the carrying value of the reporting unit to the fair value of the Company. Goodwill was recorded as a result of the EOS acquisition. 

 

Other Current Assets

 

Other current assets are comprised of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

December 31, 

 

 

    

2017

    

2016

 

Receivable from partners

 

$

 9

 

$

2,882

 

Prepaid insurance

 

 

1,926

 

 

1,234

 

Prepaid expenses - other

 

 

3,355

 

 

2,109

 

Receivable - other

 

 

2,023

 

 

364

 

Other

 

 

187

 

 

90

 

Total

 

$

7,500

 

$

6,679

 

 

Other Accrued Expenses

 

Other accrued expenses are comprised of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

December 31, 

 

 

    

2017

    

2016

 

Accrued personnel costs

 

$

13,889

 

$

15,850

 

Accrued interest payable

 

 

2,096

 

 

2,096

 

Income tax payable

 

 

 —

 

 

556

 

Accrued corporate legal fees and professional services

 

 

415

 

 

589

 

Accrued royalties

 

 

2,984

 

 

 —

 

Accrued sales deductions

 

 

1,008

 

 

 —

 

Payable to third party logistics provider

 

 

2,661

 

 

 —

 

Accrued expenses - other

 

 

2,830

 

 

396

 

Total

 

$

25,883

 

$

19,487

 

 

Valuation of Contingent Consideration Resulting from a Business Combination

 

Subsequent to the acquisition date, we re-measure contingent consideration arrangements at fair value each reporting period and record changes in fair value to change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss. Changes in fair value are primarily attributed to new information about the IPR&D assets, including changes in timeline and likelihood of success, and the passage of time. In the absence of new information, changes in fair value reflect only the passage of time. During the fourth quarter of 2015, we recorded a $26.9 million reduction in the fair value of the contingent purchase consideration liability due to a change in the estimated probability-weighted future discounted milestone payments, as well as the timing of such payments, for the lucitanib program.  Then, during the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At December 31, 2017, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets remained at zero due to the uncertainty of achieving any of the lucitanib regulatory milestones, and therefore the remote likelihood of future milestone payouts.

 

Research and Development Expense

 

Research and development costs are charged to expense as incurred and include, but are not limited to, salary and benefits, share-based compensation, clinical trial activities, drug development and manufacturing, companion diagnostic development and third-party service fees, including contract research organizations and investigative sites. During 2015, we completed the hiring of our U.S. sales and marketing and medical affairs organizations in preparation for the potential commercial launch of Rubraca. These costs were also included in research and development expense before the FDA approval of Rubraca.

 

Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred and are reflected on the Consolidated Balance Sheets as prepaid or accrued research and development expenses.

 

Acquired In-Process Research and Development Expense

 

We have acquired and expect to continue to acquire the rights to develop and commercialize new drug candidates. The upfront payments to acquire a new drug compound, as well as subsequent milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use.  Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to product cost of sales.

 

Share-Based Compensation Expense

 

Share-based compensation is recognized as expense for all share-based awards made to employees and directors and is based on estimated fair values. We determine equity-based compensation at the grant date using the Black-Scholes option pricing model. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period. Any changes to the estimated forfeiture rates are accounted for prospectively.

 

Inventory

 

Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. Prior to the regulatory approval of Rubraca, we incurred expenses for the manufacture of drug that could potentially be available to support the commercial launch of Rubraca. Until the first reporting period when regulatory approval has been received, we record all such costs as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues.

 

The active pharmaceutical ingredient in Rubraca is currently produced by a single supplier.

 

At December 31, 2017, deposit on inventory on the Consolidated Balance Sheets is a cash deposit of $20.5 million made to a manufacturer for the purchase of inventory which we expect to be converted to finished goods within the next twelve months.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject us to concentrations of credit risk are primarily cash, cash equivalents and available-for-sale securities. We maintain our cash and cash equivalent balances in the form of money market accounts with financial institutions that we believe are creditworthy. Available-for-sale securities are invested in accordance with our investment policy. The investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that we believe minimizes the exposure to concentration of credit risk. We have no financial instruments with off-balance sheet risk of accounting loss.

 

Foreign Currency

 

The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates and the results of operations are translated at the average exchange rates for the reported periods. The resulting translation adjustments are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. Transaction gains and losses are recorded to foreign currency gains (losses) on the Consolidated Statements of Operations and Comprehensive Loss. As of December 31, 2017 and 2016, approximately 1% of our total liabilities were denominated in currencies other than the functional currency.

 

Income Taxes

 

We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized. 

 

Recently Adopted Accounting Standards

 

In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" (ASU 2016-09).  ASU 2016-09 simplifies how several aspects of share-based payments are accounted for and presented in the financial statements. ASU 2016-09 is effective for public companies for annual reporting periods beginning after December 15, 2016. We adopted this ASU in the first quarter of 2017. We had excess tax benefits for which a benefit could not be previously recognized of approximately $18.2 million. Upon adoption the balance of the unrecognized excess tax benefits were reversed with the impact recorded to retained earnings including any change to the valuation allowance as a result of the adoption. Due to the full valuation allowance on the U.S. deferred tax assets, there is no impact to the financial statements as a result of this adoption.

 

Recently Issued Accounting Standards

   

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, “Revenue from Contracts with Customers” and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability.  Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We have elected to apply the new standard using the modified retrospective method upon its adoption date on January 1, 2018. 

 

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. The standard also requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.

   

We have examined our revenue recognition policy specific to revenue streams from representative contracts governing product sales from Rubraca and have come to conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. We have reviewed a representative sample of contracts, including our collaboration agreements with Servier and Bristol-Myers Squibb discussed in Note 13, License Agreements, and determined the potential impact to our accounting policies, financial controls and operations. Our conclusions include recognizing revenue on product sales once the product is sold to the specialty distributor and specialty pharmacy providers. Currently, we anticipate the effects of adoption to be as described in Note 11, Revenue Recognition.

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. We plan to adopt on January 1, 2019. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.

 

In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” which clarifies the definition of a business in ASC 805. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. We adopted this standard on January 1, 2018 and the adoption resulted in no change to our consolidated financial statements and related disclosures.

   

In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting”, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which we would be required to apply modification accounting under ASC 718. Specifically, we would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is effective for annual reporting periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. We adopted this standard on January 1, 2018 and the adoption resulted in no change to our consolidated financial statements and related disclosures.

XML 25 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment
12 Months Ended
Dec. 31, 2017
Property and Equipment  
Property and Equipment

3. Property and Equipment

 

Property and equipment consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

   

 

December 31, 

 

 

    

2017

    

2016

 

Laboratory, manufacturing and office equipment

 

$

2,853

 

$

2,555

 

Leasehold improvements

 

 

2,285

 

 

2,276

 

Furniture and fixtures

 

 

1,416

 

 

1,411

 

Computer hardware and software

 

 

1,141

 

 

855

 

Total property and equipment

 

 

7,695

 

 

7,097

 

Less: accumulated depreciation

 

 

(3,688)

 

 

(2,657)

 

Total property and equipment, net

 

$

4,007

 

$

4,440

 

 

Depreciation expense related to property and equipment was approximately $1.0 million, $1.1 million and $0.8 million for the years ended December 31, 2017, 2016 and 2015, respectively.

XML 26 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements
12 Months Ended
Dec. 31, 2017
Fair Value Measurements  
Fair Value Measurements

4. Fair Value Measurements

 

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:

 

Level 1:

Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.

 

 

Level 2:

Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

 

 

Level 3:

Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired with the purchase of EOS in November 2013 is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer, reducing the remaining fair value to zero. The fair value and carrying value remained at zero as of December 31, 2017.

 

The change in the fair value of Level 3 instruments is included in change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss.

   

 

The following table identifies our assets that were measured at fair value on a recurring basis (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

Balance

    

Level 1

    

Level 2

    

Level 3

 

December 31, 2017

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market

 

$

433,136

 

$

433,136

 

$

 —

 

$

 —

 

U.S. treasury securities

 

 

99,533

 

 

 —

 

 

99,533

 

 

 —

 

Total assets at fair value

 

$

532,669

 

$

433,136

 

$

99,533

 

$

 —

 

December 31, 2016

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market

 

$

202,361

 

$

202,361

 

$

 —

 

$

 —

 

U.S. treasury securities

 

 

49,997

 

 

 —

 

 

49,997

 

 

 —

 

Total assets at fair value

 

$

252,358

 

$

202,361

 

$

49,997

 

$

 —

 

 

There were no liabilities that were measured at fair value on a recurring basis as of December 31, 2017. There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the year ended December 31, 2017.

Financial instruments not recorded at fair value include our convertible senior notes. At December 31, 2017, the carrying amount of the convertible senior notes was $282.4 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $388.3 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the convertible senior notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 7, Convertible Senior Notes for discussion of the convertible senior notes. The carrying amounts of accounts payable and accrued expenses approximate their fair value due to their short-term maturities.

XML 27 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Available-for-Sale Securities
12 Months Ended
Dec. 31, 2017
Available-for-Sale Securities  
Available-for-Sale Securities

5. Available-for-Sale Securities

 

As of December 31, 2017, available-for-sale securities consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

    

 

    

Gross

    

Gross

    

Aggregate

 

 

 

Amortized

 

Unrealized

 

Unrealized

 

Fair

 

 

 

Cost

 

Gains

 

Losses

 

Value

 

U.S. treasury securities

 

$

99,650

 

$

 —

 

$

(117)

 

$

99,533

 

 

As of December 31, 2017, the fair value and gross unrealized losses of available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months were as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

    

Aggregate

    

Gross

 

 

 

Fair

 

Unrealized

 

 

 

Value

 

Losses

 

U.S. treasury securities

 

$

99,533

 

$

(117)

 

 

Our investments have been in an unrealized loss position for two months. Based upon our evaluation of all relevant factors, we believe that the decline in fair value of securities held at December 31, 2017 below cost is temporary, and we intend to retain our investment in these securities for a sufficient period of time to allow for recovery of the fair value.

 

As of December 31, 2017, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):

 

 

 

 

 

 

 

 

 

 

    

Amortized

    

Fair

 

 

 

Cost

 

Value

 

Due in one year or less

 

$

99,650

 

$

99,533

 

Due in one year to two years

 

 

 —

 

 

 —

 

Total

 

$

99,650

 

$

99,533

 

 

XML 28 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories
12 Months Ended
Dec. 31, 2017
Inventories  
Inventories

6. Inventories

 

The following table presents inventories as of December 31, 2017 and December 31, 2016 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

    

2017

    

2016

 

Work in process

 

$

24,721

 

$

 —

 

Finished goods

 

 

2,787

 

 

 —

 

Total

 

$

27,508

 

$

 —

 

 

 

 

 

 

 

 

 

 

 

 

 

At December 31, 2017, deposit on inventory on the Consolidated Balance Sheets is a cash deposit of $20.5 million made to a manufacturer for the purchase of inventory which we expect to be converted to finished goods within the next twelve months.

XML 29 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Goodwill
12 Months Ended
Dec. 31, 2017
Intangible Assets and Goodwill  
Intangible Assets and Goodwill

7. Intangible Assets and Goodwill

 

At December 31, 2017 and 2016, intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

 

2017

    

2016

 

Intangible asset - milestones

 

$

21,100

 

$

21,100

 

Accumulated amortization

 

 

(1,539)

 

 

(53)

 

Total intangible asset, net

 

$

19,561

 

$

21,047

 

 

The estimated useful lives of these intangibles assets extended through 2031.

 

We recorded an amortization expense of $1.5 million and $0.053 million related to capitalized milestone payments during the year ended December 31, 2017 and December 31, 2016, respectively.  Estimated future amortization expense for intangible assets as of December 31, 2017 is as follows (in thousands):

 

 

 

 

 

 

 

 

 

2018

 

 

 

 

$

1,486

 

2019

 

 

 

 

 

1,486

 

2020

 

 

 

 

 

1,486

 

2021

 

 

 

 

 

1,486

 

2022

 

 

 

 

 

1,486

 

Thereafter

 

 

 

 

 

12,131

 

 

 

 

 

 

$

19,561

 

 

IPR&D assets and goodwill were established as part of the purchase accounting of EOS in November 2013, and consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

    

2017

    

2016

 

IPR&D assets:

 

 

  

 

 

  

 

Balance at beginning of period

 

$

 —

 

$

101,500

 

Impairment of intangible asset (a)

 

 

 —

 

 

(104,517)

 

Change in foreign currency gains and losses

 

 

 —

 

 

3,017

 

Balance at end of period

 

$

 —

 

$

 —

 

 

 

 

  

 

 

  

 

Goodwill:

 

 

  

 

 

  

 

Balance at beginning of period

 

$

57,192

 

$

59,327

 

Change in foreign currency gains and losses

 

 

8,025

 

 

(2,135)

 

Balance at end of period

 

$

65,217

 

$

57,192

 


(a)

During the second quarter of 2016, we recorded a $104.5 million impairment charge due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At December 31, 2017, the IPR&D intangible asset recorded on the Consolidated Balance Sheets was zero.

 

During the fourth quarter of 2015, we recorded an $89.6 million impairment charge due to our and our development partner’s decision to terminate the development of lucitanib for lung cancer, as well as updates to the probability-weighted discounted cash flow assumptions for the breast cancer indication.

 

These reductions were included in impairment of intangible asset on the Consolidated Statements of Operations and Comprehensive Loss.

 

As of December 31, 2017, no impairment to the carrying value of the goodwill was identified.

XML 30 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Convertible Senior Notes
12 Months Ended
Dec. 31, 2017
Convertible Senior Notes  
Convertible Senior Notes

8. Convertible Senior Notes

 

On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “Notes”) resulting in net proceeds of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

 

The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year. The Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.

 

Holders may convert all or any portion of the Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

 

On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.    

 

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the Notes, holders may require us to repurchase for cash all or any portion of the Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

 

The Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

 

In connection with the issuance of the Notes, we incurred $9.2 million of debt issuance costs. The debt issuance costs are amortized as interest expense over the expected life of the Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the Notes. As of December 31, 2017 and 2016, the balance of unamortized debt issuance costs was $5.1 million and $6.4 million, respectively, and is recorded as a reduction to the convertible senior notes at the Consolidated Balance Sheets.

 

The following table sets forth total interest expense to the Notes and the milestone liability during the years ended December 31, 2017 and 2016 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

2017

    

2016

    

2015

Contractual interest expense

 

$

7,188

 

$

7,187

 

$

7,167

Accretion of interest on milestone liability

 

 

1,961

 

 

62

 

 

 —

Amortization of debt issuance costs

 

 

1,279

 

 

1,242

 

 

1,205

Total interest expense

 

$

10,428

 

$

8,491

 

$

8,372

 

XML 31 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity
12 Months Ended
Dec. 31, 2017
Stockholders’ Equity  
Stockholders' Equity

9. Stockholders’ Equity

 

Common Stock

 

In July 2015, we sold 4,054,487 shares of our common stock in a public offering at $78.00 per share. The net proceeds from the offering were $298.5 million, after deducting underwriting discounts and commissions and offering expenses.

 

In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses.

 

In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses.

 

The holders of common stock are entitled to one vote per share on all matters to be voted upon by our stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors.

 

Accumulated Other Comprehensive Loss

 

Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities.

 

The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign Currency

 

Unrealized

 

Total Accumulated

 

 

Translation Adjustments

 

(Losses) Gains

 

Other Comprehensive Loss

Balance at December 31, 2015

 

$

(47,077)

 

$

(383)

 

$

(47,460)

Other comprehensive income (loss)

 

 

(1,693)

   

 

224

   

 

(1,469)

Total before tax

 

 

(48,770)

 

 

(159)

 

 

(48,929)

Tax effect

 

 

1,336

 

 

13

 

 

1,349

Balance at December 31, 2016

 

 

(47,434)

 

 

(146)

 

 

(47,580)

Other comprehensive income (loss)

 

 

8,735

 

 

(110)

 

 

8,625

Total before tax

 

 

(38,699)

 

 

(256)

 

 

(38,955)

Tax effect

 

 

(3,218)

 

 

 —

 

 

(3,218)

Balance at December 31, 2017

 

$

(41,917)

 

$

(256)

 

$

(42,173)

 

The other comprehensive income (loss) related to foreign currency translation adjustments was primarily due to the currency translation of the IPR&D intangible assets, goodwill and deferred income taxes (see Note 7, Intangible Assets and Goodwill). There were no reclassifications out of accumulated other comprehensive loss in the years ended December 31, 2017, 2016 and 2015.

XML 32 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation
12 Months Ended
Dec. 31, 2017
Share-Based Compensation  
Share-Based Compensation

10. Share-Based Compensation

 

Stock Options

 

In August 2011, our Board of Directors approved the 2011 Stock Incentive Plan (the “2011 Plan”), which became effective upon the closing of our initial public offering in November 2011. The 2011 Plan provides for the granting of incentive and nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards and other share-based awards to our employees, directors and consultants. Common shares authorized for issuance under the 2011 Plan were 9,590,378 at December 31, 2017, which represents the initial reserve of 1,250,000 shares of common stock plus 192,185 shares of common stock remaining for future grant from the 2009 Equity Incentive Plan (the “2009 Plan”), which was terminated upon the closing of our initial public offering in November 2011, and 8,148,193 new shares authorized by the Board of Directors at the annual meetings of stockholders. Future forfeitures and cancellations of options previously granted under the 2009 Plan were transferred to and also available for grant under the 2011 Plan. Stock options granted vest ratably over either a one-year period or three-year period for Board of Director grants. Employee stock options generally vest over a four-year period with 25% of the options cliff-vesting after year one and the remaining options vesting ratably over each subsequent month. All stock options expire 10 years from the date of grant.

 

Share-based compensation expense for the years ended December 31, 2017, 2016 and 2015, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

 

2017

    

2016

    

2015

 

Research and development

 

$

20,335

 

$

27,558

 

$

27,321

 

Selling, general and administrative

 

 

24,372

 

 

12,238

 

 

13,036

 

Total share-based compensation expense

 

$

44,707

 

$

39,796

 

$

40,357

 

 

We did not recognize a tax benefit related to share-based compensation expense during the years ended December 31, 2017, 2016 and 2015 as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of December 31, 2017.

 

The following table summarizes the activity relating to our options to purchase common stock:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

  

 

 

  

Weighted

  

 

 

 

 

 

 

 

Weighted

 

Average

 

Aggregate

 

 

 

 

 

Average

 

Remaining

 

Intrinsic

 

 

 

Number of

 

Exercise

 

Contractual

 

Value

 

 

 

Options

 

Price

 

Term (Years)

 

(Thousands)

 

Outstanding at December 31, 2016

 

5,520,482

 

$

42.00

 

  

 

 

  

 

Granted

 

1,048,700

 

 

66.09

 

  

 

 

  

 

Exercised

 

(465,690)

 

 

29.90

 

  

 

 

  

 

Forfeited

 

(313,757)

 

 

49.20

 

  

 

 

  

 

Outstanding at December 31, 2017 (a)

 

5,789,735

 

$

46.77

 

7.1

 

$

145,067

 

Vested and expected to vest at December 31, 2017

 

5,505,557

 

$

46.52

 

7.0

 

$

139,526

 

Vested and exercisable at December 31, 2017

 

3,481,931

 

$

44.60

 

6.1

 

$

95,463

 


(a)

Includes 33,750 performance-based stock options granted to our executives in the first quarter of 2015, which vested on approval by the FDA in December 19, 2016 to commercially distribute, sell or market Rubraca. Related stock compensation expense was recognized on that date.

 

The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $68.00 as of December 31, 2017, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.

 

The following table summarizes information about our stock options as of and for the years ended December 31, 2017, 2016 and 2015:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

 

2017

    

2016

    

2015

 

Weighted-average grant date fair value per share

 

$

48.79

 

$

16.62

 

$

52.70

 

Intrinsic value of options exercised

 

$

18,986,726

 

$

3,118,097

 

$

19,976,769

 

Cash received from stock option exercises

 

$

13,924,174

 

$

3,267,721

 

$

5,478,211

 

 

 

The fair value of each share-based award is estimated on the grant date using the Black-Scholes option pricing model based upon the weighted-average assumptions provided in the following table:

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Dividend yield

 

 —

 

 —

 

 —

 

Volatility (a)

 

89

%  

93

%  

72

%

Risk-free interest rate (b)

 

2.16

%  

1.77

%  

1.77

%

Expected term (years) (c)

 

5.8

 

5.8

 

6.1

 

 


(a)

Volatility: The expected volatility was estimated using our historical data.

(b)

Risk-free interest rate: The rate is based on the yield on the grant date of a zero-coupon U.S. Treasury bond whose maturity period approximates the option’s expected term.

(c)

 Expected term: The expected term of the award was estimated using our historical data.

 

The total fair value of stock options vested during the years ended December 31, 2017, 2016 and 2015 was $36.0 million, $40.8 million and $36.5 million, respectively.

 

Restricted Stock

 

During 2016, we issued restricted stock units (“RSUs”) to certain employees under the 2011 Stock Incentive Plan. The RSUs vest either (i) over two years, with 50% vesting one year from the date of grant and the remaining 50% vesting two years from the date of grant or (ii) over four years, with 25% vesting one year from the date of grant and the remaining 75% vesting ratably each subsequent quarter over the following three years, as defined in the grant agreement. Vested RSUs are payable in shares of our common stock at the end of the vesting period. RSUs are measured based on the fair value of the underlying stock on the grant date. The minimum statutory tax on the value of common stock shares  issued to employees upon vesting are paid by us through the sale of registered shares of our common stock.

 

The following table summarizes the activity related to our unvested RSUs:

 

 

 

 

 

 

 

 

    

 

    

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

Average

 

 

 

Number of

 

Grant Date

 

 

 

Units

 

Fair Value

 

Unvested at December 31, 2016

 

562,458

 

$

24.70

 

Granted

 

249,984

 

 

64.66

 

Vested

 

(180,912)

 

 

23.83

 

Forfeited

 

(42,001)

 

 

28.09

 

Unvested as of December 31, 2017

 

589,529

 

$

41.67

 

Expected to vest after December 31, 2017

 

513,069

 

$

41.40

 

 

Unrecognized share-based compensation expense related to non-vested options and RSUs, adjusted for expected forfeitures, was $89.4 million as of December 31, 2017. The unrecognized share-based compensation expense is expected to be recognized over the weighted-average remaining vesting period of 3.3 years.

 

Common Stock Reserved for Issuance

 

As of December 31, 2017, we reserved shares of common stock for future issuance as follows:

 

 

 

 

 

 

 

 

 

 

    

 

    

Available for

    

 

 

 

 

 

 

Grant

 

Total Shares of

 

 

 

Common Stock

 

or Future

 

Common Stock

 

 

 

Outstanding

 

Issuance

 

Reserved

 

2009 Equity Incentive Plan

 

331,213

 

 —

 

331,213

 

2011 Stock Incentive Plan

 

6,048,051

 

2,589,033

 

8,637,084

 

2011 Employee Stock Purchase Plan

 

 —

 

558,870

 

558,870

 

Total

 

6,379,264

 

3,147,903

 

9,527,167

 

 

Employee Stock Purchase Plan

 

In August 2011, our Board of Directors approved the Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan (the “Purchase Plan”). Each year, on the date of our annual meeting of stockholders and at the discretion of our board of directors, the amount of shares reserved for issuance under the Purchase Plan may be increased by up to the lesser of (1) a number of additional shares of our common stock representing 1% of our then-outstanding shares of common stock, (2) 344,828 shares of our common stock and (3) a lesser number of shares as approved by the Board. The Purchase Plan provides for consecutive six-month offering periods, during which participating employees may elect to have up to 10% of their compensation withheld and applied to the purchase of common stock at the end of each offering period. The purchase price of the common stock is 85% of the lower of the fair value of a share of common stock on the first trading date of each offering period or the fair value of a share of common stock on the last trading day of the offering period. The Purchase Plan will terminate on August 24, 2021, the tenth anniversary of the date of initial adoption of the Purchase Plan. We sold 51,681 and 110,508 shares to employees in 2017 and 2016, respectively. There were 558,870 shares available for sale under the Purchase Plan as of December 31, 2017. The weighted-average estimated grant date fair value of purchase awards under the Purchase Plan during the years ended December 31, 2017 and 2016 was $23.08 and $11.70 per share, respectively. The total share-based compensation expense recorded as a result of the Purchase Plan was approximately $1.0 million, $0.8 million and $0.9 million during the years ended December 31, 2017, 2016 and 2015, respectively.

 

The fair value of purchase awards granted to our employees during the years ended December 31, 2017, 2016 and 2015, respectively, was estimated using the Black-Scholes option pricing model based upon the weighted-average assumptions provided in the following table:

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Dividend yield

 

 —

 

 —

 

 —

 

Volatility (a)

 

79

%  

92

%  

71

%

Risk-free interest rate (b)

 

0.90

%  

0.40

%  

0.11

%

Expected term (years) (c)

 

0.5

 

0.5

 

0.5

 


(a)

Volatility: The expected volatility was estimated using our historical data.

(b)

Risk-free interest rate: The rate is based on the U.S. Treasury yield in effect at the time of grant with terms similar to the contractual term of the purchase right.

(c)

Expected term: The expected life of the award represents the six-month offering period for the Purchase Plan.

 

XML 33 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue Recognition
12 Months Ended
Dec. 31, 2017
Revenue Recognition  
Revenue Recognition

11. Revenue Recognition

 

Effective January 1, 2018, we adopted ASC 606, the new revenue recognition standard, using the modified retrospective method. Upon adoption, the accounting for net product revenue is as follows:

 

Product Revenue, Net

 

We are currently approved to sell Rubraca in the United States market.  We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers.  Our customers subsequently sell our products to patients and health care providers.  Separately, we have arrangements with certain payors and other third-parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. 

 

Revenue from product sales are recognized when customers obtain control of our product, which occurs at a point in time, typically upon delivery to the customers. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less.

 

Reserves for Variable Consideration

   

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, chargebacks, discounts, co-pay assistance, estimated product returns and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product.  These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customers) or a current liability (if the amount is payable to a party other than a customer).  Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.  Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract.  The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.  Actual amounts of consideration ultimately received may differ from our estimates.  If actual results in the future vary from our estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.

 

Rebates. Rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare coverage gap program. Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. The accrual for rebates is based on statutory discount rates and known sales to specialty pharmacy patients, or expected utilization for specialty distributor sales to healthcare providers. As we gain more historical experience, the accrual will be based solely on the expected utilization from historical data we have accumulated since the Rubraca product launch. Rebates are generally invoiced and paid quarterly in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known or estimated prior quarters’ unpaid rebates.

 

Chargebacks. Chargebacks are discounts that occur when contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service organizations and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the healthcare provider. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates and known sales to specialty distributors adjusted for the estimated utilization by healthcare providers.

 

Discounts. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts from product sales when revenue is recognized. Service fees are recorded as a selling expense when product sales occur.

 

Co-pay assistance. Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. The intent of this program is to reduce the patient’s out of pocket costs. Liabilities for co-pay assistance are based on actual program participation and estimates of program redemption using data provided by third-party administrators.

     

Returns. Consistent with industry practice, we generally offer customers a limited right of return for product that has been purchased based on the product’s expiration date, which lapses upon shipment to a patient. To date, we have had minimal product returns and we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience.

 

Currently, we only recognize revenue on product sales once the product is sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, i.e. when product is sold through the channel. Effective January 1, 2018, we will begin recognizing revenue when our customers, the specialty distributors and specialty pharmacy providers, take control of our product or when product is sold into the channel. This will have the impact of us recognizing revenue approximately two to four weeks earlier than before adopting the new standard and will also increase the significance of estimating variable consideration.

 

We used the modified retrospective method to adopt the new standard. This means that we will not restate previously issued financial statements, but will record a one-time adjustment to retained earnings of $2.3 million. This adjustment represents the sales of our product to our customers prior to January 1, 2018, that have not been sold to patients or healthcare providers, offset by related gross-to-net adjustments and other direct costs, including royalties and sales incentive compensation.

 

XML 34 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2017
Commitments and Contingencies  
Commitments and Contingencies

12. Commitments and Contingencies

 

We lease office space in Boulder, Colorado, San Francisco, California, Oakland, California, Cambridge, UK and Milan, Italy under non-cancelable operating lease agreements that expire through 2028. The lease agreements contain periodic rent increases that result in the recording deferred rent over the terms of certain leases.

 

In November 2017, we entered into a ten-year lease agreement for new office space in Oakland, California. Pursuant to the terms of the lease, the landlord will reimburse us for up to $2.5 million of leasehold improvement expenditures (“Tenant Improvement Allowance”). Upon completion of construction, we will record the Tenant Improvement Allowance as deferred rent, which will be amortized as a reduction to rental expense over the lease term.

 

Rental expense under these leases was $2.2 million, $2.2 million and $2.4 million for the years ended December 31, 2017, 2016 and 2015, respectively.

 

Future minimum rental commitments, by fiscal year and in the aggregate, for our operating leases are provided below (in thousands):

 

 

 

 

 

 

 

    

December 31, 

 

 

 

2017

 

2018

 

$

3,050

 

2019

 

 

3,902

 

2020

 

 

3,744

 

2021

 

 

3,855

 

2022

 

 

2,519

 

Thereafter

 

 

11,563

 

Total future minimum lease payments

 

$

28,633

 

 

Manufacture and Services Agreement Commitments

 

On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for rucaparib. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in rucaparib that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified any forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the rucaparib active ingredient. We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of December 31, 2017, $223.9 million of purchase commitments exist under the Agreement. 

 

Legal Proceedings

 

We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition.

 

Rociletinib-Related Litigation

 

Following Clovis’ regulatory announcement in November 2015 of adverse developments in its ongoing clinical trials for rociletinib, Clovis and certain of its current and former executives were named in various securities lawsuits, the largest of which was a putative class action lawsuit in the District of Colorado (the “Medina Action”) which was settled on October 26, 2017 (the “Medina Settlement”).  The open actions currently pending against Clovis are discussed below.   While other entities have threatened to bring claims relating to rociletinib and the November 2015 announcement, none have commenced litigation as of the date of this filing. 

 

On January 22, 2016, the Electrical Workers Local #357 Pension and Health & Welfare Trusts, a purported shareholder of Clovis, filed a purported class action complaint (the “Electrical Workers Complaint”) against Clovis and certain of its officers, directors, investors and underwriters in the Superior Court of the State of California, County of San Mateo (the “Electrical Workers Court”). The Electrical Workers Complaint purports to be asserted on behalf of a class of persons who purchased stock in the July 2015 Offering. The complaint asserted claims under certain provisions of the Securities Act of 1933 (the “Securities Act”) relating to a July 2015 follow-on offering of Clovis securities (the “July 2015 Offering”) based on substantially similar allegations to those asserted in the Medina Action. On June 30, 2016, the Electrical Workers Plaintiffs filed an amended complaint adding new allegations (the “Amended Complaint”).

   

On July 28, 2016, the defendants filed a motion to stay the Electrical Workers action pending resolution of the Medina Action and a demurrer to the Amended Complaint. On September 23, 2016, after hearing oral argument, the Electrical Workers Court granted the motion to stay and reserved on issuing a ruling on defendants’ pending demurrer.

 

The Company believes that the claims asserted in the Electrical Workers Action are released and barred by operation of law through the Medina Settlement, and accordingly plans to seek dismissal of the Electrical Workers Action on that basis.

 

On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the offering materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages.

   

On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.

   

On January 31, 2017, Defendants filed a motion to stay the Antipodean action pending resolution of the Medina Action in the District of Colorado. Defendants also filed a motion to dismiss the Antipodean Amended Complaint on March 29, 2017.

   

On March 14, 2017, the Clovis Defendants and Antipodean participated in a mediation, which did not result in a settlement.

   

On August 8, 2017, the parties participated in a scheduled hearing on Defendants’ motion to stay and motion to dismiss before Justice Masley of the New York Supreme Court, County of New York. At the hearing, Justice Masley granted Defendants’ motion to stay. Per the Court’s August 10, 2017 order, Defendants’ motion to dismiss was held in abeyance and deemed submitted on November 1, 2017.  On November 1, 2017, the Defendants provided a status update to the Court regarding the outcome of the hearing.  The update informed the Court that Antipodean had excluded itself from the Medina Settlement, as memorialized in the final judgment entered by the Medina Court.  No date has been scheduled for argument on Defendants’ motion to dismiss.

   

The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint.  However, there can be no assurance that the defense will be successful.

   

In March 2017, two putative shareholders of the Company, Macalinao and McKenry (the “Derivative Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”).

   

On May 18, 2017, the Derivative Plaintiffs filed a Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to prior demands for inspection of the Company’s books and records served on the Company by each of Macalinao and McKenry under 8 Del. C. § 220. The Consolidated Derivative Complaint sought, among other things, an award of money damages.

   

On July 31, 2017, the defendants filed a motion to dismiss the Consolidated Derivative Complaint. Plaintiffs filed an opposition to the motion to dismiss on August 31, 2017, and the defendants filed a reply in further support of the motion to dismiss on September 26, 2017. No date has been scheduled for argument on Defendants’ motion to dismiss the Consolidated Derivative Complaint.

   

The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful.

   

On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages.

   

On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative Complaint. On June 20, 2017, the court granted the motion to stay.

   

The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.

 

In addition, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. The Company is continuing to cooperate with these agencies with respect to their investigations. The Medina Settlement does not resolve these inquiries and the Company cannot predict their timing or outcome.

 

Director Compensation Litigation

 

On May 10, 2017, John Solak, a purported shareholder of the Company, filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware (the “Solak Complaint”) against certain directors and an officer of the Company. The Solak Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by adopting a compensation plan that overcompensated the non-employee director defendants, in relation to companies of comparable market capitalization and size. The Solak Complaint also alleged claims of waste of corporate assets and unjust enrichment due to this allegedly wrongful compensation plan. The Solak Complaint sought, among other things, an award of money damages and the imposition of corporate governance reforms.

   

The Court has entered a number of orders extending the defendants’ time to respond to the Solak Complaint based on, among other factors, the fact that the parties are engaged in discussions in an effort to resolve the Solak action. On February 14, 2018, the parties filed a joint letter to the Court requesting that all deadlines in the action be held in abeyance while the parties engaged in final settlement discussions.

 

On February 26, 2018, the defendants entered into a stipulation of compromise and settlement with plaintiff that is intended to settle the Solak action. The proposed settlement is subject to Court approval upon the conclusion of a settlement hearing concerning the fairness of the terms of the proposed settlement, which will be scheduled following the provision of notice to shareholders of the Company.

 

In accordance with the terms of the proposed settlement, the Company will present a new non-employee director compensation policy for shareholder vote at the next annual shareholder meeting. Under the proposed new non-employee director compensation policy, annual base compensation for incumbent non-employee directors would be set at an amount between $350,000 and $425,000, which would remain in place for a period between two and five years. Additionally, the proposed policy sets annual base compensation for new non-employee directors at an amount between $525,000 and $637,500 and includes fixed annual fees for board and committee service. The proposed settlement also sets forth a number of corporate governance reforms that the Company will undertake, including, enhanced proxy disclosures, the codification of the Company’s stock ownership guidelines for directors, and enhanced disclosure requirements for certain forms of director compensation. While no cash payments will be made to investors as part of the proposed settlement, plaintiff’s counsel is expected to file a fee application which the Company has agreed not to oppose up to an agreed-upon amount. The proposed settlement contains no admission of wrongdoing.

XML 35 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
License Agreements
12 Months Ended
Dec. 31, 2017
License Agreements  
License Agreements

13. License Agreements

 

Rucaparib

 

In June 2011, we entered into a license agreement with Pfizer Inc. to obtain the exclusive global rights to develop and commercialize Rubraca. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of Rubraca, we made milestones payments of $1.4 million, which were recognized as acquired in-process research and development expense.

 

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) European Commission approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones.

 

On December 19, 2016, the FDA approved Rubraca as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated with advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was paid in the first quarter of 2017. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we have exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. These payments were recognized as intangible assets and amortized over the estimated remaining useful life of rucaparib.

 

We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize Rubraca and we are responsible for all ongoing development and commercialization costs for Rubraca. We are required to make regulatory milestone payments to Pfizer of up to an additional $69.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for Rubraca are met, which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize Rubraca.

 

The license agreement with Pfizer will remain in effect until the expiration of all of our royalty and sublicense revenue obligations to Pfizer, determined on a product-by-product and country-by-country basis, unless we elect to terminate the license agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Pfizer can terminate the agreement, resulting in a loss of our rights to Rubraca and an obligation to assign or license to Pfizer any intellectual property rights or other rights we may have in Rubraca, including our regulatory filings, regulatory approvals, patents and trademarks for Rubraca.

 

In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with Rubraca under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of Rubraca for the uses claimed by these patents. Pursuant to the terms of the license agreement, we made an upfront payment of $0.25 million upon execution of the agreement. During the second quarter of 2016, we made a milestone payment of $0.3 million to AstraZeneca upon the NDA submission for Rubraca. These payments were recognized as acquired in-process research and development expense. The FDA approval of Rubraca on December 19, 2016 resulted in a final $0.35 million milestone payment to AstraZeneca as required by the license agreement. This payment was recognized in intangible assets and amortized over the estimated remaining useful life of Rubraca. AstraZeneca also receives royalties on net sales of Rubraca.

 

Lucitanib

 

In connection with our acquisition of EOS in November 2013, we gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for upfront milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments.

 

In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product candidate containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib.

 

In the first quarter of 2014, we recognized acquired in-process research and development expense of $3.4 million, which represents 25% of the sublicense agreement consideration of $13.6 million received from Servier upon the end of opposition and appeal of the lucitanib patent by the European Patent Office.

 

The license agreement with Advenchen will remain in effect until the expiration of all of our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in a loss of our rights to lucitanib.

 

In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an upfront payment of €45.0 million. We are entitled to receive additional payments upon achievement of specified development, regulatory and commercial milestones up to €100.0 million in the aggregate, €10.0 million of which was received in the first quarter of 2014. In addition, we are entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, which, in the aggregate, could total €250.0 million. We are also entitled to receive royalties at percentage rates ranging from low to mid-teens on sales of lucitanib by Servier.

 

The development, regulatory and commercial milestones represent non-refundable amounts that would be paid by Servier to us if certain milestones are achieved in the future. These milestones, if achieved, are substantive as they relate solely to past performance, are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of our performance, which are reasonable relative to the other deliverables and terms of the arrangement, and are unrelated to the delivery of any further elements under the arrangement.

 

We and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for all of the global development costs for lucitanib up to €80.0 million. Cumulative global development costs in excess of €80.0 million, if any, will be shared equally between us and Servier. During the second quarter of 2016, we and Servier agreed to discontinue the development of lucitanib for breast cancer. We are continuing to evaluate what, if any, further development of lucitanib will be pursued. During 2017, we completed the committed on-going development activities in 2017 and received full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations and Comprehensive Loss.

 

We recorded a $0.0 and $1.3 million receivable at December 31, 2017 and 2016, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. During the years ending December 31, 2017, 2016 and 2015, we incurred ($0.2) million, $7.7 million and $13.7 million, respectively, in research and development costs and recorded reductions in research and development expense of $1.0 million, $9.0 million and $11.8 million, respectively, for reimbursable development costs due from Servier.

 

Rociletinib

 

In May 2010, we entered into an exclusive worldwide license agreement with Celgene to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor (“EGFR”) gene product. Rociletinib was identified as the lead inhibitor candidate under the license agreement. We are responsible for all non-clinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib.

 

We made an upfront payment of $2.0 million upon execution of the license agreement, a $4.0 million milestone payment in the first quarter of 2012 upon the acceptance by the FDA of our Investigational New Drug application for rociletinib and a $5.0 million milestone payment in the first quarter of 2014 upon initiation of the Phase II study for rociletinib. In the third quarter of 2015, we made milestone payments totaling $12.0 million upon acceptance of the NDA and MAA for rociletinib by the FDA and EMA, respectively. We recognized all payments prior to commercial approval as acquired in-process research and development expense.

 

During the second quarter of 2016, we received a CRL from the FDA for the rociletinib NDA. We terminated enrollment in all sponsored clinical studies, although we continue to provide drug to patients whose clinicians recommend continuing rociletinib therapy. We are continuing analyses of rociletinib data to determine whether certain populations of patients may represent an opportunity for a partner committed to investing in further clinical development.

We are obligated to pay royalties at percentage rates ranging from mid-single digits to low teens based on the volume of annual net sales achieved. We are required to pay up to an additional aggregate of $98.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are required to pay up to an aggregate of $120.0 million in sales milestone payments if certain annual sales targets are achieved, which relate to annual sales targets of $500.0 million and above.

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss Per Common Share
12 Months Ended
Dec. 31, 2017
Net Loss Per Common Share  
Net Loss Per Common Share

14. Net Loss Per Common Share

 

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

 

The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

 

2017

    

2016

    

2015

 

Common shares under option

 

4,260

 

3,398

 

2,031

 

Convertible senior notes

 

4,646

 

4,646

 

4,646

 

Total potential dilutive shares

 

8,906

 

8,044

 

6,677

 

 

XML 37 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
12 Months Ended
Dec. 31, 2017
Income Taxes  
Income Taxes

15. Income Taxes

 

We are subject to U.S. federal, state and foreign income tax.  The geographical components of income (loss) before income taxes consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Domestic

 

$

(351,338)

 

$

(277,776)

 

$

(290,342)

 

Foreign

 

 

1,363

  

 

(103,395)

 

 

(91,595)

  

Total loss before income taxes

 

$

(349,975)

 

$

(381,171)

 

$

(381,937)

 

 

The income tax provision consists of the following current and deferred tax (benefit) expense amounts (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

 

2015

 

Current tax:

 

 

 

  

 

 

 

 

 

 

U.S. Federal & State

 

$

 —

 

$

 —

 

$

 —

 

Foreign

 

 

(360)

  

 

64

 

 

 —

 

Total current (benefit) expense

 

 

(360)

 

 

64

 

 

 —

 

Deferred tax:

 

 

 

  

 

 

 

 

 

 

U.S. Federal & State

 

 

(3,218)

 

 

 —

 

 

 —

 

Foreign

 

 

 —

  

 

(32,098)

 

 

(29,076)

 

Total deferred (benefit)

 

 

(3,218)

 

 

(32,098)

 

 

(29,076)

 

Total income tax (benefit)

 

$

(3,578)

 

$

(32,034)

 

$

(29,076)

 

 

A reconciliation of the U.S. federal statutory income tax rate to our effective tax rate is provided below:

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Federal income tax benefit at statutory rate

 

(34.0)

%  

(34.0)

%  

(34.0)

%

State income tax benefit, net of federal benefit

 

(3.2)

 

(3.6)

 

(3.0)

 

Tax credits

 

(1.2)

 

(10.8)

 

(13.6)

 

Limitation on future foreign tax credits

 

 —

 

(5.9)

 

(5.0)

 

Change in uncertain tax positions

 

0.2

 

4.2

 

 —

 

Other

 

(1.1)

 

2.3

 

0.4

 

Tax impact of Tax Cuts and Jobs Act of 2017

 

46.4

 

 —

 

 —

 

Change in valuation allowance

 

(8.1)

 

39.4

 

47.6

 

Effective income tax rate

 

(1.0)

%  

(8.4)

%  

(7.6)

%

 

The significant components of our deferred tax assets and liabilities are as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

    

2017

    

2016

 

Deferred tax assets:

 

 

   

  

 

 

  

Net operating loss carryforward

 

$

272,710

 

$

275,898

  

Tax credit carryforwards

 

 

222,150

 

 

217,948

  

Intangible assets

 

 

29,900

 

 

42,745

  

Share-based compensation expense

 

 

27,844

 

 

31,390

  

Foreign currency translation

 

 

3,012

 

 

10,510

  

Product acquisition costs

 

 

5,881

 

 

9,764

  

Accrued liabilities and other

 

 

3,879

 

 

5,384

  

Total deferred tax assets

 

 

565,376

 

 

593,639

  

Valuation allowance

 

 

(564,122)

 

 

(592,423)

  

Deferred tax assets, net of valuation allowance

 

 

1,254

 

 

1,216

  

Deferred tax liabilities:

 

 

 

 

 

 

  

Prepaid expenses and other

 

 

(1,254)

 

 

(1,216)

  

Total deferred tax liabilities

 

 

(1,254)

 

 

(1,216)

  

Net deferred tax liability

 

$

 —

 

$

 —

  

 

On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (the “Act”), a tax reform bill which, among other items, reduces the current corporate federal income tax rate to 21% from 35%. The rate reduction is effective January 1, 2018. We believe the Act will cause us to revalue our deferred tax assets and liabilities to the lower federal tax rate. Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through income tax expense.

 

Pursuant to the SEC Staff Accounting Bulletin ("SAB") No. 118, "Income Tax Accounting Implications of the Tax Cuts and Jobs Act" ("SAB 118"), we may select one of three scenarios to determine a reasonable estimate arising from the Tax Act. Those scenarios are (i) a final estimate which effectively closes the measurement window; (ii) a reasonable estimate leaving the measurement window open for future revisions; and (iii) no estimate as the law is still being analyzed. We were able to provide a reasonable estimate for the revaluation of deferred taxes by recording a net tax provision of $162.2 million in the period ending December 31, 2017, which is offset by a change in valuation allowance with no net impact to tax expense. Other impacts of the Act including, but not limited to, provisional transition tax, expensing of qualified property and interest limitations are not expected to have a material impact to our financial statement presentation or disclosures. The final impact of the Act may be different from the provisional amounts reported due to changes in interpretations and assumptions of the current guidance available as well as the issuance of new regulatory guidance in the future. We anticipate the full financial impact will be determined at the time our 2017 U.S. corporate income tax return is filed in 2018.

   

The realization of deferred tax assets is dependent upon a number of factors including future earnings, the timing and amount of which is uncertain. A valuation allowance was established for the net deferred tax asset balance due to management’s belief that the realization of these assets is not likely to occur in the foreseeable future. We recorded a net decrease to the valuation allowance of $28.3 million for the year ended December 31, 2017, due to the revaluation of our net deferred tax assets resulting from the reduction to the corporate federal tax rate to 21% offset by the growth in net operating losses and credit carryforwards during the year. The increase of $143.3 million recorded to our valuation allowance during the year ended December 31, 2016 was due primarily to the increase in net operating loss and tax credit carryforwards.

 

In addition, the Company recognizes tax benefits if it is more likely than not to be sustained under audit by the relevant taxing authority based on technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained during audit. If the threshold is met, the tax benefit is measured and recognized at the largest amount above the greater than 50% likelihood threshold at time of settlement. The balance of unrecognized tax benefits at December 31, 2017 of $24.5 million, if recognized, would not impact the Company’s effective tax rate as long as they remain subject to a full valuation allowance. The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

 

2017

2016

 

Balance at beginning of year

 

$

24,075

 

$

 —

 

Additions related to prior periods tax positions

 

 

 —

 

 

17,844

 

Additions related to current period tax positions

 

 

437

 

 

6,231

 

Settlements with tax authorities

 

 

 —

 

 

 —

 

Expiration of statute of limitations

 

 

 —

 

 

 —

 

Balance at end of year

 

$

24,512

 

$

24,075

 

 

As of December 31, 2017, we had approximately $1.0 billion, $1.2 billion and $0.4 million of U.S. federal, state and foreign net operating loss carryforwards, respectively. The U.S. federal net operating losses will expire from 2029 to 2037 if not utilized and the U.S state net operating losses will expire from 2024 to 2037 if not utilized.  We have research and development and orphan drug tax credit carryforwards of $245.1 million that will expire from 2029 through 2037 if not utilized.

 

We believe that a change in ownership as defined under Section 382 of the U.S. Internal Revenue Code occurred as a result of our public offering of common stock completed in April 2012. Future utilization of the federal net operating losses (“NOL”) and tax credit carryforwards accumulated from inception to the change in ownership date will be subject to annual limitations to offset future taxable income. At this time, we do not believe this limitation will prevent the utilization of the federal NOL or credit carryforward prior to expiration. It is possible that a change in ownership will occur in the future, which will limit the NOL amounts generated since the last estimated change. Our federal and state income taxes for the period from inception to December 31, 2017 remain open to an audit. Our foreign subsidiaries are also subject to tax audits by tax authorities in the jurisdictions where they operate for the periods from December 31, 2011 to December 31, 2017.

 

We may be assessed interest and penalties related to the settlement of tax positions and such amounts will be recognized within income tax expense when assessed. To date, no interest and penalties have been recognized.

XML 38 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Employee Benefit Plans
12 Months Ended
Dec. 31, 2017
Employee Benefit Plans  
Employee Benefit Plans

16. Employee Benefit Plans

 

We maintain a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code for our U.S. employees. The plan allows eligible employees to defer, at the employee’s discretion, pretax compensation up to the IRS annual limits. We matched contributions up to 4% of the eligible employee’s compensation or the maximum amount permitted by law. Total expense for contributions made to U.S. employees was approximately $1.9 million, $1.6 million and $0.8 million for the years ended December 31, 2017, 2016 and 2015, respectively. Our international employees participate in retirement plans or postretirement life insurance plans governed by the local laws in effect for the country in which they reside. We made contributions to the retirement plans or postretirement life insurance plans of international employees of approximately $0.3 million, $0.2 million and $0.2 million for the years ended December 31, 2017, 2016 and 2015, respectively.

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Quarterly Information (Unaudited)
12 Months Ended
Dec. 31, 2017
Quarterly Information  
Quarterly Information (Unaudited)

17. Quarterly Information (Unaudited)

 

The results of operations on a quarterly basis for the years ended December 31, 2017 and 2016 were as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

March 31, 

  

June 30, 

  

September 30, 

  

December 31, 

  

March 31, 

  

June 30, 

  

September 30, 

  

December 31, 

 

 

 

2017

 

2017

 

2017

 

2017

 

2016

 

2016  (1)

 

2016

 

2016

 

Revenues:

 

 

`

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

Product revenue, net

 

$

7,045

 

$

14,620

 

$

16,806

 

$

17,040

 

$

 —

 

$

 —

 

$

 —

 

$

78

 

Operating expenses:

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

Cost of sales - product

 

 

1,163

 

 

2,730

 

 

3,026

 

 

3,332

 

 

 —

 

 

 —

 

 

 —

 

 

70

 

Cost of sales - intangible asset amortization

 

 

372

 

 

372

 

 

372

 

 

370

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

Research and development

 

 

32,447

 

 

33,108

 

 

38,924

 

 

38,019

 

 

74,608

 

 

67,729

 

 

54,338

 

 

54,454

 

Selling, general and administrative

 

 

29,224

 

 

36,149

 

 

35,011

 

 

38,523

 

 

9,827

 

 

9,552

 

 

9,162

 

 

12,190

 

Acquired in-process research and development

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

300

 

 

500

 

 

500

 

Impairment of intangible asset

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

104,517

 

 

 —

 

 

 —

 

Change in fair value of contingent purchase consideration

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

516

 

 

(25,452)

 

 

 —

 

 

 —

 

 Total expenses

 

 

63,206

 

 

72,359

 

 

77,333

 

 

80,244

 

 

84,951

 

 

156,646

 

 

64,000

 

 

67,214

 

Operating loss

 

 

(56,161)

 

 

(57,739)

 

 

(60,527)

 

 

(63,204)

 

 

(84,951)

 

 

(156,646)

 

 

(64,000)

 

 

(67,136)

 

Other income (expense):

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

Interest expense

 

 

(2,581)

 

 

(2,598)

 

 

(2,618)

 

 

(2,631)

 

 

(2,104)

 

 

(2,106)

 

 

(2,108)

 

 

(2,173)

 

Foreign currency gain (loss)

 

 

(159)

 

 

76

 

 

(44)

 

 

45

 

 

(551)

 

 

183

 

 

(66)

 

 

(146)

 

Legal settlement loss

 

 

 —

 

 

(117,000)

 

 

 —

 

 

11,523

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

Other income (expense)

 

 

354

 

 

594

 

 

1,291

 

 

1,404

 

 

25

 

 

196

 

 

252

 

 

160

 

Other income (expense), net

 

 

(2,386)

 

 

(118,928)

 

 

(1,371)

 

 

10,341

 

 

(2,630)

 

 

(1,727)

 

 

(1,922)

 

 

(2,159)

 

Loss before income taxes

 

 

(58,547)

 

 

(176,667)

 

 

(61,898)

 

 

(52,863)

 

 

(87,581)

 

 

(158,373)

 

 

(65,922)

 

 

(69,295)

 

Income tax (expense) benefit

 

 

83

 

 

1,281

 

 

1,234

 

 

980

 

 

4,181

 

 

29,059

 

 

227

 

 

(1,433)

 

Net loss

 

$

(58,464)

 

$

(175,386)

 

$

(60,664)

 

$

(51,883)

 

$

(83,400)

 

$

(129,314)

 

$

(65,695)

 

$

(70,728)

 

Basic and diluted net loss per common share

 

$

(1.33)

 

$

(3.88)

 

$

(1.24)

 

$

(1.04)

 

$

(2.17)

 

$

(3.37)

 

$

(1.70)

 

$

(1.83)

 

Basic and diluted weighted average common shares outstanding

 

 

44,039

 

 

45,176

 

 

48,917

 

 

49,973

 

 

38,360

 

 

38,389

 

 

38,538

 

 

38,624

 


(1)

In the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&D intangible asset related to our lucitanib product candidate.

XML 40 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2017
Summary of Significant Accounting Policies  
Liquidity

Liquidity

 

We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenue from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless and until it does, we will continue to need to raise additional cash.

 

In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including commercial planning and sales and marketing expenses associated with the launch of Rubraca in the United States and, if approved by the European Commission in Europe, funding of its development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on our current estimates, we believe that our cash, cash equivalents and available-for-sale securities will allow us to fund activities through the next 12 months.

Basis of Presentation

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include our accounts and our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Revenue Recognition

Revenue Recognition

 

We are currently approved to sell Rubraca in the United States market.  We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers.  Our customers subsequently sell our products to patients and health care providers.  Separately, we have arrangements with certain payors and other third-parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. 

 

Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Product sales are recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns. Estimating rebates, chargebacks, discounts, product returns and other deductions requires significant judgments about future events and uncertainties, and requires us to rely heavily on assumptions, as well as historical experience. We only recognize revenue on product sales once the product is sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns.

 

For the year ended December 31, 2017, we recognized $55.5 million of product revenue. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the costs of Rubraca units recognized as revenue during the year ended December 31, 2017 were expensed prior to the December 19, 2016 FDA approval, and a minimal amount is included in cost of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories. The majority of products sales were of pre-commercialization inventory in 2017.

 

Product revenue from each of our customers who individually accounted for 10% or more of total revenues consisted of the following:

 

 

 

 

 

 

December 31, 

 

    

2017

Customer A

 

35%

Customer B

 

27%

Customer C

 

12%

Customer D

 

10%

 

Effective January 1, 2018, we adopted ASC 606, the new revenue recognition standard, using the modified retrospective method. For a complete discussion of this adoption and the accounting for net product revenue, see the Recently Issued Accounting Standards section below and Note 11, Revenue Recognition.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Cash, cash equivalents, available-for-sale securities and contingent purchase consideration are carried at fair value. Financial instruments, including other current assets and accounts payable, are carried at cost, which approximates fair value given their short-term nature (see Note 4, Fair Value Measurements).    

Cash, Cash Equivalents and Available-for-Sale Securities

Cash, Cash Equivalents and Available-for-Sale Securities

 

We consider all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations. 

 

Marketable securities are considered to be available-for-sale securities and consist of U.S. treasury securities. Available-for-sale securities are reported at fair value on the Consolidated Balance Sheets and unrealized gains and losses are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense) on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on our intent to fund current operations with these securities or to make them available for current operations.

 

A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.

Accounts Receivable

Accounts Receivable

 

As of December 31, 2017 and 2016, we had no allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.

Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. Equipment purchased for use in manufacturing and clinical trials is evaluated to determine whether the equipment is solely beneficial for a drug candidate in the development stage or whether it has an alternative use. Equipment with an alternative use is capitalized. Leasehold improvements are amortized over the economic life of the asset or the lease term, whichever is shorter. Maintenance and repairs are expensed as incurred. The estimated useful lives of our capitalized assets are as follows:

 

 

 

 

 

 

 

Estimated

 

 

    

Useful Life

 

Computer hardware and software

 

3 to 5 years

 

Leasehold improvements

 

6 years

 

Laboratory, manufacturing and office equipment

 

5 to 7 years

 

Furniture and fixtures

 

10 years

 

 

Long-Lived Assets

Long-Lived Assets

 

We review long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. If the carrying value of the assets exceed their future net undiscounted cash flows, an impairment charge is recognized for the amount by which the carrying value of the assets exceeds the fair value of the assets.

Intangible Assets, Net

Intangible Assets, Net

 

Definite-lived intangible assets related to capitalized milestones under license agreements are amortized on a straight-line basis over their remaining useful lives, which are estimated to be the remaining patent life.  If our estimate of the product’s useful life is shorter than the remaining patent life, then a shorter period is used. Amortization expense is recorded as a component of cost of sales on the Consolidated Statements of Operations and Comprehensive Loss.

 

Intangible acquired in-process research and development (“IPR&D”) assets were established as part of the acquisition of Ethical Oncology Science, S.p.A. (“EOS”) in November 2013 and were not amortized.

 

Intangible assets are evaluated for impairment at least annually in the fourth quarter or more frequently if impairment indicators exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the decision to discontinue the development of a drug, the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate, or new information regarding potential sales for the drug. In connection with any impairment assessment, the fair value of the intangible assets as of the date of assessment is compared to the carrying value of the intangible asset. Impairment losses are recognized if the carrying value of an intangible asset is both not recoverable and exceeds its fair value. During the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&D intangible assets, reducing the remaining carrying value to zero (see Note 6, Intangible Assets and Goodwill). Previously, the Company recorded an $89.6 million impairment charge to the IPR&D intangible assets during the fourth quarter of 2015.

 

Goodwill

Goodwill

 

Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination accounted for under the acquisition method of accounting and is not amortized, but is subject to impairment testing at least annually in the fourth quarter or when a triggering event is identified that could indicate a potential impairment. We are organized as a single reporting unit and perform impairment testing by comparing the carrying value of the reporting unit to the fair value of the Company. Goodwill was recorded as a result of the EOS acquisition. 

Other Current Assets

Other Current Assets

 

Other current assets are comprised of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

December 31, 

 

 

    

2017

    

2016

 

Receivable from partners

 

$

 9

 

$

2,882

 

Prepaid insurance

 

 

1,926

 

 

1,234

 

Prepaid expenses - other

 

 

3,355

 

 

2,109

 

Receivable - other

 

 

2,023

 

 

364

 

Other

 

 

187

 

 

90

 

Total

 

$

7,500

 

$

6,679

 

 

Other Accrued Expenses

Other Accrued Expenses

 

Other accrued expenses are comprised of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

December 31, 

 

 

    

2017

    

2016

 

Accrued personnel costs

 

$

13,889

 

$

15,850

 

Accrued interest payable

 

 

2,096

 

 

2,096

 

Income tax payable

 

 

 —

 

 

556

 

Accrued corporate legal fees and professional services

 

 

415

 

 

589

 

Accrued royalties

 

 

2,984

 

 

 —

 

Accrued sales deductions

 

 

1,008

 

 

 —

 

Payable to third party logistics provider

 

 

2,661

 

 

 —

 

Accrued expenses - other

 

 

2,830

 

 

396

 

Total

 

$

25,883

 

$

19,487

 

 

Valuation of Contingent Consideration Resulting from a Business Combination

Valuation of Contingent Consideration Resulting from a Business Combination

 

Subsequent to the acquisition date, we re-measure contingent consideration arrangements at fair value each reporting period and record changes in fair value to change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss. Changes in fair value are primarily attributed to new information about the IPR&D assets, including changes in timeline and likelihood of success, and the passage of time. In the absence of new information, changes in fair value reflect only the passage of time. During the fourth quarter of 2015, we recorded a $26.9 million reduction in the fair value of the contingent purchase consideration liability due to a change in the estimated probability-weighted future discounted milestone payments, as well as the timing of such payments, for the lucitanib program.  Then, during the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At December 31, 2017, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets remained at zero due to the uncertainty of achieving any of the lucitanib regulatory milestones, and therefore the remote likelihood of future milestone payouts.

Research and Development Expense

Research and Development Expense

 

Research and development costs are charged to expense as incurred and include, but are not limited to, salary and benefits, share-based compensation, clinical trial activities, drug development and manufacturing, companion diagnostic development and third-party service fees, including contract research organizations and investigative sites. During 2015, we completed the hiring of our U.S. sales and marketing and medical affairs organizations in preparation for the potential commercial launch of Rubraca. These costs were also included in research and development expense before the FDA approval of Rubraca.

 

Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred and are reflected on the Consolidated Balance Sheets as prepaid or accrued research and development expenses.

Acquired In-Process Research and Development Expense

Acquired In-Process Research and Development Expense

 

We have acquired and expect to continue to acquire the rights to develop and commercialize new drug candidates. The upfront payments to acquire a new drug compound, as well as subsequent milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use.  Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to product cost of sales.

Share-Based Compensation Expense

Share-Based Compensation Expense

 

Share-based compensation is recognized as expense for all share-based awards made to employees and directors and is based on estimated fair values. We determine equity-based compensation at the grant date using the Black-Scholes option pricing model. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period. Any changes to the estimated forfeiture rates are accounted for prospectively.

Inventory

Inventory

 

Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. Prior to the regulatory approval of Rubraca, we incurred expenses for the manufacture of drug that could potentially be available to support the commercial launch of Rubraca. Until the first reporting period when regulatory approval has been received, we record all such costs as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues.

 

The active pharmaceutical ingredient in Rubraca is currently produced by a single supplier.

 

At December 31, 2017, deposit on inventory on the Consolidated Balance Sheets is a cash deposit of $20.5 million made to a manufacturer for the purchase of inventory which we expect to be converted to finished goods within the next twelve months.

Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments that potentially subject us to concentrations of credit risk are primarily cash, cash equivalents and available-for-sale securities. We maintain our cash and cash equivalent balances in the form of money market accounts with financial institutions that we believe are creditworthy. Available-for-sale securities are invested in accordance with our investment policy. The investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that we believe minimizes the exposure to concentration of credit risk. We have no financial instruments with off-balance sheet risk of accounting loss.

Foreign Currency

Foreign Currency

 

The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates and the results of operations are translated at the average exchange rates for the reported periods. The resulting translation adjustments are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. Transaction gains and losses are recorded to foreign currency gains (losses) on the Consolidated Statements of Operations and Comprehensive Loss. As of December 31, 2017 and 2016, approximately 1% of our total liabilities were denominated in currencies other than the functional currency.

Income Taxes

Income Taxes

 

We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized. 

Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

 

In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" (ASU 2016-09).  ASU 2016-09 simplifies how several aspects of share-based payments are accounted for and presented in the financial statements. ASU 2016-09 is effective for public companies for annual reporting periods beginning after December 15, 2016. We adopted this ASU in the first quarter of 2017. We had excess tax benefits for which a benefit could not be previously recognized of approximately $18.2 million. Upon adoption the balance of the unrecognized excess tax benefits were reversed with the impact recorded to retained earnings including any change to the valuation allowance as a result of the adoption. Due to the full valuation allowance on the U.S. deferred tax assets, there is no impact to the financial statements as a result of this adoption.

Recently Issued Accounting Standards

Recently Issued Accounting Standards

   

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, “Revenue from Contracts with Customers” and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability.  Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We have elected to apply the new standard using the modified retrospective method upon its adoption date on January 1, 2018. 

 

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. The standard also requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.

   

We have examined our revenue recognition policy specific to revenue streams from representative contracts governing product sales from Rubraca and have come to conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. We have reviewed a representative sample of contracts, including our collaboration agreements with Servier and Bristol-Myers Squibb discussed in Note 13, License Agreements, and determined the potential impact to our accounting policies, financial controls and operations. Our conclusions include recognizing revenue on product sales once the product is sold to the specialty distributor and specialty pharmacy providers. Currently, we anticipate the effects of adoption to be as described in Note 11, Revenue Recognition.

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. We plan to adopt on January 1, 2019. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.

 

In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” which clarifies the definition of a business in ASC 805. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. We adopted this standard on January 1, 2018 and the adoption resulted in no change to our consolidated financial statements and related disclosures.

   

In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting”, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which we would be required to apply modification accounting under ASC 718. Specifically, we would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is effective for annual reporting periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. We adopted this standard on January 1, 2018 and the adoption resulted in no change to our consolidated financial statements and related disclosures.

Fair Value Measurements

 

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:

 

Level 1:

Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.

 

 

Level 2:

Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

 

 

Level 3:

Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired with the purchase of EOS in November 2013 is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer, reducing the remaining fair value to zero. The fair value and carrying value remained at zero as of December 31, 2017.

 

The change in the fair value of Level 3 instruments is included in change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations and Comprehensive Loss.

   

 

Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss

 

Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities.

Net Loss Per Common Share

 

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

 

XML 41 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2017
Estimated Useful Lives of Property and Equipment

The estimated useful lives of our capitalized assets are as follows:

 

 

 

 

 

 

 

Estimated

 

 

    

Useful Life

 

Computer hardware and software

 

3 to 5 years

 

Leasehold improvements

 

6 years

 

Laboratory, manufacturing and office equipment

 

5 to 7 years

 

Furniture and fixtures

 

10 years

 

 

Other Current Assets

Other current assets are comprised of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

December 31, 

 

 

    

2017

    

2016

 

Receivable from partners

 

$

 9

 

$

2,882

 

Prepaid insurance

 

 

1,926

 

 

1,234

 

Prepaid expenses - other

 

 

3,355

 

 

2,109

 

Receivable - other

 

 

2,023

 

 

364

 

Other

 

 

187

 

 

90

 

Total

 

$

7,500

 

$

6,679

 

 

Other Accrued Expenses

Other accrued expenses are comprised of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

December 31, 

 

 

    

2017

    

2016

 

Accrued personnel costs

 

$

13,889

 

$

15,850

 

Accrued interest payable

 

 

2,096

 

 

2,096

 

Income tax payable

 

 

 —

 

 

556

 

Accrued corporate legal fees and professional services

 

 

415

 

 

589

 

Accrued royalties

 

 

2,984

 

 

 —

 

Accrued sales deductions

 

 

1,008

 

 

 —

 

Payable to third party logistics provider

 

 

2,661

 

 

 —

 

Accrued expenses - other

 

 

2,830

 

 

396

 

Total

 

$

25,883

 

$

19,487

 

 

Sales Revenue, Net | Customer Concentration Risk  
Product revenue from each customers

 

 

 

 

 

December 31, 

 

    

2017

Customer A

 

35%

Customer B

 

27%

Customer C

 

12%

Customer D

 

10%

 

XML 42 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment (Tables)
12 Months Ended
Dec. 31, 2017
Property and Equipment  
Property and Equipment

Property and equipment consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

   

 

December 31, 

 

 

    

2017

    

2016

 

Laboratory, manufacturing and office equipment

 

$

2,853

 

$

2,555

 

Leasehold improvements

 

 

2,285

 

 

2,276

 

Furniture and fixtures

 

 

1,416

 

 

1,411

 

Computer hardware and software

 

 

1,141

 

 

855

 

Total property and equipment

 

 

7,695

 

 

7,097

 

Less: accumulated depreciation

 

 

(3,688)

 

 

(2,657)

 

Total property and equipment, net

 

$

4,007

 

$

4,440

 

 

XML 43 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2017
Fair Value Measurements  
Assets Measured at Fair Value on Recurring Basis

The following table identifies our assets that were measured at fair value on a recurring basis (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

Balance

    

Level 1

    

Level 2

    

Level 3

 

December 31, 2017

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market

 

$

433,136

 

$

433,136

 

$

 —

 

$

 —

 

U.S. treasury securities

 

 

99,533

 

 

 —

 

 

99,533

 

 

 —

 

Total assets at fair value

 

$

532,669

 

$

433,136

 

$

99,533

 

$

 —

 

December 31, 2016

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market

 

$

202,361

 

$

202,361

 

$

 —

 

$

 —

 

U.S. treasury securities

 

 

49,997

 

 

 —

 

 

49,997

 

 

 —

 

Total assets at fair value

 

$

252,358

 

$

202,361

 

$

49,997

 

$

 —

 

 

XML 44 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Available-for-Sale Securities (Tables)
12 Months Ended
Dec. 31, 2017
Available-for-Sale Securities  
Summary of Available-for-Sale Securities

As of December 31, 2017, available-for-sale securities consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

    

 

    

Gross

    

Gross

    

Aggregate

 

 

 

Amortized

 

Unrealized

 

Unrealized

 

Fair

 

 

 

Cost

 

Gains

 

Losses

 

Value

 

U.S. treasury securities

 

$

99,650

 

$

 —

 

$

(117)

 

$

99,533

 

 

Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position

As of December 31, 2017, the fair value and gross unrealized losses of available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months were as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

    

Aggregate

    

Gross

 

 

 

Fair

 

Unrealized

 

 

 

Value

 

Losses

 

U.S. treasury securities

 

$

99,533

 

$

(117)

 

 

Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity

As of December 31, 2017, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):

 

 

 

 

 

 

 

 

 

 

    

Amortized

    

Fair

 

 

 

Cost

 

Value

 

Due in one year or less

 

$

99,650

 

$

99,533

 

Due in one year to two years

 

 

 —

 

 

 —

 

Total

 

$

99,650

 

$

99,533

 

 

XML 45 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories (Tables)
12 Months Ended
Dec. 31, 2017
Inventories  
Schedule of Inventories

The following table presents inventories as of December 31, 2017 and December 31, 2016 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

    

2017

    

2016

 

Work in process

 

$

24,721

 

$

 —

 

Finished goods

 

 

2,787

 

 

 —

 

Total

 

$

27,508

 

$

 —

 

 

XML 46 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Goodwill (Tables)
12 Months Ended
Dec. 31, 2017
Intangible Assets and Goodwill  
Intangible assets related to capitalized milestones under license agreements

At December 31, 2017 and 2016, intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

 

2017

    

2016

 

Intangible asset - milestones

 

$

21,100

 

$

21,100

 

Accumulated amortization

 

 

(1,539)

 

 

(53)

 

Total intangible asset, net

 

$

19,561

 

$

21,047

 

 

Estimated future amortization expense for intangible assets

Estimated future amortization expense for intangible assets as of December 31, 2017 is as follows (in thousands):

 

 

 

 

 

 

 

 

 

2018

 

 

 

 

$

1,486

 

2019

 

 

 

 

 

1,486

 

2020

 

 

 

 

 

1,486

 

2021

 

 

 

 

 

1,486

 

2022

 

 

 

 

 

1,486

 

Thereafter

 

 

 

 

 

12,131

 

 

 

 

 

 

$

19,561

 

 

Summary of IPR&D Assets and Goodwill

IPR&D assets and goodwill were established as part of the purchase accounting of EOS in November 2013, and consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

    

2017

    

2016

 

IPR&D assets:

 

 

  

 

 

  

 

Balance at beginning of period

 

$

 —

 

$

101,500

 

Impairment of intangible asset (a)

 

 

 —

 

 

(104,517)

 

Change in foreign currency gains and losses

 

 

 —

 

 

3,017

 

Balance at end of period

 

$

 —

 

$

 —

 

 

 

 

  

 

 

  

 

Goodwill:

 

 

  

 

 

  

 

Balance at beginning of period

 

$

57,192

 

$

59,327

 

Change in foreign currency gains and losses

 

 

8,025

 

 

(2,135)

 

Balance at end of period

 

$

65,217

 

$

57,192

 


(a)

During the second quarter of 2016, we recorded a $104.5 million impairment charge due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At December 31, 2017, the IPR&D intangible asset recorded on the Consolidated Balance Sheets was zero.

 

During the fourth quarter of 2015, we recorded an $89.6 million impairment charge due to our and our development partner’s decision to terminate the development of lucitanib for lung cancer, as well as updates to the probability-weighted discounted cash flow assumptions for the breast cancer indication.

 

These reductions were included in impairment of intangible asset on the Consolidated Statements of Operations and Comprehensive Loss.

XML 47 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Convertible Senior Notes (Tables)
12 Months Ended
Dec. 31, 2017
Convertible Senior Notes  
Schedule of Total Interest Expense Recognized Related to Notes

The following table sets forth total interest expense to the Notes and the milestone liability during the years ended December 31, 2017 and 2016 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

2017

    

2016

    

2015

Contractual interest expense

 

$

7,188

 

$

7,187

 

$

7,167

Accretion of interest on milestone liability

 

 

1,961

 

 

62

 

 

 —

Amortization of debt issuance costs

 

 

1,279

 

 

1,242

 

 

1,205

Total interest expense

 

$

10,428

 

$

8,491

 

$

8,372

 

XML 48 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2017
Stockholders’ Equity  
Component of Other Comprehensive Income (Loss)

 

The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign Currency

 

Unrealized

 

Total Accumulated

 

 

Translation Adjustments

 

(Losses) Gains

 

Other Comprehensive Loss

Balance at December 31, 2015

 

$

(47,077)

 

$

(383)

 

$

(47,460)

Other comprehensive income (loss)

 

 

(1,693)

   

 

224

   

 

(1,469)

Total before tax

 

 

(48,770)

 

 

(159)

 

 

(48,929)

Tax effect

 

 

1,336

 

 

13

 

 

1,349

Balance at December 31, 2016

 

 

(47,434)

 

 

(146)

 

 

(47,580)

Other comprehensive income (loss)

 

 

8,735

 

 

(110)

 

 

8,625

Total before tax

 

 

(38,699)

 

 

(256)

 

 

(38,955)

Tax effect

 

 

(3,218)

 

 

 —

 

 

(3,218)

Balance at December 31, 2017

 

$

(41,917)

 

$

(256)

 

$

(42,173)

 

XML 49 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2017
Share-Based Compensation  
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations

Share-based compensation expense for the years ended December 31, 2017, 2016 and 2015, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

 

2017

    

2016

    

2015

 

Research and development

 

$

20,335

 

$

27,558

 

$

27,321

 

Selling, general and administrative

 

 

24,372

 

 

12,238

 

 

13,036

 

Total share-based compensation expense

 

$

44,707

 

$

39,796

 

$

40,357

 

 

Summary of Stock Options Activity

 

The following table summarizes the activity relating to our options to purchase common stock:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

  

 

 

  

Weighted

  

 

 

 

 

 

 

 

Weighted

 

Average

 

Aggregate

 

 

 

 

 

Average

 

Remaining

 

Intrinsic

 

 

 

Number of

 

Exercise

 

Contractual

 

Value

 

 

 

Options

 

Price

 

Term (Years)

 

(Thousands)

 

Outstanding at December 31, 2016

 

5,520,482

 

$

42.00

 

  

 

 

  

 

Granted

 

1,048,700

 

 

66.09

 

  

 

 

  

 

Exercised

 

(465,690)

 

 

29.90

 

  

 

 

  

 

Forfeited

 

(313,757)

 

 

49.20

 

  

 

 

  

 

Outstanding at December 31, 2017 (a)

 

5,789,735

 

$

46.77

 

7.1

 

$

145,067

 

Vested and expected to vest at December 31, 2017

 

5,505,557

 

$

46.52

 

7.0

 

$

139,526

 

Vested and exercisable at December 31, 2017

 

3,481,931

 

$

44.60

 

6.1

 

$

95,463

 


(a)

Includes 33,750 performance-based stock options granted to our executives in the first quarter of 2015, which vested on approval by the FDA in December 19, 2016 to commercially distribute, sell or market Rubraca. Related stock compensation expense was recognized on that date.

Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award

The following table summarizes information about our stock options as of and for the years ended December 31, 2017, 2016 and 2015:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

 

2017

    

2016

    

2015

 

Weighted-average grant date fair value per share

 

$

48.79

 

$

16.62

 

$

52.70

 

Intrinsic value of options exercised

 

$

18,986,726

 

$

3,118,097

 

$

19,976,769

 

Cash received from stock option exercises

 

$

13,924,174

 

$

3,267,721

 

$

5,478,211

 

 

Weighted-Average Assumptions

The fair value of each share-based award is estimated on the grant date using the Black-Scholes option pricing model based upon the weighted-average assumptions provided in the following table:

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Dividend yield

 

 —

 

 —

 

 —

 

Volatility (a)

 

89

%  

93

%  

72

%

Risk-free interest rate (b)

 

2.16

%  

1.77

%  

1.77

%

Expected term (years) (c)

 

5.8

 

5.8

 

6.1

 

 


(a)

Volatility: The expected volatility was estimated using our historical data.

(b)

Risk-free interest rate: The rate is based on the yield on the grant date of a zero-coupon U.S. Treasury bond whose maturity period approximates the option’s expected term.

(c)

 Expected term: The expected term of the award was estimated using our historical data.

Summary of activity related to our unvested RSUs

The following table summarizes the activity related to our unvested RSUs:

 

 

 

 

 

 

 

 

    

 

    

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

Average

 

 

 

Number of

 

Grant Date

 

 

 

Units

 

Fair Value

 

Unvested at December 31, 2016

 

562,458

 

$

24.70

 

Granted

 

249,984

 

 

64.66

 

Vested

 

(180,912)

 

 

23.83

 

Forfeited

 

(42,001)

 

 

28.09

 

Unvested as of December 31, 2017

 

589,529

 

$

41.67

 

Expected to vest after December 31, 2017

 

513,069

 

$

41.40

 

 

Reserved Shares of Common Stock for Future Issuance

As of December 31, 2017, we reserved shares of common stock for future issuance as follows:

 

 

 

 

 

 

 

 

 

 

    

 

    

Available for

    

 

 

 

 

 

 

Grant

 

Total Shares of

 

 

 

Common Stock

 

or Future

 

Common Stock

 

 

 

Outstanding

 

Issuance

 

Reserved

 

2009 Equity Incentive Plan

 

331,213

 

 —

 

331,213

 

2011 Stock Incentive Plan

 

6,048,051

 

2,589,033

 

8,637,084

 

2011 Employee Stock Purchase Plan

 

 —

 

558,870

 

558,870

 

Total

 

6,379,264

 

3,147,903

 

9,527,167

 

 

Weighted-Average Assumptions Used to Estimate Fair Value of Purchase Awards Granted

The fair value of purchase awards granted to our employees during the years ended December 31, 2017, 2016 and 2015, respectively, was estimated using the Black-Scholes option pricing model based upon the weighted-average assumptions provided in the following table:

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Dividend yield

 

 —

 

 —

 

 —

 

Volatility (a)

 

79

%  

92

%  

71

%

Risk-free interest rate (b)

 

0.90

%  

0.40

%  

0.11

%

Expected term (years) (c)

 

0.5

 

0.5

 

0.5

 


(a)

Volatility: The expected volatility was estimated using our historical data.

(b)

Risk-free interest rate: The rate is based on the U.S. Treasury yield in effect at the time of grant with terms similar to the contractual term of the purchase right.

(c)

Expected term: The expected life of the award represents the six-month offering period for the Purchase Plan.

XML 50 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2017
Commitments and Contingencies  
Future Minimum Rental Commitments

Future minimum rental commitments, by fiscal year and in the aggregate, for our operating leases are provided below (in thousands):

 

 

 

 

 

 

 

    

December 31, 

 

 

 

2017

 

2018

 

$

3,050

 

2019

 

 

3,902

 

2020

 

 

3,744

 

2021

 

 

3,855

 

2022

 

 

2,519

 

Thereafter

 

 

11,563

 

Total future minimum lease payments

 

$

28,633

 

 

XML 51 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss Per Common Share (Tables)
12 Months Ended
Dec. 31, 2017
Net Loss Per Common Share  
Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share

The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

 

2017

    

2016

    

2015

 

Common shares under option

 

4,260

 

3,398

 

2,031

 

Convertible senior notes

 

4,646

 

4,646

 

4,646

 

Total potential dilutive shares

 

8,906

 

8,044

 

6,677

 

 

XML 52 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2017
Income Taxes  
Income (Loss) Before Income Taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Domestic

 

$

(351,338)

 

$

(277,776)

 

$

(290,342)

 

Foreign

 

 

1,363

  

 

(103,395)

 

 

(91,595)

  

Total loss before income taxes

 

$

(349,975)

 

$

(381,171)

 

$

(381,937)

 

 

Current and Deferred Tax (Benefit) Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

 

2015

 

Current tax:

 

 

 

  

 

 

 

 

 

 

U.S. Federal & State

 

$

 —

 

$

 —

 

$

 —

 

Foreign

 

 

(360)

  

 

64

 

 

 —

 

Total current (benefit) expense

 

 

(360)

 

 

64

 

 

 —

 

Deferred tax:

 

 

 

  

 

 

 

 

 

 

U.S. Federal & State

 

 

(3,218)

 

 

 —

 

 

 —

 

Foreign

 

 

 —

  

 

(32,098)

 

 

(29,076)

 

Total deferred (benefit)

 

 

(3,218)

 

 

(32,098)

 

 

(29,076)

 

Total income tax (benefit)

 

$

(3,578)

 

$

(32,034)

 

$

(29,076)

 

 

Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

2017

    

2016

    

2015

 

Federal income tax benefit at statutory rate

 

(34.0)

%  

(34.0)

%  

(34.0)

%

State income tax benefit, net of federal benefit

 

(3.2)

 

(3.6)

 

(3.0)

 

Tax credits

 

(1.2)

 

(10.8)

 

(13.6)

 

Limitation on future foreign tax credits

 

 —

 

(5.9)

 

(5.0)

 

Change in uncertain tax positions

 

0.2

 

4.2

 

 —

 

Other

 

(1.1)

 

2.3

 

0.4

 

Tax impact of Tax Cuts and Jobs Act of 2017

 

46.4

 

 —

 

 —

 

Change in valuation allowance

 

(8.1)

 

39.4

 

47.6

 

Effective income tax rate

 

(1.0)

%  

(8.4)

%  

(7.6)

%

 

Components of Deferred Tax Assets and Liabilities

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

    

2017

    

2016

 

Deferred tax assets:

 

 

   

  

 

 

  

Net operating loss carryforward

 

$

272,710

 

$

275,898

  

Tax credit carryforwards

 

 

222,150

 

 

217,948

  

Intangible assets

 

 

29,900

 

 

42,745

  

Share-based compensation expense

 

 

27,844

 

 

31,390

  

Foreign currency translation

 

 

3,012

 

 

10,510

  

Product acquisition costs

 

 

5,881

 

 

9,764

  

Accrued liabilities and other

 

 

3,879

 

 

5,384

  

Total deferred tax assets

 

 

565,376

 

 

593,639

  

Valuation allowance

 

 

(564,122)

 

 

(592,423)

  

Deferred tax assets, net of valuation allowance

 

 

1,254

 

 

1,216

  

Deferred tax liabilities:

 

 

 

 

 

 

  

Prepaid expenses and other

 

 

(1,254)

 

 

(1,216)

  

Total deferred tax liabilities

 

 

(1,254)

 

 

(1,216)

  

Net deferred tax liability

 

$

 —

 

$

 —

  

 

Schedule of Unrecognized tax benefits

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

    

 

2017

2016

 

Balance at beginning of year

 

$

24,075

 

$

 —

 

Additions related to prior periods tax positions

 

 

 —

 

 

17,844

 

Additions related to current period tax positions

 

 

437

 

 

6,231

 

Settlements with tax authorities

 

 

 —

 

 

 —

 

Expiration of statute of limitations

 

 

 —

 

 

 —

 

Balance at end of year

 

$

24,512

 

$

24,075

 

 

XML 53 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Quarterly Information (Unaudited) (Tables)
12 Months Ended
Dec. 31, 2017
Quarterly Information  
Results of Operations on Quarterly Basis

The results of operations on a quarterly basis for the years ended December 31, 2017 and 2016 were as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

March 31, 

  

June 30, 

  

September 30, 

  

December 31, 

  

March 31, 

  

June 30, 

  

September 30, 

  

December 31, 

 

 

 

2017

 

2017

 

2017

 

2017

 

2016

 

2016  (1)

 

2016

 

2016

 

Revenues:

 

 

`

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

Product revenue, net

 

$

7,045

 

$

14,620

 

$

16,806

 

$

17,040

 

$

 —

 

$

 —

 

$

 —

 

$

78

 

Operating expenses:

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

Cost of sales - product

 

 

1,163

 

 

2,730

 

 

3,026

 

 

3,332

 

 

 —

 

 

 —

 

 

 —

 

 

70

 

Cost of sales - intangible asset amortization

 

 

372

 

 

372

 

 

372

 

 

370

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

Research and development

 

 

32,447

 

 

33,108

 

 

38,924

 

 

38,019

 

 

74,608

 

 

67,729

 

 

54,338

 

 

54,454

 

Selling, general and administrative

 

 

29,224

 

 

36,149

 

 

35,011

 

 

38,523

 

 

9,827

 

 

9,552

 

 

9,162

 

 

12,190

 

Acquired in-process research and development

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

300

 

 

500

 

 

500

 

Impairment of intangible asset

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

104,517

 

 

 —

 

 

 —

 

Change in fair value of contingent purchase consideration

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

516

 

 

(25,452)

 

 

 —

 

 

 —

 

 Total expenses

 

 

63,206

 

 

72,359

 

 

77,333

 

 

80,244

 

 

84,951

 

 

156,646

 

 

64,000

 

 

67,214

 

Operating loss

 

 

(56,161)

 

 

(57,739)

 

 

(60,527)

 

 

(63,204)

 

 

(84,951)

 

 

(156,646)

 

 

(64,000)

 

 

(67,136)

 

Other income (expense):

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

Interest expense

 

 

(2,581)

 

 

(2,598)

 

 

(2,618)

 

 

(2,631)

 

 

(2,104)

 

 

(2,106)

 

 

(2,108)

 

 

(2,173)

 

Foreign currency gain (loss)

 

 

(159)

 

 

76

 

 

(44)

 

 

45

 

 

(551)

 

 

183

 

 

(66)

 

 

(146)

 

Legal settlement loss

 

 

 —

 

 

(117,000)

 

 

 —

 

 

11,523

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

Other income (expense)

 

 

354

 

 

594

 

 

1,291

 

 

1,404

 

 

25

 

 

196

 

 

252

 

 

160

 

Other income (expense), net

 

 

(2,386)

 

 

(118,928)

 

 

(1,371)

 

 

10,341

 

 

(2,630)

 

 

(1,727)

 

 

(1,922)

 

 

(2,159)

 

Loss before income taxes

 

 

(58,547)

 

 

(176,667)

 

 

(61,898)

 

 

(52,863)

 

 

(87,581)

 

 

(158,373)

 

 

(65,922)

 

 

(69,295)

 

Income tax (expense) benefit

 

 

83

 

 

1,281

 

 

1,234

 

 

980

 

 

4,181

 

 

29,059

 

 

227

 

 

(1,433)

 

Net loss

 

$

(58,464)

 

$

(175,386)

 

$

(60,664)

 

$

(51,883)

 

$

(83,400)

 

$

(129,314)

 

$

(65,695)

 

$

(70,728)

 

Basic and diluted net loss per common share

 

$

(1.33)

 

$

(3.88)

 

$

(1.24)

 

$

(1.04)

 

$

(2.17)

 

$

(3.37)

 

$

(1.70)

 

$

(1.83)

 

Basic and diluted weighted average common shares outstanding

 

 

44,039

 

 

45,176

 

 

48,917

 

 

49,973

 

 

38,360

 

 

38,389

 

 

38,538

 

 

38,624

 


(1)

In the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&D intangible asset related to our lucitanib product candidate.

 

XML 54 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Nature of Business (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Jun. 30, 2017
USD ($)
$ / shares
shares
Jan. 31, 2017
USD ($)
$ / shares
shares
Jul. 31, 2015
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
segment
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Nature of Business            
Number of operating segments | segment       1    
Issuance of common stock, net of issuance costs (in shares) | shares 3,920,454 5,750,000 4,054,487      
Sale of stock, price per share | $ / shares $ 88.00 $ 41.00 $ 78.00      
Proceeds from offering | $ $ 324,600 $ 221,200 $ 298,500 $ 545,838 $ 0 $ 298,509
Minimum estimated number of months operating plan funded       12 months    
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Product revenue from customers (Details) - Customer Concentration Risk - Sales Revenue, Net
12 Months Ended
Dec. 31, 2017
Customer A  
Concentration Risk [Line Items]  
Percentage of revenues 35.00%
Customer B  
Concentration Risk [Line Items]  
Percentage of revenues 27.00%
Customer C  
Concentration Risk [Line Items]  
Percentage of revenues 12.00%
Customer D  
Concentration Risk [Line Items]  
Percentage of revenues 10.00%
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)
12 Months Ended
Dec. 31, 2017
Computer Hardware and Software | Minimum  
Property, Plant and Equipment  
Property and equipment, estimated useful lives 3 years
Computer Hardware and Software | Maximum  
Property, Plant and Equipment  
Property and equipment, estimated useful lives 5 years
Leasehold Improvements  
Property, Plant and Equipment  
Property and equipment, estimated useful lives 6 years
Laboratory, Manufacturing and Office Equipment | Minimum  
Property, Plant and Equipment  
Property and equipment, estimated useful lives 5 years
Laboratory, Manufacturing and Office Equipment | Maximum  
Property, Plant and Equipment  
Property and equipment, estimated useful lives 7 years
Furniture and Fixtures  
Property, Plant and Equipment  
Property and equipment, estimated useful lives 10 years
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Summary of Significant Accounting Policies                        
Product revenue, net $ 17,040 $ 16,806 $ 14,620 $ 7,045 $ 78 $ 0 $ 0 $ 0   $ 55,511 $ 78 $ 0
Allowance for doubtful accounts 0       0         0 0  
Impairment of intangible asset 0 0 0 0 0 0 104,517 0   0 104,517 89,557
Intangible assets, net 19,561       21,047         19,561 21,047  
Change in fair value of contingent purchase consideration 0 $ 0 $ 0 $ 0 0 $ 0 (25,452) $ 516 $ 26,900 0 (24,936) $ (24,611)
Contingent purchase consideration 0           0     0    
Deposit on inventory $ 20,461       $ 0         $ 20,461 $ 0  
Total liabilities denominated in currencies other than functional currency                   1.00% 1.00%  
In Process Research and Development                        
Summary of Significant Accounting Policies                        
Impairment of intangible asset             104,500   $ 89,600 $ 0 $ 104,517  
Intangible assets, net             $ 0          
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Other Current Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Summary of Significant Accounting Policies    
Receivable from partners $ 9 $ 2,882
Prepaid insurance 1,926 1,234
Prepaid expenses - other 3,355 2,109
Receivable - other 2,023 364
Other 187 90
Total $ 7,500 $ 6,679
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Other Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Summary of Significant Accounting Policies    
Accrued personnel costs $ 13,889 $ 15,850
Accrued interest payable 2,096 2,096
Income tax payable 0 556
Accrued corporate legal fees and professional services 415 589
Accrued royalties 2,984 0
Accrued sales deductions 1,008 0
Payable to third party logistics provider 2,661 0
Accrued expenses - other 2,830 396
Total $ 25,883 $ 19,487
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Property, Plant and Equipment    
Property and equipment, gross $ 7,695 $ 7,097
Less: accumulated depreciation (3,688) (2,657)
Total property and equipment, net 4,007 4,440
Laboratory, Manufacturing and Office Equipment    
Property, Plant and Equipment    
Property and equipment, gross 2,853 2,555
Leasehold Improvements    
Property, Plant and Equipment    
Property and equipment, gross 2,285 2,276
Furniture and Fixtures    
Property, Plant and Equipment    
Property and equipment, gross 1,416 1,411
Computer Hardware and Software    
Property, Plant and Equipment    
Property and equipment, gross $ 1,141 $ 855
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Property and Equipment      
Depreciation expense on property and equipment $ 1.0 $ 1.1 $ 0.8
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Fair Value Measurements                        
Change In Fair Value of Contingent Purchase Consideration $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 25,452 $ (516) $ (26,900) $ 0 $ 24,936 $ 24,611
Contingent purchase consideration 0           $ 0     0    
Assets at fair value 532,669       252,358         532,669 252,358  
Money market                        
Fair Value Measurements                        
Assets at fair value 433,136       202,361         433,136 202,361  
U.S. treasury securities                        
Fair Value Measurements                        
Assets at fair value 99,533       49,997         99,533 49,997  
Fair Value, Inputs, Level 1                        
Fair Value Measurements                        
Assets at fair value 433,136       202,361         433,136 202,361  
Fair Value, Inputs, Level 1 | Money market                        
Fair Value Measurements                        
Assets at fair value 433,136       202,361         433,136 202,361  
Fair Value, Inputs, Level 1 | U.S. treasury securities                        
Fair Value Measurements                        
Assets at fair value 0       0         0 0  
Fair Value, Inputs, Level 2                        
Fair Value Measurements                        
Assets at fair value 99,533       49,997         99,533 49,997  
Fair Value, Inputs, Level 2 | Money market                        
Fair Value Measurements                        
Assets at fair value 0       0         0 0  
Fair Value, Inputs, Level 2 | U.S. treasury securities                        
Fair Value Measurements                        
Assets at fair value 99,533       49,997         99,533 49,997  
Fair Value, Inputs, Level 3                        
Fair Value Measurements                        
Assets at fair value 0       0         0 0  
Fair Value, Inputs, Level 3 | Money market                        
Fair Value Measurements                        
Assets at fair value 0       0         0 0  
Fair Value, Inputs, Level 3 | U.S. treasury securities                        
Fair Value Measurements                        
Assets at fair value $ 0       $ 0         $ 0 $ 0  
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Fair Value Measurements    
Liabilities at fair value $ 0  
Transfers between level 1 and level 2, assets 0  
Transfers between level 2 and level 1, assets 0  
Transfers between level 1 and level 2, liabilities 0  
Transfers between level 2 and level 1, liabilities 0  
Transfer of assets into level 3 0  
Transfer of assets out of level 3 0  
Transfer of liabilities into level 3 0  
Transfer of liabilities out of level 3 0  
Convertible senior notes 282,406 $ 281,126
Convertible Senior Notes    
Fair Value Measurements    
Convertible senior notes 282,400  
Convertible Senior Notes | Fair Value, Inputs, Level 2    
Fair Value Measurements    
Convertible senior notes, fair value $ 388,300  
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
Available-for-Sale Securities (Details)
$ in Thousands
Dec. 31, 2017
USD ($)
Available-for-Sale Securities  
Amortized Cost $ 99,650
Aggregate Fair Value 99,533
U.S. treasury securities  
Available-for-Sale Securities  
Amortized Cost 99,650
Gross Unrealized Gains 0
Gross Unrealized Losses (117)
Aggregate Fair Value $ 99,533
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
Available-for-Sale Securities - Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2017
USD ($)
Available-for-Sale Securities  
Maximum number of months available-for-sale securities in a continuous unrealized loss position 2 months
U.S. treasury securities  
Available-for-Sale Securities  
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Fair Value $ 99,533
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Gross Unrealized Losses $ (117)
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Details)
$ in Thousands
Dec. 31, 2017
USD ($)
Available-for-Sale Securities  
Amortized Cost, Due in one year or less $ 99,650
Amortized Cost, Due in one year to two years 0
Amortized Cost 99,650
Fair Value, Due in one year or less 99,533
Fair Value, Due in one year to two years 0
Aggregate Fair Value $ 99,533
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Inventories    
Work in process $ 24,721 $ 0
Finished goods 2,787 0
Total 27,508 0
Deposit on inventory $ 20,461 $ 0
Maximum number of months purchased inventory converted to finished goods 12 months  
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Goodwill - Capitalized Milestones (Details) - Licensing Agreements - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Finite Lived Intangible Assets [Line Items]    
Intangible asset - milestones $ 21,100 $ 21,100
Accumulated amortization (1,539) (53)
Total intangible asset, net $ 19,561 $ 21,047
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Goodwill - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Licensing Agreements    
Finite Lived Intangible Assets [Line Items]    
Amortization of Intangible Assets $ 1,500 $ 53
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Goodwill - Estimated Future Amortization (Details) - Licensing Agreements - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Finite Lived Intangible Assets    
2018 $ 1,486  
2019 1,486  
2020 1,486  
2021 1,486  
2022 1,486  
Thereafter 12,131  
Total intangible asset, net $ 19,561 $ 21,047
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Goodwill - Summary of Goodwill (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
IPR&D assets:                        
Impairment of intangible asset $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ (104,517) $ 0   $ 0 $ (104,517) $ (89,557)
Goodwill:                        
Balance at beginning of period       57,192           57,192    
Balance at end of period 65,217       57,192         65,217 57,192  
In Process Research and Development                        
IPR&D assets:                        
Balance at beginning of period       0       101,500   0 101,500  
Impairment of intangible asset             $ (104,500)   $ (89,600) 0 (104,517)  
Change in foreign currency gains and losses                   0 3,017  
Balance at end of period 0       0       101,500 0 0 101,500
Ethical Oncology Science, S.p.A.                        
Goodwill:                        
Balance at beginning of period       $ 57,192       $ 59,327   57,192 59,327  
Change in foreign currency gains and losses                   8,025 (2,135)  
Balance at end of period $ 65,217       $ 57,192       $ 59,327 $ 65,217 $ 57,192 $ 59,327
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Goodwill - Summary of IPR&D Assets and Goodwill (Parenthetical) (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Impairment of intangible asset $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 104,517,000 $ 0   $ 0 $ 104,517,000 $ 89,557,000
Ethical Oncology Science, S.p.A.                        
Impairment of goodwill                   0    
In Process Research and Development                        
Impairment of intangible asset             $ 104,500,000   $ 89,600,000 $ 0 $ 104,517,000  
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.8.0.1
Convertible Senior Notes (Details) - Convertible Senior Notes
$ / shares in Units, $ in Millions
12 Months Ended
Sep. 09, 2014
USD ($)
D
item
$ / shares
Dec. 31, 2017
USD ($)
item
Dec. 31, 2016
USD ($)
Debt Instrument      
Debt Instrument, Face Amount $ 287.5    
Convertible senior notes, interest rate 2.50%    
Net proceeds from convertible senior notes $ 278.3    
Convertible senior notes, maturity date   Sep. 15, 2021  
Common stock initial conversion rate per $1,000 in principal amount 16.1616    
Convertible senior notes, initial conversion price per share | $ / shares $ 61.88    
Debt instrument, redemption period start date   Sep. 15, 2018  
Last reported sale price of common stock 150.00%    
Debt instrument, conversion in effect for number of trading days | item 20    
Debt instrument conversion, consecutive trading day period | D 30    
Debt instrument, trading days preceding redemption notice, maximum | item   2  
Debt instrument redemption price percentage to principal amount 100.00%    
Debt instrument repurchase percentage   100.00%  
Debt issuance costs $ 9.2    
Debt instrument term   7 years  
Unamortized debt issuance costs   $ 5.1 $ 6.4
Semi Annual Payment, First payment date      
Debt Instrument      
Interest payment date on senior notes   --03-15  
Semi Annual Payment, Second payment date      
Debt Instrument      
Interest payment date on senior notes   --09-15  
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.8.0.1
Convertible Senior Notes - Schedule of Total Interest Expense Recognized Related to Notes (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Convertible Senior Notes                      
Contractual interest expense                 $ 7,188 $ 7,187 $ 7,167
Accretion of interest on milestone liability                 1,961 62 0
Amortization of debt issuance costs                 1,279 1,242 1,205
Total interest expense $ 2,631 $ 2,618 $ 2,598 $ 2,581 $ 2,173 $ 2,108 $ 2,106 $ 2,104 $ 10,428 $ 8,491 $ 8,372
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Jun. 30, 2017
USD ($)
$ / shares
shares
Jan. 31, 2017
USD ($)
$ / shares
shares
Jul. 31, 2015
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
Vote
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Stockholders’ Equity            
Common stock, shares issued | shares 3,920,454 5,750,000 4,054,487      
Sale of stock, price per share | $ / shares $ 88.00 $ 41.00 $ 78.00      
Proceeds from the sale of common stock, net of issuance costs | $ $ 324,600 $ 221,200 $ 298,500 $ 545,838 $ 0 $ 298,509
Number Of Vote Per Common Stock | Vote       1    
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity - Component of Other Comprehensive Income (Loss) (Details) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Accumulated Other Comprehensive Loss      
Beginning balance $ (47,580,000) $ (47,460,000)  
Other comprehensive income (loss) 8,625,000 (1,469,000)  
Total before tax (38,955,000) (48,929,000)  
Tax effect (3,218,000) 1,349,000  
Ending balance (42,173,000) (47,580,000) $ (47,460,000)
Reclassifications out of accumulated other comprehensive loss 0 0 0
Foreign Currency Translation Adjustments      
Accumulated Other Comprehensive Loss      
Beginning balance (47,434,000) (47,077,000)  
Other comprehensive income (loss) 8,735,000 (1,693,000)  
Total before tax (38,699,000) (48,770,000)  
Tax effect (3,218,000) 1,336,000  
Ending balance (41,917,000) (47,434,000) (47,077,000)
Unrealized (Losses) Gains      
Accumulated Other Comprehensive Loss      
Beginning balance (146,000) (383,000)  
Other comprehensive income (loss) (110,000) 224,000  
Total before tax (256,000) (159,000)  
Tax effect 0 13,000  
Ending balance $ (256,000) $ (146,000) $ (383,000)
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Aug. 31, 2011
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Share-based compensation expense, tax benefit recognized   $ 0 $ 0 $ 0
Closing Stock Price   $ 68.00    
Stock options vested   $ 36,000 40,800 36,500
Unrecognized stock-based compensation expense related to non-vested options and RSUs   $ 89,400    
Unrecognized stock-based compensation expense related to non-vested options and RSUs, weighted-average remaining vesting period   3 years 3 months 18 days    
Stock-based compensation expense   $ 44,707 $ 39,796 40,357
2009 Equity Incentive Plan        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Shares of common stock remaining for future grant   192,185    
2011 Stock Incentive Plan        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Common stock shares authorized   9,590,378    
Initial Reserve Common Stock Authorized   1,250,000    
Common stock additional shares authorized   8,148,193    
Stock options vesting period   4 years 4 years  
Percentage of grant vest contingent on approval   25.00%    
Stock options expiration period   10 years    
2011 Stock Incentive Plan | Vesting after year one        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Stock options vesting period     1 year  
Percentage of grant vest contingent on approval     50.00%  
2011 Stock Incentive Plan | Vesting after year two        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Stock options vesting period     2 years  
Percentage of grant vest contingent on approval     50.00%  
2011 Stock Incentive Plan | One year from date of grant        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Stock options vesting period     1 year  
Percentage of grant vest contingent on approval     25.00%  
2011 Stock Incentive Plan | End of the vesting period        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Stock options vesting period     3 years  
Percentage of grant vest contingent on approval     75.00%  
2011 Employee Stock Purchase Plan        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Increase in amount of shares reserved for issuance as percentage of outstanding shares of common stock 1.00%      
Increase in amount of shares reserved for issuance 344,828      
Employee stock purchase plan offering period 6 months      
Purchase plan participating employees compensation withheld and applied to purchase of common stock 10.00%      
Share based compensation arrangement by share based payment award purchase price of common stock percent 85.00%      
Purchase Plan termination date Aug. 24, 2021      
Common stock shares sold to employees   51,681 110,508  
Shares of common stock remaining for future grant   558,870    
weighted-average estimated grant date fair value of purchase awards under Purchase Plan   $ 23.08 $ 11.70  
Stock-based compensation expense   $ 1,000 $ 800 $ 900
Minimum | Board Of Directors | 2011 Stock Incentive Plan        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Stock options vesting period   1 year    
Maximum | Board Of Directors | 2011 Stock Incentive Plan        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Stock options vesting period   3 years    
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations      
Share-based compensation expense $ 44,707 $ 39,796 $ 40,357
Research and development      
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations      
Share-based compensation expense 20,335 27,558 27,321
Selling, general and administrative      
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations      
Share-based compensation expense $ 24,372 $ 12,238 $ 13,036
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation - Summary of Stock Options Activity (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2017
USD ($)
$ / shares
shares
Beginning Balance, Number of Options Outstanding | shares 5,520,482
Number of Options, Granted | shares 1,048,700
Number of Options, Exercised | shares (465,690)
Number of Options, Forfeited | shares (313,757)
Ending Balance, Number of Options Outstanding | shares 5,789,735
Number of Options, Vested and expected to vest at December 31,2017 | shares 5,505,557
Number of Options, Vested and exercisable at December 31, 2017 | shares 3,481,931
Beginning Balance, Weighted Average Exercise Price | $ / shares $ 42.00
Granted, Weighted Average Exercise Price | $ / shares 66.09
Exercised, Weighted Average Exercise Price | $ / shares 29.90
Forfeited, Weighted Average Exercise Price | $ / shares 49.20
Ending Balance, Weighted Average Exercise Price | $ / shares 46.77
Vested and expected to vest, Weighted Average Exercise Price | $ / shares 46.52
Vested and exercisable, Weighted Average Exercise Price | $ / shares $ 44.60
Outstanding, Weighted Average Remaining Contractual Term (Years) 7 years 1 month 6 days
Vested and expected to vest, Weighted Average Remaining Contractual Term (Years) 7 years
Exercisable, Weighted Average Remaining Contractual Term (Years) 6 years 1 month 6 days
Outstanding at December 31, 2017, Aggregate Intrinsic Value | $ $ 145,067
Vested and expected to vest at December 31, 2017, Aggregate Intrinsic Value | $ 139,526
Vested and exercisable at December 30, 2017, Aggregate Intrinsic Value | $ $ 95,463
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation - Summary of Stock Options Activity (Parenthetical) (Performance Shares) (Details) - shares
3 Months Ended 12 Months Ended
Mar. 31, 2015
Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Number of Options, Granted   1,048,700
Performance Shares | Executive Officer    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Number of Options, Granted 33,750  
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Share-Based Compensation      
Weighted-average grant date fair value per share $ 48.79 $ 16.62 $ 52.70
Intrinsic value of options exercised $ 18,986,726 $ 3,118,097 $ 19,976,769
Cash received from stock option exercises $ 13,924,174 $ 3,267,721 $ 5,478,211
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation - Weighted-Average Assumptions Used to Estimate Fair Value of Purchase Awards Granted (Details)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Dividend yield 0.00% 0.00% 0.00%
Volatility 89.00% 93.00% 72.00%
Risk-free interest rate 2.16% 1.77% 1.77%
Expected term (years) 5 years 9 months 18 days 5 years 9 months 18 days 6 years 1 month 6 days
Employee Stock Purchase Plans      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Dividend yield 0.00% 0.00% 0.00%
Volatility 79.00% 92.00% 71.00%
Risk-free interest rate 0.90% 0.40% 0.11%
Expected term (years) 6 months 6 months 6 months
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation - Summary of Activity Relating to Company's Unvested Restricted Stock Units (Details) - Restricted Stock Units (RSUs)
12 Months Ended
Dec. 31, 2017
$ / shares
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Unvested as of December 31, 2016 | shares 562,458
Number of Units, Granted | shares 249,984
Number of Units, Vested | shares (180,912)
Number of Units, Forfeited | shares (42,001)
Unvested as of December 31, 2017 | shares 589,529
Number of Units, Expected to vest after December 31, 2017 | shares 513,069
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares $ 24.70
Weighted Average Grant Date Fair Value, Granted | $ / shares 64.66
Weighted Average Grant Date Fair Value, Vested | $ / shares 23.83
Weighted Average Grant Date Fair Value, Forfeited | $ / shares 28.09
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares 41.67
Weighted Average Grant Date Fair Value, Expected to vest after December 31, 2017 | $ / shares $ 41.40
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation - Reserved Shares of Common Stock for Future Issuance (Details)
Dec. 31, 2017
shares
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations  
Common Stock Outstanding 6,379,264
Available for Grant or Future Issuance 3,147,903
Total Shares of Common Stock Reserved 9,527,167
2009 Equity Incentive Plan  
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations  
Common Stock Outstanding 331,213
Available for Grant or Future Issuance 0
Total Shares of Common Stock Reserved 331,213
2011 Stock Incentive Plan  
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations  
Common Stock Outstanding 6,048,051
Available for Grant or Future Issuance 2,589,033
Total Shares of Common Stock Reserved 8,637,084
2011 Employee Stock Purchase Plan  
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations  
Common Stock Outstanding 0
Available for Grant or Future Issuance 558,870
Total Shares of Common Stock Reserved 558,870
XML 85 R70.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue Recognition (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Revenue Recognition    
Retained earnings accumulated deficit $ (1,477,440) $ (1,131,043)
ASU 2014-09 | Revenue guidance effect before and after adopted ASC 606    
Revenue Recognition    
Retained earnings accumulated deficit $ 2,300  
XML 86 R71.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details)
1 Months Ended 12 Months Ended
Nov. 30, 2017
USD ($)
Mar. 31, 2017
shareholder
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Operating lease agreements expiration year     2028    
Operating lease term 10 years        
Leasehold improvement expenditures $ 2,500,000        
Rental expenses     $ 2,200,000 $ 2,200,000 $ 2,400,000
Purchase commitment     223,900,000    
Number of purported shareholders | shareholder   2      
Board Of Directors | Maximum          
Officers' Compensation     $ 425,000    
Number of years compensation agreement in place     5 years    
Board Of Directors | Minimum          
Officers' Compensation     $ 350,000    
Number of years compensation agreement in place     2 years    
New Directors | Maximum          
Officers' Compensation     $ 637,500    
New Directors | Minimum          
Officers' Compensation     $ 525,000    
XML 87 R72.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies - Future Minimum Rental Commitments (Details)
$ in Thousands
Dec. 31, 2017
USD ($)
Commitments and Contingencies  
2018 $ 3,050
2019 3,902
2020 3,744
2021 3,855
2022 2,519
Thereafter 11,563
Total future minimum lease payments $ 28,633
XML 88 R73.htm IDEA: XBRL DOCUMENT v3.8.0.1
License Agreements (Details)
$ in Thousands, € in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 19, 2016
USD ($)
item
Sep. 30, 2012
EUR (€)
Apr. 30, 2012
USD ($)
Jun. 30, 2011
USD ($)
May 31, 2010
USD ($)
Oct. 31, 2008
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Mar. 31, 2014
EUR (€)
Mar. 31, 2014
USD ($)
Mar. 31, 2012
USD ($)
Dec. 31, 2017
EUR (€)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2017
USD ($)
License Agreements                                            
Development cost receivable                     $ 2,882                 $ 2,882   $ 9
Research and development             $ 38,019 $ 38,924 $ 33,108 $ 32,447 54,454 $ 54,338 $ 67,729 $ 74,608         $ 142,498 251,129 $ 269,251  
Acquired in-process research and development             $ 0 $ 0 $ 0 0 500 500 300 $ 0         0 1,300 12,000  
License Agreements Lucitanib                                            
License Agreements                                            
Development cost receivable                     $ 1,300                 1,300   0
Research and development                                       7,700 13,700  
Research and development credit                                     (200)      
Reduction in research and development expense for reimbursable development costs due from Servier                                     1,000 $ 9,000 $ 11,800  
License Agreements Licensor Celgene Avilomics Research Inc | Name of drug product in licensed by the entity Rociletinib                                            
License Agreements                                            
Upfront payment         $ 2,000                                  
Annual sales target for sales milestone payments                                     500,000      
License Agreements Licensor Pfizer | Rucaparib                                            
License Agreements                                            
Milestone payments                   $ 750                        
Milestone payment due prior to deferment of milestone payment                                     20,000      
Deferred milestone payment                                     $ 23,000      
Maximum number of months after FDA approval                                   18 months 18 months      
License Agreements Licensor Pfizer | Rucaparib | Minimum                                            
License Agreements                                            
Minimum number of chemotherapies | item 2                                          
Annual sales target for sales milestone payments                                     $ 250,000      
License Agreements Licensor Pfizer | Rucaparib | Maximum                                            
License Agreements                                            
Maximum potential future development, regulatory milestone payments                                     69,750      
Additional maximum payments payable on attaining the sales target                                           170,000
License Agreements Licensor Astra Zeneca U K Ltd | Rucaparib                                            
License Agreements                                            
Upfront payment     $ 250                                      
Milestone payments $ 350                       $ 300                  
License Agreement Terms | License Agreements Lucitanib                                            
License Agreements                                            
Upfront payment | €   € 45.0                                        
Sublicense agreement consideration                               $ 13,600            
Payments received on milestone achievement | €                             € 10.0              
License Agreement Terms | License Agreements Lucitanib | Maximum                                            
License Agreements                                            
Additional maximum payments payable on attaining the sales target | €                                   € 250.0        
Initial global development costs reimbursable | €                                   80.0        
Additional payments receivable on milestone achievements | €                                   € 100.0        
License Agreement Terms | License Agreements Licensor Pfizer | Rucaparib                                            
License Agreements                                            
Upfront payment       $ 7,000                                    
Milestones paid to Pfizer prior to FDA approval       $ 1,400                                    
License Agreement Terms | Advenchen Laboratories LLC | License Agreements Lucitanib                                            
License Agreements                                            
Percentage of Non-Royalty Consideration Payable on Sublicense Agreements           25.00%                                
Acquired in-process research and development                               3,400            
Regulatory Milestone Payment | License Agreements Licensor Celgene Avilomics Research Inc | Name of drug product in licensed by the entity Rociletinib                                            
License Agreements                                            
Milestone payments                       $ 12,000       $ 5,000 $ 4,000          
Regulatory Milestone Payment | License Agreements Licensor Celgene Avilomics Research Inc | Name of drug product in licensed by the entity Rociletinib | Maximum                                            
License Agreements                                            
Maximum potential future development, regulatory milestone payments                                     $ 98,000      
Additional maximum payments payable on attaining the sales target                                           $ 120,000
XML 89 R74.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss Per Common Share (Details) - shares
shares in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share      
Total potential dilutive shares 8,906 8,044 6,677
Common shares under option      
Antidilutive Securities Excluded From Computation Of Earnings Per Share      
Total potential dilutive shares 4,260 3,398 2,031
Convertible senior notes      
Antidilutive Securities Excluded From Computation Of Earnings Per Share      
Total potential dilutive shares 4,646 4,646 4,646
XML 90 R75.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Taxes                      
Domestic                 $ (351,338) $ (277,776) $ (290,342)
Foreign                 1,363 (103,395) (91,595)
Loss before income taxes $ (52,863) $ (61,898) $ (176,667) $ (58,547) $ (69,295) $ (65,922) $ (158,373) $ (87,581) $ (349,975) $ (381,171) $ (381,937)
XML 91 R76.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes - Current and Deferred Tax (Benefit) Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Current tax:                      
U.S. Federal & State                 $ 0 $ 0 $ 0
Foreign                 (360) 64 0
Total current (benefit) expense                 (360) 64 0
Deferred tax:                      
U.S. Federal & State                 (3,218) 0 0
Foreign                 0 (32,098) (29,076)
Total deferred (benefit)                 (3,218) (32,098) (29,076)
Total income tax (benefit) $ (980) $ (1,234) $ (1,281) $ (83) $ 1,433 $ (227) $ (29,059) $ (4,181) $ (3,578) $ (32,034) $ (29,076)
XML 92 R77.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Taxes      
Federal income tax benefit at statutory rate (34.00%) (34.00%) (34.00%)
State income tax benefit, net of federal benefit (3.20%) (3.60%) (3.00%)
Tax credits (1.20%) (10.80%) (13.60%)
Limitation on future foreign tax credits (0.00%) (5.90%) (5.00%)
Change in uncertain tax positions 0.20% 4.20% 0.00%
Other (1.10%) 2.30% 0.40%
Tax impact of Tax Cuts and Jobs Act of 2017 46.40% 0.00% 0.00%
Change in valuation allowance (8.10%) 39.40% 47.60%
Effective income tax rate (1.00%) (8.40%) (7.60%)
XML 93 R78.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Deferred tax assets:    
Net operating loss carryforward $ 272,710 $ 275,898
Tax credit carryforwards 222,150 217,948
Intangible assets 29,900 42,745
Share-based compensation expense 27,844 31,390
Foreign currency translation 3,012 10,510
Product acquisition costs 5,881 9,764
Accrued liabilities and other 3,879 5,384
Total deferred tax assets 565,376 593,639
Valuation allowance (564,122) (592,423)
Deferred tax assets, net of valuation allowance 1,254 1,216
Deferred tax liabilities:    
Prepaid expenses and other (1,254) (1,216)
Total deferred tax liabilities (1,254) (1,216)
Net deferred tax liability $ 0 $ 0
XML 94 R79.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Taxes        
Income tax rate   34.00% 34.00% 34.00%
Provision for income tax   $ 162,200    
Increase (decrease) to valuation allowance   (28,300) $ 143,300  
Unrecognized tax benefits   24,512 $ 24,075 $ 0
Research and development and orphan drug tax credit carryforwards   245,100    
ASU 2016-09        
Income Taxes        
Excess tax benefits   18,200    
Forecast        
Income Taxes        
Income tax rate 21.00%      
U.S. federal        
Income Taxes        
Net operating loss carryforwards   1,000,000    
State        
Income Taxes        
Net operating loss carryforwards   1,200,000    
Foreign        
Income Taxes        
Net operating loss carryforwards   $ 400    
Minimum | U.S. federal        
Income Taxes        
Net operating loss carryforwards expiration year   2029    
Minimum | State        
Income Taxes        
Net operating loss carryforwards expiration year   2024    
Maximum        
Income Taxes        
Income tax rate   35.00%    
Maximum | U.S. federal        
Income Taxes        
Net operating loss carryforwards expiration year   2037    
Maximum | State        
Income Taxes        
Net operating loss carryforwards expiration year   2037    
XML 95 R80.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns    
Balance at beginning of year $ 24,075 $ 0
Additions related to prior periods tax positions   17,844
Additions related to current period tax positions 437 6,231
Settlements with tax authorities   0
Expiration of statute of limitations   0
Balance at end of year $ 24,512 $ 24,075
XML 96 R81.htm IDEA: XBRL DOCUMENT v3.8.0.1
Employee Benefit Plans - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Employee Benefit Plans      
Defined contribution plan, employer's contribution percentage 4.00%    
UNITED STATES      
Employee Benefit Plans      
Matching contributions to employees $ 1.9 $ 1.6 $ 0.8
Foreign Defined Contribution Plan      
Employee Benefit Plans      
Matching contributions to employees $ 0.3 $ 0.2 $ 0.2
XML 97 R82.htm IDEA: XBRL DOCUMENT v3.8.0.1
Quarterly Information (Unaudited) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Revenues:                        
Product revenue, net $ 17,040 $ 16,806 $ 14,620 $ 7,045 $ 78 $ 0 $ 0 $ 0   $ 55,511 $ 78 $ 0
Operating expenses:                        
Cost of sales - product 3,332 3,026 2,730 1,163 70 0 0 0   10,251 70 0
Cost of sales - intangible asset amortization 370 372 372 372 0 0 0 0   1,486 0 0
Research and development 38,019 38,924 33,108 32,447 54,454 54,338 67,729 74,608   142,498 251,129 269,251
Selling, general and administrative 38,523 35,011 36,149 29,224 12,190 9,162 9,552 9,827   138,907 40,731 30,524
Acquired in-process research and development 0 0 0 0 500 500 300 0   0 1,300 12,000
Impairment of intangible asset 0 0 0 0 0 0 104,517 0   0 104,517 89,557
Change in fair value of contingent purchase consideration 0 0 0 0 0 0 (25,452) 516 $ 26,900 0 (24,936) (24,611)
Total expenses 80,244 77,333 72,359 63,206 67,214 64,000 156,646 84,951   293,142 372,811 376,721
Operating loss (63,204) (60,527) (57,739) (56,161) (67,136) (64,000) (156,646) (84,951)   (237,631) (372,733) (376,721)
Other income (expense):                        
Interest expense (2,631) (2,618) (2,598) (2,581) (2,173) (2,108) (2,106) (2,104)   (10,428) (8,491) (8,372)
Foreign currency gain (loss) 45 (44) 76 (159) (146) (66) 183 (551)   (82) (580) 2,740
Legal settlement loss 11,523 0 (117,000) 0 0 0 0 0   (105,477) 0 0
Other income (expense) 1,404 1,291 594 354 160 252 196 25   3,643 633 416
Other income (expense), net 10,341 (1,371) (118,928) (2,386) (2,159) (1,922) (1,727) (2,630)   (112,344) (8,438) (5,216)
Loss before income taxes (52,863) (61,898) (176,667) (58,547) (69,295) (65,922) (158,373) (87,581)   (349,975) (381,171) (381,937)
Income tax (expense) benefit 980 1,234 1,281 83 (1,433) 227 29,059 4,181   3,578 32,034 29,076
Net loss $ (51,883) $ (60,664) $ (175,386) $ (58,464) $ (70,728) $ (65,695) $ (129,314) $ (83,400)   $ (346,397) $ (349,137) $ (352,861)
Basic and diluted net loss per common share $ (1.04) $ (1.24) $ (3.88) $ (1.33) $ (1.83) $ (1.70) $ (3.37) $ (2.17)   $ (7.36) $ (9.07) $ (9.79)
Basic and diluted weighted average common shares outstanding 49,973 48,917 45,176 44,039 38,624 38,538 38,389 38,360   47,047 38,478 36,026
EXCEL 98 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end

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end XML 99 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 100 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 102 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 217 412 1 false 65 0 false 10 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.clovisoncology.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.clovisoncology.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 2 false false R3.htm 00200 - Statement - Consolidated Balance Sheets Sheet http://www.clovisoncology.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 00205 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.clovisoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 00300 - Statement - Consolidated Statements of Stockholders??? Equity (Deficit) Sheet http://www.clovisoncology.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders??? Equity (Deficit) Statements 5 false false R6.htm 00305 - Statement - Consolidated Statements of Stockholders??? Equity (Deficit) (Parenthetical) Sheet http://www.clovisoncology.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical Consolidated Statements of Stockholders??? Equity (Deficit) (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - Consolidated Statements of Cash Flows Sheet http://www.clovisoncology.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Nature of Business Sheet http://www.clovisoncology.com/role/DisclosureNatureOfBusiness Nature of Business Notes 8 false false R9.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10301 - Disclosure - Property and Equipment Sheet http://www.clovisoncology.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 10 false false R11.htm 10401 - Disclosure - Fair Value Measurements Sheet http://www.clovisoncology.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 10501 - Disclosure - Available-for-Sale Securities Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecurities Available-for-Sale Securities Notes 12 false false R13.htm 10601 - Disclosure - Inventories Sheet http://www.clovisoncology.com/role/DisclosureInventories Inventories Notes 13 false false R14.htm 10701 - Disclosure - Intangible Assets and Goodwill Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 14 false false R15.htm 10801 - Disclosure - Convertible Senior Notes Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotes Convertible Senior Notes Notes 15 false false R16.htm 10901 - Disclosure - Stockholders' Equity Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 11001 - Disclosure - Share-Based Compensation Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensation Share-Based Compensation Notes 17 false false R18.htm 11101 - Disclosure - Revenue Recognition Sheet http://www.clovisoncology.com/role/DisclosureRevenueRecognition Revenue Recognition Notes 18 false false R19.htm 11201 - Disclosure - Commitments and Contingencies Sheet http://www.clovisoncology.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 11301 - Disclosure - License Agreements Sheet http://www.clovisoncology.com/role/DisclosureLicenseAgreements License Agreements Notes 20 false false R21.htm 11401 - Disclosure - Net Loss Per Common Share Sheet http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShare Net Loss Per Common Share Notes 21 false false R22.htm 11501 - Disclosure - Income Taxes Sheet http://www.clovisoncology.com/role/DisclosureIncomeTaxes Income Taxes Notes 22 false false R23.htm 11601 - Disclosure - Employee Benefit Plans Sheet http://www.clovisoncology.com/role/DisclosureEmployeeBenefitPlans Employee Benefit Plans Notes 23 false false R24.htm 11701 - Disclosure - Quarterly Information (Unaudited) Sheet http://www.clovisoncology.com/role/DisclosureQuarterlyInformationUnaudited Quarterly Information (Unaudited) Notes 24 false false R25.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies 25 false false R26.htm 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies 26 false false R27.htm 30303 - Disclosure - Property and Equipment (Tables) Sheet http://www.clovisoncology.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.clovisoncology.com/role/DisclosurePropertyAndEquipment 27 false false R28.htm 30403 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.clovisoncology.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.clovisoncology.com/role/DisclosureFairValueMeasurements 28 false false R29.htm 30503 - Disclosure - Available-for-Sale Securities (Tables) Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesTables Available-for-Sale Securities (Tables) Tables http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecurities 29 false false R30.htm 30603 - Disclosure - Inventories (Tables) Sheet http://www.clovisoncology.com/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.clovisoncology.com/role/DisclosureInventories 30 false false R31.htm 30703 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwill 31 false false R32.htm 30803 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotesTables Convertible Senior Notes (Tables) Tables http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotes 32 false false R33.htm 30903 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.clovisoncology.com/role/DisclosureStockholdersEquity 33 false false R34.htm 31003 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.clovisoncology.com/role/DisclosureShareBasedCompensation 34 false false R35.htm 31203 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.clovisoncology.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.clovisoncology.com/role/DisclosureCommitmentsAndContingencies 35 false false R36.htm 31403 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShare 36 false false R37.htm 31503 - Disclosure - Income Taxes (Tables) Sheet http://www.clovisoncology.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.clovisoncology.com/role/DisclosureIncomeTaxes 37 false false R38.htm 31703 - Disclosure - Quarterly Information (Unaudited) (Tables) Sheet http://www.clovisoncology.com/role/DisclosureQuarterlyInformationUnauditedTables Quarterly Information (Unaudited) (Tables) Tables http://www.clovisoncology.com/role/DisclosureQuarterlyInformationUnaudited 38 false false R39.htm 40101 - Disclosure - Nature of Business (Details) Sheet http://www.clovisoncology.com/role/DisclosureNatureOfBusinessDetails Nature of Business (Details) Details http://www.clovisoncology.com/role/DisclosureNatureOfBusiness 39 false false R40.htm 40201 - Disclosure - Summary of Significant Accounting Policies - Product revenue from customers (Details) Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesProductRevenueFromCustomersDetails Summary of Significant Accounting Policies - Product revenue from customers (Details) Details 40 false false R41.htm 40202 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details) Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyAndEquipmentDetails Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details) Details 41 false false R42.htm 40203 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 42 false false R43.htm 40204 - Disclosure - Summary of Significant Accounting Policies - Other Current Assets (Details) Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherCurrentAssetsDetails Summary of Significant Accounting Policies - Other Current Assets (Details) Details 43 false false R44.htm 40205 - Disclosure - Summary of Significant Accounting Policies - Other Accrued Expenses (Details) Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails Summary of Significant Accounting Policies - Other Accrued Expenses (Details) Details 44 false false R45.htm 40301 - Disclosure - Property and Equipment (Details) Sheet http://www.clovisoncology.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.clovisoncology.com/role/DisclosurePropertyAndEquipmentTables 45 false false R46.htm 40302 - Disclosure - Property and Equipment - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails Property and Equipment - Additional Information (Details) Details 46 false false R47.htm 40401 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.clovisoncology.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 47 false false R48.htm 40402 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 48 false false R49.htm 40501 - Disclosure - Available-for-Sale Securities (Details) Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesDetails Available-for-Sale Securities (Details) Details http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesTables 49 false false R50.htm 40502 - Disclosure - Available-for-Sale Securities - Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Details) Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOfAvailableForSaleSecuritiesInContinuousUnrealizedLossPositionDetails Available-for-Sale Securities - Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Details) Details 50 false false R51.htm 40503 - Disclosure - Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Details) Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetails Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Details) Details 51 false false R52.htm 40601 - Disclosure - Inventories (Details) Sheet http://www.clovisoncology.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://www.clovisoncology.com/role/DisclosureInventoriesTables 52 false false R53.htm 40701 - Disclosure - Intangible Assets and Goodwill - Capitalized Milestones (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillCapitalizedMilestonesDetails Intangible Assets and Goodwill - Capitalized Milestones (Details) Details 53 false false R54.htm 40702 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails Intangible Assets and Goodwill - Additional Information (Details) Details 54 false false R55.htm 40703 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillEstimatedFutureAmortizationDetails Intangible Assets and Goodwill - Estimated Future Amortization (Details) Details 55 false false R56.htm 40704 - Disclosure - Intangible Assets and Goodwill - Summary of Goodwill (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfGoodwillDetails Intangible Assets and Goodwill - Summary of Goodwill (Details) Details 56 false false R57.htm 40705 - Disclosure - Intangible Assets and Goodwill - Summary of IPR&D Assets and Goodwill (Parenthetical) (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfIprDAssetsAndGoodwillParentheticalDetails Intangible Assets and Goodwill - Summary of IPR&D Assets and Goodwill (Parenthetical) (Details) Details 57 false false R58.htm 40801 - Disclosure - Convertible Senior Notes (Details) Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotesDetails Convertible Senior Notes (Details) Details http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotesTables 58 false false R59.htm 40802 - Disclosure - Convertible Senior Notes - Schedule of Total Interest Expense Recognized Related to Notes (Details) Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotesScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails Convertible Senior Notes - Schedule of Total Interest Expense Recognized Related to Notes (Details) Details 59 false false R60.htm 40901 - Disclosure - Stockholders' Equity (Details) Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) Details http://www.clovisoncology.com/role/DisclosureStockholdersEquityTables 60 false false R61.htm 40902 - Disclosure - Stockholders' Equity - Component of Other Comprehensive Income (Loss) (Details) Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquityComponentOfOtherComprehensiveIncomeLossDetails Stockholders' Equity - Component of Other Comprehensive Income (Loss) (Details) Details 61 false false R62.htm 41001 - Disclosure - Share-Based Compensation - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails Share-Based Compensation - Additional Information (Details) Details 62 false false R63.htm 41002 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseRecognizedInAccompanyingStatementsOfOperationsDetails Share-Based Compensation - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Details) Details 63 false false R64.htm 41003 - Disclosure - Share-Based Compensation - Summary of Stock Options Activity (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationSummaryOfStockOptionsActivityDetails Share-Based Compensation - Summary of Stock Options Activity (Details) Details 64 false false R65.htm 41004 - Disclosure - Share-Based Compensation - Summary of Stock Options Activity (Parenthetical) (Performance Shares) (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationSummaryOfStockOptionsActivityParentheticalPerformanceSharesDetails Share-Based Compensation - Summary of Stock Options Activity (Parenthetical) (Performance Shares) (Details) Details 65 false false R66.htm 41005 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) Details 66 false false R67.htm 41006 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions Used to Estimate Fair Value of Purchase Awards Granted (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfPurchaseAwardsGrantedDetails Share-Based Compensation - Weighted-Average Assumptions Used to Estimate Fair Value of Purchase Awards Granted (Details) Details 67 false false R68.htm 41007 - Disclosure - Share-Based Compensation - Summary of Activity Relating to Company's Unvested Restricted Stock Units (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationSummaryOfActivityRelatingToCompanySUnvestedRestrictedStockUnitsDetails Share-Based Compensation - Summary of Activity Relating to Company's Unvested Restricted Stock Units (Details) Details 68 false false R69.htm 41008 - Disclosure - Share-Based Compensation - Reserved Shares of Common Stock for Future Issuance (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationReservedSharesOfCommonStockForFutureIssuanceDetails Share-Based Compensation - Reserved Shares of Common Stock for Future Issuance (Details) Details 69 false false R70.htm 41101 - Disclosure - Revenue Recognition (Details) Sheet http://www.clovisoncology.com/role/DisclosureRevenueRecognitionDetails Revenue Recognition (Details) Details http://www.clovisoncology.com/role/DisclosureRevenueRecognition 70 false false R71.htm 41201 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.clovisoncology.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.clovisoncology.com/role/DisclosureCommitmentsAndContingenciesTables 71 false false R72.htm 41202 - Disclosure - Commitments and Contingencies - Future Minimum Rental Commitments (Details) Sheet http://www.clovisoncology.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalCommitmentsDetails Commitments and Contingencies - Future Minimum Rental Commitments (Details) Details 72 false false R73.htm 41301 - Disclosure - License Agreements (Details) Sheet http://www.clovisoncology.com/role/DisclosureLicenseAgreementsDetails License Agreements (Details) Details http://www.clovisoncology.com/role/DisclosureLicenseAgreements 73 false false R74.htm 41401 - Disclosure - Net Loss Per Common Share (Details) Sheet http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShareDetails Net Loss Per Common Share (Details) Details http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShareTables 74 false false R75.htm 41501 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details) Sheet http://www.clovisoncology.com/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxesDetails Income Taxes - Income (Loss) Before Income Taxes (Details) Details 75 false false R76.htm 41502 - Disclosure - Income Taxes - Current and Deferred Tax (Benefit) Expenses (Details) Sheet http://www.clovisoncology.com/role/DisclosureIncomeTaxesCurrentAndDeferredTaxBenefitExpensesDetails Income Taxes - Current and Deferred Tax (Benefit) Expenses (Details) Details 76 false false R77.htm 41503 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) Sheet http://www.clovisoncology.com/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) Details 77 false false R78.htm 41504 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) Sheet http://www.clovisoncology.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) Details 78 false false R79.htm 41505 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 79 false false R80.htm 41506 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) Sheet http://www.clovisoncology.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes - Unrecognized Tax Benefits (Details) Details 80 false false R81.htm 41601 - Disclosure - Employee Benefit Plans - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails Employee Benefit Plans - Additional Information (Details) Details 81 false false R82.htm 41701 - Disclosure - Quarterly Information (Unaudited) (Details) Sheet http://www.clovisoncology.com/role/DisclosureQuarterlyInformationUnauditedDetails Quarterly Information (Unaudited) (Details) Details http://www.clovisoncology.com/role/DisclosureQuarterlyInformationUnauditedTables 82 false false All Reports Book All Reports clvs-20171231.xml clvs-20171231.xsd clvs-20171231_cal.xml clvs-20171231_def.xml clvs-20171231_lab.xml clvs-20171231_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 104 0001558370-18-001172-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-18-001172-xbrl.zip M4$L#!!0 ( #6"6TR(*4-C2PH" )O*+P 1 8VQVW$?L?^#R]&]T1LDKWX3XV5#YZ/>,J.VS7S)O]4@&1D(1I MBE2#I&WMKW^9 $^)NB^20LQTMR61 /(^ &3^\E\?8U-[H]QAMO7K1;5>MBU-#%,K5\-?KOV1;.M* MJWVJM3_5*M6.5K^J-*[J=>WIBWSPH\]-#=9K.;]>C%QWQF_+MM\ M""]5ZI^8Y;C$TNF%?/+*9-8?2Q['G_NPKN#QC[GGW^OBZ6JWV_TD?@T?A8$, M%CX;'[?U2?X8/*J;;\DUZZ;]QAP;,&W:PVE9M\<(#=^#G1JW:7@:J M?")X :@U)&02OC @3E\\[/\@9KBL5"^C.7 \M@$R#3H#KT/U\M!^^P0_X/"- MF>$=EH9*&+KZZ?]]>7C11W1,+F5.)_37"X>-)R8.+[X;<3KX]0(IM%SOC\.OE=KW^O5[S!,Z[N/Y.\/MC5T*1_?T+[["M/W M/I@3_@@#@ZRYK&]2_/T+'?$XJ W_1 M5VD07?P6_)H*TB^?4D>/UO,IN:!?/B5@_V5".;.-&"8$B[B_(:8OJS6@^B^? M@N^"$6+O_/+))]4\W6X\3I"FWZO?!>&:WU_MB(S-D%(O+B@D7.'MGQXL[-H> M3VP+/CHS]!R/;>O%M?4_\D'+I6#%B3H#U[X)"J3C[@VL!4G:1$%&:*-OPP>I M942/^90/OMN,\C,2V]Z0U,_4)'-#\9;2RR?4RSMZ5SO24NGEPE)6Z>6CZ^7]4GS3T$CIY7W2LGE26BJ] M7%C**KU\=+V\7XHWE%X^H5YNG)262B\7EK)*+Q]=+^^'XD'BZN"$V2A#(W;* M=H.L';@868*L>5EI[WLWJ#[G2_7>"3?F-O.>*!_8?(Q;ER\CPJEO;<+?7YEK MTL?!O66P-V9XQ$R\??M!=<\%[GX<#)A.>3[$.8&)2'P7H&*5L&XRTJIV,=[\K@^(@Y],HF5$Z=O MAMD0IJM5,!V4XNWU*-[>;:-REN*M!,5;BN)'I'AK/8JW]DOQ18<2%,4SI-7W M>1AAD5!'0;OC1''4 M4%_).*:D60WH0&>WV'OZ>W)GVCUDRX\$RL89)9OC"+C;WQ1F'%#>-4 M=^V,70"[T>,89*T4Y*S@^20#R4YIY"<.-Z5Y&15 M<1I3K;0/S]//%*1@3/@? M20M+3.H\(XX\^I6Z,WHL99CYN]V>X]IC/+HT\VP^>&D5IF*6,@U5^]1J2[ = MNZ*\'-T%R 4LO K9,_X%P./BG3N;?Z7O/5V410!+\,1M"_[4Q9&[N2.%_D,O M+K$,, C.MXD!R\*C;Y7N#,??6\QEQ.Q-$'L"MT]BT=?RF![HEMO!@.HN&A5' M'-"<2:;"KQSXAWZF[CNEEL\OOWO,P%-"]Y9\_3,=V)SV+*,W<"E_M2=,;U5: M^9"8C/UW7@U %(8Y7$.(T/D0C?OBS(;W$ M!P;&Q:&](:=2EN47-G>2WF3/>$-C2:T'TK=A6)LSZCP\7/M:-7VLY$F>^:D\ M0"NQ6']VNXLZE'!]!))V Y)HVA-\O,$T1JB]$'S&+\FG\NV15^,+8;9PBG9;/"LTK,KO8('2APZLDWC?CSA]IL,6@K$ MB&%TLQA.Q1FIG''G<8NYGA#;._:!?Q61,1:#60"^6+BYL*? H5"#E)DR=]OE3OQZ M>#MBI!TKUY.=\GBSY6S:ZQ4I:Q\ARZB*7V:J^&4&\M&[';=4G'(*3LE6433% M*=GEE!-W=I-POI*/GN>.; ZK3M[Y052";_I@Z\3\J\>98S#1\#$?G) .7>R> MSG+P=S:G;&A=RQ:AQ2!B&DS%H]P-_.BX3"\4Z5*!RB[MUO7A=ZM3 M)U(A=Q[F?/)5<"L#=>)$;B4-=P6,"S;@O@UJO16*^XY<:TUQGVJQ<[06.QG@ M@=TR$XH'5,Y!\4 >LPD1#R2,036K>T#5-75C=8<](#^NRPX.DF&/!&V7D#78 MX8O4_!TX]RY]8&_4N+=@W"'KF[3G.-1U/D^_D'_9_-HD3E+@[ZTG;NO4<=(O MX.9#_C< /-(&:T%^T%U??X]SSWD+Q05YXH)#G<-37) G+CA4WVO%!7GB@AV[ M[*Z;$5!,D7FF.&4NH1'+)2@?,^_, UYF8ZTDQ%X/W"U*1"GNR1WW'#6%55F> MPU+LDR_V 8>FRPH#I'C@%#QP'#.R,".FB'XDHA\AKZ5H>7Q: M'BH[I6AY?%KNF&/:ZZZ#+-**S4#""K/Y(.Y6[OA":'.HA16ULTCM/;<)[R1\ MZ,[\29(7 )' R,D;"OZ7> I<)TY. NQ4F&+W$E*!.JC/W%G/9^YDX@QKULFK MZBG&3W@Q+E@=+\6_3&PL0(_W;>8:HOCW./"QG%!Y%6AS=U0BV!0'Q#A E]<_ MOG][*0#)?6"NOKT4D,:+\EQ*RH\OY=EJ'ZBDO#@T7K0?IJ3\^%)^[!/=NW* MDO*LTGAQ+HTP_G=B>O3S-/SSOP'-N(<[?< =W*1L!\_<6Q//=<0#M9F[A0^V M-70I']_0OCO?!M2VWBAW,:V!O^=#0:R'I)B66(RE?=Y$3$-TO"=="J:SF_\+ MM5 7_E?SV\V%?Q>7MS) Q-FN8EWX_QI=Q>1CN^@C1=XCRVA(M3WOR"BZY4.W MYJ8=>"SUBWL>_L-.K%RH_U4^N&D58@O6/7R3]V]:+ M:^M_Y(/KUZS@,P=7=N/[A675TZ) MX_'8 _D0S#4AC41T,:A%=FX50V2 (8Y06C]V=D/DJGG@UD6 MHFL?[+'E0K8^;\<^WA/833<:W:M[>X/DX<\7U MH]:][]:#]1C,]%SV1B//XO9#-SV#&G?<'N.-3<\5@ST.;@FWF#5TGBA_&1&. MABYU@ 2OW(XGICVE5-SN?)S@2/G@E ,B)V*OA=@IP*VZ+''A3"W&O,4(1^'% M%3@J($?$T>C%;#3.47LP&+YY2+V:KO8?2BZ?FQ=/HQ6RU&%%Z M,1N\>$J]>!J.7!3!J.ZSF>D^F^&H0G%)-KGD-#[6(EUR;^GVF(:%TU*;I[U0 MTP0L_4XMRHG9LXR>,09\.Z+8Z1N]_9@ &O-BJY8 '"LMNPG$!=0INW#+,W4H MIK8OK8GHB*?1%F!>&0-.,^(,[!EW5FMBY>9\\$,<.+_D\@;0%9 +%OD5EF3[%B3;'&&LB:GL2:GX8)%/L5Z/0]ZAL%P-&(^$6;<6]=D MPEQBYH,7UNQ_L!3&,_(O%$>68TN0:__(< M%U\N%B^L!6QN*L#L0.NOU/UF<4I,]K^XK?1&)0)^)\QZL)VCY5[< MBZ!%93M+&J>]6XM*"5GM>TTP:2=+D'4N*[7+VO[#_]X[X48H=K$=(9HK;*+\PN9.]; M!9_VP^\]/!?P/]2B.OGVMP?74)R_+N>G8^X\9$#X3=7N6OMT^-B.,M".[=QV M@X;@>Q* :VH.@8B]-V;:8Z8[P=&(>TM?*@M/9(K_38K$,QUB+&WSZ1=F@I6% MB-M_;B>YLG48S64Y=?4.AG6>/0V_/MM;;G*UT1 M>^PH]HV8V+?V+/;*[BF[MY4 --83@-8^!, /=!KQ0*>A[%Y1)4O9O8S:O<9Z M(5]C7R&?%/M:7.QK2NR5V"NQ/ZK8U]83^]I^Q7[V!JW:'SKR_E &[\\J'C@E M#V3C5+KB@5/RP+'OJE0$$U0Z@@DJD@G@TT9.8,]XHQ90TWH@?9NC06?4>7BX MWL4YF\'YBIMS/%X"]3\J\>98S ]JM(822_2(-GT!'SLL3?.MLPE M[[S.8B%V)7HY&O;*Y0$F8VU6XJ@LH+-Z?-XD'XHW]\2;<50JW@Q^OH$?'9?I MU[8'-FEZ7MHR%7BE(W/!AT72C"?APS/5ARM46OCM*W--^CBXMPSVQ@R/)!LQ MW3!.=8AE\L%_NZJA3>9*Q5N,U1.(.V^^BTO@V?#=)FI'\=T:?%=/.R-^\FL, MLQBI%^<@\=X/SN?=W3[G _:YB0:.?)#Y@%N\&YM4E;'/7(;\B(Y!,;+Q&?-F MUZLT %^/;4MSG*)7Y4=G.,[**5;SANEHI5/=T$;8IE4(%E4+3 MC[4J)[X1IVZQ;8;&<[DU5KFL--<0#?'8KA7K.[XL5%4OD^/W,HE5-@,]U]EW M9;.5^T,9\G[4#FVA?19U7E.Y&AD2..5J*-G(1&&*O)_$SK\\%KZ Q:YV^LS. ML^?04SXC17&6GO*926!TUB5H'./_I.E[D8=;PB=L6_*E+6XW)/[).$O/!"QZQG61X>,Q.>W0N%X8VDEQ_NI]G6T*5\ MC(/-;;9=V]8;Y2[KFQ1_SP?_S*/%YZ)U\+)/BY>&VOB1T!3<%DF%[8M[[QAW M7,6\J]&B>/=8O%L\OCM/>B]L>#3O8 G7XQZ\4X#AK3B>U3I@9;?MT0;TDR?S M4R#]'\KMK\RBN27AFI 5@XHJS,DZ-6?K-,X:T:Q=-%^G9-W>_(IV#"7=S/1& MG+6\ZS0R:>_W4'<[?J8U>QA9YY1O>[^=+3)>GN&H?=XJJ:6?LX63UGJ:9%^5 MD%/[?F4-(Z=OB90YC)R@1TXKKDFRAY'UZH?O5Y/,%!#/%DZ:ZVF2'>MIK]DX M79U5.9LM:'56Y3S/JAPPDE=G3K(L\.K,2=XE2=7!.K?* :H.UE'E,*>'*O,E M3^=AN'*P'[KGDEZZ[HW1@:?&*^@,QQ1C1R< L\VJF];V6@M8Q2.+>>0K=;]9 MG!(39-NXM]ZH1-SOA%D/MI-Q1V%[;ED+[ +RS6P?1Z5;LJQ;3M/G<6\\HG3+ MB73+3[_8(F TV_?Q$!K'32V.CFDV3.2V4)))GK_9@LEAVN%^W\O M+[]9S-5>J.B =WDIO_;P.T03_EBM5D)TC"EQ/$YEZ.HK\%\^!=_*"?#EM&&Z MZ:/"P<#,L1NU:OOJV\O,;!(_Z>^+86^H M98^9M6A@M''LRAD13IU%(\\/\5PP2/;--!. MKS=2))"8]F4)V-B>G\>G$)>*Z KMA@ZCTO=M9&K5ALJP;J]J0+ MGO4S5BRXVFU5=UVR1XUKFT^PG35]H$-BWE'J]"SCB=L#ZCBB)OP+Y6],I\ZU MQSDR5QR$.2]PQ9J;G6YRR5LLX+ @K$1[H]H\ CI>QJW'Q-,[3H[X;S>K'8[ M/N$^%[B:D3N-UCQ.-UW@"P%>OZ&&)U3?;BB;6&U)_IP.;8N'.?*O.RT>G6D@*]T5J.!,:ATS.K ML%1M%AE'R]*J?;;&8>C%.+0:W9*C".=A&#>J?5W9>* M@.5R)!)X'^!O..E6-/0+O]KN/ZF+77\.X_=ONYK#@[2AJ:M5T=>NY &R#;77 M24'*"N<=&HP-N2VK8&P:H>XD,[/ Q)J4B;/6-QY]M6_H@'+\]#B8/8N]D=[/ MZGFI91AN@EJJ5!(HWA1'R_ +]-$I>R-]D\8R"3U]Q(!8XH&E<4[13X;.4*8V M2YIJ905M5N,W3ITAK&$(+D%P(\'^3+\0 ][LN2[X85B!#&/$5\*'='F"(ZN\ MOO;A]V4RT0+$MV<0OQ'JCHKSLQ&&6C,W-%$7R]84-=1QL_9G:[*^$6:B)@0& MQ"=>J.YQ4)>8].J[7XCK?^H-7,H?+?HZXK8W'+V^V_\$9#N]LW M[&X(R1X7M#\X[PCC?R>F1[, 8[B8&'S7Q!GA/Q@UO\&0&#!;QN*)GFR3Z=-7 M@.2S:>M_;.1\_O:?IONSP=[^<^C^K,7^_O=_^S__!S].-,>=FO37BS%P&[.N M*A/W9Y-9]')$V7#D7H&!_H^?!S#AY8",F3F]>F5CZFA?Z;OV;(^)51*?2P[E M;""?YLKYM&G(&Q&5)PW]K M,91JQ#*T$*F7H+@O$:U:A%>!CT\X9APCGR;9PX]X\#_)>/*SU7]PP =\H>E8JFW ='^YP3@EP,-X3+G. +H)F2 ^8.1OY9=R MQ!=#^XUR2X1URW\$6ZQ/-;MOLJ'0'DZY(,QUMH+R13 7:CK-B10<4RY"O F,!_R$.:R\4IBVGLN?*,:IT;!F;FP+O5#0#I1XUI^8O[9 M O\G/(.$,@_^@(78F%F\7# 3*6OM1RKW;G]*76Z8<'=P!8\3*HV_G#61 =